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Summary 
Chronic Obstructive Pulmonary disease (COPD) is an irreversible inflammatory disease of the lung, 
characterised by abnormal inflammation of the lungs in response to inhalation of noxious particles or 
toxic gases, especially cigarette smoke. COPD exacerbations, defined as acute sustained worsening of 
symptoms from usual stable state, accounts for significant morbidity and mortality. Improved 
diagnostics which give advanced warning of an exacerbation could help prevent further declines in 
lung function. The quest to identify a marker or a combination of markers associated with COPD 
exacerbations has been pursued for some time. Many groups have studied biomarkers in plasma, 
serum, sputum and bronchoalveolar lavage (BAL) fluid and uncovered useful markers for prediction of 
exacerbations, disease severity and mortality. However, there is limited research on urine biomarkers. 
Profiling inflammatory mediators in urine samples presents a simple, convenient, non-invasive 
measure of inflammation in COPD patients and can be done repeatedly within their own home or in 
the clinic, allowing easier monitoring of time-dependent changes in biomarker levels. The research 
described in this thesis is the first investigation where a large panel of biomarkers has been evaluated 
in urine samples from subjects in various stages of COPD.  This has provided new insights into the 
relevance and origin of the biomarkers. Prototype point-of-care tests were developed that could be 
used routinely by patients in their own homes to monitor their inflammation status and predict 
pulmonary exacerbations. This was evaluated in a prospective observational study, results of which 
were used to develop a simple algorithm that showed the potential for differentiating between stable 
state and exacerbation events.  
The research described here is part of a major research initiative carried out within the Mologic R&D 
group and constitutes investigations designed and directed by the author, and conclusions derived 
from the author’s analysis of the data collected by the biomarker immunoassays.  The findings 
constitute a key scientific foundation for a new approach to personalised medicine for COPD sufferers.    
v 
Acknowledgements 
 
Firstly, I must give my thanks to the person who inspired me to take on this challenge, who believed in 
me and supported me throughout this journey – Professor Paul Davis. 
I could not have got this far without the input from my colleagues at Mologic, who helped to carry out 
the experiments as part of the wider Mologic respiratory programme. Specifically, reference assay 
testing was carried out in chapters 3 and 4, 1000s of urine samples were analysed with the assays 
described in chapters 2, the subsequent biomarker measurements allowed me to perform the 
statistical analysis and refine the biomarker selection from 36 down to 10, I could not have achieved 
this within the timeframe without their help. There has been nothing more motivating than carrying 
out the research within an expert, interactive team. 
Special thanks to my supervisors Professor Ian Weeks and Professor Simon Jones at Cardiff University 
who have also advised me over the past 4 years. 
I would also like to thank all of the clinical partners for their expertise as well the donation of clinical 
samples as noted in this thesis. Professor Chris Brightling has been of great importance, it is 
recognised that it might be possible to get all of the science and technology right, while missing the 
point from the patient or healthcare provider aspects. 
Of course, I am very grateful to all the COPD and CF patients who participated in the clinical studies. 
This research would not be possible without them. 
I would like to thank my family, especially my mother, sister and brother-in-law for supporting me 
throughout the writing this thesis.  
Lastly, I dedicate this to my father who wanted nothing more than to see me complete this thesis. He 
sadly passed away just 6 months before submission, but I know how proud he would have been 
should he have been here today. 
 
 
 
 
 
vi 
Publications and presentations 
 
PUBLICATIONS 
Zhang, J., Friberg, I.M., Kift-Morgan, A., Parekh, G., Morgan, M.P., Liuzzi, A.R., Lin, C.Y., Donavan, K.L., 
Colmont, C.S., Morgan, P.H., Davis, P., Weeks, I., Fraser, D., Topley, N., Eberl, M. ‘Machine-learning 
algorithms define pathogen-specific local immune fingerprints in peritoneal dialysis patients with 
bacterial infections’. Kidney int 92(1): 179-191 (2017). 
 
Elliott, T.S., Casey., A.L., Karpanen, T.J., David, M.D., Whitehouse, T., Lambert, P.A., Vernalis, A.B., 
Worthington, T., Parekh, G., Dunston, C.R., Kirby, J., Davis, P. ‘Addition of PLA2 to CRP enhances 
sepsis diagnosis’. The Journal of infection 73(4) 386-388 (2016) 
 
PRESENTATIONS 
Nash, E.F., Parekh, G., Davis, P., Whitehouse, J.L., Stevens, M. 35th Annual Meeting of the European 
Cystic Fibrosis Society (ECFS) 6-9 June 2012, Dublin, Ireland.  ‘Urinary inflammatory markers in the 
assessment of clinical status in adults with CF’. (Poster) 
Parekh, G., Donaldson, G., Singh, R., Davis, P., Wedzicha. J.A. American Thoracic Society 2014 
international Conference (ATS) 16-21 May 2014, San Diego, US. ‘Urinary Biomarkers at Exacerbation 
of Chronic Obstructive Pulmonary Disease (COPD)’. (Poster) 
Knightly, R., Parekh, G., Stolbrink, M., Davis, P., Turner, A. American Thoracic Society 2014 
international Conference (ATS) 16-21 May 2014, San Diego, US. ‘Urinary Biomarkers Implicate 
Proteinase Activity In Acute Exacerbations Of Chronic Obstructive Pulmonary Disease (COPD)’ 
(Poster) 
Parekh, G, Tunney, M., Vallières, E., McGrath, S., McIlreavey, L., Johnston, E., Downey, D., Woolston, 
K., Davis, P., Elborn, S., European Respiratory Society (ERS) International congress 6-10 September 
2014, Munich, Germany. ‘Inflammatory biomarkers in urine of cystic fibrosis patients’. (Poster) 
Vallières, E., Parekh, G., Tunney, M., McGrath, S., McIlreavey, L., Johnston, Woolston, K., Downey, D., 
Davis, P., Elborn, S., The 28th Annual North American Cystic Fibrosis Conference (NACFC) 9-11 October 
2014, Atlanta, Georgia. ‘Urinary Biomarkers in Patients with Cystic Fibrosis’. (poster) 
Parekh, G., Davis, P., Miller, B.M., Tal-Singer, R. The 10th International, Multidisciplinary meeting 
dedicated to Chronic Obstructive Pulmonary Disease (COPD10) 29 June – 1 July 2016, Birmingham, UK. 
‘Can Urinary Biomarkers Be Used to Improve Prediction of COPD Exacerbations?’ (Poster) 
vii 
Parekh, G. Division of infection and immunity Seminar Series, School of Medicine, Cardiff University 22 
June 2017. ‘Urinary biomarkers in COPD’. (Oral) 
Shidhani, K.A., Cox, D., Linnane, B., Parekh, G., Reilly, R., Obande E., McNally, P. Irish Thoracic Society. 
November 10-11 2017, Limerick, Dublin.  ‘Cystic Fibrosis Urinary Biomarker Study (CUBS) Interim 
analysis’ (Oral – presented by Shidhani, K.A) 
Yousuf, A., Parekh, G., Watson, L., George, L., Singapuri, A., Mistry, V., Davis, P., Brightling, C. British 
Thoracic Society (BTS) Winter Meeting 2017 6-8 December 2017, London, UK. ‘Urine Biomarker 
profiles associated with COPD Exacerbations’ (Poster) 
Yousuf, A., Watson, L., George., Parekh, G., Mistry, V., Finch, J., Parker, S., Beadle, L., Glover, S., 
George, L., Brightling, C.E. American Thoracic Society 2018 international Conference (ATS) 18-23 May 
2018, San Diego, US. ‘Urine Biomarkers of COPD Exacerbation; A Feasibility Study’ (Poster) 
Yousuf, A., Parker, S., Finch, J., Parekh, G., Glover, S., Watson, L., Beadle, L., White, C., Brightling, C.E. 
American Thoracic Society 2018 international Conference (ATS) 18-23 May 2018, San Diego, US. ‘Do 
Raised Serum Ige and Eosinophils Have an Affect on Quality of Life and Patient Related Outcome in 
COPD?’ (Poster) 
Parekh, G., Yousuf, A., Watson, L., Duvoix, A., Davis, P., Brightling, C.E. American Thoracic Society 2018 
international Conference (ATS) 18-23 May 2018, San Diego, US. ‘Urinary Biomarkers Profiles During 
COPD Exacerbations’ (Poster) 
Yousuf, A., Parekh, G., Parker, S., Finch, J., Glover, S., O’Brien, L., Rees, S., Mistry, L., Watson, L., 
Duvoix, A., Carr, L., Lewis, K.E., Brightling, C.E. European Respiratory Society (ERS) International 
congress 6-10 September 2018, Paris, France. ‘Changes in urinary biomarkers stable state and 
exacerbation of COPD’. (Poster) 
Shidhani, K.A., Cox, D., Linnane, B., Parekh, G., Reilly, R., McNally, P. North American Cystic Fibrosis 
Conference (NACFC) 18-20 October 2018, Denver, CO. ‘Cystic fibrosis urinary biomarker study (cubs): 
a multicentre longitudinal study aimed at discovering urinary biomarkers of lung injury in children 
with CF’ (Poster) 
 
 
  
viii 
Abbreviations  
A1AT α1-antitrypsin / Alpha-1-antitrypsin 
Ac-PGP N-acetyl Proline-Glycine-Proline 
AECOPD Acute Exacerbation of Chronic Obstructive Pulmonary Disease 
AERIS  Acute Exacerbation and Respiratory InfectionS in COPD clinical study 
(Clinical Trial Study Ref. NCT01360398, sponsored by GSK) 
AUC Area Under the Curve 
B2M β2 Microglobulin / Beta-2 Microglobulin 
BAL Bronchoalveolar lavage 
BL  Baseline 
CAT Com 
CC16 Club (Clara) Cell secretory protein-16 
CHI3L1 Chitinase 3 like protein  
COPD Chronic Obstructive Pulmonary Disease 
CF Cystic Fibrosis 
BEAT-COPD Biomarkers to Target Antibiotic and Systemic Corticosteroid Therapy in COPD 
Exacerbations (clinical study) 
CRF Case Report Form (used in clinical studies) 
CRP  C-reactive protein 
DES Desmosine 
DPD Deoxypyridinoline 
ECLIPSE Evaluation of COPD Longitudinally to identify Predictive Surrogate Endpoints. 
GSK sponsored clinical study (www.eclipse-copd.com)  
ECM Extracellular Matrix 
ECP  Eosinophil Cationic Protein 
EDN Eosinophil Derived Neurotoxin  
EPO Eosinophil peroxidase  
ELISA/EIA Enzyme-Linked ImmunoSorbent Assay 
ELTABA Enzyme Linked Transformation Affinity Binding Assay (Mologic patent) 
EXACT-PRO EXAcerbations of Chronic Pulmonary Disease Tool for Patient Reported Outcomes 
(www.exactproinitiative.com)  
Fib Fibrinogen 
fMLP N-formyl-Methionine-Leucine-Phenylalanine 
HNE Human Neutrophil Elastase 
ix 
HSA Human Serum Albumin 
IL-1β Interleukin 1 beta  
IL-6 Interleukin-6 
IL-8 Interleukin-8 
ICS Inhaled Corticosteroids  
KLH Keyhole limpet hemocyanin 
LTB4 Leukotriene B4 
LF Lateral Flow 
MBP Major Basic protein 
MMP Matrix Metalloproteinase (e.g. MMP-2, MMP-12 etc.)  
MPO  Myeloperoxidase 
NF-kB  Nuclear factor kappa B  
NGAL Neutrophil gelatinase-associated lipocalin 
PEx Pulmonary Exacerbation 
PG Prostaglandin 
pNPP p-Nitrophenyl Phosphate 
PSA Polystreptavidin 
PYD pyridinoline 
QEH Queen Elizabeth Hospital, Birmingham, UK  
RBP4 Retinol Binding Protein 4 
RNS Reactive Nitrogen Species 
ROC Receiver operator curve 
ROS Reactive Oxygen Species 
RT Room temperature 
SLPI Secretory Leukocyte Protease Inhibitor 
SOD Superoxide Dismutase 
SP-D Surfactant Protein- D 
sRAGE soluble Receptor for Advanced Glycation End products 
TIMP Tissue inhibitor of metalloproteinase (e.g. TIMP-1, TIMP-2) 
TNF-α Tumour necrosis factor-α  
UTI Urinary tract infection 
 
x 
CONTENTS 
 
Declaration ................................................................................................................................................ iii 
Summary ................................................................................................................................................... iv 
Acknowledgements.................................................................................................................................... v 
Publications and presentations ................................................................................................................ vi 
Abbreviations .......................................................................................................................................... viii 
List of Figures ............................................................................................................................................. 3 
Chapter 1.  Introduction ........................................................................................................................ 7 
1.1 Definition and epidemiology of Chronic obstructive pulmonary disease (COPD) ................. 8 
1.1.1 COPD .............................................................................................................................. 8 
1.1.2 COPD exacerbations ....................................................................................................... 8 
1.2 Pathology of COPD ................................................................................................................. 8 
1.3 COPD diagnosis and treatment .............................................................................................. 9 
1.4 Systemic manifestations and Comorbidities ........................................................................ 11 
1.5 Heterogeneity and exacerbation phenotypes ..................................................................... 11 
1.6 Cystic Fibrosis ....................................................................................................................... 15 
1.7 Asthma ................................................................................................................................. 15 
1.8 COPD and oxidative stress ................................................................................................... 16 
1.8.1 Sources of ROS ............................................................................................................. 16 
1.8.2 The consequences of oxidative stress in relation to COPD ......................................... 17 
1.9 Phagocytes ........................................................................................................................... 19 
1.10 The role of neutrophils in COPD .......................................................................................... 19 
1.11 The role of eosinophils in COPD ........................................................................................... 22 
1.12 Bacterial infections in COPD ................................................................................................ 23 
1.13 Viral infections in COPD ....................................................................................................... 24 
1.14 Biomarkers in COPD exacerbations ..................................................................................... 25 
xi 
1.14.1 Exhaled Breath Condensate ......................................................................................... 37 
1.14.3 Biomarkers in BAL ........................................................................................................ 39 
1.14.4 Plasma/serum/blood biomarkers ................................................................................ 39 
1.14.5 Biomarkers in urine ...................................................................................................... 41 
1.15 Urine, a non-invasive method of monitoring COPD status .................................................. 42 
1.16 Selected biomarkers for evaluation and molecular weights ............................................... 43 
1.17 Aims and hypothesis ............................................................................................................ 45 
Chapter 2. Methods ............................................................................................................................. 46 
2.1 Introduction ......................................................................................................................... 47 
2.2 Part 1 Methods for measuring biomarkers in clinical samples ............................................ 48 
2.2.1 Commercial DuoSet kits (R&D systems) ...................................................................... 48 
2.2.1.1 Materials and reagents ............................................................................................ 48 
2.2.1.2 Generic method for DuoSet assays (table 2.2 details dilutions used) ..................... 48 
2.2.2 Commercial full kits...................................................................................................... 50 
2.2.2.1 Calprotectin measurements .................................................................................... 50 
2.2.2.2 Creatinine measurement ......................................................................................... 50 
2.2.2.3 Beta 2 Microglobulin measurement ........................................................................ 51 
2.2.2.4 Fibrinogen measurement ......................................................................................... 51 
2.2.2.5 Major Basic Protein measurement .......................................................................... 52 
2.2.2.6 Eosinophil cationic protein (RNASE3) measurement ............................................... 52 
2.2.3 Substrate assays ........................................................................................................... 52 
2.2.3.1 MMP substrate assay (Active protease (Composite MMP 2,8,9,12,13,7)) .............. 52 
2.2.3.2 HNE activity .............................................................................................................. 53 
2.2.4 Mologic in-house developed assays ............................................................................ 53 
2.2.4.1 Materials and reagents ............................................................................................ 53 
2.2.4.2 fMLP measurement - Novel assay developed in-house ........................................... 54 
2.2.4.3 N-acetyl Proline-Glycine-Proline (Ac-PGP) measurement- Novel assay developed in-
house 54 
xii 
2.2.4.4 Desmosine measurement – Novel assay developed in-house (appendix) .............. 55 
2.2.4.5 Large Elastin Fragments measurement – Novel assay developed in-house ............ 55 
2.2.4.6 Desmosine fragments measurement – Novel assay developed in-house ............... 55 
2.2.4.7 Siglec 8 measurement- Novel assay developed in-house ........................................ 55 
2.2.4.8 Ultimate ELTABA (Active protease (Composite MMP’s)) -Novel assay developed in-
house 56 
2.2.4.9 Human Neutrophil Elastase (HNE) measurement ................................................... 56 
2.2.4.10 Alpha-1 antitrypsin (A1AT) measurement .............................................................. 56 
2.2.4.11 Secretory leukocyte protease inhibitor (SLPI) measurement ................................. 57 
2.2.4.12 Soluble receptor for advanced glycation end products (sRAGE) measurement .... 57 
2.3 Part 2 Statistical analysis ...................................................................................................... 58 
2.3.1 T-tests ........................................................................................................................... 58 
2.3.2 Receiver-operator characteristic (ROC) curves ............................................................ 58 
2.3.3 Sensitivity/specificity/PPV and NPV ............................................................................. 59 
2.3.4 Logistic regression ........................................................................................................ 60 
2.3.5 Correlation methods: Bland-Altman plots and spearman’s / pearsons r .................... 60 
Chapter 3. Biomarkers in urine ............................................................................................................ 62 
3.1 Introduction ......................................................................................................................... 63 
3.2 Methods – patient selection and assessment ..................................................................... 65 
3.2.1 Healthy controls ........................................................................................................... 65 
3.2.2 Stable COPD ................................................................................................................. 65 
3.3.3     Stable CF (1) ..................................................................................................................... 66 
3.3.4 Stable CF (2) ................................................................................................................. 66 
3.2.5 Suspected UTI and recovered UTI subjects.................................................................. 66 
3.3 Results .................................................................................................................................. 67 
3.3.1 Patient characteristics .................................................................................................. 67 
3.3.2 Biomarker levels in normal, stable COPD, stable CF and UTI ...................................... 69 
3.3.3 Biomarker correlations ................................................................................................ 78 
xiii 
3.3.4 Gender specific urinary biomarkers ............................................................................. 83 
3.3.5 Influence of age............................................................................................................ 83 
3.3.6 Biomarkers and frequency of exacerbations ............................................................... 88 
3.3.6.1 Single biomarker analysis ......................................................................................... 88 
3.3.6.2 Multiplex biomarker analysis ................................................................................... 88 
3.4 Discussion ............................................................................................................................. 90 
Chapter 4. Identification of biomarkers associated with COPD exacerbations ................................... 93 
4.1 Introduction ......................................................................................................................... 94 
4.2 Methods ............................................................................................................................... 96 
4.2.1 Patient selection and assessment ................................................................................ 96 
4.2.2 COPD subjects – QEH Birmingham .............................................................................. 96 
4.2.3 COPD subjects – GSK AERIS study ................................................................................ 96 
4.2.4 COPD subjects – Leicester BEAT-COPD study .............................................................. 97 
4.2.5 Laboratory methods..................................................................................................... 97 
4.2.6 Biomarker measurements ........................................................................................... 97 
4.2.7 Statistical analysis ........................................................................................................ 98 
4.3 Results .................................................................................................................................. 99 
4.3.1 Patient characteristics .................................................................................................. 99 
4.3.2 COPD subjects – QEH Birmingham .............................................................................. 99 
4.3.3 COPD subjects – GSK AERIS study ................................................................................ 99 
4.3.4 COPD subjects – Leicester BEAT-COPD study .............................................................. 99 
4.3.5 Individual Biomarker measurements ......................................................................... 101 
4.3.5.1.  Birmingham study ................................................................................................. 101 
4.3.5.2  Leicester study ...................................................................................................... 101 
4.3.5.3. GSK AERIS study ..................................................................................................... 102 
4.3.6 Multiplex biomarker analysis of exacerbations ......................................................... 108 
4.3.6.1 QEH Birmingham study .......................................................................................... 108 
4.3.6.2 GSK AERIS study ..................................................................................................... 109 
xiv 
4.3.6.3 Leicester COPD study- Multi-Marker assessment with baseline measurements 
(stable to exacerbation) ......................................................................................................... 111 
4.4 Discussion ........................................................................................................................... 115 
Chapter 5. Development of a point of care lateral flow test to measure biomarkers of interest in 
urine ................................................................................................................................................... 119 
5.1 Introduction ............................................................................................................................. 120 
5.1.1 Lateral flow technology ............................................................................................. 120 
5.1.2 Next generation development of the test device ...................................................... 123 
5.2 Methods ............................................................................................................................. 125 
5.2.1 Development of new cassette moulding ................................................................... 125 
5.2.2 Development of Headstart V2 prototype tests ......................................................... 125 
5.2.3 Development of final Headstart V3 prototype tests (a and b) .................................. 129 
5.2.4 Materials/reagents .................................................................................................... 134 
5.2.5 Equipment .................................................................................................................. 134 
5.2.6 Testing buffer standards ............................................................................................ 134 
5.2.7 Headstart Usability study at Leicester ....................................................................... 135 
5.2.8 Statistical analysis ...................................................................................................... 135 
5.3 Results ................................................................................................................................ 136 
5.3.1 Headstart Usability study at Leicester ....................................................................... 136 
5.3.2 Standard curves and assay range ............................................................................... 136 
5.4 Discussion ........................................................................................................................... 141 
Chapter 6. Verification and validation of the point of care multiplex lateral flow tests ................... 143 
6.1 Introduction ....................................................................................................................... 144 
6.2. Methods ............................................................................................................................. 145 
6.2.1 Materials/reagents .................................................................................................... 145 
6.2.2 Equipment .................................................................................................................. 145 
6.2.3 Testing buffer standards - pipette method ................................................................ 146 
6.2.4 Testing urine samples ................................................................................................ 146 
xv 
6.2.5 Testing dipping variation............................................................................................ 147 
6.2.6 Blood spiking testing .................................................................................................. 147 
6.2.7 Cross-reactivity testing .............................................................................................. 147 
6.2.8 Transport /Stability Study .......................................................................................... 148 
6.2.9  Comparison of fresh and frozen samples ................................................................. 149 
6.2.10 Stability of urine throughout the day ........................................................................ 149 
6.2.11 Testing Line development/measurement time ......................................................... 150 
6.2.12  Batch to batch reproducibility .................................................................................. 150 
6.3 Results ................................................................................................................................ 151 
6.3.1 Testing dipping variation............................................................................................ 151 
5.3.2 Blood spiking testing .................................................................................................. 156 
6.3.3 Cross-reactivity testing .............................................................................................. 158 
6.3.4 Transport stability study ............................................................................................ 160 
6.3.5 Fresh and frozen samples .......................................................................................... 164 
6.3.6 Stability of urine samples throughout the day .......................................................... 169 
6.3.7 Line development ...................................................................................................... 169 
6.3.8 Batch to batch variation ............................................................................................. 169 
6.4 Discussion ........................................................................................................................... 173 
Chapter 7.  Validation of biomarkers in longitudinal study ............................................................... 175 
7.1 Introduction ....................................................................................................................... 176 
7.2 Methods ............................................................................................................................. 177 
7.2.1 Study design ............................................................................................................... 177 
7.2.2 Individual patient biomarker profiles ............................................................................... 182 
7.2.3 Multiple biomarker analysis .............................................................................................. 182 
7.2.4 Patient profiles with algorithm ......................................................................................... 182 
7.3 Results ................................................................................................................................ 183 
7.3.1 Outcomes from entire study ...................................................................................... 183 
7.3.2 Patient characteristics for all patients in the study ................................................... 184 
xvi 
7.3.3 Verification of results from patients .......................................................................... 186 
7.3.4 Outcomes from the interim analysis.......................................................................... 191 
7.3.4.1 individual patient biomarker profiles .................................................................... 191 
7.3.4.2 Multiplex biomarker analysis ................................................................................. 193 
7.3.4.3 Patient biomarker profiles with Algorithm (5 biomarkers) ................................... 197 
7.4 Discussion ........................................................................................................................... 201 
Chapter 8. General discussion ........................................................................................................... 204 
8.1 Introduction ....................................................................................................................... 205 
8.2 Main findings ..................................................................................................................... 206 
8.2.1 Urinary biomarkers in health, disease and severity .................................................. 206 
8.2.2 Changes in levels of certain urinary biomarkers are indicative of exacerbation in 
retrospective samples ................................................................................................................ 212 
8.2.3 Changes in levels of selected urinary biomarkers are indicative of exacerbation in 
prospective samples .................................................................................................................. 215 
8.2.4 Urinary biomarker profiles in individual patients confirm already documented 
biological pathways .................................................................................................................... 219 
8.3 Biological relevance of selected biomarkers contributing to prediction of exacerbations
 222 
8.4 Future impacts of the research .......................................................................................... 225 
8.5 Limitations and strengths .................................................................................................. 227 
8.6 Conclusion .......................................................................................................................... 227 
8.5 Future work ........................................................................................................................ 228 
References ............................................................................................................................................. 230 
Appendix ............................................................................................................................................ 240 
I. Development and validation of novel assays ........................................................................ 241 
I.i Desmosine .............................................................................................................................. 241 
I.i.i Materials and Methods .................................................................................................. 241 
I.i.ii Results ............................................................................................................................ 245 
I.i.iii Discussion ....................................................................................................................... 253 
xvii 
I.ii Measurement of MMP activity (ELTABA) .............................................................................. 255 
I.ii.i ELTABA ........................................................................................................................... 255 
I.ii.ii Reverse ELTABA ............................................................................................................. 256 
I.ii.iii Ultimate ELTABA ............................................................................................................ 256 
I.ii.iv Materials and Methods .................................................................................................. 260 
I.ii.v Results ............................................................................................................................ 264 
I.ii.vi Discussion ....................................................................................................................... 267 
 
 
1 
LIST OF TABLES 
Table 1.1. A review of studies evaluating biomarkers in AECOPD in various sample matrices ............... 28 
Table 1.2. Biomarker panel and molecular weights (kDA) sorted from small to large. ........................... 44 
Table 2.1. Biomarker panel and assay format (24 commercial (C) and 11 developed in-house (IH)) ..... 47 
Table 2.2. DuoSet details ......................................................................................................................... 49 
Table 2.3. Calculation of sensitivity/specificity/PPV and NPV ................................................................. 59 
Table 3.1. Urine sample collection time points and groupings for GSK ECLIPSE study ........................... 65 
Table 3.2. Mean (SD) values of the main characteristics for all 5 cohorts with common information 
available ................................................................................................................................................... 67 
Table 3.3. Main characteristics of the stable COPD cohort and two subgroups- Infrequent Exacerbator 
(IF) & Frequent Exacerbator (F) at baseline ............................................................................................. 68 
Table 3.4.  Biomarker results in healthy urines- Median (IQR) ................................................................ 70 
Table 3.5. Biomarker results in stable COPD urines, median (IQR) and differentiation from healthy 
urines ....................................................................................................................................................... 71 
Table 3.6. Biomarker results in stable CF (1) urines (median (IQR) and differentiation from healthy 
urines ....................................................................................................................................................... 72 
Table 3.7. Biomarker results in stable CF (2) urines (median (IQR) and differentiation from healthy 
urines ....................................................................................................................................................... 73 
Table 3.8. Biomarker results in suspected UTI urines .............................................................................. 74 
Table 3.9. Summary table from all studies and significance levels ......................................................... 77 
Table 3.10. Summary table displaying biomarker levels with age and gender ....................................... 86 
Table 4.1. Characteristics of the patients included in the paired sample analyses for all three studies
 ............................................................................................................................................................... 100 
Table 4.2. Birmingham study; Biomarker results at exacerbation and recovery state ......................... 103 
Table 4.3. Leicester study; Biomarker results at stable and exacerbation state ................................... 104 
Table 4.4. AERIS study; Biomarker results at pre-exacerbation, exacerbation and post-exacerbation 
state ....................................................................................................................................................... 105 
Table 4.5. AERIS study; Pre-exacerbation vs exacerbation, exacerbation vs post exacerbation and pre-
exacerbation vs. post exacerbation comparisons (p-values). ................................................................ 106 
Table 4.6. BEAT-COPD study; stable vs. exacerbation fold change values from baseline ..................... 113 
Table 4.7. Summary of results from all retrospective studies ............................................................... 117 
Table 5.1. Component change from version 1 ....................................................................................... 128 
Table 5.2. Standards used for standard testing ..................................................................................... 135 
Table 5.3. A1AT and TIMP-2 ................................................................................................................... 137 
2 
Table 5.4. NGAL and Fib ......................................................................................................................... 137 
Table 5.5. CRP and RBP4 ........................................................................................................................ 137 
Table 5.6. CC16 and B2M ....................................................................................................................... 137 
Table 5.7. TIMP-2 and fMLP ................................................................................................................... 138 
Table 5.8. Assay range for biomarkers in urine samples ....................................................................... 138 
Table 6.1. Standards used for standard testing ..................................................................................... 146 
Table 6.2. Standards used for cross-reactivity testing ........................................................................... 148 
Table 6.3. Summary of the spiking of the pooled samples .................................................................... 149 
Table 6.4. Standards used for Line development test ........................................................................... 150 
Table 6.5. The average, %CV for 3 different method of sample application for RBP4, CC16 and B2M 154 
Table 6.6. The average, %CV for 3 different methods of sample application for TIMP-1 and fMLP ..... 155 
Table 7.1. Expected number of exacerbations, based on GOLD categories .......................................... 180 
Table 7.2. Characteristics of the patients included in the entire observational study (n=105) ............ 185 
Table 7.3. selected data for analysis and indication of days pre- or post-exacerbation ....................... 192 
Table 7.4. Biomarker levels at stable and exacerbation with statistical tests ....................................... 192 
Table 7.5. selected data for analysis and indication of days pre- or post-exacerbation ....................... 194 
Table A. Desmosine measured in urine samples from COPD patients and healthy individuals ............ 250 
Table B. Details of the immunogens (sequence and ID) ........................................................................ 260 
Table C. Details of the peptides, sequence and ID ................................................................................ 261 
 
 
  
3 
List of Figures 
Figure 1.1. COPD, a combination of chronic bronchitis and Emphysema. .............................................. 10 
Figure 1.2. Linkages between phenotype, disease progression and intervention. ................................. 14 
Figure 1.3. Origins of ROS and RNS and oxidative stress in COPD. .......................................................... 18 
Figure 1.4. Cells involved in the Innate immune system. ........................................................................ 19 
Figure 1.5. sample collection methods and invasiveness. ....................................................................... 26 
Figure 1.6. Biomarker selection rationale ................................................................................................ 27 
Figure 2.1. Example of mechanism for selecting threshold values ......................................................... 59 
Figure 2.2. Example bland-Altman plots .................................................................................................. 61 
Figure 3.1. Urine samples received from Belfast City Hospital and Royal Belfast Hospital for Sick 
Children .................................................................................................................................................... 66 
Figure 3.2. Scatter plots showing the difference between all 5 cohorts ................................................. 76 
Figure 3.3. Heat map for biomarker correlation in healthy volunteers................................................... 79 
Figure 3.4. Heat map for biomarker correlation in COPD stable samples, shown with all samples then 
stratified by gender .................................................................................................................................. 80 
Figure 3.5. Heat map for biomarker correlation in CF stable samples (1) shown with all samples then 
stratified by gender .................................................................................................................................. 81 
Figure 3.6. Heat map for biomarker correlation in CF stable samples (2) shown with all samples then 
stratified by gender .................................................................................................................................. 82 
Figure 3.7. Detailed analysis of gender-biased biomarker values, showing spread and significance levels
 ................................................................................................................................................................. 85 
Figure 3.8. Box and Whiskers plot for stable CF (1) cohort stratified by age and gender ....................... 87 
Figure 3.9. Urine marker IL-1β differing significantly between COPD subgroups in the stable state ..... 89 
Figure 3.10. Statistical analysis of the data from 10 urinary biomarkers combined with FEV1% 
predicted .................................................................................................................................................. 89 
Figure 3.11. Correlations between biomarkers within clusters in healthy and stable COPD .................. 91 
Figure 4.1: Birmingham study; Multiple urinary biomarker panel for AECOPD .................................... 108 
Figure 4.2. Diagrammatic representation of the value of each biomarker alone or in combination with 
other biomarkers ................................................................................................................................... 110 
Figure 4.3. Example of how the analysis fits in with the proposed use of the test ............................... 111 
Figure 4.4. BEAT-COPD study; All data n=55 (male and female combined), discrimination between 
stable and exacerbation ......................................................................................................................... 114 
Figure 4.5. BEAT-COPD study; Female data n= 19, discrimination between stable and exacerbation . 114 
Figure 4.6. BEAT-COPD study; Male only n=36, discrimination between stable and exacerbation ...... 114 
4 
Figure 4.7. BEAT-COPD study; Combined Male and females n=55 with final 10 selected biomarkers . 118 
Figure 5.1. A typical lateral flow assay ................................................................................................... 121 
Figure 5.2. A sandwich assay format ..................................................................................................... 121 
Figure 5.3. A competitive assay format ................................................................................................. 122 
Figure 5.4. An inhibition assay format ................................................................................................... 122 
Figure 5.5. Headstart V1 procedure....................................................................................................... 124 
Figure 5.6. Headstart V2/V3 procedure ................................................................................................. 124 
Figure 5.7. Development of plastic housing from point of concept to manufacturing ......................... 127 
Figure 5.8. Visual representation of the different strip architecture .................................................... 128 
Figure 5.9. Diagrammatic representation of assembly process for test device version 2..................... 130 
Figure 5.10. Diagrammatic representation of the first version test that measured 4 biomarkers, A1AT, 
TIMP-2, TIMP-1 and CRP ........................................................................................................................ 131 
Figure 5.11. Diagrammatic representation of the second version test (a) that measured 5 biomarkers, 
A1AT, TIMP-2, NGAL, Fibrinogen and CRP ............................................................................................. 132 
Figure 5.12. Diagrammatic representation of the second version test (b) that measured 5 biomarkers, 
RBP4, CC16, B2M, TIMP-1 and fMLP...................................................................................................... 133 
Figure 5.13. Graphical representation of the standard curves for each of the assays within the 
multiplex assay ....................................................................................................................................... 139 
Figure 5.14. Graphical representation of the standard curves for each ELISA ...................................... 140 
Figure 6.1. Multistix results regarding blood detection in urine ........................................................... 147 
Figure 6.2. Graphical representation of the variation of each assay (cube units) for the samples tested 
with 3 different methods ....................................................................................................................... 153 
Figure 6.3. Optimisation of blood spiking for Multistix testing ............................................................. 157 
Figure 6.4.  Pre- and post-spike of blood (1/100,000 blood) into 10 urine samples for each individual 
assay ....................................................................................................................................................... 157 
Figure 6.5. Graphical representation of the cube unit averages (3 replicates) for cross-reactivity 
experiments on Multiplex A ................................................................................................................... 159 
Figure 6.6.  Graphical representation of the cube unit averages (3 replicates) for cross-reactivity 
experiments on Multiplex B ................................................................................................................... 159 
Figure 6.7. Graphical representation of the concentrations of each assay during the sample stability 
study....................................................................................................................................................... 163 
Figure 6.8. Graphical representation of the correlation of fresh and frozen samples for each asssay 
when tested by ELISA ............................................................................................................................. 167 
5 
Figure 6.9. Graphical representation of the correlation of fresh and frozen samples for each asssay 
when tested by Multiplex Lateral Flow assays ...................................................................................... 168 
Figure 6.10. Graphical representation of the stability of fresh samples over a 24hr period for all 10 
biomarkers ............................................................................................................................................. 170 
Figure 6.11. Graphical representation of the test line development for all assays ............................... 171 
Figure 6.12. Graphical representation of Interbatch validation, comparison of three batches ............ 172 
Figure 7.1. Schematic overview of the observational study .................................................................. 177 
Figure 7.3. Distribution of exacerbations across all patients ................................................................. 184 
Figure 7.4. Concentration plotted against raw cube value and representation on the standard curve for 
three batches of devices ........................................................................................................................ 190 
Figure 7.5. Combined Male and females n=55 with final 10 selected biomarkers (BEAT-COPD study) 195 
Figure 7.6. Combined Male and females n=55 with 5 selected biomarkers (BEAT-COPD study) ......... 195 
Figure 7.7. Combined Male and females n=24 with all 10 selected biomarkers (new study) ............... 196 
Figure 7.8. Combined Male and females n=24 with 5 selected biomarkers (new study). .................... 196 
Figure 8.1. KEY: Colour code for biomarker groupings .......................................................................... 206 
Figure 8.2. Biomarkers that were significantly different in health and disease and gender specific 
biomarkers ............................................................................................................................................. 209 
Figure 8.3. Correlations between urinary biomarkers in stable state ................................................... 210 
Figure 8.4. Correlations between urinary biomarkers in stable and exacerbation. .............................. 211 
Figure 8.5. Urine biomarkers associated with AECOPD ......................................................................... 214 
Figure 8.6. Biomarker correlations associated with AECOPD as shown in blood and urine ................. 218 
Figure 8.7. Biomarker profiles established through clinical study. ........................................................ 221 
Figure 8.8. Interactions between the biomarkers involved in COPD exacerbations ............................. 224 
Figure A. Purification scheme for sheep anti desmosine CF1316, by sequential immunoadsorption on a 
set of antigen affinity columns .............................................................................................................. 245 
Figure B. The progression of antibody binding efficiency from Sheep anti desmosine CF1316 collected 
over 78 weeks of immunisations ........................................................................................................... 246 
Figure C. Example desmosine calibration curves ................................................................................... 246 
Figure D. Cross reactivity with PYD and DPD. ........................................................................................ 248 
Figure E. Binding affinities of anti-desmosine ....................................................................................... 249 
Figure F. Analysis of healthy (n=20) and COPD (n=100) groups for desmosine/creatinine ratios ........ 251 
Figure G. Bland-Altman plots for LF determination of desmosine compared to standard method LC-
MS/MS ................................................................................................................................................... 251 
Figure H. Bland-Altman plots for EIA compared to LC-MS/MS .............................................................. 252 
6 
Figure I.  Principle of the ELTABA MMP/HNE activity test ..................................................................... 257 
Figure J.  Principle of the Reverse ELTABA MMP/HNE activity test ....................................................... 258 
Figure K.  Principle of the Ultimate ELTABA MMP activity test ............................................................. 259 
Figure L. Different formats evaluated with different combinations of peptides and antibodies.......... 263 
Figure M. Selection of best performing format in ELISA ....................................................................... 265 
Figure N. Comparison of best performing peptide for each format ...................................................... 265 
Figure O.  Comparison of Ultimate ELTABA with commercial kits......................................................... 266 
Figure P. specificity of Ultimate ELTABA with wound fluid and urine ................................................... 267 
Figure Q. Ultimate ELTABA MMP selectivity.......................................................................................... 267 
 
  
7 
 
 
 
 
 
 
 
 
Chapter 1.  Introduction 
 
  
8 
1.1 Definition and epidemiology of Chronic obstructive pulmonary disease (COPD)  
1.1.1 COPD  
COPD is an inflammatory disease of lung, characterised by progressive airflow limitation that is not 
fully reversible (1). It is defined as a preventable and treatable respiratory disease and characterised 
by abnormal inflammation of the lungs in response to inhalation of noxious particles or toxic gases, 
especially cigarette smoke (2).  COPD is a major global epidemic that predominantly affects the elderly 
population (3). Its prevalence is increasing, and it contributes to substantial morbidity and mortality. 
There are an estimated 80 million people that have moderate to severe COPD worldwide. COPD has 
an estimated annual death rate of over 4 million people globally. By 2020 it is predicted to be the third 
leading cause of mortality worldwide. In developed countries COPD now affects female and male 
subjects equally, reflecting the equal prevalence of smoking (4).  
1.1.2 COPD exacerbations 
COPD exacerbations, defined as an acute sustained worsening of the patient’s symptoms from their 
usual stable state, which is beyond normal day-to-day variations, are a particularly important feature 
of the disease, accounting for significant morbidity, mortality and health care costs. They are 
responsible for about 15% of all medical admissions (5), one million bed days and an annual UK NHS 
expenditure of £500 million [NICE 2010]. COPD and in particular COPD exacerbations are of a high 
public health and financial relevance associated with a significant negative impact on the quality of life 
(6).  Nowadays, the recognized criterion used to classify AECOPD according to symptoms is the 
Anthonisen standard (7). Anthonisen et al divided exacerbations into three types. Type 1 
exacerbations involve increased dyspnea, sputum volume, and sputum purulence, Type 2 involve any 
two of the latter symptoms, and Type 3 just involves one of those symptoms combined with cough, 
wheeze, or symptoms of an upper respiratory tract infection. It has been shown that a single 
exacerbation (the first) may result in significant increase in the rate of decline in lung function (8). 
1.2 Pathology of COPD 
COPD is primarily characterised by the presence of airflow limitation resulting from chronic 
inflammation and remodelling of small airways or ‘chronic bronchitis’ and is often associated with lung 
parenchymal destruction, resulting in loss of the alveolar attachments or ‘emphysema’ (9) (Figure 1.1). 
Chronic inflammation causes structural changes, small airways narrowing, and destruction of lung 
parenchyma as demonstrated by tissue biopsies, sputum analysis, and post-mortem samples (10).  
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In COPD, repeated exposure to noxious particles triggers an inflammatory cascade in the small airways 
and lung parenchyma involving several different cell types (eg, neutrophils, macrophages, 
lymphocytes) and inflammatory mediators (eg, growth factors, cytokines, chemokines, proteases) (11). 
These changes are believed to result in mucus hypersecretion, extracellular matrix degradation leading 
to chronic bronchiolitis, and injury to alveolar epithelial cells, leading to emphysematous changes (10). 
A fraction of people with COPD has inherited PiZZ (Glu342Lys) alpha-1 antitrypsin deficiency (A1ATD), 
a major genetic determinant influencing the development of early-onset COPD with emphysema, 
especially in cigarette smokers (12). A1ATD-related COPD is associated with low circulating levels of 
A1AT (10-15% or normal levels) (13). Consequences of this is explained in more detail later. 
1.3 COPD diagnosis and treatment 
Currently, COPD patients self-report when they perceive symptoms that result from deteriorating lung 
function and or gross physiological changes that result from relatively advanced host responses and/or 
pathogen virulence.  Current practice investigations are chest X-ray, SaO2, ABG, ECG, FBC, 
U+E/glucose, Theophylline level if appropriate, Sputum MC & S if purulent, BCs if pyrexial. At present, 
the best method for recognising the onset of an exacerbation is through the recording and monitoring 
of patient symptoms or physiological measures, which can be subjective. 
Upon presentation of symptoms, it is likely that the damage to the lung has already started or 
occurred.  Advanced warning of an exacerbation would give reassurance and additional information to 
help patients manage their condition more efficiently 
 Current guidelines advocate the use of oral corticosteroids and antibiotics for people with COPD 
exacerbations. The clinical response to treatment varies considerably and is associated with significant 
side effects; the inability to target therapy means some patients are inappropriately treated placing a 
vulnerable population at further risk i.e. the elderly population. The benefit of antibiotics in mild to 
moderate AECOPD remains controversial and their overuse can contribute to the development of 
bacterial resistance. Systemic corticosteroids bear the risk of adverse side effects (hyperglycaemia, 
increased risk of diabetes and cardiovascular disease), especially in patients with co-morbidities. 
Furthermore, in some patients oral corticosteroid therapy is associated with increased treatment 
failures (defined as retreatment, hospitalisation, or death within 30 days) (14).  This has led to 
strategies to reduce the duration of oral corticosteroid treatment (15).  A recent review concluded 
that current COPD guidelines are of little help in identifying which AECOPD patients might benefit 
from treatment with corticosteroids and antibiotics in a primary care setting (16) and stresses the 
importance of developing better methods for targeting corticosteroid treatment as well as gaining a 
better understanding of COPD phenotypes. 
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Figure 1.1. COPD, a combination of chronic bronchitis and Emphysema. The most important risk factor for chronic obstructive pulmonary disease (COPD) is 
cigarette smoking. Other exposures including passive smoke and biomass fuel use also play roles. The innate immune system includes mucociliary transport 
and coughing that, together clear the airway surface. After distress the production of mucus is increased, and the epithelial barrier is disrupted. Epithelial 
cells and resident monocytes/macrophages respond by generating a wide variety of cytokines and chemokines that control the movement of migrating 
innate inflammatory immune cells (all originating in the bone marrow) into the injured tissue. These include polymorphonuclear leukocytes (PMNs); 
monocytes/ macrophages; eosinophils; as well as a smaller number of natural killer and dendritic cells (Hogg, 2006). Continuous bronchial irritation and 
inflammation is associated with an increased number of epithelial, goblet and squamous cells, dysfunction, damage and loss of cilia and enlarged 
submucosal mucous secreting glands, which result in the mucous hypersecretion that is characteristic of chronic bronchitis (17). In the lung parenchyma, 
which includes the gas exchanging surface of the lungs (bronchioles, alveoli, pulmonary capillary system), destruction can occur in the form of emphysema, 
which involves dilation and destruction of the bronchioles and surrounding alveoli (17).
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1.4 Systemic manifestations and Comorbidities 
The impact of COPD extends beyond the lung and several systemic manifestations can further impair 
functional capacity and health-related quality of life. In addition, COPD is associated with several other 
diseases, such as cardiovascular diseases, osteoporosis, diabetes, and metabolic syndrome, more 
commonly than expected by chance. It is believed that the link between them is in the form of a spill 
over of inflammatory mediators from the lung (9, 18).  
1.5 Heterogeneity and exacerbation phenotypes 
There is increasing recognition that COPD is a heterogeneous condition with variability between 
sufferers in terms of their symptoms, age of onset, lung function, exercise capacity, microbiome shifts 
and patterns, comorbidities, medication, and airway inflammation. The frequency of COPD acute 
exacerbations (AECOPD) varies as does disease progression defined by loss of lung function. There is a 
series of clinically relevant subgroups in COPD i.e. patients with clearly defined clinical characteristics 
(phenotypes) with prognostic or therapeutic implications (19, 20). Comorbidities do not represent a 
specific subgroup as they are treated independently (20). The Linkages between phenotype, disease 
progression and intervention are summarised in figure 1.2. 
A distinct patient group expressing the ‘’frequent exacerbation phenotype’’ has greater susceptibility 
to exacerbations irrespective of disease severity.  It is now widely recognised, having been identified 
by data collected as part of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate 
Endpoints (ECLIPSE) study. In this study, 2138 patients with a range of disease severity were observed 
over 3 years. It was concluded that exacerbations became more frequent and more severe as the 
severity of the disease increased and that history of exacerbations is the single most effective 
predictor of a frequent exacerbator phenotype (21). This represented 12% of the study population and 
has now been incorporated into the current GOLD multidimensional assessment of COPD (22). 
Alternatively, data from the ECLIPSE study led to the identification of a ‘systemic inflammatory COPD 
phenotype’ with persistent systemic inflammation (elevated levels of 2 or more of WBC, CRP, IL-6, 
Fibrinogen) for 1 year.  These patients presented with significantly increased all-cause mortality and 
elevated exacerbation frequency at follow up visits (23). The group, representing 16% of the study 
population, is different to the frequent exacerbation phenotype group, as only 40% of the inflamed 
group were frequent exacerbators (2+), 28% had a single exacerbation and 32% had no exacerbations. 
This suggests that a diagnostic criterion other than exacerbation history would improve the ability to 
predict susceptibility to exacerbations. Other studies support the findings from the ECLIPSE study with 
the observation that even those patients with milder COPD (and in those without previous 
exacerbations) can be subject to increased risk of exacerbations in the following year (24). These 
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patients had simultaneously elevated levels of inflammatory biomarkers (plasma CRP, fibrinogen and 
white blood leukocyte counts). In the latter study it was suggested that high levels of inflammatory 
biomarkers reflected bacterial colonisation or latent viral infections persisting in airway epithelial cells, 
after a previous exacerbation.  This would be a good explanation for the frequent exacerbators but, 
for the inflamed group, it could be that low-grade systemic inflammation had a negative effect on the 
immunological response, thereby increasing susceptibility to exacerbations (24). 
It has also been demonstrated that patients with frequent exacerbations have a faster rise in systemic 
inflammation over time compared to those with infrequent exacerbations (25). In the Donaldson 
study, plasma fibrinogen, sputum interleukin-6 and neutrophils were significantly increased over 1-7 
years across 148 patients. Longitudinal studies of populations with COPD over many years 
demonstrated that only about 50% of patients given a diagnosis of COPD had an accelerated decrease 
in lung function, whereas the remainder had a normal age-related decrease but started from a lower 
value, presumably because of impaired lung development (26). This implies that only half of patients 
with COPD have inflammation, whereas those with normal decreases in lung function presumably do 
not. Aaron et al (27) divided the exacerbations of COPD into two distinct patterns, such as sudden and 
gradual onsets, according to worsening respiratory symptoms from diary cards. Patients who 
experienced sudden onset exacerbations had greater mean daily symptom scores, greater peak 
symptom scores, earlier peak symptoms, and shorter median recovery times back to baseline health 
status. The frequent exacerbators are further divided into the following two types: those with 
emphysema predominant and those with chronic bronchitis predominant. The treatment for the two 
types is also different. For the emphysema phenotype, the basis of pharmacological treatment is long-
acting bronchodilators, and in some cases with Inhaled Corticosteroids (ICS). The bronchitis-
predominant exacerbator patients may be treated with bronchodilators and ICS, and in contrast to 
exacerbators with emphysema, they respond to treatment with Roflumilast (19). 
With regard to response to treatment, one study demonstrated that frequent exacerbators had a 
reduced response to treatment of exacerbation, although there were limitations to its validity.  
Although there were significant differences between levels of biomarkers (MPO, IL-6 and CRP) in 
infrequent and frequent exacerbators from exacerbation to recovery at each timepoint (over 2 
weeks)(28), only CRP gave no difference at admission and a significant change during the recovery 
timepoints.  The recovery period was also variable and could be seasonal. A study has demonstrated 
that COPD exacerbations in colder periods of the year take longer to recover, are more likely to 
involve cough or coryzal symptoms and more likely to cause hospital admission (29). A different study 
looking at sputum (neutrophils, MPO, IL-8) and serum inflammatory markers (IL-6, CRP) revealed a 
time lag between the resolution of airway and systemic inflammation, which were correlated with the 
13 
improvements in different clinical indices (lung function, Dyspnea score and COPD assessment test 
(CAT) score. This supports the requirement for completing long-term treatment (14 days) to ensure 
resolution of exacerbation. 
It has been suggested that eosinophil-driven inflammation is characteristic of viral exacerbations, 
whereas neutrophil-derived mediators are associated with both viral and bacterial exacerbations (10).  
However, exacerbations are heterogeneous with respect to inflammation and aetiology, typically 
neutrophilic driven exacerbations and some associated with eosinophilic airway inflammation. How 
these alter lower airway inflammation and relate to treatment response is not clear, although, in 
stable state, sputum eosinophilia is associated with corticosteroid responsiveness whereas high 
bacterial load and sputum purulence associate with favourable outcomes with antibiotics. 
Subpopulations were identified by the Bafadhel study (14) in which 4 biologic clusters were 
determined, relating to identifiable patterns of inflammation and potential causative pathogens. The 
biologic exacerbation clusters were bacterial-, viral-, or eosinophilic-predominant, and a fourth was 
associated with limited changes in the inflammatory profile and was termed “pauciinflammatory’’ 
(14). In this study, it was found that the best serum biomarkers associated with bacterial and viral 
associated exacerbations were CRP with an AUC of 0.65 and CXCL10 (IP-10) with an AUC of 0.76 
respectively. The best sputum biomarkers associated with bacterial and viral associated exacerbations 
were IL-1β with an AUC of 0.89 and CCL5 with an Area Under the Curve (AUC) of 0.69 respectively. 
Blood eosinophil, sputum CCL17, sputum IL5, were the most strongly associated with sputum 
eosinophilia with an AUC of 0.85, 0.8 and 0.73 respectively. A further study identified subgroups for 
improved treatment stratification, Eosinophilic (EO), Neutrophilic (NE), mixed granulocytic (MG) and 
paucigranulocytic (PG). The MG and NE group had higher sputum inflammatory cells, higher levels of 
sputum MMP-9, IL-6 and CRP and serum SAA, lower lung function, and longer hospital stay (30).  83% 
with NE displayed evidence of bacterial infection and responded poorly to standard therapies. Patients 
with EO had a better response to corticosteroids. The stratification in the latter study was based on 
sputum eosinophils and neutrophils, the EO group >2.5% sputum eosinophils, the NE group >61% 
neutrophils, the PG group <2.5% eosinophils and <61% and neutrophils and the MG group >2.5% 
eosinophils and >61% neutrophils. 
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Figure 1.2. Linkages between 
phenotype, disease progression and 
intervention. Frequent exacerbators, 
those with 2 or more exacerbations per 
year can be sub-grouped into chronic 
bronchitis (approx. 45% of COPD 
patients, linked to higher exacerbation 
frequency) and emphysema; 
Eosinophilic COPD, Steroids are more 
effective in this subgroup; neutrophil 
driven exacerbation, antibiotics are 
more effective.  Those patients with 
systemic inflammation (approx. 16%), 
with increased mortality and 
exacerbations than those without 
persistent inflammation should be 
monitored with a possible transition 
into a frequent exacerbator, treatment 
is unknown 
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1.6 Cystic Fibrosis 
Unlike COPD, In Cystic Fibrosis (CF), the inflammatory response is driven mainly by bacterial infections, 
especially Pseudomonas species, which leads to tissue breakdown and severe lung damage (31). Early 
eradication of P. aeruginosa infection results in improvement of overall survival and better patient 
care (32). CF produces progressive lung disease and related morbidity and mortality in >90% of 
patients (33). Abnormalities in the CF transmembrane conductance regulator protein result in 
abnormal airway surface liquid that impairs mucociliary clearance. Mucus becomes a site for bacterial 
colonization and a resulting neutrophilic inflammatory response.  These neutrophils release oxidants 
and proteases that degrade tissue and eventually cause permanent fibrotic change of the airways and 
lung parenchyma of patients with CF.  
1.7 Asthma 
Asthma, like COPD, is associated with airway inflammation, but the components of inflammatory 
response and the site of inflammation differ between both conditions. Asthma is a condition of 
inflammation predominantly in the large airways, although the chronic condition is also associated 
with inflammation in the small airways or bronchiolitis (17). In both diseases, there is chronic 
inflammation of the respiratory tract, which is mediated by the increased expression of inflammatory 
proteins including cytokines, chemokines, adhesion molecules, inflammatory enzymes and, in both 
diseases, there are acute episodes of exacerbations (34). Exacerbations in Asthmatic individuals are 
usually triggered by rhinoviruses, and less commonly by inhaled allergens and air pollution, unlike 
COPD which is triggered by either bacteria or viral infections and inflammatory stimuli – eg smoke 
(34). Patients often have overlapping clinical features of both Asthma and COPD which makes it 
difficult to diagnose (35). An estimated 15%-50% of patients with obstructive airway disease older 
than 50 years show a mixture of criteria. This group was classified as the asthma-COPD overlap 
syndrome (ACOS) by the Global Initiative for Asthma (GINA) committee back in 2016 but this is no 
longer advised. 
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1.8 COPD and oxidative stress 
Oxidative stress in known to play an important role in the development of COPD (36) and during acute 
exacerbations (37). It occurs when there is an imbalance between the formation of reactive oxygen 
species (ROS) and antioxidant defence mechanisms (in favour of oxidants) resulting in harmful effects, 
including cell damage, mucous hypersecretion, antiprotease inactivation and increased pulmonary 
inflammation through the activation of transcription factors (2). The ‘harmful effects’ are a 
consequence of ‘carbonyl stress’, where oxidative damage to the surrounding tissues leads to the 
formulation of highly reactive organic molecules that can modify proteins nonenzymatically (37) 
targeting specific residues, such as lysine, arginine, cysteine, and histidine. ROS include hydroxyl 
radical (·OH) and superoxide anion (O2·-) which contain unpaired electrons, the unstable nature of 
these ROS permit transfer of electrons to other molecules via oxidation, resulting in damage, 
inactivation or creation of further ROS (36).   
1.8.1 Sources of ROS 
Cell-derived ROS: The inflammatory-immune response results in activation of epithelial cells and 
resident macrophages, and the recruitment and activation of neutrophils, eosinophils, monocytes and 
lymphocytes, particularly during exacerbations (37).  Activation of these inflammatory and structural 
cells in response to various stimuli including cytokines produce ROS (17). There are 4 key processes 
described that result in different ROS elements summarised in figure 1.3. a) The generated superoxide 
anion (O2·-) is rapidly converted to (catalysed by the enzyme- superoxide dismutase (SOD)) to 
Hydrogen peroxide (H202) and OH is formed nonenzymatically in the presence of Fe2+ as a secondary 
reaction. b) ROS and reactive nitrogen species (RNS) can be generated intracellularly from several 
sources, such as mitochondrial respiration, NADPH oxidase system, Xanathine Oxidase system (37). 
Nitrotyrosine is considered an indicator of the production of NOS (38). c) Activity of haem peroxidases 
(myeloperoxidase) or eosinophil peroxidase (EPO) formulate potent oxidant hypochlorous acid (HOCl) 
and hypobromous acid (HOBr) from H202 in the presence of chloride and bromide ions, respectively.  
Inhaled oxidants and cigarette smoke: Inhalation of cigarette smoke and airbourne pollutants results 
in direct lung damage as well as the activation of inflammatory responses in the lungs. Oxidants 
present in cigarette smoke can stimulate alveolar macrophages to produce ROS and to release a 
number of mediators, some of which attract neutrophils and other inflammatory cells into the lungs. 
Neutrophils and macrophages are known to be increased in the lungs in smokers compared to non-
smokers and generate ROS via the NADPH oxidase system. Smoking is associated with increased 
content of MPO in neutrophils. Smokers and people with COPD are have increased levels particularly 
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during exacerbations (39). While exposure to cigarette smoke can drive the onset of COPD once the 
disease has been established cessation of smoking does not stop the continued presence of oxidative 
stress and progression of disease (37). 
1.8.2 The consequences of oxidative stress in relation to COPD 
Oxidative stress and neutrophil traffic in the lungs: Neutrophils from people with COPD have been 
shown to release increased amounts of ROS spontaneously and following stimulation (40). During 
migration, neutrophils release proteases and ROS as they move through lung tissues, this migration is 
affected (inaccurate migration) by ROS which in turn may result in moving across a larger surface area 
(36). 
Oxidative stress and protease/antiprotease imbalance – leading to emphysema: Oxidative stress can 
also impair the function of the antiproteases, such as Alpha-1 antitrypsin (A1AT) and Secretory 
Leukocyte Protease Inhibitor secretory (SLPI), as a consequence, the imbalance accelerates the 
breakdown of elastin in lung parenchyma by human neutrophil elastase (HNE). ROS are able to 
inactivate A1AT via oxidation of the methionine 358 residue in the active site (36) promoting 
inflammation. In addition, it has been shown in various studies that active HNE, cathepsin G and 
proteinase-3 can activate matrix metalloproteinase-2 (MMP-2), and this activation is blocked by A1AT 
but not by a proteinase inhibitor (41).  There is evidence that altered protease and antiprotease 
balance during a COPD exacerbation contributes to mucus obstruction (42).  
Oxidative Stress and inflammation in the airways: ROS activate transcription factors such as nuclear 
factor-kappaB (NF-kB), which switches on multiple inflammatory genes, resulting in amplification of 
the inflammatory response (17). Genes for many inflammatory mediators such as interleukin-8, TNF-a, 
are regulated by such transcription factors. It is believed that oxidants cause the release of 
inflammatory mediators that are also associated with increased expression of the genes. Carbonyl 
stress in the form of electrophilic carbonyls can also impact on many different signalling pathways.  As 
with oxidative stress, this is propagated through the targeting of critical cysteine residues in 
susceptible signalling molecules (37).  Phagocytosis is impaired in COPD as a consequence of Carbonyl 
stress, the failure to remove apoptotic cells can lead to continued inflammation in COPD (37).  
Oxidative stress and aging: Oxidative stress reduces the expression and activity of sirtuin-1, a key 
repair molecule that is implicated in aging, which could contribute to the accelerated aging response 
seen in patients with COPD. The accelerated aging lung increases the likelihood of developing 
emphysema (37). In addition, reduced sirtuin-1 is believed to an increased expression of MMP-9.  
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Figure 1.3. Origins of ROS and RNS and oxidative stress in COPD. Overproduction of ROS/NOS from environment and cellular sources cause tissue damage 
through lipid peroxidation and the oxidation of proteins and carbohydrates resulting in the formulation of carbonyl stress. Biological systems are 
continuously exposed to oxidants which can be either generated endogenously by metabolic reactions e.g. from mitochondrial electron transport during 
respiration or during activation of phagocytes or exogenously such as inhaled from air pollutants or cigarette smoke.  O2.-, a free radical with a short 
biological lifespan is reduced to the more stable H202 mediated by a key antioxidant defence enzyme -SOD (of which there are 3 different forms and SOD 1 
and SOD3 expression is reduced in the lung and blood of tobacco smokers (38). Fe2+, implicated in the formulation of hydroxyl radicals is a critical factor 
related to toxicity induced by ROS generation (Fenton reaction). Abbreviations: ROS, reactive oxygen species; NOS, Reactive nitrogen species; SOD, 
Superoxide dismutase; O2.-, superoxide; NO, nitric oxide; H202, hydrogen peroxide; HOCL, Hypochlorous acid; HOBr, hypobromous acid; ONOO-, 
peroxynitrite; NOX, NADPH oxidase. 
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1.9 Phagocytes 
Phagocytes detect surface molecules that are present on pathogen cells but not on host cells. They 
detect evolutionarily conserved surface molecules shared by many microorganisms. Toll-like 
receptors (TLR) on our own phagocytes cells bind to pathogen surface molecules. The binding is a 
signal to the phagocyte to engulf its target and release cytokines that recruit other immune cells to 
the site of injury or infection. It is not possible to cover all of these in this thesis, therefore focus will 
be on neutrophils and eosinophils and their role in COPD.  
 
 
Figure 1.4. Cells involved in the Innate immune system. Phagocytes are immune cells that engulf and 
destroy foreign cells; i.e. macrophages, neutrophils and dendritic cells. Neutrophil and macrophages 
migrate from blood vessels into tissues. 
1.10 The role of neutrophils in COPD 
Neutrophils are the most abundant leukocytes in blood and are part of our native or innate 
immunity, and together with NK cells, platelets and macrophages, they act as part of our defence to 
protect against microbes (18). However, in COPD, there is excessive neutrophil recruitment, 
activation, and defective apoptosis resulting in the production of reactive oxygen species, the 
release of serine proteases, matrix metalloproteinases, myeloperoxidase, and lysozymes that then 
contribute to lung tissue damage and airway remodelling (18). Neutrophils for a long time have been 
recognised to be involved in smoking-induced tissue injury, as the major destroyers of the elastic 
matrix of the alveoli, as shown by numerous findings of increased numbers of activated neutrophils 
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in sputum and BAL fluid that correlate with disease severity. However, the location of the 
neutrophils accounting for circulating neutrophil-derived enzymes remains uncertain (40). 
Several proteins are involved in the chemoattraction, adhesion and transmigration of neutrophils.  
Neutrophil recruitment to the airways and parenchyma from the circulation involves initial adhesion 
to vascular endothelial cells through E-selectin (upregulated in people with COPD (4)) and tight 
adhesion using integrins followed by migration across the epithelial monolayer through the 
paracellular space, where they are retained on the luminal side as a defence barrier and to clear 
invading pathogens (18). The process is propagated by increased neutrophil chemotactic factors, 
including but not restricted to LTB4, CXCL1, CXCL5, and CXCL8 (IL-8). These are derived from alveolar 
macrophages, T cells, and epithelial cells, but the neutrophil itself might be a major source of CXCL8 
(4). A host- microorganism interaction-associated chemoattractant, formyl-met-leu-phe (fMLP) 
produced in bacteria and mitochondria is also suspected to contribute to driving neutrophils to 
infiltrate the damaged lung parenchyma (43) via the seven-transmembrane G-protein-coupled 
receptor FPR1 (44). In vitro, blockade of neutrophil FPR1 with inhibitory antibodies or the selective 
antagonist cyclosporin H (CsH) significantly attenuated neutrophil chemotaxis toward necrotic cells 
(45). Bacterial derived fMLP is a consequence of their protein processing mechanisms and/or from 
degraded proteins (which start out as pathogen associated molecular pattern molecules or 
‘’PAMPs’’). Mitochondrial derived fMLP results from damaged eukaryotic cells by degradations of 
proteins similar to bacterial proteins (in this case, molecules known as damage associated molecular 
patterns or ‘’DAMPs’’). 
Neutrophils store an assortment of molecules in three types of granules, primary; antimicrobial 
proteins and proteases (e.g. MPO, neutrophil serine proteases NSPs), secondary; lactoferrin, and 
tertiary; gelatinases (e.g. MMP-9). In addition, secretory vesicles contain a reservoir of membrane-
associated proteins (44). During chronic neutrophilic inflammation, an increasing number of 
activated neutrophils secrete granule contents into the extracellular spaces, where the excess of 
proteases can become destructive, especially in the absence of pathogens. Myeloperoxidase (MPO), 
produced in the neutrophil and monocyte precursor cells in the bone marrow, is an enzyme that 
contributes to the destruction of bacteria during activation of the host immune system (46). 
Confirmation that the neutrophils are activated comes from increased concentrations of granule 
proteins, such as MPO and human neutrophil lipocalin (HNL, also known as NGAL). NSPs include 
Human neutrophil elastase (HNE), Proteinase 3 (PR3) and Cathepsin G (CG). Together they are 
capable of degrading most of the extracellular matrix components such as elastin and collagen (18). 
The imbalance of HNE and its inhibitor, A1AT (as presented in A1ATD and oxidative stress) is 
believed to result in emphysema.  It also worsens mucus-driven airway obstruction (hypersecretion), 
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which is a common feature in cystic fibrosis, bronchiectasis, and COPD. Two known processes 
activate the sodium channel and indirect degradation of the cystic fibrosis transmembrane 
conductance regulator (CFTR) leading to dehydration of the airway surface and further weakening of 
the ability of the airways to effectively clear not only mucus, but also any pathogens (18). It has been 
suggested that PR3 can modify key cytokines such as IL-8, leading to enhanced stability and potency, 
and release of IL-1β and TNF-a from monocytic cells. NSPs have also been reported to inactivate the 
IL-6 trans-signalling pathway (47), this would have a negative impact on leukocyte recruitment. 
MMPs are proteolytic enzymes that degrade matrix components both in stable and exacerbation 
states. There are 26 different types of MMP, stratified according to structure, substrate specificity 
and function (48), classified into subgroups of collagenases (MMP-1, 8, 13), gelatinases (MMP-2,9), 
stromelysins (MMP-3,10), stromelysin-like (MMP-11, 12), matrilysins (MMP-7, 26), transmembrane 
(MMP-14, 15, 16, 24), glycosyl-phosphatidly-inositol-type (MMP-17, 25), MMP-19-like (MMP19, 28), 
and other MMPs (MMP-18, 20, 23) (48). Most MMPs are secreted as latent pro-enzymes and are 
activated by proteolytic conversion (49).  It is the active form in which they become directly 
disruptive.  Their activity is regulated or inhibited by Tissue Inhibitors of MMPs (TIMPs) (50). Matrix 
metalloproteinases MMP-8 (neutrophil collagenase) and MMP-9 (gelatinase B) regulate extracellular 
matrix turnover and can degrade matrix components such as elastin and, similar to the NSPs, when 
in excess their activity can lead to tissue destruction. The protease-antiprotease imbalance might 
also be altered by the degradation of the TIMPs by HNE (51), similarly, MMP-9 and MMP-12 may 
also inactivate A1AT and at the same time, HNE may activate MMP-9 (18). Macrophage elastase 
(MMP-12), is mainly produced by macrophages and has been shown to be involved in COPD (elastin 
degradation).  It has been suggested that MMP-12 gene polymorphism may account for this disease 
variability and one of the causative factors in smoking related injury (52).  It has also been shown in 
vitro that MMP-12 can also cause production and release of IL-8 (49) and TNF-α (52). 
As a consequence of the collagen degradation that occurs during neutrophil degranulation and 
release of the molecules described, the consequent fragments can activate inflammatory cells and 
drive chronic inflammation further. The increase in elastase activity in patients with COPD might 
contribute to the development of emphysema and neutrophilic inflammation through generation of 
chemotactic peptides, such as N-acetyl Pro-Gly-Pro (Ac-PGP, a matrikines), which are potent 
neutrophil chemoattractants that activate CXCR2.This might be self- perpetuating because 
neutrophils release MMP-9 which, in turn, generates more PGP (4, 53), which can readily diffuse 
through the dense ECM. Furthermore, its unusual structure owing to the cycling back of the proline 
side chains onto the backbone amino group results in a matrikine that is resistant to generic 
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protease degradation (54). PGP is normally degraded by leukotriene A4 hydrolase, limiting 
neutrophil influx, but this mechanism is disrupted by cigarette smoke, thus enabling increased 
neutrophil inflammation to continue (49, 55). PGP can be chemically acetylated to Ac-PGP through 
the action of reactive aldehydes present in cigarette smoke. 
Very recently, it has been reported that neutrophils can be ‘de-primed’ or revert back to the 
unprimed quiescent state. This is a novel finding because it has been assumed that neutrophil 
priming was an irreversible process (56).  
1.11 The role of eosinophils in COPD 
Eosinophils are generated in the bone marrow, and circulating eosinophils migrate to, and largely 
reside in, the gastrointestinal tract and thymus. Under certain condition, they are recruited to 
tissues, where they secrete chemokines, cytokines, and cytotoxic granular products that facilitate an 
inflammatory reaction.  Until recently, COPD was considered to be a mainly neutrophil-mediated 
inflammatory disease (in contrast to asthma which is mainly eosinophilic). However, the growing 
body of evidence now indicates that some exacerbations can be eosinophil driven. Airway biopsies 
and numerous studies evaluating levels in blood have shown higher levels of eosinophils in the 
exacerbation state compared to stable state (57). Human eosinophils contain four basic proteins 
stored in secondary granules which have been shown to exert toxic effects on numerous cell types 
(58). Major basic protein (MBP) is found in the core, while eosinophil derived neurotoxin (EDN), 
eosinophil cationic protein (ECP) and eosinophil peroxidase (EPO) are found in the matrix (59). EPO is 
believed to cause oxidative tissue injury; MBP may disrupt the epithelial barrier allowing the 
penetration of inhaled antigens; ECP and EDN are believed to cause apoptosis of airway epithelial 
cells (60).  The mechanisms for increased eosinophil counts in people with COPD is not clear, but 
there has been interest in the role of type 2 innate lymphoid cells (ILC2s), which are regulated by 
epithelial mediators, such as IL-33 released as a result of epithelial cell injury (61). In the general 
population, sputum and blood eosinophil levels are typically <1.1% (of total white blood cells) and 
below an absolute count of 300 cells/µl respectively (60). Blood being a less invasive sample is 
preferable and a 2% cut-off (approximately 150 cells/µl absolute count) has been used as the 
specified threshold in the majority of studies to date (majority of which failed to meet their primary 
outcomes).  In a prospective cohort study (SPIROMICS) of approximately 3200 participants, it was 
found that blood, sputum eosinophil counts related to clinical outcomes and subsequently 
demonstrated the usefulness of eosinophil counts to advance management decisions (62). Using 
eosinophil cut-offs of more than 1.25% for sputum and 200 cells/µL for blood to categorise high and 
low eosinophil counts, the SPIROMICS investigators found that baseline characteristics were 
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different according to eosinophil counts, including the proportion of current smokers (lower in the 
high blood eosinophil group vs low), a number of whom had taken inhaled corticosteroid medication 
(higher in the high vs low blood and sputum eosinophil groups), serum IgE levels (higher in the high 
vs low blood eosinophil group), and quality of life or lung function (most parameters worse in the 
high vs low blood and sputum eosinophil groups). The degree of emphysema, quantified by CT, was 
associated with high sputum but not blood eosinophils, particularly in the upper lobes. Furthermore, 
blood but not sputum eosinophils were found to be more reproducible in participants with repeated 
measures. Other studies suggest that blood eosinophils can be used as a biomarker in severe COPD 
exacerbations for predicting 12- month readmissions (63). It was found in this study that higher 
blood eosinophil counts at admission were associated with a more than threefold increase in 12-
month readmission and a shorter time to first COPD-related admission. Evidence is now 
accumulating to show that in patients with COPD and a risk of exacerbations, blood eosinophil count 
identifies a group of patients with an increased risk, which could be modifiable with treatment. 
However, target eosinophil concentrations might need to be different, depending on the outcome 
that is to be modified— eg, whether aiming to decrease exacerbation risk, improve lung function, or 
relieve symptoms. Further studies that investigate mechanisms and risk modification will be 
required to clarify the role of eosinophils in COPD.  
1.12 Bacterial infections in COPD 
Acute infection results when higher loads of bacteria overcome the local defences, leading to acute 
inflammation involving both innate and adaptive defences. Bacterial colonisation may result from 
abnormal innate defences, chronic infection occurs when an inflammatory response generated by 
host defence mechanism fails to clear the bacteria, with continued tissue destruction (64).  In 
bacterial exacerbations, purulent sputum (yellow or green) is the typical symptom, as is neutrophil-
driven inflammation in both blood and airway (65). Bacteria overcome primary host defences by a 
number of pathogenic mechanisms, including release of ciliary toxins, pneumolysin, endotoxin, and 
IgA proteases, thereby disrupting mucociliary clearance (hence the change in sputum production). 
Subsequently, bacteria adhere to the epithelium, resulting in activation of dendritic cells, 
macrophages, and epithelial cells through toll like receptors (TLRs), initiating an inflammation 
response (64).   
In patients with COPD, bacterial detection in lower airway derived samples is associated with 
increased airway inflammation, reduced lung function and more frequent exacerbations (66). 
Bacteria are isolated from sputum in 40-60% of acute exacerbations of COPD. The three-
predominant bacterial species isolated were Haemophilus influenzae, Moraxella catarrhalis, and 
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Streptococcus pneumoniae, although Gram negative enteric bacilli, and Pseudomonas spp are also 
frequently isolated in patients with severe COPD (67).  
The Acute Exacerbation and Respiratory InfectionS in COPD (AERIS) study is the first longitudinal 
study that includes molecular microbiological assessments (including viruses as potential airway 
pathogens) (68). After 1 year into the study, the finding was that at exacerbation, the most common 
bacterial species were Haemophilus influenzae and Moraxella catarrhalis (69), Haemophilus 
influenzae driven with a greater risk and frequency during high season (October-March). In addition, 
it was found that the lung microbiome shows significantly less variation within an individual than 
between individuals, that exacerbations within individuals showed higher microbiome variability 
during exacerbations compared to stable timepoints which was more significant in frequent 
exacerbators (70).  It is also well known that Haemophilus, catarrhalis and Pseudomonas produce 
biofilms protecting the microbes from the immune system and antibiotics, a component of antibiotic 
resistance. 
1.13 Viral infections in COPD 
Viruses activate the innate immune system through cell surface and cytosolic PRRs, which detect 
viral components (especially nucleic acids) (64). Patients with detectable respiratory pathogens have 
been shown to exhibit a more marked impact on lung function and longer duration of hospitalisation 
than patients with exacerbations of non-infectious etiology (71). Viral exacerbations are associated 
with higher IL-6 levels, lower levels of CRP, and longer duration of hospital stay (average 9 days) (65). 
The frequency of dual viral and bacterial infections is low (72). 
Respiratory viruses commonly associated with AECOPD are diverse and include human rhinoviruses, 
influenza and parainfluenza viruses, respiratory syncytial virus, coronavirus and adenovirus (68). 
Viruses are implicated as a major cause of exacerbations and are detected in approximately half of 
severe COPD exacerbations (73). Findings from the AERIS study indicate that the most common virus 
was rhinovirus with 23% of sputum samples positive at exacerbation (69). Rhinovirus has been 
shown to increase cytokine production in an epithelial cell line and thus repeated viral infection may 
lead to upregulation of airway cytokine expression (74). It has also been shown that viral infection 
alone is sufficient to induce COPD exacerbation and to lead to a secondary bacterial infection. 
Rhinovirus infections are frequently followed by secondary bacterial infections in COPD (36%). 
However, 71% of bacterial driven exacerbations had reported symptoms of a viral infection before 
onset. Cleavage of the antimicrobial peptides SLPI and elafin by virus-induced neutrophil elastase 
may precipitate these secondary bacterial infections (72). 
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1.14 Biomarkers in COPD exacerbations 
There are biomarkers at different cellular and subcellular levels in exacerbation, which can provide 
information before, during and after the exacerbation (22). Sputum sampling reflects biofluid in the 
central airways rather than the lower and peripheral lungs, whereas, bronchoalveolar lavage (BAL) 
samples the more peripheral airways and alveoli. Exhaled breath condensate reflects inflammation 
in the respiratory tract (75) and blood carries the biomarkers from the lungs where they can be 
cleared from the body via the urine. 
Barnes et al in 2006 and  members of the American Thoracic Society (ATS)/European Respiratory 
Society (ERS) task force, reviewed biomarkers in COPD and concluded that, although there are many 
biomarkers of inflammation and oxidative/nitrative stress in the airways of patients with COPD, 
there was still a lack of information about a) how they related to disease severity; b) how 
reproducible they were, and c) could they be affected by concurrent therapies (76).  An ideal 
biomarker is reproducible, derived from a standardised procedure, demonstrates disease specificity 
and has the ability to detect changes attributed either to therapeutic interventions or exacerbations 
(77). The review of > 600 published studies suggested that few of these biomarkers were validated, 
reproducible and related to disease development, severity, or progression (78). This meta- analysis 
covered 146,255 patients with COPD and revealed the poor sensitivity of current biomarkers to 
define clinical status and quantify the effect of treatment. Only sputum neutrophils and interleukin-8 
(IL-8), as well as serum tumour necrosis factor-α (TNF-α) and C-reactive protein (CRP), showed any 
trend toward separating different stages of COPD (76). In another review of COPD-related 
biomarkers, Lock-johansson et al, noted that surfactant protein-D (SP-D), Club cell protein-16 (CC16), 
IL-8, CRP and fibrinogen did not fit the criteria individually but, in combination with each other or 
with additional biomarkers, they may be more useful (79). A similar study showed that different 
combinations of 5 plasma biomarkers: CC16, soluble Receptor for Advanced Glycation End products 
(sRAGE), fibrinogen, CRP and SP-D could differentiate between airflow limitation (p<0.001), 
emphysema, (p<0.01), decline of FEV1 (p<0.05), progression of emphysema (p<0.01) and all 5 for 
mortality (p<0.05) (80). A different review that included 59 studies, indicated that CRP, IL-6 and TNF-
α were the most studied and only CRP showed consistent elevations in exacerbation compared to 
control subjects (81). It has been stated that biomarkers may come to the forefront for diagnosis of 
disease in the complex patient (82).  
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Figure 1.5. sample collection methods and invasiveness. The most invasive method being biopsy and 
the most non-invasive method being urine. 
It is not possible within the scope of this thesis to review the thousands of studies undertaken to 
date that evaluate the different findings of biomarkers in different sample matrices.  However, table 
1.1. lists examples of studies selected to provide evidence of the shortlisted biomarkers selected for 
evaluation in urine and what is known about these biomarkers associated with exacerbations in 
different sample matrices; EBC, blood, sputum, BAL fluid and urine. It is to be noted that there are a) 
few studies assessing biomarkers in urine, b) few longitudinal studies due to the inability to collect 
other sample types frequently over a long period of time (see figure 1.5) and c) most of the 
exacerbation studies have less than adequate numbers of samples/patients due to the same reasons 
stated previously.  The short list of biomarkers selected are shown in figure 1.6. these include: 
• Signalling molecules that recruit neutrophils to the inflammation site 
• Acute phase proteins regulated by signalling molecules 
• Degranulation molecules including proteases released by the neutrophils to fight off the 
infection that can become self-destructive 
• Protease inhibitors that usually regulate the proteases that are impaired thus causing a 
further imbalance 
• Degradation molecules that are a consequence of the damage caused by the proteases to 
the lung structure such as elastin and collagen 
• Other additional biomarkers which are contributed by the kidneys themselves as a result of 
the downstream damage  
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Figure 1.6. Biomarker selection rationale (diagram courtesy of Prof. Paul Davis, Mologic). 
Inflammatory leukocytes active in the lung cause a wide range of biomarkers to be released into lung 
fluid and blood, some originating from the leukocytes, some from the damage they cause to the 
surrounding tissue and some as a consequence of the signalling pathways that call them into the 
lung or control their activity  
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Table 1.1. A review of studies evaluating biomarkers in AECOPD in various sample matrices 
Biomarker Country Year Ref Study detail Notes Follow up visits N EBC Sputum Blood Urine BAL 
TNF-a Canada 2001 (83) Stable- AECOPD   1 month and 9-15 
months 
50   ↑ AECOPD vs. BL 
(p<0.01) 
      
TNF-a Germany 2005 (84) AECOPD -
recovery 
ICU n= 11 
General ward n = 34 
ICU after 10 days 
GW after 1 week 
45 ↑ AECOPD vs. 
recovery (both 
groups) 
        
IL-6 UK 2000 (74) Stable - 
AECOPD.  
37 AECOPD  57 
 
↑ AECOPD vs. stable 
(p<0.05) 
   
IL-6 Germany 2005 (84)  AECOPD -
recovery 
ICU n= 11 
General ward n = 34 
ICU after 10 days 
GW after 1 week 
45 ↑ AECOPD vs. 
recovery 
(both groups) 
    
IL-6 China 2014 (28)  AECOPD- 
stable.  
non-frequent (n=78) 
frequent (n=57) 
Day 0, 4,7,14 week 
8 after discharge 
135 
  
↑ AECOPD vs. stable 
(serum)  
  
IL-6 China 2014 (85) AECOPD - 
stable 
Resolved day 4 in 
sputum and day 14 
serum 
Day 0, 4, 7, 14, week 
8 (after discharge) 
93 
  
↑ AECOPD vs. stable 
(p=<0.001)  
  
Il-1β Germany 2005 (84)  AECOPD -
recovery 
ICU n= 11 
General ward n = 34 
ICU after 10 days 
GW after 1 week 
45 ↑ AECOPD vs. 
recovery 
(both groups) 
        
IL-8 Canada 2001 (83) Stable- AECOPD   1 month and 9-15 
months 
50   ↑ AECOPD vs. stable 
(p<0.05) 
      
IL-8 Netherland
s 
2004 (86)  AECOPD -
recovery 
 Day 1, 3, 7 14 
  
↑ AECOPD vs. 
recovered (p=<0.002)  
(serum) 
  
IL-8 Germany 2005 (84)  AECOPD -
recovery 
ICU n= 11 
General ward n = 34 
ICU after 10 days 
GW after 1 week 
45 ↑ AECOPD vs. 
recovery 
(both groups) 
    
IL-8 China 2014 (85) AECOPD - 
stable.  
Resolved day 4 in 
sputum and day 14 
serum 
Day 0, 4, 7, 14, week 
8 (after discharge) 
93   ↑ AECOPD vs. stable 
(p<0.001)  
      
IL-8 USA 2009 (33) AECOPD- 
recovery  
71 expectorated 
sputum samples 
during 26 
hospitalisations (19 
patients). 
Day 0-3, day 3-8 
days and days 8-12 
days. 
19  ↑ AECOPD vs. 1wk 
stable (p = 0.01) but 
not significantly 
decreased from 
measurement 2- 3.   
↔AECOPD vs. 1wk & 
not significantly 
decreased from 
measurement 2- 3.   
(plasma) 
  
Chitinase 3 
like protein  
China 2016 (87)  AECOPD 
vs stable COPD 
vs Healthy 
controls  
AECOPD (n=37) 
Stable (n=44) 
Controls (n=47) 
N/A 128      ↑ AECOPD vs. stable 
(p= 0.0005) 
(serum) 
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Biomarker Country Year Ref Study detail Notes Follow up visits N EBC Sputum Blood Urine BAL 
MMP-8 Finland 2008 (88) AECOPD -
recovery. 
healthy non 
smokers 
healthy 
smokers stable 
COPD  
AECOPD (n=10) 
recovery (n=8) 
Healthy NS (n=32) 
Healthy S (n=28) 
stable (n=15) 
Day 1, 4 weeks 85  
 
↑ AECOPD -  Recovery 
(p=0.04) ↑ AECOPD - 
stable (p < 0.001) ↑ 
AECOPD -  controls 
(p<0.0001)  
   
MMP-9 Poland 2012 (89)  Stable- AECOPD 
+ Control group  
COPD (n=17) 
Asymptomatic 
smokers (n=22) 
N/A 17 ↑ AECOPD vs. stable 
 p<0.005 
 
↑ AECOPD vs. stable 
p<0.005 
  
MMP-9 UK 2005 (90)  Stable- AECOPD  Stable (n=12)  
AECOPD (n=19) 
Pre-Stable sample 
taken 2-8 months  
19 ↑ AECOPD vs. stable p 
<0.01   
 
↑ AECOPD vs. stable p 
<0.01 (serum) 
  
MMP-9 Switzerland 2015 Papako
nstanti
nou  
AECOPD 
vs stable COPD 
AECOPD (n=44) 
stable (n=53)  
 97 
   
↑ AECOPD 
vs. stable 
P=0.012) 
MMP-9 UK 2016 (91) AECOPD -
recovery 
 Day 1, day 5-7 and 4 
weeks 
   ↑ AECOPD – recovery 
(not MMP-8 or urinary 
MMP-8/9) (serum) 
  
HNE Finland 2008 (88) AECOPD -
recovery. 
healthy non-
smokers 
healthy 
smokers stable 
COPD  
AECOPD (n=10) 
recovery (n=8) 
Healthy NS (n=32) 
Healthy S (n=28) 
stable (n=15) 
Day 1, 4 weeks 85  
 
↑ AECOPD -  Recovery 
(p=0.03) ↑ AECOPD - 
stable (p < 0.001) ↑ 
AECOPD -  controls 
(p<0.0001)  
   
HNE USA 2009 (33) AECOPD- 
recovery  
71 expectorated 
sputum samples 
during 26 
hospitalisations (19 
patients). 
Day 0-3, day 3-8 
days and days 8-12 
days. 
19  ↑ AECOPD vs. 1wk 
stable (p = 0.05) & 
decreased from 
measurement 2- 3 
(p=0.05)   
   
NGAL Turkey 2014 Gumus
,  
AECOPD -
recovery 
+ healthy 
controls 
AECOPD (n=30)  
Controls (n=20) 
day 1 (within 24hrs) 
and day 70 
50   ↑ AECOPD – recovery 
p<0.001 
  
MPO Sweden 2015 (92) Stable- AECOPD 
+ controls 
  
Smokers, 38/60 had at 
least 1 AECOPD 
Asymptomatic 
smokers (n=10) 
Never smokers (n=10) 
over 60 weeks 
(every 15 weeks) 
60      ↑ AECOPD (p<0.01). 
(+neutrophils and CRP, 
not HNE) 
 
  
MPO China 2014 (28) AECOPD- stable non-frequent (n=78) 
frequent (n=57) 
Day 0, 4, 7, 14, week 
8 (after discharge) 
135 
 
↑ AECOPD vs. stable 
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Biomarker Country Year Ref Study detail Notes Follow up visits N EBC Sputum Blood Urine BAL 
MPO China 2014 (85)  AECOPD- stable Resolved day 4 in 
sputum and day 14 
serum 
Day 0, 4, 7, 14, week 
8 (after discharge) 
93   ↑ AECOPD - vs. stable 
(p=<0.001) 
      
A1AT Germany 2012 (93) AECOPD vs 
stable 
+ healthy 
controls  
AECOPD (n=18) 
Stable (n=17) 
Healthy (n=10) 
N/A 45 ↑ AECOPD vs. stable 
(p=0.00003) 
 
↑ AECOPD vs. stable 
(p=0.04) (serum) 
  
TIMP-1 UK 2005 (90)  Stable- AECOPD 
 
Stable (n=12)  
AECOPD (n=19) 
Pre-Stable sample 
taken 2-8 months  
19 ↑ AECOPD vs. stable p 
<0.01  
 ↔ AECOPD vs. stable 
 (serum) 
  
TIMP-1 Poland 2012 (89) Stable- AECOPD 
+ Control group  
COPD (n=17) 
Asymptomatic 
smokers (n=22) 
N/A 17 ↑ AECOPD vs. stable 
 p<0.005 
 
↔ AECOPD vs. stable 
  
TIMP-1 Switzerland 2015 (94)  AECOPD 
vs stable COPD 
AECOPD (n=44) 
stable (n=53)  
 97         ↑ AECOPD 
vs. stable 
P=0.028)  
TIMP-2 Switzerland 2015 (94)  AECOPD 
vs stable COPD 
AECOPD (n=44) 
stable (n=53)  
 97         ↑ AECOPD 
vs. stable 
P=0.030)  
Cystatin C China 2016 (95)  AECOPD - 
stable. + 
healthy controls 
AECOPD (n=90) 
Controls (n=90) 
day 0, day 10 (8-13 
days) and 
convalescent 
180   ↑ AECOPD vs. stable 
(p<0.01) ↑ AECOPD 
vs. controls (p<0.01) 
↑ stable vs. controls 
(p<0.001) 
  
Desmosine Egypt 2014 (96) AECOPD - 
stable 
 Day 0 and month 1 20     ↑ AECOPD vs. stable 
(p<0.001) (Blood - not 
clear if serum, plasma 
or whole blood).  
    
Desmosine UK 2011 (97) GP1: Stable 
COPD vs 
AECOPD vs 
Healthy 
controls vs 
stable asthma  
GP2: Healthy 
volunteers, 
COPD  
Stable (n=53) 
AECOPD (n=105) 
Control non-smokers 
(n=26) control 
smokers (n=20) Stable 
Asthma (n=53) 
Healthy (n=81), COPD 
(n=105) 
N/A 204 
  
↔ AECOPD vs. stable 
COPD 
↑ AECOPD vs. all 
other groups 
(p<0.001) 
 
Desmosine Italy 2002 (98) AECOPD 
(Mod/severe)-
stable  
N/A Within 24hrs, day 3-
5 and 2 months 
9 
   
↑ AECOPD vs. 
stable (p=0.049) 
(no difference 
from day 0 to day 
5). 
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Biomarker Country Year Ref Study detail Notes Follow up visits N EBC Sputum Blood Urine BAL 
Desmosine USA 2012 (99) AECOPD- 
recovery  
155 spot urine samples 
from 53 patients 
during 63 
exacerbations. 
Day 0-3, day 3-8 
days and days 8-12 
days. 
53       ↑ AECOPD vs. 
stable  
 (SG adjusted and 
non-adjusted p 
=0.01). No correl 
with sputum DES. 
SG used instead 
of creatine as Ucr 
concentration 
significantly 
decreases during 
hospilisations. 
  
CC-16 Canada 2016 (100)  AECOPD- 
recovery  
 Day 0, 15, 30, 90, 
180 
38 
  
↓ AECOPD vs day 15 
(same as RelB, 
whereas higher levels 
of SPD during AECOPD) 
  
CC-16 Italy 2007 (101) AECOPD GOLD2 (n=10) 
GOLD3 (n=10) 
N/A 20  ↓GOLD3 vs GOLD2 
(p=0.027) 
   
CRP UK 2011 (14) Stable-AECOPD.  Predominantly 
GOLD2,3. 182 
Exacerbations  
1yr and at AECOPD 145 
  
Association with 
bacterial AECOPD AUC-
0.65 (serum) 
  
CRP Sweden 2015 (92) Stable- AECOPD 
+ controls 
  
Smokers, 38/60 had at 
least 1 AECOPD 
Asymptomatic 
smokers (n=10) 
Never smokers (n=10) 
over 60 weeks 
(every 15 weeks) 
60 
  
↑ AECOPD (p<0.001). 
(+neutrophils and 
MPO, not HNE) 
(serum) 
  
CRP Turkey 2015 (102) AECOPD - stable N/A Day 0, 7 43 
  
↑ AECOPD vs. stable  
 (p=0.001) (serum) 
  
CRP China 2014 (28) AECOPD- stable.  non-frequent (n=78) 
frequent (n=57) 
Day 0, 4,7,14 week 8 
after discharge 
135 
  
↑ AECOPD vs. stable  
(serum) 
  
CRP China 2014 (85) AECOPD - stable Resolved day 4 in 
sputum and day 14 
serum 
Day 0, 4, 7, 14, week 
8 (after discharge) 
93 
  
↑ AECOPD vs. stable  
(p=<0.001) (serum) 
  
CRP Egypt 2014 (103)  AECOPD - stable N/A day 0 and 12 months 98 
  
↑ AECOPD vs. stable  
 (p<0.001) (serum) 
  
CRP China 2014 (104)  AECOPD vs 
stable  
AECOPD (n=27) 
Stable (n=26) 
N/A 54 
  
↑ AECOPD vs. stable  
(Plasma)  
  
CRP Greece 2014 (105) AECOPD - stable  90 patients Day 0, 7 90 
  
↑ AECOPD vs. stable 
(p<0.0001) (Serum)  
  
CRP Austria 2014 (106) AECOPD - stable   Day 0, week 8 29 
  
↑ AECOPD vs. stable 
(p<0.025) (Plasma) 
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Biomarker Country Year Ref Study detail Notes Follow up visits N EBC Sputum Blood Urine BAL 
CRP China 2014 (107)  AECOPD - 
stable 
 Day 0 and 12-17 
days (discharge) 
44 
  
↑ AECOPD vs. stable 
(p<0.01) (Serum) 
  
CRP Australia 2008 (108) AECOPD - 
stable 
Cross-sectional   62   ↑ AECOPD vs. stable 
(p<0.01) (Serum) 
  
CRP Australia 2008 (108) Stable-AECOPD-
recovery 
 
Longitudinal  
78 episodes in 
37 individuals 
 37   Predicting severe 
AECOPD using the 
ratio of AECOPD onset 
to stable baseline 
values for each 
inflammatory marker 
AUC of 0.71 (95% CI, 
0.56–0.87) 
  
CRP UK 2013 (109)  Stable-AECOPD-
recovery 
98 patients, 55 with 
recovery samples 
Days 3, 7, 14, and 35  98 
  
↑ AECOPD vs. stable 
(p<0.001) (Serum) 
  
CRP China 2016 (110) AECOPD vs 
stable  
+ healthy 
controls 
AECOPD (n=40) 
Stable (n=71) 
Controls (n=60) 
 171 
  
↑ AECOPD vs. stable 
(p<0.001) (Serum) 
  
CRP Chile 2012 (111) Stable-AECOPD.  70 patients, 120 
exacerbations 
day 1, 15, 30  70 
  
↑ AECOPD vs. stable 
(p<0.0001) (Serum) 
  
CRP China 2016 (95)  AECOPD - 
stable. + 
healthy controls 
AECOPD (n=90) 
Controls (n=90) 
day 0, day 10 (8-13 
days) and 
convalescent 
180 
  
↑ AECOPD vs. stable 
(p<0.001) ↑ AECOPD 
vs. controls (p<0.001) 
↑ stable vs. controls 
(p<0.001) 
  
CRP Germany 2012 (93)  AECOPD vs. 
stable COPD vs 
healthy controls 
AECOPD (n=18) 
Stable (n=17) 
Controls (n=10) 
 45     ↑ AECOPD vs. stable 
(p<0.003) (Serum) 
 
  
Periostin Greece 2017 (112) AECOPD - 
recovery 
 day 1 and discharge 155 
  
↑ AECOPD vs. stable 
(p<0.0003) (Serum) 
  
RBP-4 China 2013 (113) AECOPD vs. 
stable vs. 
healthy controls 
AECOPD (n=100) 
Stable (n=46) 
Controls (n=50) 
 196   ↓ AECOPD vs stable 
and controls (p<0.001) 
Gender differences, 
↓predictor of 
mortality 
  
Fibrinogen Turkey 2015 (102) AECOPD - 
stable 
 Day 0, 7 43     ↑ AECOPD vs. stable 
(p<0.001) (Serum) 
    
Fibrinogen Egypt 2014 (103)  AECOPD - 
stable 
N/A day 0 and 12 
months 
98 
  
↑ AECOPD vs. stable 
(p<0.001) (Serum) 
  
Fibrinogen China 2014 (107)  AECOPD - 
stable 
 Day 0 and 12-17 
days (discharge) 
44 
  
↑ AECOPD vs. stable 
(p<0.01) (plasma) 
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Biomarker Country Year Ref Study detail Notes Follow up visits N EBC Sputum Blood Urine BAL 
Fibrinogen UK 2013 (109)  Stable-AECOPD-
recovery 
98 patients, 55 with 
recovery samples 
Days 3, 7, 14, and 
35  
98   ↑ AECOPD vs. stable 
(p<0.015) (Serum) 
  
Fibrinogen Chile 2012 (111) Stable-AECOPD.  70 patients, 120 
exacerbations 
day 1, 15, 30  70     ↑ AECOPD vs. stable 
(p<0.0002) (Serum) 
    
sRAGE Austria 2014 (106) AECOPD - 
stable  
 Day 0, week 8 29     ↓AECOPD vs. 
recovery (p<0.001)  
    
sRAGE China 2014 (107)  AECOPD - 
stable 
 Day 0 and 12-17 
days (discharge) 
44     ↑ AECOPD vs. 
recovery (p<0.03) 
    
pneumoco
ccal urinary 
antigen  
Spain 2010 (67) AECOPD vs. 
stable  
AECOPD (n=17) 
Stable (n=29) 
(Pneumococcal 
exacerbations) 
 46 
   
↑13/17 AECOPD  
(77% sensitivity) 
↑12/ 29 stable  
(59% specificity) 
(conc. urine)  
 
Cts-LTs Poland 2012 (39)  AECOPD-
recovery   
 Day 1, 2-4 (during 
therapy), 4-6 (end 
of therapy, 21-28 
(follow up) 
16 ↑AECOPD vs. 
recovery (p<0.02) 
    
Leukotrien
e B4 (LTB4) 
Poland 2012 (39) AECOPD-
recovery  
 
 Day 1, 2-4 (during 
therapy), 4-6 (end 
of therapy, 21-28 
(follow up) 
16 ↑AECOPD vs. 
recovery (p<0.003) 
    
Leukotrien
e B4 (LTB4) 
UK 2003 (114) COPD vs 
healthy controls 
COPD- no steroid 
treatment (n=20) 
COPD – steroid 
treated (n=25) 
Controls (n=15) 
N/A 60 ↑COPD (both groups 
vs. controls (p<0.001) 
    
Leukotrien
e B4 (LTB4) 
UK 2003 (115) AECOPD-
recovery   
 Day 0, 2 weeks and 
2 months 
21 ↑AECOPD vs. 
recovery (p<0.0001) 
    
Leukotrien
e B4 (LTB4) 
Hungary 2014 (116) AECOPD-
recovery  
+ stable ex-
smokers  
AECOPD (n=62) 
Control (n=25) 
 
day 1 at admission 
and after treatment. 
62 
 
↑AECOPD vs. stable 
(p<0.05) 
   
Prostaglan
din E2 
(PGE2) 
Poland 2012 (39) AECOPD-
recovery   
 Day 1, 2-4 (during 
therapy), 4-6 (end 
of therapy, 21-28 
(follow up) 
16 ↑AECOPD vs. 
recovery (p<0.004) 
    
Prostaglan
din E2 
(PGE2) 
Hungary 2014 (116) AECOPD-
recovery  
+ stable ex-
smokers  
AECOPD (n=62) 
Control (n=25) 
 
day 1 at admission 
and after treatment. 
62 
 
↑AECOPD vs. stable 
(p<0.001) 
↑AECOPD vs. 
recovery (p<0.01) 
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Biomarker Country Year Ref Study detail Notes Follow up visits N EBC Sputum Blood Urine BAL 
Prostaglan
din E2 
(PGE2) 
UK 2003 (114) COPD vs 
healthy controls 
COPD- no steroid 
treatment (n=20) 
COPD – steroid 
treated (n=25) 
Controls (n=15) 
N/A 60 ↑COPD (both groups 
vs. controls (p<0.001) 
    
8 
Isoprostan
e 
Poland 2012 (39)  AECOPD-
recovery   
 Day 1, 2-4 (during 
therapy), 4-6 (end of 
therapy, 21-28 
(follow up) 
16 ↑AECOPD vs. 
recovery (p<0.001) 
    
8 
Isoprostan
e 
UK 2003 (115) AECOPD-
recovery   
 Day 0, 2 weeks and 
2 months 
21 ↑AECOPD vs. 
recovery (2wks) 
(p<0.0001) 
    
8 
Isoprostan
e 
Hungary 2014 (116) AECOPD-
recovery  
+ stable ex-
smokers  
AECOPD (n=62) 
Control (n=25) 
 
day 1 at admission 
and after treatment. 
62 
 
↑AECOPD vs. stable 
(p<0.01) 
 
  
H2O2 Poland 2012 (39) AECOPD-
recovery   
 Day 1, 2-4 (during 
therapy), 4-6 (end of 
therapy, 21-28 
(follow up) 
16 ↑AECOPD vs. 
recovery (p<0.001) 
    
H2O2 Netherland
s 
2004 (86) AECOPD-
recovery   
 Day1, 3, 7 14 ↑AECOPD vs. 
recovery (p<0.001) 
    
CXCL10 UK 2011 (14) Stable-AECOPD.  Predominantly 
GOLD2,3. 182 
Exacerbations  
1yr and at AECOPD 145 
  
Association with 
bacterial AECOPD 
AUC-0.76 (serum) 
  
sICAM-1 Netherland
s 
2004 (86) AECOPD-
recovery  
 
 Day1, 3, 7 14 
  
↑AECOPD vs. 
recovery (p<0.001) 
(serum) 
  
IL-10 Germany 2005 (84)  AECOPD -
recovery 
ICU n= 11 
General ward n = 34 
ICU after 10 days 
GW after 1 week 
45 ↑AECOPD vs. all 
groups 
    
IL-12p70 Germany 2005 (84)  AECOPD -
recovery 
ICU n= 11 
General ward n = 34 
ICU after 10 days 
GW after 1 week 
45 ↑AECOPD vs. all 
groups 
    
Neutrophil
s 
Sweden 2015 (92) Stable- AECOPD 
+ controls 
  
Smokers, 38/60 had at 
least 1 AECOPD 
Asymptomatic 
smokers (n=10) 
Never smokers (n=10) 
over 60 weeks 
(every 15 weeks) 
60 
  
 ↑ AECOPD (p<0.01). 
(+MPO and CRP, not 
HNE) 
  
Neutrophil
s 
China 2014 (28) AECOPD- stable non-frequent (n=78) 
frequent (n=57) 
Day 0, 4, 7, 14, week 
8 (after discharge) 
135 
 
↑AECOPD vs. stable 
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Biomarker Country Year Ref Study detail Notes Follow up visits N EBC Sputum Blood Urine BAL 
Neutrophil
s 
China 2014 (85) AECOPD - 
stable 
Resolved day 4 in 
sputum and day 14 
serum 
Day 0, 4, 7, 14, week 8 
(after discharge) 
93 
 
↑AECOPD vs. stable 
(p=<0.001)  
   
Neutrophil
s 
Austria 2014 (106) AECOPD - 
stable  
 Day 0, week 8 29 
  
 ↑AECOPD vs. stable 
(p<0.004)  
  
Neutrophil
s 
China 2014 (107)  AECOPD - 
stable 
 Day 0 and 12-17 days 
(discharge) 
44 
  
↑AECOPD vs. stable 
(p<0.01)  
  
Neutrophil
s 
Egypt 2014 (103)  AECOPD - 
stable 
N/A day 0 and 12 months 98 
  
↑AECOPD vs. stable 
(p<0.001) (serum) 
  
Serum soluble 
urokinase-type 
plasminogen 
activator 
receptor 
(suPAR) 
Turkey 2015 (102) AECOPD - 
stable 
 Day 0, 7 43 
  
↑AECOPD vs. stable 
(p<0.001) (serum) 
  
Microfibrillar
-associated 
protein-4 
Denmark 2014 (117) stable - 
AECOPD  
AECOPD (n=14) day 0 and day 1, 3-5, 
6-8, 9-11, 4 weeks, 3 
months and 6 months 
69 
  
↓AECOPD vs. stable week 
4 (p<0.00001) (plasma) 
  
Surfactant 
Protein-D 
(SP-D) 
Denmark 2014 (117) stable - 
AECOPD 
AECOPD (n=14) day 0 and day 1, 3-5, 
6-8, 9-11, 4 weeks, 3 
months and 6 months 
69 
  
↑AECOPD vs. stable week 
4 (p<0.008) (serum) 
  
Surfactant 
Protein-D 
(SP-D) 
China 2016 (110) AECOPD vs 
stable  
+ healthy 
controls 
AECOPD (n=40) 
Stable (n=71) 
Controls (n=60) 
 171 
  
↑AECOPD vs. stable 
(p<0.001) (serum) 
  
Osteoponti
n 
Korea 2013 (118) AECOPD vs 
stable   
AECOPD (n=64) 
Stable (n=68) 
 
 132 
  
↑AECOPD vs. stable 
(p<0.001) (plasma 
  
Adrenome
dullin 
(ADM) 
China 2014 (119) AECOPD-
recovery vs 
stable vs 
healthy controls  
AECOPD (n=79) 
Stable (n=29) 
Controls (n=20) 
Day 0 and follow up 6 
months 
207 
  
↑AECOPD vs. 
stable/controls (p<0.001, 
AUC 0.97) 
↑AECOPD vs. recovery 
(p<0.01) (plasma) 
 
Angiopoieti
n-2 (Ang-2) 
Greece 2014 (105)  AECOPD - 
stable 
 Day 0, 7 90 
  
↑AECOPD vs. stable 
(p<0.0001) (serum) 
  
B-type 
natriuretic 
peptide 
(BNP) 
Japan 2014 (120)  Stable-AECOPD-
recovery  
Exacerbations (n=87) 
Included patients 
(excluded those with 
readmissions) n=43 
All 3 timepoints (n=15) 
 
Day 1, day 10-14, 30 
days post discharge. 
61 
  
N= 43: ↑AECOPD vs. 
recovery (p<0.001) 
N=15: ↑AECOPD vs. stable 
(p=0.0033) 
↑AECOPD vs. recovery 
(p=0.0013) 
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Biomarker Country Year Ref Study detail Notes Follow up visits N EBC Sputum Blood Urine BAL 
Adiponecti
n 
Egypt 2014 (121)  AECOPD vs. 
Stable 
Male only 
AECOPD (n=40) stable 
(n=15) 
 55 
  
↑AECOPD vs. stable 
(p<0.05) (serum) 
  
Adiponecti
n 
Egypt 2014 (122)  AECOPD vs. 
Stable vs. 
controls 
Male only. 
AECOPD (n=34) 
Stable (n=34)  
(non-obese (n=17), 
obese (n=17)) 
Controls-non-obese 
(n=10) 
Controls-obese (n=10) 
 88 
  
↑AECOPD vs. stable 
(p<0.001) (serum) 
  
High 
mobility 
group 
protein B1 
(HMGB1) 
hhhji 2014 (107) AECOPD - 
stable 
Day 0 and 12-17 days 
(discharge) 
 44 
  
↑AECOPD vs. stable 
(p<0.01) (plasma) 
  
Aalpha-
Val360 
UK 2013 (123) stable - 
exacerbation. 
Seen at each 
timepoint. 
N=40 studied 
over 4 years 
  81 
  
↑AECOPD vs. stable 
(p=0.036) (plasma) 
  
Serum 
Amyloid A 
Australia 2008 (108) AECOPD - 
stable 
Cross-sectional   62   ↑AECOPD vs. stable 
(p<0.01) (serum) 
  
Serum 
Amyloid A 
Australia 2008 (108) Stable-AECOPD-
recovery 
 
Longitudinal  
78 episodes in 
37 individuals 
 37   Predicting severe AECOPD 
using the ratio of AECOPD 
onset 
to stable baseline values 
AUC of 0.84 (95% CI, 0.74–
0.94) 
  
Procalciton
in 
USA 2012 (124)  AECOPD - 
stable 
 Day 1, day 2 and 1 
month 
224 
  
↑AECOPD vs. stable 
(serum) (more severe 
illness and maybe 
indicative of pneumonia) 
  
Procalciton
in 
Spain 2011 (125) AECOPD vs. 
stable vs 
pneumonia 
AECOPD (n=217) 
Stable (n=46) 
Pneumonia (n=55) 
Day 1 and 1 month for 
n=23 AECOPD events 
318   ↑AECOPD vs. stable 
(p<0.0001) (serum) 
  
Procalciton
in 
Egypt 2012 (126)  AECOPD vs. 
controls 
Bacterial AECOPD 
(n=20). Non-bacterial 
AECOPD (n=30) 
Healthy controls 
(n=10) 
Day 1 and recovery 60 
  
↑bacterial AECOPD vs. 
stable (p<0.001) 
(serum)not significantly 
different with non-
bacterial infection group 
  
37 
1.14.1 Exhaled Breath Condensate  
Exhaled breath consists of two components. The first 150 ml is “dead-space” air from the upper 
airway in which no gaseous exchange between blood and air occurs. The remaining 350 ml, known 
as “alveolar” breath, comes from the lungs, where gaseous exchange between blood and air occurs. 
EBC is saturated with water vapour which can be condensed by cooling and used to sample a wide 
range of biomarkers (127), the collection of which is a non-invasive method that reflects biochemical 
changes in the airway lining fluid (77).  Commonly used EBC methods are shown to have 
considerable variability, due to technical issues concerning both sample collection (pattern of 
breathing, collection device, effect of oral contamination), and analysis (76). There is also limited 
data regarding the repeatability and stability of the samples (77). 
Markers of oxidative stress: H2O2 is generated via non-enzymatic and enzymatic dismutation of 
superoxides in the upper and lower airways. In healthy individuals H2O2 production is ongoing 
oxygen reduction process that occurs due to electron transport in mitochondrial respiration (128). 
As described in section 1.8 an imbalance occurs in COPD and COPD exacerbations. Most of the 
published studies have reported elevated levels of H2O2 with a clear discrimination between healthy 
subjects and COPD patients H2O2 is not a specific biomarker for the disease but is further elevated 
during exacerbations (39, 86). 
Leukotrienes and prostaglandins: Leukotriene B4 (LTB4) is produced by constitutive cells (eg, mast 
cells and macrophages) and infiltrating cells (eg, neutrophils and eosinophils). LTB4 (a leukotriene) 
has no direct action on airway smooth muscle, but it may contribute to bronchoconstriction by 
increasing vascular permeability and mucus secretion. It is considered as one of the main mediators 
responsible for neutrophil recruitment. Increased levels of LTB4 have been reported in stable COPD  
(114) with further increase during exacerbations (77). Reviewed are three studies that show 
increased levels of LTB4 in exacerbation state compared to the recovery samples (39, 115, 116). PGE2 
(a prostaglandin) on the other hand is an airway smooth muscle relaxant and is likely to have 
bronchoprotective and anti-inflammatory actions (116). Increased levels of PGE2 have been reported 
in stable COPD (114) with further increase during exacerbations (39). 
- 8-Isoprostane: Isoprostanes are prostaglandin-like compounds formed by the free-radical 
lipid peroxidation of arachidonic acid and represent in vivo markers of oxidative stress (77). 
Concentrations of 8- isoprostane are greater in patients with COPD than in normal smokers, 
are related to disease severity and are further increased during exacerbations (39, 115)  
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- Cytokines (and chemokines): increased levels of TNF-α, IL-6, IL1β, IL-10, IL-12p70 and IL-8 are 
all reported biomarkers found in exacerbation (84). 
- Increased levels of Matrix Metalloproteinase (MMP) have been found in exacerbation 
compared to stable COPD (89, 90). 
- Increased levels of the protease inhibitors, alpha-1 Antitrypsin (A1AT), tissue inhibitor of 
metalloproteinase-1 (TIMP-1) have been found in exacerbation compared to stable COPD 
(89, 90, 93) . 
1.14.2 Biomarkers in Sputum 
Collection and analysis commonly used are semi-invasive. In spontaneous sputum, there are large 
quantities of dead cells, thereby induced sputum is a more reliable method, however, this induces a 
local inflammatory response (76) therefore repeated inductions within a 48 hour period is 
recommended (75). Processing the sputum sample which is variable between different laboratories 
is expensive, time consuming and require specialised equipment and trained personnel. Mucolytic 
agents such as dithiothreitol (DTT) or dithioerythritol (DTE) are commonly used to assist in 
homogenising the sample by breaking the disulphide bonds in the mucin molecules (75), this has 
been shown to affect the measurement of mediators, require addition of BSA for example and 
further processing. The lack of a validated dilution factor may lead to incomparable measurements 
among authors (129). Finally, it is not a pleasant experience for the patient, compliance is poor and 
sputum induction should not be performed in patients with severe persistent bronchoconstriction 
and/or co-morbidities such as cardiovascular disorders (129).  
Inflammatory cytokines, including IL-8, IL-6 and TNF-α have been extensively studied and reported to 
be increased in sputum of COPD patients compared to normal smokers and their concentrations are 
related to the severity of the disease and further increased with exacerbations (83, 84). TNF-α is a 
potent activator of the nuclear factor kappa B (NF-kB), and this might amplify the inflammatory 
response (4). IL-8, is a major important chemokine and chemoattractant of neutrophils, produced 
and released by neutrophils, alveolar macrophages, and other activated cells. IL-8 induces the 
release of myeloperoxidase (MPO) from neutrophils and contributes to further recruitment of 
inflammatory cells, helping to sustain inflammation. IL-1β markedly activates macrophages from 
patients with COPD to secrete inflammatory cytokines, chemokines, and MMP-9. There is an 
increase in the concentration of IL-1β in sputum of COPD, which is correlated with disease severity 
(84). IL-6 is increased in sputum of patients with COPD, particularly during exacerbations. Plasma 
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concentrations of IL-6 are correlated with increased levels of CRP, and IL-6 is the major mechanism 
that stimulates CRP release from the liver (9). 
Other biomarkers found elevated in exacerbations are neutrophils and neutrophil granulocyte 
proteins such as MPO, MMP-8, human neutrophil elastase (HNE) (28, 88).  In the Ilumets study, 
MMP-9 was also studied and shown to be significantly higher in exacerbation compared to stable 
COPD and control samples but did not reach significance for the 1-month recovery sample.  This is 
most likely due to the small sample size (10 AECOPD and 8 recovery), MMP-8 and HNE only just met 
the criteria with p values of 0.04 and 0.03 respectively. The biological role of the proteins is 
described in more detail in section 1.10. 
In sputum, LTB4 and PGE2 and 8-isoprostane were found in elevated concentrations in COPD 
exacerbations compared to recovery samples  (129). These were also found elevated in EBC and the 
roles of which have been described in more detail above. 
1.14.3 Biomarkers in BAL 
In BAL fluid, metabolites deep in the tissue at the level of bronchioles and alveolar ducts are 
sourced. BAL can generally be safely performed and is an advantage over bronchial biopsies, 
however, it may cause discomfort to the patients (78) and bronchospasm, mild fever and transient 
asymptomatic pulmonary infiltrates are occasional complications (75). This makes this sample matrix 
not suitable for large studies and is certainly not for frequent collection. Induction of BAL fluid 
samples, this is reflected by the limited published studies. In a study conducted by Papakonstantinou 
et al  (94) the results indicate that during exacerbations there are increased expression of TIMP-1, 
TIMP-2 and MMP-9 
1.14.4 Plasma/serum/blood biomarkers 
The most studied and consistent blood biomarkers are CRP, IL-6, Fibrinogen and neutrophils, and 
there are a large number of studies providing evidence that the biomarker levels are elevated in 
stable COPD and in exacerbation. Even so, they are still not accepted biomarkers for routine 
monitoring of the disease state and in the reviewed studies, although they are longitudinal, the 
frequency of testing in stable state is low. Most patients were recruited at exacerbation and then 
tested frequently over 2 weeks and then one month after discharge. However, data from samples 
taken during the lead up to an exacerbation are rare.  The biomarkers have been used to 
differentiate between different phenotypes (see section 1.5), disease severity and mortality but 
have not been evaluated for prediction of exacerbations. Frequent exacerbators have higher sputum 
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IL-6 and serum CRP during their exacerbation recovery periods, making persistent post-exacerbation 
inflammation a possible explanation for their higher baseline inflammation. A higher CRP 
concentration during the recovery period is also associated with a shorter time until the next 
exacerbation (130). 
The next group of biomarkers that have been widely studied with consistently reported elevated 
levels in exacerbations compared to recovered or stable state are TNF-α, IL-8, MMP-9, Neutrophil 
gelatinase-associated lipocalin (NGAL), MPO, and A1AT. The relevance of these biomarkers has been 
reported previously in line with findings in EBC, sputum and BAL fluid. 
sRAGE, High mobility group protein B1 (HMGB1), CC16 and SP-D have been found to be associated 
with exacerbations with supporting evidence. 
sRAGE and HMGB1 were found to be increased in exacerbation compared to recovery state (Zhang 
et al 2014). HMGB1 is a protein that acts as a cytokine when released by interacting with at least 
three receptors, one of them being RAGE, this signalling results in generation of ROS and activation 
of the transcription factor NF-kB. Fibrinogen and CRP were also significantly lower in recovery 
compared to exacerbation. The finding that sRAGE was higher in exacerbation is not consistent with 
other studies that show decreased levels in exacerbation (106).  It is clear that a better 
understanding of these two biomarkers is required before they can be deemed useful in prediction 
of exacerbations. In a review of all the eclipse studies, more than 50 publications were found to 
report that circulating sRAGE levels were associated with the severity of emphysema (lower levels) 
(131). Other proteins measured, from the above list were CC16 (found to be weakly associated with 
lung function decline, emphysema and depression) and SP-D (which had a weak association with 
COPD exacerbations) (131). Both CC16 and SP-D are specific lung-derived mediators, CC16 is 
secreted by non-ciliated bronchiolar club cells with reduced expression with lung injury and smoking 
(132), whereas SP-D is produced primarily by type II pneumocytes, and is thought to play a role in 
innate immunity and regulation of surfactant homeostasis in the lung. As the airways become more 
permeable due to injury, these lung-specific mediators can escape and be detected in the peripheral 
circulation (100). It has been demonstrated in a study that low levels of CC16 and high levels of SP-D 
are found at exacerbation that increase and decrease at day 15 respectively (100). It was observed 
that by day 30, SP-D increased back up the same levels at exacerbation which is consistent with a 
study by Johansson where the same observations were repeated, a decrease up to days 9-11 and 
then at day 30 was increased and remained stable until 6-month follow-up (117).   
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COPD biomarkers associated with exacerbations with limited supporting evidence are Chitinase -3 
like 1 protein (CHI3L1), Cystatin C, Periostin, RBP4, sICAM, Serum soluble urokinase-type 
plasminogen activator receptor (suPAR), Osteopontin, Adrenomedullin (ADM), Angiopoietin-2 (Ang-
2), B-type natriuretic peptide (BNP), Adiponectin, Alpha-Val360 and Serum Amyloid A.   
CHI3L1 is known to play a role in tissue remodelling but there is not a lot known of the role it plays in 
COPD.  It is believed that it may induce the production of MMP-9 in other diseases (87).  It is 
reported that there are elevated levels of CHI3L1 in COPD exacerbations compared to stable COPD, 
but limitations of this study are that the exacerbation and stable samples were not matched (87). 
Circulating levels of Cystatin C were found to be increased at exacerbation compared to recovery 
state and healthy controls (95). Cystatin C is a cysteine protease inhibitor and protects against 
elastolysis and tissue destruction. To further explain, as it has not been mentioned previously, 
proteases (secreted by alveolar macrophages and neutrophils) are classified into 4 groups, serine, 
metallo (MMPs that have been discussed), cysteine and aspartic. The Cathepsin family belongs in the 
cysteine group which degrades lung extracellular matrix, especially lung elastin which sets off a chain 
of events. Cystatin C is upregulated indirectly in response to the need to inhibit cathepsin activity. 
When there is an imbalance between proteases and their inhibitors the resulting state is considered 
to be pathogenic, leading to an increase in the in severity of the disease (95).  
There were conflicting results regarding the trends and significance for MMP-8, desmosine and 
procalcitonin indicating that the relevance of these markers in blood and exacerbations is not strong 
or consistent or that the studies are poorly designed or executed. 
1.14.5 Biomarkers in urine 
Desmosine is the only COPD urinary biomarker to have received substantial attention.  It has been 
found to be elevated in people with COPD above the concentrations observed in healthy controls 
(133). 
Proteases such as HNE and MMP-12 are two key inflammatory elastases contributing to the 
pathogenesis underlying COPD (134-136).  They are released by activated neutrophils and alveolar 
macrophages respectively.  Excess leukocyte activity is a critical driver of exacerbation (135) and is 
thought to contribute particularly to parenchymal lung damage by way of breakdown of elastin. 
Peptides are released from elastin during the degradation process, the rate of release from a 
particular anatomical site being, in theory, directly proportional to the elastase activity at that site.   
Mature elastin fibres are held together by desmosine and isodesmosine (together abbreviated as 
DES) working as covalent crosslinkers between the elastin polypeptide chains (137). When the 
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elastin is degraded, DES-containing elastin fragments are excreted from the kidney into the urine.  
Free DES is also passed into the urine, as well as variously sized peptide fragments with DES still 
attached (137). The amount of elastin-derived peptides accumulating in the urine may give an 
indication of how much leucocyte-driven tissue damage is occurring within the body at the time of 
testing. 
Aside from desmosine, pneumococcal urinary antigen was reported in the reviewed literature, with 
a sensitivity of 77%.  However, the results did not suggest that this marker would be useful in 
predicting pneumococcal-driven exacerbations as the specificity was very poor at just 59%  (67). 
1.15 Urine, a non-invasive method of monitoring COPD status 
Most focus to date has been on blood biomarkers, which makes sense as it is connected to every 
part of the body but, although promising blood biomarkers have been identified, no blood-borne 
biomarkers have been adopted for diagnostic testing.  This lack of uptake begs the question of 
whether, in fact, blood biomarkers are the right focus for biomarker discovery.  It has been 
suggested that, as all cells rely on a homeostatic microenvironment to survive and function, the 
blood in which they are bathed is the key provider of an internal environment for preserving the 
health and performance of all tissues and organs.  It is naturally responsible for maintaining the 
stability and balance required to protect organs (138) and that, as a result, potentially harmful 
substances introduced into the blood tend to be cleared by the liver, kidney and /or other organs via 
a variety of mechanisms to maintain homeostasis. The presence of particular products in urine, is 
likely to reflect physiological or pathophysiological changes more accurately than their presence in 
blood. In fact, urinary marker profiles can be expected to magnify any such changes that might have 
occurred fleetingly in blood prior to the molecules being cleared through the kidney. It has been 
demonstrated that more proteins can be identified in urine than in plasma (139). Our hypothesis is 
that the kidneys also produce elevated levels of protease inhibitors to protect the organ from 
destructive inflammatory factors, such as active proteases in the blood. This would also cause 
amplification of certain biomarkers in the urine. Despite the fact that urine might be a better 
biomarker source, it is also speculated that changes in urine are complex and that other nonspecific 
factors would influence the levels of the biomarkers, so it would be difficult to determine the root 
cause (140).   The early and sensitive markers are believed to be present in urine in particular in early 
stage disease when the homeostatic mechanisms are strong and effective (141).  It has been 
suggested that this could explain why prediction of early disease diagnosis has not been achieved 
when looking at blood biomarkers. The homeostatic mechanisms have already been impaired when 
the biomarkers appear in the blood and they are not easily cleared in the blood (141). Proteolytic 
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degradation may be complete prior to collection of urine and, because proteases are activated 
during blood collection, the urinary proteome shows much greater stability than that of plasma 
(139). 
Profiling inflammatory mediators in urine samples presents a simple and robust measure of 
inflammation in COPD patients and can be done repeatedly within their own home or in the clinic. 
Urine samples can be collected over a long period of time, allowing for an easier monitoring of time-
dependent changes in biomarker levels (139).  Urinary biomarker screening could be adopted into 
current COPD and primary care reviews. In COPD patients at high risk of frequent exacerbations the 
urinary biomarkers can be tested more frequently and changes in the inflammatory profile can be 
used as an early warning of an exacerbation onset and also help to determine the underlying 
biology. This early signal of an exacerbation and, potentially. a predictor of likelihood of response to 
antibiotics and or oral corticosteroids will enable the patient, together with the health care provider, 
to improve decision making for when to treat versus not and which therapy to use. This stratification 
will reduce risk of adverse events associated with antibiotics and corticosteroids on an individual 
basis but also reduce the population risks of inappropriate antibiotic prescribing. It has been 
reported that approximately 30% of patients seen at hospital with an exacerbation will be seen again 
and possibly admitted with another exacerbation within 8 weeks (142). In addition to reducing 
unnecessary therapy this biomarker approach would also ensure early treatment where needed. 
1.16 Selected biomarkers for evaluation and molecular weights 
The core biomarker panel is shown in table 1.2. TNF-α and MBP are not included, as it has been 
found in previous studies (not disclosed) that urine does not contain measurable amounts of said 
biomarkers. The molecular weight cut-off for glomerular filtration is thought to be 30–50 kDa (143) 
which would rule out the presence of A1AT, Siglec 8, MMP-12 pro form, MMP-13 pro form, MMP-8 
active form, Human Serum Albumin(HSA), MMP-2 active form, MMP-2 Pro form, MMP-8 pro form, 
MMP-9 active form, Periostin, MMP-9 pro form, CRP, MPO and Fibrinogen should this be the case. It 
is also likely that in urine (and other sample matrices) that fibrinogen and elastin will be broken 
down into smaller fragments. 
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Table 1.2. Biomarker panel and molecular weights (kDA) sorted from small to large.   
OM. Other molecule; CM, consequence molecules; SM, signalling molecule; NIRM, non-immune 
response molecule; PI, protease inhibitor; EM, effector molecule.  
Group Analyte MW kDa 
OM Creatinine 0.113 
CM N-acetyl Proline-Glycine-Proline 0.311 
SM N-Formylmethionine-leucyl-phenylalanine 0.4376 
CM Desmosine 0.5266 
SM Interleukin- 8 8.4 
NIRM Club cell- 16 10 
PI Secretory leukocyte protease inhibitor 11.7 
OM beta 2 Microglobulin 11.7 
PI Cystatin C 13.3 
OM Major Basic protein 13.8 
SM Interleukin 1- beta (IL1β) 17.5 
OM Retinol binding protein-4 20.6 
SM Interleukin-6 21 
PI Tissue inhibitor of metalloproteinase-1 23 
EM Calprotectin 24 
PI Tissue inhibitor of metalloproteinase-2  24.3 
EM Neutrophil gelatinase-associated lipocalin 25 
EM Human Neutrophil Elastase 29 
EM MMP12 active form 29.2 
OM Eosinophil cationic protein 32 
SM Chitinase 3 like protein  40 
OM Soluble receptor for advanced glycation end products 41 
EM MMP13 active form 45 
PI Alpha-1 antitrypsin 52 
SM Siglec 8 54 
EM MMP12 pro form 54 
EM MMP13 pro form 57 
EM MMP-8 active form 65 
OM Human Serum Albumin 66.5 
EM MMP2 active form 67 
EM MMP2 Pro form 72 
EM MMP-8 pro form 75 
EM MMP-9 active form 82 
NIRM Periostin 92 
EM MMP-9 pro form 92 
NIRM C reactive protein 114 
EM Myeloperoxidase 150 
OM Fibrinogen 340 
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1.17 Aims and hypothesis 
The purpose of the research is to explore if and how key biomarkers of lung tissue degradation 
(caused by neutrophil-driven inflammation) partition into urine, where they can be quantified and 
used as a new diagnostic tool. The questions to be answered: a) Which biomarkers are released by 
inflamed lungs and find their way into urine? b) Does molecular size influence the extent to which 
individual biomarkers in the urine reflect the state of lung inflammation? c) Is it possible to utilise 
the kidney as a “sentinel” of inflammatory activity elsewhere in the body? d) Are there any patterns 
in the urinary biomarker profile to indicate which organ/tissue is the source? 
The hypothesis is that the biomarkers arise in the urine is as follows: 
- As neutrophil leukocytes, in particular, infiltrate the lungs and become activated, large 
amounts of proteases and other molecular biomarkers are produced and these spill-over 
into the blood. 
- Any active protease in the blood will quickly encounter the kidneys. 
- As the kidneys have a copious vascular supply and high blood perfusion rates, they cannot 
risk any protease-mediated tissue damage, so, they produce their own inhibitor supplies 
- During episodes of acute inflammation, the kidneys are affected by the presence of active 
inflammatory mediators in the blood, causing changes in the molecular permeability of the 
glomeruli and, consequently, measurable changes in urinary concentration certain 
biomarker molecules. 
- Consequently, kidneys become sentinel organs, releasing molecular messages that warn of 
impending exacerbation, although the messages need to be de-convoluted. 
- Small but measurable amounts of inflammation biomarkers traverse the kidney to become 
detectable in the urine. The relative amounts depend on molecular size of the biomarkers, 
so the process of traversing the kidney effectively scrambles the overall biomarker message. 
Specifically, this project aims to: 
- explore the presence of urinary biomarkers in COPD regarding the presence, influence of 
gender and age, severity of disease. 
- Determine biomarkers in urine that can measure the heterogeneity of the inflammatory 
profile, predict future risk of exacerbations  
- Develop a point of care diagnostic test that can be used repeatedly in the home to monitor 
the inflammation status and predict pulmonary exacerbations. 
Evaluate the test and biomarker levels in a real-life study and develop a simple algorithm to 
assess the performance and ability to predict and diagnose exacerbations 
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Chapter 2. Methods 
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2.1 Introduction 
A shortlist of 35 biomarkers were selected for analysis in urine and blood samples. For most 
biomarkers, commercially available assays were available, for novel biomarkers, good quality assays 
were not always available and needed to be developed and subsequently validated for use. Methods 
for each assay are described in part 1. Two examples of the in-house developed assays (desmosine 
and active MMP Lateral flow assay) are described in the appendix, both assays required specialised 
reagents, therefore immunisations were undertaken to generate sheep or rabbit polyclonal 
antibodies. In part 2, the various statistical methods used for data analysis are described. 
Table 2.1. Biomarker panel and assay format (24 commercial (C) and 11 developed in-house (IH)) 
No Biomarker  Assay                          Analyte (full description) 
Signalling molecules 
1 IL-6 ELISA (C) Interleukin-6 
2 fMLP  ELISA (IH) & Lateral flow (IH) N-Formylmethionine-leucyl-phenylalanine 
3 Il-1β ELISA (C) Interleukin-1β 
4 IL-8 ELISA (C) Interleukin- 8 
5 Siglec 8 ELISA (IH) Siglec 8 
6 CHI3L1 ELISA (C) Chitinase 3 like protein  
Effector molecules 
7 Active MMP Lateral flow (ultimate ELTABA) (IH) Active protease (Composite MMP 2,8,9,12,13) 
8 Active MMP  Plate assay (substrate assay) (C) Active protease (Composite MMP 2,8,9,12,13,7) 
9 Active HNE Plate assay (substrate assay) (C) Active Human Neutrophil Elastase 
10 MMP-8 ELISA (C) Total Matrix Metalloproteinase -8 
11 MMP-9 ELISA (C) Total Matrix Metalloproteinase -9 
12 HNE ELISA (IH) Human Neutrophil Elastase 
13 NGAL ELISA (C) Neutrophil gelatinase-associated lipocalin 
14 Calprotectin ELISA (C) Calprotectin 
15 MPO ELISA (C) Myeloperoxidase 
Protease Inhibitors 
16 A1AT ELISA (IH) & Lateral flow (IH) Alpha-1 antitrypsin 
17 TIMP-1 ELISA (C) & Lateral flow (IH) Tissue inhibitor of metalloproteinase-1 
18 TIMP-2 ELISA (C) & Lateral flow (IH) Tissue inhibitor of metalloproteinase-2  
19 SLPI ELISA (IH) Secretory leukocyte protease inhibitor 
20 Cystatin C ELISA (C) Cystatin C 
Consequence molecules 
21 Ac-PGP ELISA (IH) N-acetyl Proline-Glycine-Proline 
22 Desmosine ELISA (IH) & Lateral flow (IH) Desmosine 
23 LEF ELISA (IH) Large Elastin Fragments 
24 Desmosine Fragments ELISA (IH) Desmosine fragments 
Non- immune response molecules and other molecules 
25 CC16 ELISA (C) Club cell- 16 
26 CRP ELISA (C) & Lateral flow (IH) C reactive protein 
27 Periostin ELISA (C) Periostin 
28 Creatinine Plate assay (C) Creatinine 
29 B2M ELISA (C) beta 2 Microglobulin 
30 RBP-4 ELISA (C) Retinol binding protein-4 
31 HSA ELISA (C) Human Serum Albumin 
32 Fibrinogen ELISA (C) Fibrinogen 
33 sRAGE ELISA (IH) Soluble receptor for advanced glycation end products 
34 RNASE-3 ELISA (C) Eosinophil cationic protein 
35 MBP ELISA (C) Major Basic protein 
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2.2 Part 1 Methods for measuring biomarkers in clinical samples 
Biotek 405LS Plate washer 
Flurostar plate reader (BMG Labtech) 
Plate shaker 
2.2.1 Commercial DuoSet kits (R&D systems) 
2.2.1.1 Materials and reagents 
• SigmaFast OPD Substrate composing of:  
o Stable peroxidase buffer [Fisher 11889270] 
o OPD tablet: Sigma 10 mg P8287  
o 1 tablet of each added to 20ml de-ionised water 
• Costar high bind clear polystyrene plate: cat # 9018 
• R&D Reagent Diluent: R&D Systems DY955 concentrate diluted 1 in 10 with deionised water 
before use 
• Wash buffer (50mM tris buffered saline pH8, supplemented with 0.1% (v/v) Tween20) 
• Streptavidin-HRP part number 893975 
2.2.1.2 Generic method for DuoSet assays (table 2.2 details dilutions used) 
The plate was sensitised with capture antibody at working concentration diluted in PBS overnight at 
ambient, 100μl/well. After a wash step, the sensitised-well surfaces were blocked (R&D reagent 
diluent) with 120μl/well for 1hour at room temperature.   
Assay running procedure: The specific standard was diluted in the reagent buffer to give the top 
standard stated in table 2.2. and then serially diluted ½ in reagent buffer to prepare the 7-point 
standard curve (buffer only for the negative standard). The standard and urine sample (diluted as 
specified in reagent diluent) was added to the plate 100μl/well after a wash step and incubated for 2 
hours at room temperature with gentle agitation. After a further wash step, the detection antibody 
diluted in reagent buffer to working concentration was added 100μl/well and incubated for 2 hours 
at room temperature with gentle agitation. After a further wash step, the streptavidin HRP 
conjugate diluted 1/200 in reagent diluent was added 100μl/well and incubated for 20 minutes at 
room temperature with gentle agitation After the final plate wash, the colour reaction was initiated 
with the addition of 100μl of OPD substrate to each well and incubated in the dark. Once colour had 
been allowed to develop (approximately 30 minutes), the absorbance was measured at 450nm using 
an Omega plate reader and the standard curve was approximated in a sigmoid 4 parameter logistic 
model. 
49 
 
 Table 2.2. DuoSet details, catalogue number, reagent dilutions (capture, detection and standard) 
and sample dilutions for both blood and urine. Mouse Anti-Human (MAH), Goat anti-Human (GAH)  
 
 
 
  
Assay Cat. No Capture antibody Detection antibody Standard Sample dilution 
Part. 
No 
Working 
conc 
µg/ml 
(dilution) 
GAH or 
RAH 
Part. No 
Biotinylated 
Goat Anti-
Human 
Working 
conc 
µg/mL 
(dilution) 
Part. 
No 
Working 
conc µg/ml 
(dilution) 
urine blood 
IL -6 DY206 MAH 
840113 
2µg/ml 840114 50ng/ml 840115 9.38 -
600pg/ml 
1:2 1:2 
IL-1β DY201 MAH 
840168 
4µg/ml 840169 200ng/ml 840170 3.91 -
250pg/ml 
1:2 1:2 
IL-8 DY208 MAH 
890804 
4µg/ml 890805 20ng/ml 890806 31.3 - 
2000pg/ml 
1:2 1:2 
CHI3L1 DY2599 RAH 
842869 
2µg/ml 842870 200ng/ml 842871 31.25 -   
2000 pg/ml 
1:10 1:100 
MMP-8 DY908 MAH 
841031 
2µg/ml 841032 122.2ng/ml 841033 62.5 – 
4000pg/ml 
1:10 1:1000 
MMP-9 DY911 MAH 
841028 
1µg/ml 841029 100ng/ml 841030 31.25 -   
2000 pg/ml 
1:10 1:1000 
MPO DY3174 RAH 
842842 
4µg/ml 842843 50ng/ml 842844 62.5 -     
4000 pg/ml 
1:10 1:750 
NGAL DY1757 843371 2µg/ml 842272 25ng/ml 842273 0.078 - 
5ng/ml 
1:100 1:100 
TIMP-1 DY970 MAH 
840294 
2µg/ml 840295 50ng/ml 840296 31.25 -   
2000 pg/ml 
1:10 1:4000 
TIMP-2 DY971 MAH 
840528 
2µg/ml 840529 12.ng/ml 840530 31.25 -   
2000 pg/ml 
1:10 1:4000 
CC16 DY4218 RAH 
843195 
2µg/ml 843196 2µg/ml 843197 31.25 -   
2000 pg/ml 
1:10 1:1000 
CRP DY1707 MAH 
842676 
2µg/ml 842677 90ng/ml 842678 15.6 – 
1000pg/ml 
1:10 1:100K 
Periostin DY3548b MAH 
844441 
2µg/ml 844442 500ng/ml 843260 62.5 – 
4000pg/ml 
1:2 1:1000 
HSA DY1455 843250 2µg/ml 843251 125ng/ml 843252 2.5 - 
160ng/ml 
1:100 1:100K 
RBP4 DY3378 842954 2µg/ml 842955 500ng/ml 842956 23.4 - 
1500pg/ml 
1:2000 1:100K 
Cystatin 
C 
DY1196 842942 4µg/ml 842943 250ng/ml 842944 62.5-
2000ng/ml 
1:500 1:1000 
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2.2.2 Commercial full kits 
2.2.2.1 Calprotectin measurements 
The Calprotectin Kit (Biolegend cat. 439707) was provided with pre-coated plates (Anti-Human 
MRP8/14) and specific reagents for each kit, this included the standard, detection reagent, substrate 
(solution D), sample buffer (Assay Buffer A) required to run the assay. The standard used was 
lyophilized and required storage at -20°C upon arrival, remaining assay components was stored at 2-
8°C. The wash buffer used was 50mM tris buffered saline pH8, supplemented with 0.1% (v/v) 
Tween20. 
Assay running procedure: Calprotectin was diluted in buffer A to give concentrations between 3.13 
and 200ng/ml to generate the standard curve. Urine samples or serum samples were diluted 1 in 10 
or 1 in 200 respectively in buffer A. Equal volumes of standard or diluted sample and buffer A were 
added per well such that the final volume was 100μl.  These mixtures were incubated for 1hour at 
room temperature with gentle agitation (600rpm). The plate was washed 3 times (100μL per well) 
with wash buffer followed by addition of 100µl Human MRP8/14 Detection Ab to each well and 
incubated at RT for 30mins with shaking.  After a second wash step, 100µl Avidin-HRP B solution was 
added to each well and incubated at RT for 30mins with shaking. After a third wash step, the colour 
reaction was initiated with the addition 100µl Substrate Solution D was added to each well and 
incubated in the dark for 25 minutes and then stopped by adding 100µl of Stop solution to each well. 
The absorbance was measured at 450nm using the Omega plate reader and the standard curve was 
approximated in a sigmoid 4 parameter logistic model. 
 
2.2.2.2 Creatinine measurement 
The Parameter creatinine assay (R&D solutions cat. KGE005) was supplied as a complete kit including 
plates (part 892880), Creatinine standard (stock at 100mg/dl, stored 2-8°C, part 892890), picric acid 
reagent (0.13% stored at RT, part 892891) and NaOH (1N, part No.  891236).  
Assay running procedure: Standards were prepared at 0.3-20mg/dl in distilled water (1 in 2 
dilution). Urine samples were centrifuged at 3,000 x g for 10 minutes and diluted 1 in 20 in distilled 
water. The Alkaline Picrate solution was prepared according to the manufacturer’s instructions. To 
the plate, 50ul of standards and samples were added in duplicate with 100ul Alkaline Picrate 
Solution, the plate was incubated for 30 minutes at room temperature and subsequently read at 
490nm with the Omega plate reader using a prepared programme. 
 
 
51 
2.2.2.3 Beta 2 Microglobulin measurement 
the Human beta 2 Microglobulin ELISA kit (Abcam, 108885) was supplied as a complete kit (stored at 
2-8°C unless specified) that included pre-coated plates, B2M standard (lyophilized), 10x diluent 
concentrate, Biotinylated B2M antibody (stored at -20°C), 100x streptavidin-peroxidase conjugate 
(stored at -20°C), chromogen substrate and stop solution. The wash buffer used was 50mM tris 
buffered saline pH8, supplemented with 0.1% (v/v) Tween20. 
Assay running procedure: prior to running the assay, the 10x diluent was diluted to 1x in distilled 
water, the biotinylated B2M antibody was diluted to the specified concentration with the 1x diluent 
and the streptavidin-peroxidase conjugate was diluted 1:100 with the 1x diluent.  The standards 
were prepared at 0.049-50ng/ml in 1x diluent (1 in 4 dilution). Urine samples were centrifuged at 
3,000 x g for 10 minutes and diluted 1:100 in 1x diluent and serum samples were diluted 1:1000 in 
1x diluent. To the microtitre plate, 50µl of standard or diluted sample was added per well in 
duplicate and incubated for 2 hours at room temperature with gentle agitation (600rpm). After a 
wash step, 50µl of 1x biotinylated B2M antibody was added per well and incubated for 1 hour with 
shaking. After a second wash step, 50µl of 1x SP conjugate was added to each well and incubated for 
30 minutes at room temperature with shaking. After a final wash step, 50µl of chromogen substrate 
was added, incubated for 10 minutes in the dark before addition of 50µl of stop solution. The colour 
changed from blue to yellow. The absorbance was read at 450nm with the Omega plate reader. 
 
2.2.2.4 Fibrinogen measurement 
the Human Fibrinogen ELISA kit (Abcam, 108841) was supplied as a complete kit (stored at 2-8°C 
unless specified) that included pre-coated plates, Fibrinogen standard, 10x diluent concentrate, 
Biotinylated fibrinogen antibody (stored at -20°C), 100x streptavidin-peroxidase conjugate (stored at 
-20°C), chromogen substrate and stop solution. The wash buffer used was 50mM tris buffered saline 
pH8, supplemented with 0.1% (v/v) Tween20. 
Assay running procedure: prior to running the assay, the 10x diluent was diluted to 1x in distilled 
water, the biotinylated fibrinogen antibody was diluted to the specified concentration with the 1x 
diluent and the streptavidin-peroxidase conjugate was diluted 1:100 with the 1x diluent.  The 
standards were prepared at 1.25-80ng/ml in 1x diluent (1 in 2 dilution). Urine samples were 
centrifuged at 3,000 x g for 10 minutes and diluted 1:2 in 1x diluent and serum samples were diluted 
1:200 in 1x diluent. Remaining methodology same as B2M assay described above but using 1x 
biotinylated fibrinogen antibody. 
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2.2.2.5 Major Basic Protein measurement 
The Human MBP ELISA kit (Cloud-clone Corp, SEB650Hu) was supplied as a complete kit that 
included pre-coated plates, MBP standard (lyophilised), standard diluent, Detection reagent A, Assay 
diluent A, Detection reagent B, Assay diluent B, TMP substrate, Stop solution.  The wash buffer used 
was 50mM tris buffered saline pH8, supplemented with 0.1% (v/v) Tween20. 
Assay running procedure: prior to running the assay, the standard was reconstituted with 1ml of 
standard diluent and standard curve was prepared at 3.12-100ng/ml in standard diluent (1 in 2 
dilution). Detection reagent A and B were diluted to working concentration 100-fold with assay 
diluent A and B respectively. Samples were diluted 1 in 5 in standard diluent. To the microtitre plate, 
100µl of standard or diluted sample was added per well in duplicate and incubated for 1 hour at 
37°C. After the incubation period, 100µl of detection reagent A was added and incubated for 1 hour 
at 37°C. After a wash step, 100µl of detection reagent B was added and incubated for 30 minutes at 
37°C. A final wash step was undertaken before adding 90µl of substrate solution to each well, 
incubated for 10-20 minutes at 37°C (in the dark) followed by 50µl of stop solution. The colour 
changed from blue to yellow. The absorbance was read at 450nm with the Omega plate reader. 
2.2.2.6 Eosinophil cationic protein (RNASE3) measurement 
The Human RNASE3 ELISA kit (Cloud-clone Corp, SEB758Hu) was supplied as a complete kit that 
included pre-coated plates, RNASE3 standard (lyophilised), standard diluent, Detection reagent A, 
Assay diluent A, Detection reagent B, Assay diluent B, TMP substrate, Stop solution.  The wash buffer 
used was 50mM tris buffered saline pH8, supplemented with 0.1% (v/v) Tween20. 
Assay running procedure: prior to running the assay, the standard was reconstituted with 1ml of 
standard diluent and standard curve was prepared at 0.078-5ng/ml in standard diluent (1 in 2 
dilution). Detection reagent A and B were diluted to working concentration 100-fold with assay 
diluent A and B respectively. Samples were diluted 1 in 4 in standard diluent.  
Assay was run as described above for the MBP assay. 
2.2.3 Substrate assays 
2.2.3.1 MMP substrate assay (Active protease (Composite MMP 2,8,9,12,13,7)) 
MMP-9 standard (Alere pro MMP standard activated in house with APMA) was prepared at 
concentrations ranging from 2.7 – 2000ng/ml (1 in 3 dilution) diluted in MMP buffer (50mM Tris, 
10mM Calcium chloride dihydrate, 100mM Sodium chloride, 0.05mM Zinc chloride, 0.025% 2/vol 
Brij-35 and 0.05% w/vol Sodium azide).  The MMP fluorogenic substrate (Enzo BML-P276-001, 
sequence: Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) was diluted in MMP buffer to give a final 
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concentration of 10μM. To a plate (Costar, black, Cat. 3925), 5µl of standard or neat sample was 
added (2 replicates) followed by 195μl of diluted substrate solution.  The Plate was immediate read 
(1-minute cycles for 30 minutes) with the Omega plate reader using a prepared programme for 
EX330 EM400. Mca fluorescence is quenched by the Dpa group until cleavage separates them 
(MMPs cleave between Gly-Leu). 
2.2.3.2 HNE activity 
HNE standard (Lee BioSolutions 342-40) was prepared at concentrations ranging from 0.04 – 
30ng/ml (1 in 3 dilution) diluted in MMP buffer (50mM Tris, 10mM Calcium chloride dihydrate, 
100mM Sodium chloride, 0.05mM Zinc chloride, 0.025% 2/vol Brij-35 and 0.05% w/vol Sodium 
azide).  The HNE fluorogenic substrate (Bachem 1-1270, sequence: MeOSuc-AAPV-AMC) was diluted 
in MMP buffer to give a final concentration of 20μM. To a plate (Costar, black, Cat. 3925), 5µl of 
standard or neat sample was added (2 replicates) followed by 195μl of diluted substrate solution.  
The Plate was immediate read (1-minute cycles for 30 minutes) with the Omega plate reader using a 
prepared programme for EX380 EM450.  
2.2.4 Mologic in-house developed assays 
For all assays after addition of substrate and subsequent colour development or stop solution, the 
absorbance was measured at 405 (for pNPP) or 450nm (for TMB) using an Omega plate reader and 
the standard curve was approximated in a sigmoid 4 parameter logistic model. 
2.2.4.1 Materials and reagents 
Nunc plates (Maxisorp™ flat bottomed 442404) 
Fisher Scientific plates (Corning ™ 9018 flat bottomed 9018) 
PBS buffer (10mM phosphate buffered saline pH7.5) 
Wash buffer (50mM tris buffered saline pH8, supplemented with 0.1% (v/v) Tween20) 
Buffer 1 (50mM tris buffered saline pH8, supplemented with 0.1% (v/v) Tween20 and 1% (w/v) BSA) 
Buffer 2 (10mM phosphate buffered saline pH7.5, supplemented with 0.1% (v/v) Tween20 and 1% 
(w/v) BSA) 
Buffer 3 (10mM phosphate buffered saline pH7.5, supplemented with 1% (w/v) BSA) 
Buffer 4 (50mM tris buffered saline pH8, supplemented with 1% (v/v) Tween20) 
Buffer 5 (MMP buffer; 50mM Tris, 10mM Calcium chloride dihydrate, 100mM Sodium chloride, 
0.05mM Zinc chloride, 0.025% 2/vol Brij-35 and 0.05% w/vol Sodium azide) 
Buffer 6 (50mM tris buffered saline pH8, supplemented with 1% (w/v) BSA) 
pNPP (Biopanda, cat no pNPP-001) 
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streptavidin-HRP (Invitrogen, Cat. SA100-01) 
TMB solution (Biopanda, Cat. TMB-S-004) 
stop solution (Biopanda, Cat. STP-001) 
2.2.4.2 fMLP measurement - Novel assay developed in-house 
Disposable 96-well polystyrene plates were obtained from Nunc. fMLP (Sigma-Aldrich, Prod. No. 
47729).  fMLP-ovalbumin conjugate was prepared using an “imm-link” (carboxyl) immunogen 
conjugation kit purchased from Innova Bioscience (Cat No 471-0500).  The plate was sensitised with 
ovalbumin-FMLP conjugate at 2μg/ml in PBS overnight at ambient, 100μl/well. After a wash step, 
the sensitised-well surfaces were blocked (buffer 1) with 120μl/well for 1hour at room temperature.   
Assay running procedure: fMLP was diluted in the buffer 1 to give concentrations between 1.56 and 
100ng/ml to generate the standard curve. Equal volumes of standard or urine sample (diluted 1 in 2 
in buffer 1) and sheep anti-fMLP alkaline phosphatase conjugate (at predetermined dilutions) were 
added to duplicate microtitre wells sequentially, such that the final volume was 100μl.  These 
mixtures were incubated for 1hour at room temperature with gentle agitation. After the final plate 
wash, the colour reaction was initiated with the addition of 100μl of pNPP solution to each well.   
2.2.4.3 N-acetyl Proline-Glycine-Proline (Ac-PGP) measurement- Novel assay developed in-house 
Disposable 96-well polystyrene plates were obtained from Fisher Scientific. The plate was sensitised 
with Sheep Anti Ac-PGP (Mologic CF1763 affinity purified) at 0.5µg/ml in PBS overnight at ambient, 
100μl/well. After a wash step, the sensitised-well surfaces were blocked (buffer 2) with 120μl/well 
for 1 hour at room temperature.   
Assay running procedure: Ac-PGP was diluted in buffer 2 to give concentrations between 62.5 and 
4000ng/ml (1 in 2 serial dilution) to generate the standard curve. Equal volumes of standard or urine 
sample (diluted 1 in 5 in buffer 2) and competitor – biotinylated Ac-PGP (Peptide synthetics, custom 
designed) at 4µg/ml were added to duplicate microtitre wells sequentially, such that the final 
volume was 100μl.  The final top standard was 2000ng/ml and the final sample dilution was 1 in 10). 
These mixtures were incubated for 1hour at room temperature with gentle agitation. After a wash 
step, 100µl/well of streptavidin-HRP at a 1 in 5000 was added and left to incubate for 30 minutes 
with gentle agitation.  After the final plate wash, the colour reaction was initiated with the addition 
of 100μl of TMB solution to each well followed by 100μl of stop solution after approximately 15 
minutes.  
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2.2.4.4 Desmosine measurement – Novel assay developed in-house (appendix) 
Disposable 96-well polystyrene plates were obtained from Nunc. Desmosine was supplied by Elastin 
Products Company, Inc. (Cat No, D866). Desmosine-ovalbumin conjugate was prepared using an 
“imm-link” (carboxyl) immunogen conjugation kit purchased from Innova Bioscience (Cat No 471-
0500).  The plate was sensitised with ovalbumin-desmosine conjugate at 1μg/ml in PBS overnight at 
ambient, 100μl/well. After a wash step, the sensitised-well surfaces were blocked (buffer 1) with 
120μl/well for 1hour at room temperature.   
Assay running procedure: Desmosine was diluted in buffer 1 to give concentrations between 0.82 
and 200ng/ml (1 in 2.5 serial dilution) to generate the standard curve. Equal volumes of standard or 
urine sample (diluted 1 in 5 in buffer 1) and sheep anti-desmosine alkaline phosphatase conjugate 
(at predetermined dilutions) were added to duplicate microtitre wells sequentially, such that the 
final volume was 100μL.  These mixtures were incubated for 1 hour at room temperature with gentle 
agitation. After the final plate wash, the colour reaction was initiated with the addition of 100μL of 
pNPP solution to each well.   
2.2.4.5 Large Elastin Fragments measurement – Novel assay developed in-house 
As Desmosine 2.2.4.4, but the antibody used was sheep anti-large elastin fragment (CF1670) alkaline 
phosphatase conjugate diluted 1/4000 in buffer 3. 
2.2.4.6 Desmosine fragments measurement – Novel assay developed in-house 
As Desmosine 2.2.4.4, but the antibody used was sheep anti-small elastin fragment (CF1674) alkaline 
phosphatase conjugate diluted 1/3000 in buffer 3. 
2.2.4.7 Siglec 8 measurement- Novel assay developed in-house 
Disposable 96-well polystyrene plates were obtained from Fisher Scientific. The plate was sensitised 
with Sheep anti Siglec 8 (Mologic, SA122 purified against peptide MOL624) at 2μg/ml in PBS 
overnight at ambient, 120μl/well. After a wash step, the sensitised-well surfaces were blocked 
(buffer 3) with 120μl/well for 1 hour at room temperature.   
Assay running procedure: Recombinant SIGLEC8 binding domain (Mologic, York) was diluted in 
buffer 3 to give concentrations between 7.81 and 500ng/ml to generate the standard curve. The 
standard and urine sample (diluted 1 in 10 in buffer 3) were added to the plate 100μl/well after a 
wash step and incubated for 1 hour at room temperature with gentle agitation. After a further wash 
step, sheep anti-siglec 8 (Mologic, SA122 purified against Siglec 8) alkaline phosphatase conjugate at 
1 in 2000 were added 100μl/well and incubated for 1 hour at room temperature with gentle 
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agitation. After the final plate wash, the colour reaction was initiated with the addition of 100μL of 
pNPP solution to each well.   
2.2.4.8 Ultimate ELTABA (Active protease (Composite MMP’s)) -Novel assay developed in-house  
The peptide (MOL378 stock concentration 1mg/ml) was diluted to 2µg/ml in buffer 4. MMP-9 
standard (Alere pro MMP standard activated in house with APMA) was prepared at top 
concentration of 500ng/ml diluted in buffer 5 and then further diluted down to 3.9ng/ml in buffer 4. 
Assay running procedure: Eppendorfs were pre-loaded with 12.5µl of peptide solution.  Standards 
or samples (neat) were added to the peptide solutions, 75µl per vial and mixed thoroughly. After a 
10 minute incubation period at room temperature, the entire solution (approximately 87µl) was 
added to the Ultimate ELTABA cassette and then read after a further 10 minutes. The reader used 
for measuring the line intensity was the cube reader (Optricon) and the raw values were converted 
to concentration values using the 4-parameter logistic model with the ‘myassay’ software. 
2.2.4.9 Human Neutrophil Elastase (HNE) measurement 
Disposable 96-well polystyrene plates were obtained from Nunc. The plate was sensitised with 
mouse anti HNE (Alere, 1871) at 1.5μg/ml in PBS overnight at ambient, 100μl/well. After a wash 
step, the sensitised-well surfaces were blocked (buffer 3) with 120μl/well for 1hour at room 
temperature.   
Assay running procedure: HNE (Lee biosolutions, 342-40) was diluted in the buffer 2 to give 
concentrations between 0.39 and 25ng/ml to generate the standard curve. The standard and sample 
(urine sample diluted 1 in 10 and serum sample diluted 1 in 100 in buffer 2) was added to the plate 
100μl/well after a wash step and incubated for 1.5 hours at room temperature with gentle agitation. 
After a further wash step, mouse anti-HNE (Alere, 1241) alkaline phosphatase conjugate at 1 in 
25000 diluted in buffer 2 were added 100μl/well and incubated for 1hour at room temperature with 
gentle agitation. After the final plate wash, the colour reaction was initiated with the addition of 
100μL of pNPP solution to each well.   
2.2.4.10 Alpha-1 antitrypsin (A1AT) measurement 
Disposable 96-well polystyrene plates were obtained from Nunc. The plate was sensitised with 
mouse anti A1AT (Alere, 1521) at 2μg/ml in PBS overnight at ambient, 100µl per well. 
After a wash step, the sensitised-well surfaces were blocked (buffer 6) with 120μl/well for 1hour at 
room temperature.   
Assay running procedure: A1AT (Calbiochem, Prod. No. 178251) was diluted in buffer 2 to give 
concentrations between 0.13 and 80ng/ml (1 in 2.5 serial dilution) to generate the standard curve. 
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The standard and sample (urine sample diluted 1 in 20 and serum sample diluted 1 in 200000 in 
buffer 2) was added to the plate 100μl/well after a wash step and incubated for 1.5 hours at room 
temperature with gentle agitation. After a further wash step, mouse anti-A1AT (Alere, 1951) alkaline 
phosphatase conjugate at 1 in 30000 diluted in buffer 2 were added 100μl/well and incubated for 
1hour at room temperature with gentle agitation. After the final plate wash, the colour reaction was 
initiated with the addition of 100μl of pNPP solution to each well.   
2.2.4.11 Secretory leukocyte protease inhibitor (SLPI) measurement 
Disposable 96-well polystyrene plates were obtained from Fisher Scientific. The plate was sensitised 
with sheep anti SLPI (Mologic, CF1099 IgG cut) at 20μg/ml in PBS overnight at ambient, 100μl/well. 
After a wash step, the sensitised-well surfaces were blocked (buffer 3) with 120μl/well for 1hour at 
room temperature.   
Assay running procedure: recombinant SLPI (R&D systems cat. 1274-P1) was diluted in buffer 2 to 
give concentrations between 0.781 and 50ng/ml (1 in 2 serial dilution) to generate the standard 
curve. The standard and sample (urine sample diluted 1 in 2 and serum sample diluted 1 in 2 in 
buffer 2) was added to the plate 100μl/well after a wash step and incubated for 1.5 hours at room 
temperature with gentle agitation. After a further wash step, mouse anti-SLPI (Alere, 431) alkaline 
phosphatase conjugate at 1 in 2500 diluted in sample diluent were added 100μl/well and incubated 
for 1 hour at room temperature with gentle agitation. After the final plate wash, the colour reaction 
was initiated with the addition of 100μl of pNPP solution to each well.   
2.2.4.12 Soluble receptor for advanced glycation end products (sRAGE) measurement 
Disposable 96-well polystyrene plates were obtained from Fisher Scientific. The plate was sensitised 
with sheep anti sRAGE (Mologic, SA056 affinity purified) at 1μg/ml in PBS overnight at ambient, 
100μl/well. After a wash step, the sensitised-well surfaces were blocked (buffer 2) with 120μl/well 
for 1hour at room temperature.   
Assay running procedure: recombinant sRAGE (Novoprotein cat. C423) was diluted in buffer 2 to 
give concentrations between 0.02 and 5ng/ml (1 in 2 serial dilution) to generate the standard curve. 
After a wash step, the standard and sample (neat urine) was added to the plate 50μl/well with 
50μl/well of sample diluent and incubated for 1.5 hours at room temperature with gentle agitation. 
After a further wash step, rabbit anti-sRAGE (Mologic, RA040) alkaline phosphatase conjugate at 1 in 
5000 diluted in sample diluent were added 100μl/well and incubated for 1 hour at room 
temperature with gentle agitation. After the final plate wash, the colour reaction was initiated with 
the addition of 100μl of pNPP solution to each well.    
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2.3 Part 2 Statistical analysis 
2.3.1 T-tests 
For all parametric tests, the distribution of quantitative variables in the population was assumed to 
be normally distributed. Data was normalized by log transforming, however, normality tests were 
done to ensure that the data was normally distributed. Otherwise, nonparametric tests were used 
for data that was not normalized such as Mann Whitney tests for unpaired data or Wilcoxon 
matched-pairs signed rank test for paired data. A threshold of p= 0.05 was used which has been 
most commonly used. When performing a large number of statistical tests (multiple comparison 
tests), some will have P values less than 0.05 purely by chance, even if all the null hypotheses are 
really true. The Bonferroni correction is one simple way to take this into account; adjusting the false 
discovery rate using the Benjamini-Hochberg procedure is a more powerful method. These 
correction methods were not taken into account for any of the analysis in particular results displayed 
in chapter 3 where multiple t tests were performed to compare different groups. 
2.3.2 Receiver-operator characteristic (ROC) curves 
Area: The AUC was used to quantify the overall ability of the test to discriminate between those 
individuals with the disease and those without the disease or between different states. The general 
grading system used was:  test not useful (<0.5), bad (0.5-0.6), sufficient (0.6-0.7), good (0.7-0.8), 
very good (0.8-0.9), excellent (0.9-1). 
Confidence Interval of Area: These results were computed by a nonparametric method that did not 
make any assumptions about the distributions of test results in the different groups.  Interpretation 
of the confidence interval was straightforward. If the patient and control groups for example 
represented a random sampling of a larger population, then there was a 95% sure that the 
confidence interval would contain the true area 
P Value: The reported P value tested the null hypothesis that the area under the curve was equal to 
0.50. If the p value was small then it concluded that the test was able to discriminate between the 2 
groups tested. 
Sensitivity and specificity: In most cases the distribution of the values within each group would 
overlap, therefore sensitivity and specificity derived from the ROC curve would be used to select the 
threshold value. Sensitivity was deemed to be the fraction of people with the disease that the test 
correctly identified as positive and specificity was the fraction of people without the disease that the 
test correctly identified as negative. In GraphPad prism, the sensitivity and specificity using each 
value in the data table as the cut-off value was calculated, this allowed the cut-off value to be 
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selected see figure 2.1 for an example. The selected threshold value would be based upon one which 
would give the better overall performance based on the specifications i.e. if a bias towards either 
sensitivity or specificity was required. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Example of mechanism for selecting threshold values. Displayed are many pairs of 
sensitivity and specificity. If a high threshold is selected, the specificity of the test is increased with a 
loss in sensitivity. If a low threshold is selected, the test's sensitivity is increased but with a loss in 
specificity.  
2.3.3 Sensitivity/specificity/PPV and NPV 
Table 2.3. Calculation of sensitivity/specificity/PPV and NPV. Classification of true positives (TP), false 
positives (FP), false negatives (FN) and true negatives (TN). 
  Diagnostic test result  
  Positive Negative Total 
Reference 
assay/disease status 
Positive/present a (TP) c (FN) a+c 
Negative/Absent b (FP) d (TN) b+d 
 
• Sensitivity (true positives) = TP/(TP+FN) = a/(a+c) 
Optimal 
threshold 
value 
Threshold 
values 
Highest 
specificity with 
highest 
sensitivity 
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• Specificity (True negatives) = TN/(TN+FP) =d/(b+d) 
• Relative agreement = (TP+TN)/(TP+FN+FP+TN) = (a+d)/((a+c) +(b+d))  
• Positive predicted value =TP/(TP+FP) = a/(a+b) 
• Negative predicted value = TN/(TN+FN) = d/(c+d) 
2.3.4 Logistic regression 
All data were analysed using SPSS (version 21).  Logistic regression analysis was used to develop 
predictive models, combining biomarkers that predicted exacerbation outcome. The rules were that 
there were not more variables (i.e. biomarkers) than there were observations (i.e. exacerbations). 
This would lead to overfitting. In addition, variables that correlated would contribute to inaccuracy 
in the analysis. Internal validation was addressed by dividing the cases into 80% training set and 20% 
test set. This process was repeated 5 times using assignment to training and validation sets by 
random number generation in SPSS. 
2.3.5 Correlation methods: Bland-Altman plots and spearman’s / pearsons r 
Bland-Altman: The difference scores of two measurements were plotted against the mean for each 
subject upon which, the mean difference was studied with constructed limits of agreements either 
by fold differences or % differences. The graph was plotted on the XY axis where X represented the 
difference of the two measurements, and the Y-axis showed the mean of the two measurements 
(see figure 2.2 for examples). When interpreting this kind of analysis, the limits should not be used 
to define acceptable ranges but should be defined before, based on varying factors, for example, 
inter-patient variability is known to be higher than intra-patient variability. Perhaps wrongly, bland-
Altman plots are generally interpreted informally, without further analyses or limits but based on 
questions such as (taken from GraphPad prism guide): 
• How big is the average discrepancy between methods (the bias)? You must interpret this 
clinically. Is the discrepancy large enough to be important? This is a clinical question, not a 
statistical one. 
• How wide are the limits of agreement? If it is wide (as defined clinically), the results are 
ambiguous. If the limits are narrow (and the bias is tiny), then the two methods are 
essentially equivalent. 
• Is there a trend? Does the difference between methods tend to get larger (or smaller) as the 
average increases? 
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• Is the variability consistent across the graph? Does the scatter around the bias line get larger 
as the average gets higher? 
It has been recommended that 95% of the data points should lie within ±1.96 SD of the mean 
difference – limits of agreement (144). The ideal bias is ‘0’. More recently, Critchley and Critchley 
accepted limits of agreement within ±30% of the reference standard.  
 
 
Figure 2.2. Example bland-Altman plots. A) If measurements with the two methods are similar, then 
the differences between them will be small, with an average near zero they will be consistent over 
the range of measurement values, and the limits of agreement will be narrow, B) methods do not 
appear to be similar post midrange values where there is no trend and points are scattered and C) 
standard deviation decreasing with concentration and /or with a proportional difference i.e. as the 
concentrations increase with one method, the concentrations decrease with the other.  
Spearman’s r and Pearsons r values: Spearman’s rank correlation coefficient (spearman’s r) was 
used as a non-parametric measure of correlation.  Pearson’s correlation was used on normalised 
data. In terms of the strength of relationship, the value of the correlation coefficient varies between 
+1 and -1.  (± 1 indicates a perfect degree of association between the two variables).  As the 
correlation coefficient value goes towards 0, the relationship between the two variables will be 
weaker. The results were displayed either graphically or by heatmaps, in some cases other diagrams 
were manually drawn to summarise the relationships.  
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Chapter 3. Biomarkers in urine 
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3.1 Introduction 
This chapter explores biomarkers found in urine. Most of the biomarkers selected have been 
investigated in other matrices such as blood, sputum, BAL, saliva, but little is known of their 
presence in urine and their relative concentrations in various disease states. The questions to 
address are a) what biomarkers from the shortlist can be found in the urine and b) are there any 
influences such as age, gender and severity of disease.  
Urinary biomarker profiles were explored in 5 separate studies to provide further insight into their 
role in inflammation. The selected urine samples were obtained from healthy controls, from donors 
with stable lung disease, COPD and CF and from people with suspected urinary tract infection (UTI). 
The justification for each population studied was to understand the biomarkers in health and stable 
disease before looking at changes that occur during an inflammatory insult. The UTI cohort was 
studied as it is hypothesised that the kidney has an influence on the biomarker levels and a local 
infection in the urinary tract would alter the levels in the urine non-specifically which would be 
unrelated to the infection in the lung.  
Healthy controls. Samples from 40 ‘healthy’ subjects were collected from Mologic Ltd. These 
samples were not matched to any particular disease in terms of gender or age as the number of 
volunteers was limited. 
Stable COPD subjects. The stable samples came from the GlaxoSmithKline (GSK) ECLIPSE study 
(Evaluation of COPD Longitudinally to identify Predictive Surrogate Endpoints).  ECLIPSE, was an 
observational, longitudinal study in which, after the baseline visit, participants were evaluated at 3 
months, 6 months and subsequently every 6 months over 3 years.  In the larger ECLIPSE study, 2164 
patients with COPD were recruited and blood, sputum and urine samples were donated at each 
timepoint, for this analysis, urine samples from 98 patients were evaluated. Full details of the study 
have been reported (21), and one of the main findings was that the single best predictor of 
exacerbation of COPD was the patient’s own history of exacerbations.  Another conclusion was that 
exacerbations became more frequent and more severe as COPD progresses. Over the three-year 
study period, of 296 patients who had frequent exacerbations in years 1 and 2, 210 continued to 
have frequent exacerbations in year 3. Of 521 patients with no exacerbations in years 1 and 2, 388 
had no exacerbations in year 3. Blood samples from the study have been extensively studied by 
different groups (145, 146) but the urine samples collected have never been tested or if so never 
reported. The feedback from GSK was that limited analysis had not provided any significant results 
that were worth pursuing for the specific aims towards which they were working. 
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Stable CF subjects (1). The wider purpose of this run-in study for the investigators was to help design 
a therapeutic trial and to select the patients most likely to be able to demonstrate benefit.  This 
study was led by the UK Cystic Fibrosis Gene Therapy Consortium (Imperial College, University of 
Edinburgh and University of Oxford) and sponsored by Imperial College managed by Professor Eric 
Alton and funded by the Cystic Fibrosis Trust. Approximately 200 CF patients were recruited from 
two centres, measurements were taken over several years which included tests of lung function, 
bacterial infection and inflammation in the lungs.  Measurements and samples (blood and urine) 
were collected at 4 timepoints over the first 12-18 months (4 monthly intervals). Patients were 
recruited from the adult and paediatric clinics at the Royal Brompton Hospital (approximately 150) 
and Scotland (approximately 50). This study helped the consortium to decide which tests would be 
best at showing any benefits that might result from treatment with gene therapy.  
Stable CF subjects (2). These stable CF samples were obtained from Queens university Belfast (QUB). 
In the Belfast study, 129 clinically stable CF patients attending the adult and paediatric CF centres in 
Belfast were recruited to the study. The study was supported by the UK NHS NOCRI Translational 
Research Partnership & US Ireland Partnership Grant.  Some additional samples were collected at 
the start and/or end of antibiotic treatment of an infective exacerbation.   
Suspected UTI and recovered UTI subjects. Samples were received from adult women who 
consulted their GP with symptoms of UTI. Correct diagnosis of UTI is difficult. GPs will usually send a 
urine sample to the hospital laboratory for culture and in about 50% cases, samples are 
contaminated and do not provide useful information. GPs are therefore faced with the dilemma that 
the diagnostic results are often not very helpful, but that truly infected patients need to be treated 
as early as possible to avoid complications. As a consequence, GPs often inappropriately give 
antibiotics to patients with suspected infections even though some of those individuals may have 
unrelated illnesses or prescribe antibiotics to which the bacteria are resistant. 
It is important to note that as the project progressed the shortlist of biomarkers expanded with time 
so not all 34 biomarkers were evaluated in this early work. Reference assays were used to measure 
the levels of biomarkers in urine as described in chapter 2. 
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3.2 Methods – patient selection and assessment 
In all cases with the exception of the healthy controls, the samples were received from other sites.  
Samples were received frozen, transferred on dry ice in 1,5 or 10ml tubes and immediately stored at 
-80°C. At the point of testing, the samples were thawed, equilibrated to room temperature and 
tested with the reference assays.  Remaining sample was aliquoted in to 1ml vials and stored at -
80°C.  
3.2.1 Healthy controls 
Samples from 40 ‘healthy’ subjects were collected from Mologic Ltd. Consent was given and samples 
were anonymised.  The main inclusion criterion was that the volunteer felt well at the time of 
donating the sample. Urine samples were aliquoted, labelled and stored at -80°C upon within 3 
hours of collection. The samples were thawed and equilibrated to room temperature before testing 
with the reference assays as described in chapter 2. 
3.2.2 Stable COPD  
A total of 98 patients from the ECLIPSE study with collections from each patient at 8 different 
timepoints as shown in table 3.1 (total of 800 samples) were received from GSK. Of the 98 patients, 
50% exhibited ‘infrequent’ exacerbation and 50% exhibited ‘frequent’ exacerbations. After testing 
with reference assays detailed in chapter 2, biomarker measurements from samples collected at visit 
1 (baseline) were taken forward for analysis, biomarkers were explored in stable state and then 
stratified into the two subgroups for further analysis. Analysis performed explored single biomarkers 
and multiplex biomarkers that could differentiate frequent and infrequent exacerbators and 
prediction of severity of disease over subsequent years. 
Table 3.1. Urine sample collection time points and groupings for GSK ECLIPSE study 
Month Time Point Number Year 
0 1  baseline 
3 2 Year 1 samples 
6 3 
12 4 
18 5 Year 2 samples 
24 6 
30 7 Year 3 samples 
36 8 
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Figure 3.1. Urine samples received from Belfast 
City Hospital and Royal Belfast Hospital for Sick 
Children. All CF patient urine samples were 
received and analysed. After testing with 
reference assays detailed in chapter 2, 
biomarker measurements from stable samples 
only were taken forward for analysis exploring 
biomarkers in stable state (all patients). 
 
3.3.3     Stable CF (1)  
A total of 157 patients with collections from each patient at 4-6 different timepoints taken 4 months 
apart (total of 822 samples) were received from Imperial College London. After testing with 
reference assays detailed in chapter 2, biomarker measurements from samples at visit 1 (baseline) 
were taken forward for analysis exploring biomarkers in stable state. The total number of baseline 
samples taken forward for analysis was 157. 
3.3.4 Stable CF (2) 
A total of 146 samples from CF patients were received from QUB, stratified according to figure 3.1. 
For analysis, only the 1st stable visit data was included n=129. 
 
 
 
 
 
 
 
3.2.5 Suspected UTI and recovered UTI subjects 
A total of 202 urine samples from adult women presenting with suspected uncomplicated UTI were 
received from Cardiff. A second sample from some of the volunteers was subsequently collected 2 
weeks  once treatment had finished.  Fresh urine samples from primary care sites were transported 
to the hospital laboratories where they were aliquoted into 1ml vials and stored at -80°C. The 
samples were thawed and equilibrated to room temperature before testing with the reference 
assays as described in chapter 2. 
3.2.6 Statistical analysis 
All data were analysed using SPSS (version 21) or GraphPad PRISM. Data normality was explored, 
and appropriate parametric or non-parametric tests chosen accordingly. Receiver-operator 
characteristic (ROC) analysis and Wilcoxon’s signed rank test, Mann-Whitney or students t-test with 
significance levels p<0.05 was used to compare biomarker levels in different disease states, 
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subgroups, gender and age. Correlation matrix were performed with each study using GraphPad 
Prism, Spearman's rank correlation coefficient for nonparametric measure of rank correlation. 
Logistic regression was used to develop predictive models, combining biomarkers that determined 
the outcome of exacerbation.  
3.3 Results 
3.3.1 Patient characteristics 
There was limited clinical information available for the healthy, CF and UTI samples, that which was 
available is summarised in table 3.2. The stable COPD ECLIPSE were much older with a median age of 
62yrs whereas the median age for the CF stable donors were younger 22.8 and 24.8yrs for the 2 
cohorts ranging from 10 - 68yrs collectively. The healthy cohort had median age of the 42yrs and the 
range overlapped both COPD and CF cohorts.  There was no information available on the age of the 
UTI cohort. With regards to gender, the COPD, healthy and CF cohorts were similar with a 
predominately male population whereas the UTI cohort consisted of all females. Both the CF cohorts 
were similar with regards to the FEV1% prediction values. 
The Stable COPD cohort was broken down into 2 sub-groups - frequent and infrequent exacerbators 
(table 3.3). Both subgroups were very similar in terms of age, gender, smoking status, BMI, 
comorbidities, the key difference was frequency of exacerbations in the year prior to recruitment >2 
exacerbations, hospitalisation’s, FV950 (Emphysema score) and Gold status (severity of disease).  
 
Table 3.2. Mean (SD) values of the main characteristics for all 5 cohorts with common information 
available 
 
STABLE COPD HEALTHY STABLE CF (1) STABLE CF (2) UTI 
      
 
N = 98 N=40 N=158 N=146 N=49 
Age (yrs.) 61.6 (5.2) 42 22.8 (11.7) 24.8 (14.2) - 
Age min-max (yrs.) 46-74 18-69 10-59 6-68 - 
Male (%) 58 (59%) 21 (52.5%) 87 (55.4%) 75 (58.1%) 0 (0%) 
FEV1, post-BD 
 mean (SD) 
1.4 (0.6) - 2.26 (0.79) 2.3 (0.9) - 
FEV1% PRED  
mean (SD) 
- - 70.4 (19.5) 75.1 (21.3) - 
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Table 3.3. Main characteristics of the stable COPD cohort and two subgroups- Infrequent 
Exacerbator (IF) & Frequent Exacerbator (F) at baseline. Mean (SD) values and number (%) 
 
 Stable COPD Infrequent 
Exacerbators 
Frequent 
Exacerbators  
 N = 98 N=49 N=49 
Demographics  
   
Age (yrs.) Mean (SD) 61.6 (5.2) 61.5 (5.1) 61.8 (5.4) 
Age min-max (yrs.) Min-max 46-74 46-74 50-74 
Male No (%) 58 (59%) 29 (60.4%) 29 (60.4%) 
Smoking, pack-years No (%) 47.1 (27.6) 48.4 (28.5) 45.8 (26.9) 
BMI, kg/m2 Mean (SD) 25.3 (4.4) 25.8 (4) 24.8 (4.8) 
Frequent exacerbators (≥2 
pa) 
No (%) 49 (50) 0 100% 
mMRC Score Mean (SD) 1.5 (1) 1.2 (0.9) 1.8 (1) 
SGRQ-C Total Score Mean (SD) 46.6 (18.7) 36.9 (18.1) 56.5 (13.5) 
Exacerbations in year prior 
to recruitment 
Mean (SD) 1.2 (1.5) 0.2 (0.6) 2.2 (1.5) 
ICS use No (%) 13 (13.3%) 5 (10.2%) 8 (16.3%) 
Oral CS use  1 (1%) 0 1 (2%) 
Cardiovascular disease No (%) 31 (31.6%) 15 (30.6%) 16 (32.7%) 
Hx Osteoporosis No (%) 12 (12.2%) 4 (8.2%) 8 (16.3%) 
Diabetes No (%) 5 (5.1%) 2 (4.1%) 3 (6.1%) 
Statin Use No (%) 22 (22.4%) 9 (18.4%) 13 (26.5%) 
Physiology and Imaging  
   
FEV1 (L), post-BD Mean (SD) 1.4 (0.6) 1.65 (0.6) 1.2 (0.4) 
FVC (L), post-BD Mean (SD) 3.3 (0.9) 3.5 (0.9) 3.1 (0.8) 
FEV1/FVC, post-BD Mean (SD) 42.6 (12.1) 46.3 (10.9) 38.8 (12.3) 
6MWD, m Mean (SD) 425.6 (124.2) 462 (115.6) 388.9 (122.6) 
BODE index Mean (SD) 2.7 (2) 1.9 (1.8) 3.5 (1.8) 
Oxygen sat Mean (SD) 95.2 (2.3) 95.8 (2.3) 94.7 (2.2) 
FV950 Mean (SD) 15.5 (10.6) 11.4 (8.2) 19.6 (11.2) 
GOLD Risk index  
   
A No (%) 18 (18.4%) 18 (36.7%) 0 
B No (%) 3 (3%) 3 (6.1%) 0 
C No (%) 28 (28.6%) 28 (57.1%) 0 
D  No (%) 49 (50%) 0 49 100%) 
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3.3.2 Biomarker levels in normal, stable COPD, stable CF and UTI 
The biomarker levels in each of the 5 groups are shown in table 3.4-3.8. The COPD and CF cohorts 
were all compared to the biomarker levels measured in the healthy samples whereas the suspected 
UTI samples were compared to the 2-week recovery samples (post antibiotics) which should have 
been similar to the ‘healthy’ ranges. A graphical representation of all the data is shown in figure 3.2 
for 22 biomarkers.  
A summary of the significance levels is shown in table 3.9. There were 8 biomarkers that 
unexpectedly behaved differently with both the CF cohorts irrespective of the age and gender 
similarities. These were fMLP, IL-1β, active MMP (ultimate ELTABA and substrate assay), MMP-8, 
NGAL, MPO, B2M and desmosine. There may have been other parameters that made these 2 
cohorts different such as bacterial species or even genotype. 
It was expected that the normal and UTI recovery samples would contain similar levels, however, the 
UTI recovery patients may still have an active infection (UTI or other dependent on actual diagnosis 
that have been overlooked). Those biomarkers that were significantly different (p<0.05) between 
healthy and UTI recovered were active MMP (ultimate ELTABA and substrate assay), HNE, NGAL, 
Cystatin C, Desmosine and HSA. UTI markers that were significantly different from both the healthy 
and recovered samples were IL-1β, active MMP (as measured by Ultimate ELTABA), IL-8, MMP-9, 
MMP-8, HNE, NGAL, HSA and fibrinogen. Biomarkers that were only significantly different in relation 
to recovered samples were IL-6 and RBP4. The 1 biomarkers that was significantly different in 
relation to healthy samples was cystatin C. 
There were 3 biomarkers that were significantly higher in stable COPD compared to healthy (and 
specific to COPD) with a p value <0.05. These consisted of 2 signalling molecules – IL-1β and IL-6 and 
fibrinogen which is regulated by IL-6.  There were 4 biomarkers that were significantly higher in 
stable CF (and specific to CF) in relation to healthy state which were 2 effector molecules -MMP-8 
and NGAL, creatinine and RBP4 (RBP4 was significantly higher in only one of the CF cohorts). There 
were three biomarkers that were significantly different in COPD and CF (cohort 1 and 2), these were 
IL-8, active MMP (as measured by ultimate ELTABA) and TIMP-1. To add to the list of biomarkers 
associated with both COPD and CF which had conflicting results between the 2 CF cohorts were 
fMLP, MMP-9, A1AT, desmosine, HSA, and Cystatin C.  lastly biomarkers that remained the same 
regardless of either respiratory condition was HNE, calprotectin, B2M, TIMP-2 and MPO. 
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Table 3.4.  Biomarker results in healthy urines- Median (IQR) 
Biomarker assay Unit Number 
of 
values 
Minimum Maximu
m 
Median (IQR) 
IL-6 pg/ml 40 0 23.61 0.4625 (0.18- 1.614) 
fMLP ng/ml 40 0.648 19.98 6.9 (4.675-11) 
IL-1β pg/ml 40 1.119 38.71 5.489 (4.587-7.2410 
Siglec 8 ng/ml - - - - 
Chitinase 3 like 
protein 
ng/ml - - - - 
Ultimate ELTABA  ng/ml 40 181 4496 442 (270.5-1010) 
MMP substrate 
assay 
ng/ml 40 0 177.4 19.58 (8.319-37.82) 
HNE substrate 
assay 
ng/ml 40 0 30 0 (0-5.5) 
IL-8 pg/ml 40 0 61.66 0 (0-0) 
MMP-8 Total ng/ml 40 0 7.639 0 (0-0.6733) 
MMP-9 Total ng/ml 40 0 9.363 0.21 (0-1.529) 
HNE ng/ml 40 0 250 2.059 (0-23.61) 
NGAL ng/ml 40 0 102.4 0 (0-18.27) 
Calprotectin ng/ml 40 0 80.8 20.29 (3.9-44.28) 
MPO ng/ml 40 0 42.27 0.9747 (0.1716-11.35) 
RNASE-3 ng/ml - - - - 
A1AT ng/ml 40 1.5 252.3 26.4 (11.2 -86.25) 
TIMP-1 ng/ml 40 0 4.592 0 (0-0.207) 
SLPI ng/ml - - - - 
Cystatin C ng/ml 40 63.76 216.1 107.1 (84.79-128.2) 
Creatinine mg/dl 40 17.5 219.9 83.6 (39.38-120.8) 
Beta 2 
Microglobulin 
ng/ml 40 4.252 86.76 24.68 (15.52-37.97) 
RBP4 ng/ml 40 66.61 272.9 142.9 (112.2-198.5) 
TIMP-2 ng/ml 40 0.264 13.14 2.853 (1.009-6.34) 
Ac-PGP ng/ml - - - - 
Desmosine V1 
ELISA 
ng/ml 40 0 33.21 3.55 (0.625 -8.625) 
LEF ng/ml - - - - 
Desmosine 
fragments 
ng/ml - - - - 
CC16 ng/ml - - - - 
CRP ng/ml - - - - 
Periostin ng/ml - - - - 
H.S.A ng/ml 40 253.9 11780 1021 (528-1557) 
Fibrinogen Abcam ng/ml 40 1.753 177.3 8.626 (5.583-20.13) 
sRAGE ng/ml - - - - 
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Table 3.5. Biomarker results in stable COPD urines, median (IQR) and differentiation from healthy 
urines.  Significant p values <0.05 highlighted in bold. 
Biomarker assay unit Number 
of values 
Minimum Maximum Median (IQR) P value 
IL-6 pg/ml 100 0 43.94 0.4145 (0-5.321) 0.0391 
fMLP ELISA ng/ml 100 0 38.71 4.741 (2.222-7.9790 0.0150 
IL1b pg/ml 100 0 20.47 0.3165 (0-5.141) 0.0011 
Siglec 8 ng/ml - - - - - 
Chitinase 3 like 
protein 
ng/ml - - - - - 
Ultimate ELTABA  ng/ml 100 0 282.9 37.37 (17.93-66.78) <0.0001 
MMP substrate 
assay 
ng/ml 100 0 65.14 2.585 (0-7.627) <0.0001 
HNE substrate assay ng/ml 100 0 482 0 (0-0) 0.7567 
IL-8 pg/ml 100 0 226.7 0 (0-7.57) 0.0369 
MMP-8 Total ng/ml 70 0 40 0 (0-0.7588) 0.2515 
MMP-9 Total ng/ml 100 0 21.44 0.6645 (0.05075-
2.717) 
0.0191 
HNE ng/ml 100 0 284.3 0 (0-10.09) 0.1660 
NGAL ng/ml 100 0 500 15.25 (6.997-26.78) 0.0691 
Calprotectin ng/ml 100 0 90.27 17.69 (7.575-44.21) 0.8611 
MPO ng/ml 100 0 56.3 4.867 (0.999-20.44) 0.2699 
RNASE-3 ng/ml - - - - - 
A1AT ng/ml 100 0 1735 65.5 (15.33-160.6) 0.0313 
TIMP-1 ng/ml 100 0 16.16 1.327 (0.7153-3.437) <0.0001 
SLPI ng/ml 100 0 15.83 1.226 (0.02525-
5.332) 
- 
Cystatin C ng/ml 100 0 484.3 68.7 (35.65-109.8) 0.0207 
Creatinine mg/dl 100 10.4 307.4 96.02 (47-141.5) 0.1157 
Beta 2 Microglobulin ng/ml 100 3 12500 72 (29.72-183.8) 0.1420 
RBP4 ng/ml 100 14.06 1706 122 (85.46-177.9) 0.8050 
TIMP-2 ng/ml 100 0 16.71 4.033 (2.049-6.388) 0.4079 
Ac-PGP ng/ml 100 0 21114 270 (0-775.6)  
Desmosine V1 ELISA ng/ml 100 0 68.1 6.485 (2.825-16.1) 0.0105 
LEF ng/ml 40 0 2986 449.4 (111.1-1029) - 
Desmosine 
fragments 
ng/ml 100 15.2 6850 349.4 (122-995.6) - 
CC16 ng/ml 100 0 205.9 11.76 (1.791-35.09) - 
CRP ng/ml 100 0 10000 399.8 (0-916.2) - 
Periostin ng/ml - - - - - 
H.S.A ng/ml 100 178.1 16000 1796 (1005-4256) 0.0038 
Fibrinogen Abcam ng/ml 100 2 222 23.55 (11-44) 0.0364 
sRAGE ng/ml - - - - - 
 
 
72 
Table 3.6. Biomarker results in stable CF (1) urines (median (IQR) and differentiation from healthy 
urines. Significant p values <0.05 highlighted in bold. 
Biomarker assay unit Number 
of 
values 
Minimum Maximum Median P value 
IL-6 pg/ml 157 0 150 0 (0-3.422) 0.2566 
fMLP ELISA ng/ml 155 0 49.91 7.091 (3.113-11.91) 0.5076 
IL1b pg/ml 157 0 48.9 3.597 (0.3705-5.972) 0.2327 
Siglec 8 ng/ml - - - - - 
Chitinase 3 like 
protein 
ng/ml - - - - - 
Ultimate ELTABA  ng/ml 157 0 314.7 35.24 (13.68-78.38) <0.0001 
MMP substrate 
assay 
ng/ml 157 0 117 1.892 (0-10.92) <0.0001 
HNE substrate assay ng/ml 157 0 322 0 (0-0) 0.7858 
IL-8 pg/ml 157 0 1480 0 (0-47.54) 0.0344 
MMP-8 Total ng/ml 157 0 42.65 1.669 (0-5.162) 0.0021 
MMP-9 Total ng/ml 157 0 20 0.421 (0-4.678) 0.0078 
HNE ng/ml 157 0 322.5 0 (0-44.49) 0.4011 
NGAL ng/ml 157 0 550.9 17.68 (0-56.73) 0.004 
Calprotectin ng/ml 157 0 101.2 24.68 (2.519-50.7) 0.6436 
MPO ng/ml 157 0 49.29 3.02 (0-34.57) 0.0805 
RNASE-3 ng/ml - - - - - 
A1AT ng/ml 157 0 2005 41.05 (11.1-116.8) 0.1201 
TIMP-1 ng/ml 157 0 15.45 0.5036 (0.2214-
1.316) 
0.0037 
SLPI ng/ml - - - - - 
Cystatin C ng/ml 157 0 224.7 56.05 (32.51-111.4) <0.0001 
Creatinine mg/dl 157 8.343 345.7 107.2 (55.88-155.3) 0.0156 
Beta 2 Microglobulin ng/ml 157 0 5262 82.93 (29.14-162.5) 0.0592 
RBP4 ng/ml 157 0 873.3 75.94 (47.15-112.5) <0.0001 
TIMP-2 ng/ml 157 0 18.15 4.561 (2.524-6.958) 0.0859 
Ac-PGP ng/ml 157 0 28204 4984 (1542-11866) - 
Desmosine V1 ELISA ng/ml 157 0 167.9 17 (5.515-35.35) <0.0001 
LEF ng/ml 156 0 1177 371.3 (172.2-631.2) - 
Desmosine 
fragments 
ng/ml 156 2.831 1376 281.1 (82.33-797.9) - 
CC16 ng/ml 157 0 200 0 (0-12.81) - 
CRP ng/ml 157 0 14705 365.5 (20.29-1369) - 
Periostin ng/ml - - - - - 
H.S.A ng/ml 157 14.35 16000 1454 (686.7-3439) 0.0135 
Fibrinogen Abcam ng/ml 157 0 195.8 10.27 (4.738-24.36) 0.8269 
sRAGE ng/ml - - - - - 
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Table 3.7. Biomarker results in stable CF (2) urines (median (IQR) and differentiation from healthy 
urines. Significant p values <0.05 highlighted in bold. 
Biomarker assay unit Number 
of 
values 
Minimum Maximum Median p value 
IL-6 pg/ml 129 0 90.35 2.19 (0.59-4.4.39) 0.0582 
fMLP ELISA ng/ml 129 0.034 3.173 0.86 (0.49-1.34) <0.0001 
IL1b pg/ml 129 0 103.4 6.6 (3.38-10.18) 0.3227 
Siglec 8 ng/ml - - - - - 
Chitinase 3 like 
protein 
ng/ml - - - - - 
Ultimate ELTABA  ng/ml 129 107 1462 377 (262-643) 0.0005 
MMP substrate 
assay 
ng/ml 129 0 441.4 10 (4.28-28.99 0.4831 
HNE substrate 
assay 
ng/ml 129 0 288 0 (0-6) 0.1814 
IL-8 pg/ml 129 0 1048 14.22 (0.62-50.87) 0.0085 
MMP-8 Total ng/ml 129 0 27.36 0 (0-2.75) 0.0323 
MMP-9 Total ng/ml 129 0 40 0 (0-1.47) 0.1351 
HNE ng/ml 129 0 565 0 (0-30.95) 0.2947 
NGAL ng/ml 129 0 231.8 15.09 (0-36.29) 0.0333 
Calprotectin ng/ml 129 0 97.2 19.4 (4.25-62.45) 0.2926 
MPO ng/ml - - - - - 
RNASE-3 ng/ml - - - - - 
A1AT ng/ml 129 0 2108 126.5 (48.25-264.7) 0.0015 
TIMP-1 ng/ml 129 0 15.31 0.69 (0.14-2.19) 0.0015 
SLPI ng/ml - - - - - 
Cystatin C ng/ml 129 0 592.9 76.05 (41.54-110.9) 0.0743 
Creatinine mg/dl 129 16.3 533.5 108 (62.15-172.4) 0.0048 
Beta 2 
Microglobulin 
ng/ml 129 8.864 20000 212 (77.19-432.3) 0.1111 
RBP4 ng/ml 129 4.869 3864 96.78 (64.41-139.8) 0.8521 
TIMP-2 ng/ml 129 0.317 20.09 4.43 (2.33-6.85) 0.1005 
Ac-PGP ng/ml - - - - - 
Desmosine V1 
ELISA 
ng/ml 129 0 50.4 2.81 (0.96-5.85) 0.3936 
LEF ng/ml - - - - - 
Desmosine 
fragments 
ng/ml - - - - - 
CC16 ng/ml - - - - - 
CRP ng/ml - - - - - 
Periostin ng/ml - - - - - 
H.S.A ng/ml 129 399.6 32000 1366 (849.8-2198) 0.1776 
Fibrinogen Abcam ng/ml 129 0 174 8.38 (4.4-14.91) 0.4272 
sRAGE ng/ml - - - - - 
 
74 
Table 3.8. Biomarker results in suspected UTI urines, median (IQR) and differentiation from UTI 
recovery from urines after treatment administered. Significant p values <0.05 highlighted in bold. 
Biomarker 
assay 
unit UTI SUSPECTED POSITIVES UTI RECOVERY  
Number 
of 
values 
Min Median Max Number 
of 
values 
Min Median Max p value 
IL-6 pg/ml 202 0 0 (0-21.69) 1384 222 0 0 (0-1.28) 600 <0.0001 
fMLP ELISA ng/ml 202 0 5.57 (2.81-9.78 24.26 222 0 5.139 (2.78-8.80) 26.45 0.3566 
IL1b pg/ml 202 0 20.75 (6.83-83.48 1364 219 0 6.783 (0.003-13.39) 301.8 <0.0001 
Siglec 8 ng/ml - - - - - - - - - 
Chitinase 3 
like protein 
ng/ml - - - - - - - - - 
Ultimate 
ELTABA  
ng/ml 69 6 151 (49-33) 1261 89 0 117 (43-384.5) 4063 0.2542 
MMP 
substrate 
assay 
ng/ml 96 0 0 (0-8.05) 536 92 0 0 (0-0.995) 509.1 0.1051 
HNE 
substrate 
assay 
ng/ml - - - - - - - - - 
IL-8 pg/ml 202 0 133.2 (3.44-
702.5) 
5764 222 0 3.473 (0-54.31) 3298 <0.0001 
MMP-8 Total ng/ml 202 0 5.744 (0-39.6) 418.2 222 0 0 (0-0) 97.63 <0.0001 
MMP-9 Total ng/ml 202 0 20 (1.06-113.4) 222.1 222 0 0 (0-5.92) 218.8 <0.0001 
HNE ng/ml 202 0 250 (32.62-769.3) 3176 222 0 27.04 (0-158.6) 2500 <0.0001 
NGAL ng/ml 202 0 79.16 (22.26-
295.1) 
789.6 222 0 19.67 (0-46.52) 500 <0.0001 
Calprotectin ng/ml - - - - - - - - - 
MPO ng/ml - - - - - - - - - 
RNASE-3 ng/ml - - - - - - - - - 
A1AT ng/ml - - - - - - - - - 
TIMP-1 ng/ml - - - - - - - - - 
SLPI ng/ml - - - - - - - - - 
Cystatin C ng/ml 202 0 32.03 (14.55-
62.94) 
255.4 222 0 28.69 (14.7-54.26) 782.2 0.6582 
Creatinine mg/dl 202 8.5 68.1 (33.06-110) 400 222 0.6 76 (41.28-125.4) 316.8 0.1536 
Beta 2 
Microglobulin 
ng/ml - - - - - - - - - 
RBP4 ng/ml 202 0 102.7 (60.1-
164.4) 
1937 222 0 79.73 (44.38-128) 3000 0.0129 
TIMP-2 ng/ml 27 0.437 3.806 (1.225-
7.154) 
25.94 - - - - - 
Ac-PGP ng/ml 121 0 565.6 (0-1953) 26963 157 0 807.5 (0-2542) 20000 0.5235 
Desmosine 
V1 ELISA 
ng/ml 202 0 9.5 (3.3-28.51) 1673 222 0 8.4 (3.2-20.91) 204.5 0.0785 
LEF ng/ml 121 3.061 403.9 (233.6-
796.3) 
2747 157 0 419.6 (219.2-688.2) 2091 0.5486 
Desmosine 
fragments 
ng/ml 121 14.95 1000 (295.8-
1000) 
2319 157 19.44 1000 (319.6-1000) 2404 0.8962 
CC16 ng/ml - - - - - - - - - 
CRP ng/ml - - - - - - - - - 
Periostin ng/ml - - - - - - - - - 
H.S.A ng/ml 202 238.5 8635 (2357-
24000) 
30268 222 41.14 2328 (1098-4987) 24000 <0.0001 
Fibrinogen 
Abcam 
ng/ml 194 0 58.75 (7-160) 407 221 0 12 (3-32) 320 <0.0001 
sRAGE ng/ml - - - - - - - - - 
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Figure 3.2. Scatter plots showing the difference between all 5 cohorts. Scatter plots for healthy 
controls, stable COPD, stable CF (2 cohorts) and UTI (subdivided into those with suspected UTI and 
recovered) for each biomarker are shown. Median with interquartile range shown for each plot. 
Unpaired t tests are displayed for each combination, >0.05 = not significant (ns), degree of 
significance indicated by *, 1 star being just significant to 4 stars being very significant.  
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Table 3.9. Summary table from all studies and significance levels. Unpaired t tests are displayed for 
each combination, >0.05 = not significant (ns), degree of significance indicated by *, 1 star being just 
significant to 4 stars being very significant.  
 
 Healthy 
vs. 
stable 
COPD 
Healthy 
vs. 
stable 
CF (1) 
Healthy 
vs. 
stable 
CF (2) 
Healthy 
vs. 
suspected 
UTI 
Healthy 
vs. 
recovered 
UTI 
Stable 
COPD 
vs. 
stable 
CF (1) 
Stable 
COPD 
vs 
stable 
CF (2) 
Stable 
CF (1) 
vs 
Stable 
CF (2) 
Suspected 
UTI vs 
recovery 
IL6 * ns ns ns ns ns ns ns **** 
fMLP * ns **** ns ns *** **** **** ns 
IL-1β ** ns ns ** ns * *** ** **** 
Ultimate 
ELTABA 
**** **** *** **** *** ns **** **** **** 
MMP 
substrate 
**** **** ns ns * * **** *** ns 
IL-8 * * ** *** ns * ** ns **** 
HNE ns ns ns **** * ** ** ns **** 
MMP-8 ns ** * ** ns ** ns ** **** 
MMP-9 * ** ns **** ns ns ns ns **** 
NGAL ns ** * **** ** ns ns ** **** 
Calprotectin ns ns ns - - ns ns ns - 
MPO ns ns - - - ns - - - 
A1AT * ns ** - - ns ns ns - 
TIMP-1 **** ** ** - - **** * * - 
Cystatin C * **** ns **** **** ns ns ns ns 
Creatinine ns * ** ns ns ns * ns ns 
B2M ns ns ns - - ns ns ** - 
RBP4 ns **** ns ns ns *** ns ns * 
TIMP-2 ns ns ns - - ns ns ns - 
Desmosine * **** ns ns ** **** **** **** ns 
HSA ** * ns **** *** ns ns ns **** 
Fibrinogen * ns ns **** ns ** **** ns **** 
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3.3.3 Biomarker correlations 
Correlation matrices were performed with each study using GraphPad Prism, each study consisted of 
different number panels of biomarkers and number of participants. 
There were clear biomarkers that correlated in all cohorts and some that may have been influenced 
by gender as shown by figure 3.3 – 3.7. 
In the healthy samples there were 2 groups or clusters of biomarkers that correlated with a 
spearman’s r> 0.7. 
Cluster 1: MMP-8, MMP-9, HNE, NGAL, Calprotectin, MPO and IL-8 of which the greatest correlation 
was with MMP-9, HNE and MPO. 
Cluster 2: Cystatin C, Creatinine, B2M, RBP4, TIMP-2, desmosine and fMLP of which creatine and 
TIMP-2 gave the greatest correlation.  
The correlations observed in the ‘healthy’ cohort extended to all the other cohorts, however, with 
further stratification with gender, it was established that the strength of the correlations was 
influenced by gender for some biomarkers. for example, as shown in figure 3.4, IL-8 remained in 
group 1 only in females as did TIMP-1. Active HNE also seemed to negatively correlate in the male 
group compared to the female.  
In general cluster 1 correlation was stronger in females and cluster 2 correlation was stronger in 
males and this was qualified through all the COPD and CF cohorts. 
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Healthy samples n = 40 
 
Figure 3.3. Heat map for biomarker correlation in healthy volunteers. Scale of colour is shown on the 
right, purple with Spearman’s r closer to ‘1’ green for no correlation and towards red for a negative 
correlation. Spearman’s r values shown on heatmap. This scale was used for all the remaining heat 
maps. 
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Figure 3.4. Heat map for biomarker correlation in COPD stable samples, shown with all samples then stratified by gender. Scale of colour is shown on the 
right, purple with Spearman’s r closer to ‘1’ green for no correlation and towards red for a negative correlation. Spearman’s r values shown on heatmap. 
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CF Imperial n= 157      CF-imperial Females n= 71     CF-imperial Males n= 86 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Heat map for biomarker correlation in CF stable samples (1) shown with all samples then stratified by gender. Scale of colour is shown on the 
right, purple with Spearman’s r closer to ‘1’ green for no correlation and towards red for a negative correlation. Spearman’s r values shown on heatmap. 
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CF Belfast n = 129     CF Belfast Females n = 54   CF Belfast Males n = 75   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Heat map for biomarker correlation in CF stable samples (2) shown with all samples then stratified by gender. Scale of colour is shown on the 
right, purple with Spearman’s r closer to ‘1’ green for no correlation and towards red for a negative correlation. Spearman’s r values shown on heatmap. 
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3.3.4 Gender specific urinary biomarkers 
Biomarkers were analysed to determine influence of gender.  Mann Whitney test was used to 
evaluate significance between the two groups. Sixteen of the biomarkers were found to be gender 
specific.   
In females, higher levels of IL-8, MMP-9, HNE, Calprotectin and MPO were significant for all cohorts, 
COPD and CF. IL-1β, MMP-8, NGAL, and fibrinogen were found only to be significant in the CF 
cohorts. 
In males, higher levels of TIMP-1, SLPI, Cystatin C, Creatinine, TIMP-2, Desmosine, LEF and CC16 
were found in the COPD cohort. Higher levels of TIMP-1 and Creatinine were found in both CF 
cohorts, whereas Cystatin C and Desmosine were only found to be significantly higher in one of the 
CF cohorts. CC16 was only tested in 1 of the cohorts but likely to be significant in both based on the 
p-value. SLPI was not tested in any of the CF cohorts.  
In summary, there are strong gender specific biomarkers with p values that go below 0.0001 for 
some biomarkers.  Females exhibit higher levels of IL-8, MMP-9, HNE, Calprotectin and MPO were 
obtained and in males, higher levels of TIMP-1, Creatinine and CC16 were found 
3.3.5 Influence of age 
To explore if there were any biomarkers associated with age, the CF cohort 1 was analysed and 
findings were confirmed with the Belfast CF data.  The data were split into 2 groups, age group <18 
(n = 78) with a median of 13yrs with an age range of 10yrs to 18yrs and age group >18yrs (n=79) with 
a median of 28yrs with an age range of 18-59yrs.  Analysis into gender and age was also explored. 
There were 7 biomarkers that showed a significant difference p < 0.05 (unpaired t test) described in 
table 3.10.). These were MMP activity (Ultimate ELTABA), TIMP-2, Cystatin C, Ac-PGP, Desmosine, 
LEF and CC16. The only biomarker that appeared to increase with age was CC16. When sub dividing 
these into gender, biomarkers associated with females and age were Ultimate ELTABA, Ac-PGP, and 
LEF and those that were associated with males and age were IL-1β, TIMP-2, Cystatin C, Ac-PGP, 
desmosine and CC16. 
Interestingly, if we to take the biomarkers where the gender difference in the CF cohort was not as 
significant compared to COPD i.e. TIMP-1, Calprotectin and CC16, and stratified gender differences 
by age, it is notable with aging (the more significant the result), this may explain why in COPD the 
gender difference is more significant (with less outliers) (figure 3.9). 
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Figure 3.7. Detailed analysis of gender-biased biomarker values, showing spread and significance 
levels. Scatter plots showing the difference in each biomarker between females (F) and males (M) 
across 3 cohorts (COPD and CF). Median with interquartile range shown for each plot. Unpaired t 
tests displayed for each combination, >0.05 = not significant (ns), degree of significance indicated by 
*, 1 star being just significant to 4 stars being very significant.  
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Table 3.10. Summary table displaying biomarker levels with age and gender. Median and 
interquartile ranges and p values unpaired t-tests for selected biomarkers of interest.  Groups are 
subdivided into gender and age (18yrs being the cut off).  Significant p values <0.05 highlighted in 
bold. 
Biomarker All data Females Males 
<18yr 
n = 78 
>18yr 
n =79 
P 
value 
<18yr 
n = 36 
>18yr 
n = 35 
P value <18yr 
n = 42 
>18yr 
n = 44 
P 
value 
Il-1β 4.7  
(1-7.2) 
2.4  
(0.3-4.8) 
0.6558 4.7  
( 
2.6-6.4) 
4.1 
(1.2-
6.6) 
0.4613 4.7  
(0-7.7) 
2.1  
(0-4.4) 
0.0024 
Ultimate 
ELTABA 
50.8 
(23-91.7) 
27.5  
(9.7-52.5) 
0.0133 36.7 
(14.8-
83.3) 
16.3 
(8.8-
29.6) 
0.0242 63 
(36.1-
95.7) 
32.7 
(13.4-
63.7) 
0.1716 
TIMP-2 5.1  
(3.3-7.5) 
4.3  
(1.8-6.2) 
0.0033 4.9  
(3.3-
9.5) 
4.7 
(1.8-
7.1) 
0.1461 5.4 
(3.2-
7.3) 
4 (1.6-
5.7) 
0.0063 
Cystatin C 81  
(37.7-126) 
44.2 
(28.1-
93.6) 
0.0033 46.7 
(33-
94.8) 
34.2 
(21.5-
70.3) 
0.0781 105.3 
(43.4-
153) 
71.9 
(36.1-
103.3) 
0.0093 
Ac-PGP 1175  
(790-1870) 
861.6 
(519.1-
1284) 
0.0021 1030 
(692.2-
1514) 
759.9 
(475-
1162) 
0.011 1492 
(905.1-
2296) 
1044 
(595.9-
1508) 
0.0338 
Desmosine 
EIA 
21.8  
(8.7-45.8) 
11.1  
(3.7-24.8) 
0.0002 12.7 
(6.3-37) 
6.1 
(2.5-
23.5) 
0.0509 27.7 
(13.7-
48.4) 
14.8 
(4.9-
25.8) 
0.001 
LEF 557.2 
(314.5-
777.6) 
417.9 
(203.7-
689.2) 
0.0056 528.9 
(338.4-
734.1) 
357.7 
(161.6-
649.7) 
0.0360 602.7 
(311.1-
866.7) 
444.3 
(242.9-
760.2) 
0.0688 
CC16 0  
(0-3.2) 
5.7  
(0-23.0) 
0.0368 0  
(0-0) 
0  
(0-4.5) 
0.4847 0  
(0-8.2) 
14.5 
(5.2-
43.3) 
0.0478 
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Figure 3.8. Box and Whiskers plot for stable CF (1) cohort stratified by age and gender. Non-
parametric test Mann Whitney p values <0.05 deemed to be significant. Median and interquartile 
ranges shown. 
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3.3.6 Biomarkers and frequency of exacerbations 
Repeated exacerbations of COPD are associated with a faster decline in lung function and poor 
health status.   Currently the single best predictor of exacerbation is the patient’s own history of 
exacerbations.  To better predict and understand exacerbations, biomarkers associated with COPD 
exacerbations have been intensively investigated with limited success.  Evaluated was the potential 
of a single biomarker or combination of urine biomarkers to characterize exacerbation status and 
improve the prediction of future COPD exacerbations.  The donor group was divided into two 
subgroups of subjects, based on their apparent status as frequent or infrequent exacerbators.  
Patients were assigned according to the number of pulmonary exacerbations (PEx) experienced in 
year 1.  The infrequent group consisted of subjects who experienced 1 or no PEx, and the frequent 
group comprised those individuals who had 2 or more in the first year (the maximum being a total of 
8).  These patients were either treated with oral corticosteroids (OCS) and/or antibiotics, either in 
hospital or at home. Table 3.3 presents the main demographical and clinical characteristics of the 
two groups at baseline. From the ECLIPSE data supplied to us, it was concluded that there were no 
significant differences in the baseline characteristics between infrequent and frequent exacerbators, 
except for the exacerbation frequency itself.  
Urine samples donated by 98 COPD subjects enrolled in the ECLIPSE study were evaluated. Half of 
the donors had been identified as frequent exacerbators (n=49) and half as infrequent exacerbators 
(n=49) on the basis of their exacerbation rate in the first year of the study. 
➢ Of the 49 subjects in the frequent exacerbation group, sixteen had <1 exacerbations prior to 
year one and 2-7 exacerbations in year 1. 
➢ Of the 49 subjects in the infrequent exacerbation group, 1 had >1 exacerbations prior to 
year one.  
3.3.6.1 Single biomarker analysis 
At timepoint 1, the only biomarker showing promise was IL-1β with a p value of 0.02.  The finding 
was confirmed in a second cohort from Birmingham cohort (chapter 4) where IL-1β was shown to be 
significantly higher in the frequent exacerbator group compared to the infrequent group.  Results 
shown in figure 3.10. 
3.3.6.2 Multiplex biomarker analysis  
Combinations of markers giving the best discrimination between infrequent and frequent 
exacerbator groups were identified by logistic regression. Analysis using logistic regression allows for 
the examination of independent covariates (markers) in relation to a binary outcome.  The analysis 
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started using a saturated model (all covariates included) with the number covariates reduced by 
exclusion based on their level of significance until only the significant (p<0.05) covariates remained. 
In this instance a backward elimination was more successful than a forward selection. Diagnostic 
accuracy was evaluated by AUC. A combination of 10 biomarkers was selected – Composite MMP 
activity, Pro MMP-9, TIMP-1, desmosine, fibrinogen, IL-6, IL-8, IL-1β, Cystatin C and A1AT with post-
bronchodilator FEV1 %-predicted and SGRQ score (quality of life 50 item questionnaire). This panel 
differentiated the infrequent and frequent groups (specificity, 91.5%; sensitivity, 90.6%; AUC = 0.92), 
as shown in Figure 3.10, below.  
The model correctly predicted 13 of the 16 subjects who converted from infrequent to frequent 
exacerbation, with a sensitivity of 81.3% and the one subject from frequent to infrequent state.  
These 13 subjects would have been missed on the basis of exacerbation history but were correctly 
identified by these biomarkers. 
 
Figure 3.9. Urine marker IL-1β differing significantly between COPD subgroups in the stable state. 
The graph shows the difference in urinary IL1β between frequent and infrequent exacerbators a) 
COPD ECLIPSE samples (p-0.0156) and b) Birmingham COPD samples (p<0.001).  
 
Figure 3.10. Statistical analysis of the data from 10 urinary biomarkers combined with FEV1% 
predicted. A) Box and whiskers plot, risk scores derived from the algorithm applied to all data B) ROC 
curve with AUC of 0.923 obtained in differentiation between infrequent and frequent exacerbations 
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3.4 Discussion 
These results clearly show that the selected biomarkers can be measured in urine, have distinctive 
trends when associated with other biomarkers and there is strong evidence for individual thresholds.  
It is also apparent that with appropriate subgrouping selected biomarkers can define frequent and 
infrequent exacerbators. 
Associations with low level inflammation found in stable COPD and CF 
In relation to the biomarkers found in healthy samples, there were 15 biomarkers that were 
significantly different in either COPD or CF with a p value <0.05. There were 11 biomarkers 
associated with UTI, 9 of which overlapped with both COPD and CF thus leaving 2 biomarkers that 
were specific to UTI (HNE and RBP4). To note the other 9 biomarkers that overlapped with both 
COPD and CF were the proteases and signalling molecules and non-specific molecules (MMP-8, 
MMP-9 (both active and pro form), IL-1β, IL-6, IL-8, fibrinogen and HSA) which left just 5 markers 
specific to COPD/CF which comprised of all the protease inhibitors, a signalling molecule and a 
consequence molecule (Cystatin C, TIMP-1, A1AT, fMLP and desmosine). It can be concluded that 
there are biomarkers (n=15) that are associated with both stable COPD and CF in relation to healthy 
state and biomarkers (n=5) that remain unchanged.  With regards to the specificity, it is clear that 
the signalling molecules are also associated with a UTI, however it is less clear regarding the 
protease and protease inhibitors. Although it appears from the data that proteases are more 
strongly associated with UTI in relation to the inhibitors, both protease and inhibitors are influenced 
by gender and the UTI cohort is entirely female whereas the other cohorts between 50-60% males. 
Correlations: Cluster 1: IL-8, MMP-8, MMP-9, HNE, NGAL, Calprotectin and MPO (of which the 
greatest correlation was with MMP-9, HNE and MPO) had the strongest correlation in females and 
cluster 2: fMLP, Cystatin C, Creatinine, B2M, RBP4, TIMP-2 and desmosine (of which creatine and 
TIMP-2 gave the greatest correlation) had the strongest correlation in Males. This was demonstrated 
in 4 study cohorts – normal, stable COPD and stable CF.  Group 1 consists of neutrophil released 
biomarkers and group 2 consists of protease inhibitors, degradation molecules and other molecules 
less defined. These defined correlations are strong with some of the markers exhibiting high 
Spearmans Rank r values > 0.7, tested in multiple cohorts to show repeatability, if the correlations 
are disrupted in more severe COPD states then it would increase the knowledge as to which 
biomarkers are involved and positioned in relevant biomarker pathways. 
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Figure 3.11. Correlations between biomarkers within clusters in healthy and stable COPD. A) healthy 
state cluster 1 B) Healthy state cluster 2 C) Stable COPD cluster 1 D) Stable COPD cluster 2. 
Spearmans rank r values shown with colour coded key ranging from red 0.5 to purple r =1. 
Influence of gender:  When stratifying the groups by gender the picture is further complicated by the 
fact that many of the markers were found to be gender-biased.  This is relevant to findings reported 
in a previous paper on studies with the ECLIPSE cohort in which it was found that exacerbations were 
significantly more frequent in women with moderate COPD than men with moderate COPD.  The 
results presented here are consistent with this reported gender bias in susceptibility to exacerbation, 
in that we have found higher levels of proteases and lower levels of inhibitors in female COPD.  This 
biochemical imbalance is usually associated with inflammatory disorders and it is known what the 
consequence is of active proteases that are not inhibited. There have been some investigations 
focusing on gender specific markers in plasma and serum but results have been very limited, especially 
in association with COPD (147).  There could be some links that could be explored further for example 
it was found in the ECLIPSE study that FEV1 decline, continued smoking and presence of emphysema 
were the strongest predictors of progression; CC16 was a potential biomarker for disease activity 
(decreased levels of CC16 related to more severe COPD) (148). The strongest predictors of emphysema 
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were continued smoking and female sex (149). In the urine testing that has been completed here it 
was found that there were marked gender differences with CC16, with lower levels in females when 
compared to males. Understanding how gender influences immunological mechanisms in health and 
disease and identifying gender-specific biomarkers would be invaluable in terms of targeted 
treatment. 
Influence of Age:   
There were 7 biomarkers that showed a significant difference p < 0.05 (unpaired t test) they were a 
mix of proteases, protease inhibitors, consequence molecules and CC16. There were not any 
differences observed with any of the signalling molecules. The only biomarker that appeared to 
increase with age was CC16. When sub dividing these into gender, biomarkers associated with 
females and age were Ultimate ELTABA, Ac-PGP, and LEF and those that were associated with males 
and age were IL-1β, TIMP-2, Cystatin C, Ac-PGP, desmosine and CC16.  Further analysis by stratifying 
into smaller age groups did show better discrimination with ageing however, the numbers in these 
subgroups were limited.  
Frequent and infrequent exacerbators: This study with urine samples from well-defined subjects in 
the ECLIPSE cohort enabled us to investigate and compare two different methods of identifying and 
predicting frequent and infrequent exacerbator status. The current and generally accepted method 
for prediction of exacerbation frequency is based on the actual number of exacerbation events in 
the previous year.  Using this method of prediction at recruitment retrospectively gave a sensitivity 
of 67% and specificity of 98% (> 1 moderate/severe exacerbation in prior year). The urine algorithm 
developed modelling 10 biomarkers and 2 other non-biomarker tests applied to the samples 
collected at recruitment gave a substantial improvement, with sensitivity of 90% and specificity of 
92% with the same subjects. This is the first-time urinary biomarkers in addition to clinical 
characteristics have been shown to predict frequency of exacerbations. This approach, if confirmed 
in larger cohorts, could be used to complement existing methods for monitoring disease activity and 
management of COPD exacerbations.  
There was one single marker IL-1β that was able to differentiate with good significance between 
frequent and infrequent exacerbators in 2 different cohorts, ECLIPSE and samples from a 
Birmingham study (described in chapter 4) with p values of 0.0156 and <0.001 respectively. 
These findings auger well for the wider use of urinary biomarkers in respiratory inflammatory 
disease or infections. 
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Chapter 4. Identification of biomarkers 
associated with COPD exacerbations 
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4.1 Introduction 
The quest to identify a marker or a combination of markers associated with COPD exacerbations has 
been pursued for some time. Many groups have studied biomarkers in plasma, serum, sputum and 
bronchoalveolar lavage fluid (BAL fluid) to uncover markers that can not only predict an event but 
are also linked to disease severity and mortality.  Repeated exacerbations are associated with a 
faster decline in lung function and it has been suggested that there may be a sub-group of patients 
that are more susceptible to exacerbations caused by persistently high levels of mediators that can 
be measured (23).  One group found that IL-6, CRP and TNFα measurements were repeatable over a 
12 month period in COPD patients and confirmed an association between IL-6 and CRP (CRP is 
regulated by IL-6 ) (150).  Plasma CRP levels are increased in COPD patients and are associated with 
increased mortality as well as cardiovascular risk (151). TNFα has been shown to play a central role 
in the muscle wasting and weight loss seen in COPD patients (150).  In another study, plasma CRP 
levels combined with a major exacerbation symptom such as dyspnoea, sputum volume, or sputum 
purulence was found to be useful in predicting exacerbation severity (152).  CRP again was 
highlighted in another study where higher measurements in plasma were associated with greater 
perception of breathlessness during mobilisation.  This led to the conclusion that CRP is an important 
predictor of future exacerbation and hospitalisation (153).  Previous testing of the ECLIPSE blood 
samples led to the conclusion that elevations in white blood cell (WBC) count, CRP, IL-6, IL-8, 
fibrinogen and TNFα, if persistent, could be associated with worse clinical outcomes. Fibrinogen was 
associated with poor survival, risk of exacerbation and poor clinical outcome (23).  This was also 
observed in a study looking at serum biomarkers in inflammation (IL-6, IL-8, IL-16 and TNFα), repair 
and injury (MMP-9, VEGF) and chemoattractants (PARC, MCP-3), but there was no significant 
increase with rising disease severity (154).  In a study exploring recovery and recurrence at COPD 
exacerbation (155) it was found that the time-course of systemic inflammation following 
exacerbation was different between frequent and infrequent exacerbators, and that a high serum 
CRP concentration after 14 days following an exacerbation may be used as a predictor of recurrent 
exacerbations within 50 days.  Conversely, a similar study evaluated plasma CRP and IL-6 levels over 
3 years and found no difference in CRP concentrations but did find that IL-6 elevation was persistent, 
progressive and associated with worsening of symptoms and mortality (156).  
Although clinical predictors of death have not been investigated in this thesis, a previous ECLIPSE 
study (157) has shown that a combination of WBC, IL-8, fibrinogen, CCL-18/PARC and SP-D 
measurements could significantly improve the ability to predict mortality in patients with COPD.  A 
different marker not mentioned above was sputum IL-1β (14) (AUC, 0.89; 95% CI, 0.83-0.95).  This 
mediator was also identified in the chapter 3 as a promising urinary biomarker.  It was found in the 
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previous published study, that IL-1β, together with serum CXCL10 and peripheral eosinophil count, 
were biomarkers of bacteria-, virus-, or eosinophil-associated exacerbations of COPD (14).  Other 
markers in sputum have been well studied, including MPO, elastase, leukotriene-B4, IL-8, SLPI and 
CRP.  SLPI was significantly lower in the frequent exacerbators.  There have been numerous studies 
of biomarkers in BAL fluid, gathered through an invasive and unpleasant sampling technique.  It was 
found that BAL fluid IL-8 was significantly higher in COPD patients with frequent exacerbation than 
infrequent (P=0.001) n=39.  MPO, and TNFα were also measured and a significant difference was 
found with these markers when compared to controls. 
Apart from urinary desmosine, no other urinary biomarker has been associated with COPD 
exacerbations.  Desmosine and isodesmosine (by products of lung elastin degradation) have been 
found to be raised in exacerbations above the level found in the stable disease state (158). 
Urine samples were obtained from 3 separate studies aimed to explore urinary biomarker profiles in 
stable, exacerbation and recovery states. 
- QEH Birmingham, Samples were collected at QEH Birmingham at time of exacerbation then at 
subsequent days back to recovery – 7, 14 and 56.  
- GSK AERIS – GSK provided sample sets of urine collected from a subgroup of COPD subjects 
participating in the AERIS study (the so-called “nasopharyngeal swab” cohort).  Urine samples were 
provided from each planned monthly clinic visit during the first 12 months of the study for 35 
patients.  In addition, urine samples collected at the time of each unscheduled clinic visit for a COPD 
exacerbation was also provided (The study investigator made a clinical judgement that the subject 
was experiencing an exacerbation).  
 – Leicester BEAT-COPD study - blood and urine samples from COPD subjects were longitudinally 
collected at four visit types: namely stable state, exacerbation, two weeks post therapy and at 
recovery (six weeks post exacerbation visit).  
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4.2 Methods  
4.2.1 Patient selection and assessment 
For each cohort, the patient selection and assessment was varied, the reason for this was due to 
accessibly to clinical samples, all the samples were obtained from samples banks and it was not 
possible to specify inclusion and exclusion criteria or to contribute to the design of the clinical trials 
as they were all retrospective studies. Criteria were established based on the aims and objectives of 
each individual study. The details for each individual study are described below. 
4.2.2 COPD subjects – QEH Birmingham 
Patients with AECOPD admitted to 2 hospitals were approached from September 2012 to January 
2014. Eligible patients had major symptom deterioration (sputum volume, sputum colour or 
dyspnoea) for ≥2 consecutive days and a documented clinical diagnosis of COPD. Exclusion criteria 
included lung cancer, interstitial lung disease, active pulmonary tuberculosis and pneumonia. The 
study was ethically approved (09/H1210/75) and informed consent taken within 24 hours of 
admission. Subjects underwent symptom and clinical assessment, completed the COPD assessment 
test (CAT), and had blood and a random urine sample (early morning) collected on admission (day 1) 
and at day 56. Urine was also collected at days 7 and 14. Symptom diary cards (Bronkotest®) were 
used, with the colour chart being used to define purulence of sputum, and post bronchodilator 
spirometry was performed at day 56. 
4.2.3 COPD subjects – GSK AERIS study 
Acute Exacerbation and Respiratory InfectionS in COPD (AERIS) was a prospective observational 
study funded by GSK. Participants were seen for an enrolment visit and then monthly for 2 years. In 
addition to these scheduled visits, all participants were seen in the clinic within 72 h (3 days) of 
onset of symptoms of AECOPD. AECOPD was defined as worsening of at least two major symptoms 
(dyspnoea, sputum volume and sputum purulence) or worsening of at least one major symptom and 
one minor symptom (wheeze, sore throat, cold (nasal discharge and/or nasal congestion), cough and 
fever (oral temperature >37.5°C) without other cause), considered clinically relevant at the site. 
Exacerbations were identified by means of electronic diary cards that participants completed daily. 
The data recorded daily in the electronic diary cards included self-performed peak flow 
measurement (peak expiratory flow (PEF) and FEV1), a series of morning questions to identify 
symptoms of exacerbations and the EXAcerbations of Chronic Pulmonary Disease Tool V.1.0 (EXACT-
PRO) at bedtime. Data on patient-reported symptoms based on morning questions and on PEF/FEV1 
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were transmitted daily to the study clinic. Changes/worsening in these symptoms were monitored 
by the study staff and participants were contacted and invited to the clinic when an exacerbation 
was suspected. 
Biological specimen collection. A wide range of biological specimens were collected from study 
participants, blood, sputum, nasopharyngeal swabs, breath and urine were collected. Urine samples 
were collected from all patients at study entry and at exacerbation and from a subcohort of 30 
patients at monthly follow-up visits during the first year and at exacerbation.   
Study procedures. In addition to the daily monitoring undertaken through the patient-completed 
electronic diary cards, a wide range of study procedures were performed at study entry, scheduled 
monthly visits and exacerbation visits (table 4.1). 
4.2.4 COPD subjects – Leicester BEAT-COPD study  
Samples (banked, frozen) were provided from a previous University of Leicester study (MRC funded 
BEAT-COPD (Biomarkers to Target Antibiotic and Systemic Corticosteroid Therapy in COPD 
Exacerbations) study ISRCTN2422949). 
Study details: From a two-staged single centre study, blood, sputum and urine samples from COPD 
subjects were longitudinally collected at four visit types: namely stable state (defined as being eight 
weeks free from an exacerbation visit), exacerbation (defined according to Anthonisen criteria 
[Anthonisen 2006] and healthcare utilisation), two weeks post therapy and at recovery (six weeks 
post exacerbation visit). Exacerbations were treated with oral corticosteroids and antibiotics 
according to guidelines or trial study design. Clinical data including demographics, symptoms, lung 
function, inflammatory profiling in blood and sputum, bacteriology including standard culture, qPCR 
for common pathogens and microbiomics, viruses by PCR and fungal culture were undertaken. 
4.2.5 Laboratory methods 
Blood samples were analysed for white cell count and C-reactive protein measurement as per usual 
care, and serum and plasma were isolated by centrifuge (10 minutes, 3000rpm) before storage at -
80°C. Sputum samples were sent for standard laboratory microscopy, culture and sensitivity analysis 
where patients were able to produce a sample. Urine samples were stored at -80°C before transfer 
to Mologic Ltd. for testing. 
4.2.6 Biomarker measurements 
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Urine samples were transferred to Mologic and stored at -80°C until analysis. The samples were 
analysed with the assays reported in Chapter 2 if available at the time. For the earlier studies, limited 
assays were undertaken as new assays were not introduced until a later date. The samples, once 
thawed, were tested on the same day.  
4.2.7 Statistical analysis 
All data were analysed using SPSS (version 21), GraphPad PRISM Version 7.  Data normality was 
explored, and appropriate parametric or non-parametric tests chosen accordingly. Receiver-operator 
characteristic (ROC) analysis and Wilcoxon’s signed rank test, Mann-Whitney or students t-test with 
significance levels p<0.05 was used to compare biomarker levels in different disease states, 
subgroups and gender.  Logistic regression and decision tree analysis was used to develop predictive 
models, combining biomarkers that determined the outcome of exacerbation. Internal validation 
was addressed by dividing the cases into 80% training set and 20% test set. This process was 
repeated 5 times using assignment to training and validation sets by random number generation in 
SPSS. 
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4.3 Results 
4.3.1 Patient characteristics 
Combined patient characteristics are shown in table 4.1. Matched demographics were not possible 
across all three studies as the criteria were different for each study and CRF.  There was not one 
criterion that stood out as being different except that the Leicester study recruited more males 65% 
compared to 54% for the other two studies. Comorbidities were variable but this information was 
not available for the Birmingham study so a complete comparison was not possible. 
4.3.2 COPD subjects – QEH Birmingham 
86 patients were consented to the study at the start of an exacerbation. A high proportion of 
patients re-exacerbated (n=13, based on their report or diary card) within the follow up period, thus 
a stable state 56 day sample was not available. Other losses to follow up included 4 patients who 
died, 2 who withdrew and 7 who failed to attend their day 56 appointment; this left 56 patients 
remaining in the study. 1 patient who had PiZZ AATD was excluded from analysis. Characteristics of 
the patients included in the final biomarker analyses (both day 0 and stable day 56 urine available) 
are shown in table 4.1. From exacerbation to recovery, CAT score improved (-6.8 (1.5); p<0.0001) 
whilst CRP fell in 54% patients and was static in the rest (median difference -1.0, p=0.458). 
4.3.3 COPD subjects – GSK AERIS study 
From the sub study of 37 participants, separated by gender, it was observed that males had a higher 
BMI, creatinine levels and procalcitonin whereas females had higher cholesterol, cholesterol HDL 
and platelets as shown by Mann-Whitney and unpaired t tests. 
4.3.4 COPD subjects – Leicester BEAT-COPD study  
One hundred fifty-six patients were enrolled; 145 (101 male, 70%) completed the first visit and 115 
completed 12 months. For the urine analysis, 55 patients were selected, 66% were male, baseline 
clinical characteristics are shown in table 4.1. At baseline 0%, 23%, 22%, and 7% had GOLD I, II, III, and 
IV, respectively.  
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Table 4.1. Characteristics of the patients included in the paired sample analyses for all three studies. 
Data are shown as Number (%), mean (SD) or mean (SE*) 
Criteria  Birmingham Cohort  AERIS Leicester BEAT-
COPD 
 Baseline  Baseline Baseline 
 N= 56 N = 37 N = 55 
Age yrs.  Mean (SE*) or (SD) 69.34 (1.39*) 69.16 (7.2) 72.8 (29.4) 
Male  No (%) 31 (55%) 20 (54%) 36 (66%) 
Smoking, pack-years  Mean (SE*) or (SD) 38  43.62 (18) 46 (4*) 
Current smokers  No (%) 20 (36%) 9 (24%) 15 (27%) 
BMI, kg/m2 Mean (SE*) or (SD)  - 27.02 (5.6) 24.0 (1.5*) 
Frequent exacerbators (≥2 pa) No (%) 43 (77%) 21 (57%)  - 
mMRC Score Mean (SE*) or (SD)  - -  3.1 (0.9) 
SGRQ-C Total Score Mean (SE*) or (SD)  -  - 55.5 (18.9) 
Exacerbations in year prior to 
recruitment 
Mean   - -  0.8 
Emphysema No (%) 32 (57%) 20 (54%)  - 
Hypertension  No (%)  - 16 (43%)  - 
Cardiovascular disease  No (%) 15 (27%) 7 (19%)  - 
Hx Osteoporosis No (%)  - 3 (8%)  - 
Diabetes  No (%) 11 (20%) 3 (8%)  - 
Physiology    -  -  - 
FEV1 (L), post-BD Mean (SE*) or (SD) 1.10  1.1 (0.4) 1.3 (0.5) 
FVC (L), post-BD Mean (SE*) or (SD)  - 2.8 (0.7) 2.6 (0.8) 
FEV1/FVC, post-BD Mean (SE*) or (SD)  - 45 (12.5) 51.1 (1.0*) 
Oxygen sat Mean (SE*) or (SD)  - 95.1 (2.1)  - 
OLD GOLD Risk Index      
Mild [1] No (%)  - 0 0 
Moderate [2] No (%)  - 15 (41%) 23 (42%) 
Severe [3] No (%)  - 17 (46%) 22 (40%) 
Very severe [4] No (%)  - 5 (14%) 7 (13%) 
Inflammatory biomarkers      
White Blood Cell Count (X 106 
/ml) 
Mean (SE*) or (SD)  - 7.9 (1.7) -  
Serum creatinine (mg/dl) Mean (SE*) or (SD) 82.17 (5.15*) 72 (19.2) 81.4 
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4.3.5 Individual Biomarker measurements 
In this section, the individual biomarkers according to the disease state were reported.  
- Biomarker profiles from exacerbation to recovery (QEH Birmingham) 
- Biomarker profiles from stable to exacerbation (Leicester BEAT-COPD) 
- Longitudinal profiles – Pre-exacerbation/exacerbation/post exacerbation (GSK AERIS) 
 
4.3.5.1.  Birmingham study  
Only samples that had a matched exacerbation and recovery sample at day 56 were included in the 
analysis. Data from 56 patients were taken forward, however, not all biomarkers were measured for 
each sample, the number of samples tested are reported in table 4.2.   
Using paired t-test analysis and Wilcoxon matched-pairs pair signed rank test, markers that were 
significantly different between exacerbations and recovery states were calculated.  The p values are 
shown in Table 4.2, criteria of values <0.05 were deemed significant. There were six biomarkers that 
were significantly different from exacerbation to recovery states, in order of significance these were 
HSA, A1AT, TIMP-1, fibrinogen and RBP4. For cystatin C, the p value was 0.0507, this value was 
deemed to be significant. 
4.3.5.2  Leicester study  
In total 1216 urine samples were tested, of which, 427 sample were classified as stable, 168 as 
exacerbation samples, 89 as pre-exacerbation samples, 138 as 2-week recovery samples and 96 as 4-
6-week recovery samples. From a total of 85 patients there were 168 PEx events, not all of them had 
a 2-week and 4-week recovery sample.  Some of the patients also had other stable samples collected 
within the 1 year but some of these samples were not deemed to be ‘stable’ based on the close 
proximity collected to a reported exacerbation. From this cohort, 55 patients were identified with 
stable timepoints and enough collection points to establish a baseline. These patients and samples 
were taken forward for further analysis. 
Using paired t-test analysis and Wilcoxon matched-pairs pair signed rank test, markers that were 
significantly different between stable and exacerbation states were calculated.  The p values are 
shown in Table 4.3, and values <0.05 were deemed significant. There were thirteen biomarkers that 
were significantly different from stable to exacerbation states, in order of significance these were 
A1AT, creatinine, CRP, cystatin C, CHI3L1, fibrinogen, TIMP-2, calprotectin, NGAL, CC16, TIMP-1, 
MMP-9, RNASE-3. 
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4.3.5.3. GSK AERIS study 
35 patients had samples collected over 1 year (a total of 454 samples were tested, 106 Exacerbation 
samples, 24 not recovered and 324 ‘stable’). 
71 exacerbation events were selected, on the basis that each event had a ‘pre- exacerbation’ and a 
‘post exacerbation’ sample, allowing longitudinal tracking. It should be noted that not all pre or post 
samples were deemed to be stable or recovery samples respectively due to the close proximity to 
the date of when the exacerbation sample was collected. 
• Pre-exacerbation sample was collected between 3-66 days before the exacerbation 
• Post exacerbation sample was collected between 6 and 73 days after the exacerbation event 
Using paired t-test analysis and Wilcoxon matched-pairs pair signed rank test, markers that were 
significantly different between exacerbations and pre-exacerbation and post-exacerbation were 
calculated.  The markers were also normalised with creatinine.  The median and interquartile ranges 
are shown in table 4.4 and the p values are shown in Table 4.5 with values <0.05 deemed significant. 
Paired t tests with raw data (no normalisation). There were two biomarkers that were significantly 
different from pre-exacerbation to exacerbation states, in order of significance these were CRP and 
creatinine. There were five biomarkers that were significantly different from exacerbation to post-
exacerbation, in order of significance these were CRP, Active MMP (as measured with Ultimate 
ELTABA*), calprotectin, Creatinine, A1AT. 
Paired t tests with creatinine normalised data. There were three biomarkers that were significantly 
different from pre-exacerbation to exacerbation states, in order of significance these were CRP, LEF 
and calprotectin. There were five biomarkers that were significantly different from exacerbation to 
post-exacerbation, in order of significance these were fMLP, CRP, LEF, IL-6, IL-1β. 
Wilcoxon matched-pairs signed rank test with raw data (no normalisation). There were two 
biomarkers that were significantly different from pre-exacerbation to exacerbation states, in order 
of significance these were CRP and A1AT. There were nine biomarkers that were significantly 
different from exacerbation to post-exacerbation, in order of significance these were CRP, A1AT, 
HSA, CC16, Ultimate ELTABA*, Creatinine, NGAL, fibrinogen and desmosine.  
Wilcoxon matched-pairs signed rank test with creatinine normalised data. There was only one 
biomarker that was significantly different from pre-exacerbation to exacerbation states- CRP.  There 
were two biomarkers that were significantly different from exacerbation to post exacerbation states, 
in order of significance these were CRP and fMLP*.  
* Significance was also obtained with pre-exacerbation in relation to post exacerbation. 
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Table 4.2. Birmingham study; Biomarker results at exacerbation and recovery state. The table shows 
the results in exacerbation and recovery state for each urinary marker and the paired statistical test 
results for each marker between exacerbation and recovery state. Since most were non-normally 
distributed the data is shown as median (IQR). Significant p values <0.05 highlighted in bold 
  Exacerbation Recovery Paired t 
test 
  Unit Number 
of 
values 
Median (IQR) Number 
of values 
Median (IQR) p value 
IL-6 pg/ml 54 2.561 (0-7.665) 54 2.998 (0-8.647) 0.268868 
fMLP ELISA ng/ml 28 2.164 (0.4358 -7.287) 28 1.91 (0.5318-5.717) 0.859535 
IL1b pg/ml 51 1.137 (0-4.088) 51 2.765 (0.01-7.002) 0.789275 
Siglec 8 ng/ml - - - - - 
Chitinase 3 like protein ng/ml - - - - - 
Ultimate ELTABA ng/ml 39 347 (205-827) 36 444 (236-910) 0.477047 
MMP Substrate assay ng/ml 54 3.695 (0-13.6) 54 1.42 (0-10.12) 0.307046 
HNE substrate Assay ng/ml 19 83 (0-15830) 22 4506 (0-10685) 0.875767 
IL-8 pg/ml 54 0.201 (0-34.86) 54 6.704 (0-48.93) 0.422378 
MMP-8 Total ng/ml 54 0.2545 (0-4.377) 50 0.195 (0.01425-6.385) 0.492476 
MMP-9 Total ng/ml 54 0.5735 (0.09825-4.845) 50 0.5605 (0.2518-8.284) 0.293608 
HNE ng/ml 54 13.99 (3.194-85.14) 50 15.62 (4.045-247) 0.281369 
NGAL ng/ml 54 33.63 (8.97-80.59) 50 29.71 (11.52-57.55) 0.771887 
Calprotectin ng/ml 53 26.9 (10-59) 49 37.6 (11-59.96) 0.124275 
MPO ng/ml 20 2.338 (0.9538-27.94) 18 10.41 (3.711-40) 0.075856 
RNASE-3 ng/ml - - - - - 
A1AT ng/ml 55 255.3 (27.6-759.2) 55 126.8 (15.52-326.4) 0.019691 
TIMP-1 ng/ml 55 2.936 (1.435-8.312) 55 2.351 (0.762-5.293) 0.025183 
SLPI ng/ml - - - - - 
Cystatin C ng/ml 54 89.75 (54.82-219.2) 54 88.16 (24.68-142.9) 0.050729 
Creatinine mg/dl 55 69.85 (40.7-105.4) 55 57.1 (33.8-104.4) 0.582562 
beta 2 Microglobulin ng/ml 53 281.9 (144.9-991.7) 49 147.2 (68.04-455.9) 0.129004 
RBP4 ng/ml 51 196.5 (127.5-473.7) 51 147.8 (83.04-296.9) 0.046883 
TIMP-2 ng/ml 55 4.194 (2.268-8.114) 55 3.342 (1.387-7.319) 0.178329 
Ac-PGP ng/ml - - - - - 
Desmosine V1 ELISA ng/ml 54 20.45 (2.675-44.43) 53 17.41 (2.25-49.51) 0.994632 
LEF ng/ml - - - - - 
Desmosine fragments ng/ml - - - - - 
CC16 ng/ml - - - - - 
CRP ng/ml - - - - - 
Periostin ng/ml - - - - - 
H.S.A ng/ml 51 4194 (1270-15344) 50 2321 (667.6-8475) 0.006548 
Fibrinogen Abcam ng/ml 54 11.75 (4.423-30.55) 54 13.89 (5.281-58.39) 0.034147 
sRAGE ng/ml - - - - - 
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Table 4.3. Leicester study; Biomarker results at stable and exacerbation state. The table shows the 
results in stable and exacerbation state for each urinary marker and the paired statistical test results 
for each marker between stable and exacerbation state. Since most were non-normally distributed 
the data is shown as median (IQR). Significant p values <0.05 highlighted in bold. For this data set, all 
‘0’ values were substituted with the Lower Limit Of Detection (LLOD) for each assay as indicated. 
Biomarker assay Unit LLOD Stable n=55 Exacerbation n=55 Paired 
t-test 
IL-6 pg/ml 1.6263 1.63 (1.63-1.63 1.63 (1.63-3.86) 0.2991 
fMLP ELISA ng/ml 0.075 3.10 (0.08-7.29) 2.96 (0.08-10.64) 0.0657 
IL1b pg/ml 0.3697 24.74 (14.78-29.56) 24.89 (17.26-29.31) 0.3860 
Siglec 8 ng/ml 0.78  179.90 (110.10-263.70) 222.60 (114.60-306.20) 0.2074 
Chitinase 3 like protein ng/ml 0.0007 0.03 (0.00-0.12) 0.06 (0.01-0.53) 0.0055 
Ultimate ELTABA  ng/ml 3.9 65.23 (27.32-140.00) 77.74 (30.17-135.60) 0.7258 
MMP Substrate assay ng/ml 7.8125 7.81 (7.81-58.67) 7.81 (7.81-53.70) 0.8976 
HNE substrate Assay ng/ml 0.027 0.03 (0.03-0.03) 0.03 (0.03-0.03) 0.1483 
IL-8 pg/ml 2.83 2.83 (2.83-2.83) 2.83 (2.83-2.83) 0.2791 
MMP-8 Total ng/ml 8.52 64.74 (8.52-193.70) 103.70 (8.52-734.70) 0.0557 
MMP-9 Total ng/ml 6.78 306.70 (38.61-1077 347.10 (53.10-2505) 0.0409 
HNE ng/ml 0.0695 0.64 (0.07-2.74) 0.88 (0.07-4.53) 0.0826 
NGAL ng/ml 0.0205 13.01 (5.88-24.89) 24.33 (6.88-41.53) 0.0262 
Calprotectin ng/ml 0.48 51.60 (0.48-253.60) 65.11 (0.48-349.10) 0.0164 
MPO pg/ml 10.37 4429 (1423-12386) 6328 (1152-24522) 0.0759 
RNASE-3 pg/ml 16 16.00 (16.00-50.63) 16.00 (16.00-299.20) 0.0465 
A1AT ng/ml 0.164 44.14 (20.02-154.40) 123.80 (37.01-268.10) 0.0001 
TIMP-1 pg/ml 14.305 1328 (424.20-3455) 1890 (530.90-5133) 0.0361 
SLPI ng/ml 0.1065 2.45 (0.11-8.78) 3.94 (0.69-11.16) 0.2236 
Cystatin C ng/ml 0.0002 31.90 (17.77-57.16) 70.11 (27.21-107.00) 0.0025 
Creatinine mg/dl 0.01 58.81 (29.71-93.38) 89.57 (40.16-128.10) 0.0005 
beta 2 Microglobulin ng/ml 0.02 16.34 (5.79-36.57) 49.69 (14.02-115.70) 0.0526 
RBP4 pg/ml 11.72 48245 (18553-90095) 79464 (34107-167925) 0.5475 
TIMP-2 pg/ml 1.5605 1899 (982.60-3519) 3121 (1415-5110) 0.0136 
Ac-PGP ng/ml 2.12 353.60 (207.70-652.20) 405.80 (213.20-632.80) 0.6569 
Desmosine V1 ELISA ng/ml 0.4095 37.54 (10.15-90.65) 41.67 (9.77-93.39) 0.0634 
LEF ng/ml 7.815 654 (354.80-1496) 1072 (356.20-2347) 0.0709 
Desmosine fragments ng/ml 0.41 1000 (1000-1000) 1000 (1000-1000) 0.1475 
CC16 ng/ml 0.0101 17.60 (6.50-66.37) 33.90 (15.43-86.05) 0.0284 
CRP pg/ml 7.8125 7.81 (7.81-191.90) 107.70 (7.81-1268) 0.0012 
Periostin pg/ml 6.25 56.82 (6.25-139.70) 63.31 (6.25-165) 0.3202 
H.S.A ng/ml 1.25 2625 (1078-8423) 3399 (1923-10459) 0.6286 
Fibrinogen Abcam ng/ml 0.5 8.40 (3.93-34.57) 12.97 (6.50-37.37) 0.0079 
sRAGE ng/ml 0.01 0.03 (0.01-0.06) 0.03 (0.01-0.08) 0.1345 
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Table 4.4. AERIS study; Biomarker results at pre-exacerbation, exacerbation and post-exacerbation 
state. The table shows the results in all three states for each urinary marker. Since most were non-
normally distributed the data is shown as median (IQR). Significant p values <0.05 highlighted in bold 
Biomarker assay Unit Median (IQR) 
Pre- exacerbation n=71 Exacerbation n=71 Post- exacerbation n=71 
IL-6 pg/ml 0.06 (0-3.90) 0.59 (0-5.92) 0 (0-2.19) 
fMLP ELISA ng/ml 3.52 (1.77-5.79) 3.92 (2.20-6.50) 4.62 (2.43-6.77) 
IL1b pg/ml 2.11 (0-5.96) 3.14 (0-6.09) 2.68 (0-6.01) 
Siglec 8 ng/ml - - - 
Chitinase 3 like protein ng/ml - - - 
Ultimate ELTABA  ng/ml 16.63 (0-46.63) 24.36 (0-48.08) 11.22 (0-34.55) 
MMP Substrate assay ng/ml 0 (0-2.41) 0 (0-2.109) 0 (0-2.28) 
HNE substrate Assay ng/ml 0 (0-0) 0 (0-0) 0 (0-0) 
IL-8 pg/ml 2.823 (0-33.87) 2.67 (0-35.72) 1.453 (0-26.8) 
MMP-8 Total ng/ml 0 (0-1.89) 0.343 (0-1.709) 0 (0-1.22) 
MMP-9 Total ng/ml 1.185 (0-5.089) 0.92 (0-4.24) 0.706 (0-3.54) 
HNE ng/ml 3.99 (0-16.06) 3.538 (0-16.93) 1.366 (0-12.38) 
NGAL ng/ml 17.10 (5.47-46.68) 22.54 (4.05-56.31) 10.39 (3.77-24.89) 
Calprotectin ng/ml 35.67 (14.54-55.81) 36.03 (15.93-61.54) 33.16 (11.14-48.68) 
MPO ng/ml 9.57 (2.23-34.85) 6.93 (1.53-40.00) 4.69 (1.19-19.18) 
RNASE-3 ng/ml - - - 
A1AT ng/ml 70.14 (12.37-144.50) 106.70 (20.82-381.30) 61.10 (12.86-162.80) 
TIMP-1 ng/ml 1.57 (0.71-4.19) 1.71 (0.71-4.65) 1.57 (0.70-3.65) 
SLPI ng/ml - - - 
Cystatin C ng/ml 62.79 (32.64-100.30) 71.03 (46.06-121.60) 61.45 (32.90-92.94) 
Creatinine mg/dl 91.72 (51.96-130.90) 106.50 (72.00-161.70) 72.95 (53.97-118.80) 
beta 2 Microglobulin ng/ml 55.33 (28.03-100.80) 67.03 (36.80-128.30) 52.05 (26.03-80.21) 
RBP4 ng/ml 94.70 (62.92-128.20) 103.10 (64.96-144.60) 94.49 (53.00-138.50) 
TIMP-2 ng/ml 4.47 (1.93-6.79) 4.59 (2.68-7.50) 3.46 (2.08-6.59) 
Ac-PGP ng/ml 2425 (1068-4678) 3213 (1714-7168) 2350 (1027-5411) 
Desmosine V1 ELISA ng/ml 10.69 (2.48-21.66) 11.62 (4.36-28.21) 5.94 (2.79-18.68) 
LEF ng/ml 707 (301-1124) 663 (394-1039) 692 (410-1180) 
Desmosine fragments ng/ml 677.2 (199-1000) 748.9 (278.1-1000) 581.8 (187.2-1000) 
CC16 ng/ml 5.97 (0-30.6) 10.84 (0-80.9) 8.762 (0-26.98) 
CRP ng/ml 211.5 (31.2-723.4) 1004 (149-3997) 237.6 (31.2-1012) 
Periostin ng/ml - - - 
H.S.A ng/ml 2259 (747.7-5845) 2266 (868.5-8286) 1285 (527.5-4649) 
Fibrinogen Abcam ng/ml 18.78 (9.19-63.12) 24.42 (12.48-60.7) 18.97 (9.005-50.42) 
sRAGE ng/ml - - - 
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Table 4.5. AERIS study; Pre-exacerbation vs exacerbation, exacerbation vs post exacerbation and pre-exacerbation vs. post exacerbation comparisons (p-
values). No creatinine ratio vs. creatinine ratio and 2 different statistical tests performed – student paired t-test and Wilcoxon matched-pairs signed rank 
tests. Significant p values <0.05 highlighted in bold 
Biomarker 
assay 
Unit Paired t-test Wilcoxon matched-pairs signed rank test 
No creatinine ratio Creatinine ratio 
 
No Creatinine ratio Creatinine ratio 
 
Pre- 
PEx to 
PEx 
PEx  
to  
post  
PEx 
Pre- 
PEx to  
Post-  
PEx 
Pre- 
PEx to 
PEx 
PEx  
to  
post  
PEx 
Pre- 
PEx to  
Post-  
PEx 
Pre- PEx 
to PEx 
PEx  
to  
post  
PEx 
Pre- 
PEx to  
Post-  
PEx 
Pre- 
PEx to 
PEx 
PEx  
to  
post  
PEx 
Pre- 
PEx to  
Post-  
PEx 
IL-6 pg/ml 0.9548 0.0680 0.2502 0.4522 0.0248 0.1894 0.2961 0.0153 0.1539 0.2804 0.0306 0.1442 
fMLP ELISA ng/ml 0.4592 0.6127 0.3101 0.2033 0.0014 0.4551 0.4032 0.5699 0.3625 0.0593 <0.0001 0.0057 
IL1b pg/ml 0.6224 0.7802 0.5617 0.3468 0.0444 0.5262 0.1914 0.9718 0.6433 0.8747 0.0632 0.2904 
Siglec 8 ng/ml - - - - - - - - - - - - 
Chitinase 3 like 
protein 
ng/ml - - - - - - - - - - - - 
Ultimate ELTABA  ng/ml 0.3564 0.0080 0.0401 0.8997 0.0628 0.1110 0.3819 0.0143 0.0462 0.4167 0.1561 0.274 
MMP Substrate assay ng/ml 0.2437 0.1751 0.7265 0.7103 0.5291 0.3965 0.7093 0.2688 0.6981 0.9886 0.795 0.3529 
HNE substrate Assay ng/ml 0.5548 0.2148 0.4679 0.2285 0.0907 0.7747 0.7209 0.8264 0.5562 0.3529 0.2069 0.4575 
IL-8 pg/ml 0.6400 0.9822 0.6935 0.3161 0.4512 0.4710 0.8602 0.2276 0.6509 0.6288 >0.9999 0.907 
MMP-8 Total ng/ml 0.5384 0.3200 0.7168 0.1817 0.1648 0.9172 0.7038 0.5773 0.2427 0.234 0.9381 0.3377 
MMP-9 Total ng/ml 0.9308 0.7547 0.6617 0.2324 0.4615 0.5492 0.7687 0.5846 0.1501 0.2306 0.956 0.3001 
HNE ng/ml 0.1691 0.2131 0.7549 0.0890 0.1331 0.9088 0.4873 0.6353 0.0543 0.1969 0.732 0.1452 
NGAL ng/ml 0.6075 0.1385 0.5221 0.2114 0.5410 0.5684 0.7726 0.02 0.0705 0.3317 0.292 0.0234 
Calprotectin ng/ml 0.5310 0.0284 0.1723 0.0361 0.1351 0.4935 0.8711 0.0564 0.2097 0.1162 0.7049 0.5925 
MPO ng/ml 0.8231 0.1639 0.0727 0.0839 0.8475 0.1157 0.5765 0.3815 0.0784 0.1475 0.9589 0.1637 
RNASE-3 ng/ml - - - - - - - - - - - - 
A1AT ng/ml 0.0998 0.0496 0.8936 0.8069 0.5920 0.5346 0.0069 0.0045 0.6168 0.1131 0.0509 0.9444 
TIMP-1 ng/ml 0.5207 0.1000 0.3787 0.5620 0.6891 0.8500 0.9846 0.3215 0.2769 0.5804 0.822 >0.9999 
SLPI ng/ml - - - - - - - - - - - - 
Cystatin C ng/ml 0.0935 0.7411 0.4538 0.6885 0.5284 0.7684 0.2555 0.0689 0.5786 0.7956 0.1363 0.4633 
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Creatinine mg/dl 0.0446 0.0475 0.9740 - - - 0.079 0.0177 0.6384 - - - 
beta 2 Microglobulin ng/ml 0.1987 0.5890 0.7372 0.2977 0.4869 0.8627 0.0661 0.0201 0.5884 0.7956 0.1363 0.4633 
RBP4 ng/ml 0.0556 0.6915 0.3757 0.7761 0.8772 0.8973 0.1216 0.0916 0.9252 0.9796 0.6022 0.7262 
TIMP-2 ng/ml 0.2670 0.1909 0.7500 0.3221 0.1901 0.8070 0.4501 0.2115 0.4198 0.4779 0.2406 0.6933 
Ac-PGP ng/ml 0.1519 0.1373 0.8272 0.4598 0.4624 0.9061 0.161 0.0829 0.9796 0.6345 0.6417 0.8176 
Desmosine V1 ELISA ng/ml 0.4496 0.1845 0.4381 0.4007 0.7739 0.3824 0.5516 0.0322 0.052 0.8891 0.1332 0.1071 
LEF ng/ml 0.7985 0.9592 0.8367 0.0323 0.0123 0.7875 0.65 0.9478 0.6507 0.1243 0.0751 0.8577 
Desmosine fragments ng/ml 0.5995 0.4921 0.8314 0.0536 0.2007 0.1841 0.5793 0.4203 0.8132 0.0714 0.2338 0.7606 
CC16 ng/ml 0.0836 0.0121 0.3680 0.4831 0.3010 0.5773 0.1288 0.007 0.7628 0.3041 0.2312 0.6254 
CRP ng/ml 0.0001 0.0027 0.3509 0.0001 0.0019 0.3301 <0.0001 0.0013 0.6038 <0.000
1 
0.0004 0.3814 
Periostin ng/ml - - - - - - - - - - - - 
H.S.A ng/ml 0.1351 0.0774 0.8065 0.1648 0.7747 0.0989 0.3029 0.0069 0.3944 0.688 0.5215 0.0448 
Fibrinogen Abcam ng/ml 0.4198 0.3667 0.7458 0.1488 0.4578 0.4002 0.3952 0.0214 0.5402 0.6922 0.6062 0.3194 
sRAGE ng/ml - - - - - - - - - - - - 
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4.3.6 Multiplex biomarker analysis of exacerbations 
4.3.6.1 QEH Birmingham study 
An exacerbation and recovery sample was available for 55 patients and for each sample there were 
up to 23 biomarker measurements.  For the multiple biomarker analysis, entering the raw 
concentration values for each state (exacerbation and recovery) into logistic regression analysis was 
not successful. This was expected as it was established from the analysis performed on stable 
samples in chapter 3 that individual threshold levels of biomarkers was essential and that trying to 
select population thresholds would be challenging due to the different baseline values that exists 
between people. For the single biomarker analysis, there were indications that certain biomarkers 
were able to differentiate between the different states with p values <0.05, these were HSA, A1AT, 
TIMP-1, fibrinogen, RBP4 and cystatin C. For the multiple biomarker analysis, a different method was 
used to analyse the data which involved using biomarker ‘’change’’ from one state to the other and 
then adding biomarkers in a stepwise order until the optimal sensitivity was obtained.   
In order to determine whether biomarker concentrations changed in the transition from 
exacerbation to recovery (day 56), the percentage difference was first calculated. The biomarker 
that identified a change greater than 10% for the majority of the 55 patients was TIMP-1 (36 cases, 
65%), the next biomarker that could be added to this panel that identified a change greater than 
10% from the remaining 35% of the group was Cystatin C, the additional 9 cases brought the 
percentage to 82%, the third biomarker, A1AT added an additional 5 cases which together 
amounted to 90%. This is illustrated in Figure 4.1. Single biomarkers provided no clear patterns. 
However, 3 urinary markers selected from each of the 3 pathophysiological pathways (NE driven, 
MMP driven, endothelial/renal dysfunction), namely A1AT, TIMP-1 and cystatin C, combined, it was 
possible to detect recovery in 90% cases. All three biomarkers individually showed a >10% decrease 
from exacerbation to recovery.  
 
Figure 4.1: Birmingham study; Multiple urinary biomarker panel for AECOPD. The flow diagram 
shows the proportion of patients whose TIMP-1 fell with recovery. If patients whose Cystatin C fell 
were added, the proportion identified rose to 82%, and addition of a fall in A1AT improved this to 
90%.  
TIMP-1 A1AT Cystatin C 
65% 82% 90% 
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4.3.6.2 GSK AERIS study 
No single marker was found to universally correlate with disease or its progression, but urinary CRP 
came very close. With the single biomarker analysis, CRP was significantly different pre-exacerbation 
in relation to exacerbation (p=0.0001) and exacerbation in relation to recovery (p=0.0027). As 
already identified, individual threshold values are critically important, as baseline values vary from 
patient to patient.  Similar to the analysis done for the exacerbation – recovery samples in section 
4.3.1.1, percentage change values were calculated from pre-exacerbation to exacerbation and then 
exacerbation to post exacerbation.  CRP was the one biomarker that gave a greater than 10% change 
for the greatest number of cases out of 71. The remaining biomarkers were then examined to 
determine which added the most value and then a final biomarker was selected to create a panel of 
three biomarkers for identification of exacerbation and a panel of three biomarkers for identification 
of recovery state. 
In summary, a combination of 3 markers was able to collectively group 94% of the exacerbation 
events into the exacerbation group relative to those in a stable group, and 93% in the recovery 
group post exacerbation i.e. increase at PEx and decrease at recovery.  Urinary CRP and desmosine 
were common markers see figure 4.2a and figure 4.2b. 
- Focussing on ‘identifying the exacerbation event’, CRP alone increased from baseline to 
exacerbation (>10% increase) for 44 of the 71 events, equating to 62% of the patient 
population, yet when combined with IL1b this was increased to 77.5% and further still to 
87.3% with the addition of Desmosine.   
- Focussing on ‘identifying the recovery state’, CRP alone decreased from exacerbation to 
recovery (>10% decrease) for 43 of the 71 exacerbation events, equating to 60.6%, yet when 
combined with Desmosine this was increased to 84.5% and to 90.1% with the addition of 
Fibrinogen. 
This does not take into account the status of the stable sample i.e. pre-exacerbation and post-
exacerbation, as some of the samples were collected less than a week before or after the event, as 
described in section 4.3.5.3, the minimum collection day prior to exacerbation was 3 days and post 
exacerbation was 6 days. 
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Figure 4.2. Diagrammatic representation of the value of each biomarker alone or in combination 
with other biomarkers. A) proportion of patients (%) with a 10% increase from pre- exacerbation to 
exacerbation.  B) proportion of patients (%) with a 10% decrease from exacerbation to post-
exacerbation.   
 
  
CRP IL1b 
Desmosine 
62% 38% 
52.1% 
77.5% 
71.8% 71.8% 
87.3% 
CRP Fib 
Desmosine 
60.6% 57.7% 
59.2% 
77.5% 
84.5% 80.3% 
90.1% 
A B 
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4.3.6.3 Leicester COPD study- Multi-Marker assessment with baseline measurements (stable to 
exacerbation) 
The approach taken for the statistical analysis closely resembled how the test would be used in 
practice which is to learn and track the biomarker profile that prevails during stable phases of the 
disease and determine whether the stable profile has shifted to an exacerbation profile by looking 
for a change in the biomarker levels (figure 4.3).  
 
Figure 4.3. Example of how the analysis fits in with the proposed use of the test. An average of 
frequently tested samples to calculate the baseline and increase to exacerbation state. 
For this analysis, one stable (S1) and one exacerbation sample (E1) were selected from each patient 
and an average of the remaining stable samples was used as the baseline (BL) sample. The 
percentage change of S1 and E1 was calculated from the baseline sample.  The stable and 
exacerbation samples % change values were analysed for each biomarker for each patient using a 
variety of statistical methods to determine the combination of biomarkers that could differentiate 
between the stable and exacerbation states.   
The distribution of the continuous variables was studied using histograms, values of skewness and 
kurtosis, and normality was tested by the Kolmogorov–Smirnov test. Paired t test and Wilcoxon 
matched-pairs signed rank test were used to compare quantitative data in the two groups. ROC 
analysis was used to study the accuracy of the various diagnostic tests and logistic regression to find 
the best combination of biomarkers. P values<0.05 were considered to be statistically significant. 
Statistical analyses were carried out through the use of computer IBM software SPSS 21 (Chicago, IL, 
USA), GraphPad Prism 5 and in R. 
1. The data were analysed with all data and male and female separately  
2. Paired t tests were performed using fold change of the log format, <0.05 was deemed 
significant 
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3. Those mediators which showed good discriminatory power at univariate level were taken 
forward for ROC analysis (fold change data) 
4. Those with individual AUC of <0.4 and >0.6 were deemed significant 
5. Logistic regression analysis was performed with % change values for stable vs. baseline and 
exacerbation vs. baseline with the selected markers to determine the best combination of 
markers 
 
The criteria for selecting the biomarkers for logistic regression analysis was a significant parametric 
pairwise t-test (p≤0.05) and a ROCAUC ≥0.59 or ≤0.41 (see table 4.6). The biomarkers that met these 
criteria and that were taken forward for further analysis were IL-6, CHI3L1, MMP-8, NGAL, A1AT 
(ELISA and LF), TIMP-1, Cystatin C, Creatinine, B2M Abcam, RBP4, TIMP-2, Desmosine (V2 ELISA), 
CC16, CRP, Fibrinogen. 
A backward stepwise regression was used, starting with all variables (all 16 from the list above) 
included the model. It then removed the least significant variable, that is, the one with the highest p-
value, at each step, until all variables had been added. By scrutinising the overall fit of the model, 
variables were automatically removed until the optimum model was found. 
Using logistic regression modelling, 5 biomarkers were selected that gave the best sensitivity and 
specificity. The combination of desmosine (V2 ELISA), CC16, CRP, MMP-8 and A1AT (LF) gave an AUC 
of 0.84 (95% confidence interval 0.76-0.92). With a cut off of 0.3959, sensitivity of 80% and 
specificity of 81.82 was obtained and a PPV of 81.48% and NPV of 80.36%. 
Further analysis subdividing the groups by gender identified a further panel of biomarkers for 
incorporation in the multiplex panel. 
For the females (n=19), the combination of fibrinogen, desmosine V2, CC16, TIMP-2 and MMP-8 
gave an AUC of 0.83 (95% confidence interval 0.69 to 0.96). At an optimal cut-off of 0.408 sensitivity 
and specificity was 84.21 and 73.68 respectively and PPV of 76.19%and NPV 82.35%.  
For the males (n=36), the combination of desmosine (V2 ELISA), CRP, MMP-8 and A1AT (LF) gave an 
AUC of 0.88 (95% confidence interval 0.79 to 0.96). At an optimal cut-off of 0.3887, the sensitivity 
and specificity were 83.3 and 80.6 respectively with a PPV of 81.48% and NPV of 80.36%. A second 
model with 6 biomarkers, fMLP (LF), CC16, desmosine (V2 ELISA), CRP, MMP-8 and A1AT (LF) 
(Figures not shown) gave an AUC of 0.89 (95% confidence interval 0.81-0.97). At an optimal cut-off 
of 0.3836 the sensitivity and specificity were 83.33% and 77.78% respectively with a PPV of 78.95 
and NPV of 82.35.  
113 
Table 4.6. BEAT-COPD study; stable vs. exacerbation fold change values from baseline. Paired t test 
using log transformed data and ROC (AUC) for each analyte. Significant p values <0.05 highlighted in 
bold 
Biomarker assay Combined M+F Females only Males only 
Paired t-
test 
AUC Paired t-
test 
AUC Paired 
t-test 
AUC 
IL-6 0.0325 0.6025 0.7403 0.4792 0.0143 0.6601 
fMLP ELISA 0.4919 0.5407 0.8394 0.4820 0.2539 0.5748 
IL1beta 0.5715 0.5045 0.1200 0.6177 0.5504 0.4460 
Siglec 8 0.7582 0.5319 0.1387 0.6039 0.6083 0.4985 
Chitinase 3 like 1 0.0139 0.6172 0.3288 0.5706 0.0149 0.6435 
Ultimate ELTABA 0.7495 0.5327 0.2321 0.6579 0.2486 0.4776 
Substrate MMP 0.6176 0.4855 0.0385 0.5776 0.1113 0.4352 
HNE substrate Assay 0.2244 0.4970 0.4842 0.5623 0.1758 0.4637 
IL8 0.0965 0.5529 0.0850 0.6150 0.4841 0.5251 
MMP-8  0.0170 0.6003 0.0477 0.6607 0.1562 0.5714 
MMP-9 0.1203 0.5481 0.5900 0.5526 0.1235 0.5459 
HNE  0.0546 0.5945 0.2968 0.5748 0.1093 0.6069 
NGAL 0.0072 0.6169 0.4778 0.5263 0.0046 0.6551 
Calprotectin 0.3195 0.5681 0.5967 0.5263 0.1099 0.5853 
MPO 0.5272 0.5380 0.2873 0.5983 0.9655 0.5181 
RNASE3 0.0339 0.5848 0.0033 0.7161 0.4720 0.5093 
A1AT ELISA 0.0000 0.7240 0.1030 0.6316 0.0000 0.7685 
A1AT LF 0.0001 0.7630 0.0088 0.7618 0.0057 0.7708 
TIMP-1 0.0325 0.6446 0.5620 0.5693 0.0118 0.6779 
SLPI 0.0268 0.5917 0.2541 0.5693 0.0513 0.5914 
Cystatin C 0.0098 0.6747 0.9160 0.5582 0.0086 0.7157 
Creatinine 0.0009 0.6460 0.8226 0.5208 0.0001 0.7037 
B2M Abcam 0.0000 0.7398 0.1786 0.6399 0.0000 0.7847 
RBP4 0.1030 0.6777 0.7724 0.5762 0.0008 0.7400 
TIMP-2 0.0287 0.6271 0.9889 0.5235 0.0059 0.6775 
Ac-PGP 0.4728 0.5246 0.7481 0.4432 0.2325 0.5748 
Desmosine V1 ELISA 0.2934 0.5656 0.8227 0.5291 0.2461 0.5826 
Desmosine V2 ELISA 0.0386 0.6210 0.1452 0.5845 0.1022 0.6424 
LEF 0.1934 0.6003 0.6122 0.5125 0.2361 0.6350 
Desmosine Fragments ELISA  0.0068 0.4036 0.6134 0.5069 0.0034 0.3665 
CC16 0.0025 0.6405 0.0600 0.6302 0.0085 0.6451 
CRP 0.0002 0.6463 0.0873 0.6302 0.0006 0.6578 
Periostin  0.7441 0.5145 0.1366 0.4169 0.1773 0.5856 
Human Serum albumin 0.1174 0.5736 0.2202 0.5983 0.3282 0.5440 
Fibrinogen Abcam 0.0019 0.6380 0.0043 0.6620 0.0483 0.6296 
sRAGE 0.1492 0.5739 0.5511 0.4571 0.0540 0.6335 
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Figure 4.4. BEAT-COPD study; All data n=55 (male and female combined), discrimination between 
stable and exacerbation. (a) Scatter plot of the predictive probabilities from models generated for 
combined male and female model (b) ROC curve (and AUC values)  
  
Figure 4.5. BEAT-COPD study; Female data n= 19, discrimination between stable and exacerbation. 
(a) Scatter plot of the predictive probabilities from models generated for combined male and female 
model (b) ROC curve (and AUC values)  
    
Figure 4.6. BEAT-COPD study; Male only n=36, discrimination between stable and exacerbation. (a) 
Scatter plot of the predictive probabilities from models generated for combined male and female 
model (b) ROC curve (and AUC values)  
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4.4 Discussion 
In order to consolidate all these results together in one simple table, the most promising biomarkers 
were taken forward for discussion (table 4.7).  Firstly, the biomarkers that showed significance 
between different disease states relating to stable, exacerbation and recovery were explored. Based 
on this analysis there were clear candidate markers, these were A1AT, and CRP which were 
significant across all groups, although CRP was not tested on the Birmingham cohort. Other 
candidate biomarkers were: TIMP-1, Cystatin C, Human serum albumin, Fibrinogen, NGAL, 
Calprotectin and CC16. The type of statistical analysis used in this case, only took into account 
population thresholds values but it has been established from the analysis performed on stable 
samples that individual threshold levels exist as a result of gender, severity of disease and even age 
as described in chapter 3 and likely to also be influenced by medication and comorbidities although 
this has not been proven.  
The second analysis considered the percentage change from the stable and/or recovery sample.  
Biomarkers that showed a greater than 10% increase from stable state compared to exacerbation 
state or a greater than 10% reduction from exacerbation state compared to a recovered state were 
taken forward for multiplex biomarker analysis (table 4.7). This allowed for both individual 
thresholds and gender differences.  Again, there were clear candidate markers, these being A1AT, 
RBP4 and B2M. Other candidate biomarkers were: TIMP-1, cystatin C, HSA, fibrinogen, CRP and 
desmosine. Combining both types of analysis, the four strongest biomarkers were CRP, A1AT, RBP4 
and B2M. 
The third study is probably the most relevant analysis. This took into account a near as possible 
baseline value for each patient by calculating a baseline based on 2 or more stable samples (for each 
biomarker), and then calculating the percentage change from the baseline for both a different stable 
sample and exacerbation sample.  The differences between the stable and exacerbation % change 
values for each biomarker was then analysed using paired t tests and ROC analysis.  When selecting 
biomarkers from this list that were significant, this brought in line other potential biomarkers: TIMP-
1, Cystatin C, Fibrinogen, CC16 with a secondary list of NGAL, TIMP-2 and desmosine.  With 11 
biomarkers in the final refined list of biomarkers from a total of 34 biomarkers this was then 
narrowed down to 10 biomarkers for the point of care test development using logistic regression 
analysis.  An additional consideration was the need to develop assays that were practical as it known 
that lateral flow is not as sensitive as ELISA. The inclusion of desmosine, although shown to be 
promising for various types of analysis, it seemed to be variable between the different assays, V1, V2 
and the lateral flow, therefore, this was eliminated from the final panel.  Finally, although a Cystatin 
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LF was available (already developed at Mologic), it was at decided at risk that fMLP was included in 
the final 10 biomarker panel, this was based on previous studies, potentially an early marker that 
would be useful for the prediction of an exacerbation and the only signalling molecule. The final 10 
biomarkers selected based on all studies were: A1AT, TIMP-1, TIMP-2, CRP, Fibrinogen, fMLP, CC16, 
NGAL, RBP4 and B2M. 
The creatinine result cannot be ignored, it was significant in most studies. The use of creatine ratio 
has been explored and it has not added value to the result in terms of reducing the variation.  
Creatinine is difficult to measure accurately at PoC and in addition, it has been shown to be highly 
variable in relation to gender, age, body mass, demographics and renal malfunction (159).  In 
addition, it is noted that this is a spot sampling result rather than a more challenging 24 hour 
collection. 
Different biomarkers may be required for different genders or at least a different statistical model 
could be developed to allow for gender. To refine the decision aid it is essential that a true baseline 
value is obtained from more frequent sampling. This will reduce the variability in the stable state and 
allow the use of a rolling mean taking in to account the within subject variability giving greater 
statistical power to detect the onset of the exacerbation event. The findings to date are promising 
and give encouragement that the likelihood of identifying clinically meaningful biomarkers is high.  
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Table 4.7. Summary of results from all retrospective studies. P values <0.05 deemed significant.  Paired t-tests were used unless indicated by * which is a 
Wilcoxon matched-pairs signed rank test.  Creatinine ratio not used. 
 Population levels of biomarkers % change from stable or recovery sample (% that had 
>10% change) 
% change from 
baseline 
 Leicester study 
Stable to PEx 
GSK Aeris study Birmingham study 
PEx to recovery 
Leicester 
Stable to PEx 
GSK Aeris study Birmingham 
study 
PEx to recovery 
Leicester 
Stable to PEx 
(including 
baseline) 
 Pre - PEX PEX - post Pre - PEX 
A1AT 0.0001 0.0069* 0.0496 
0.0045* 
0.019691 
0.0379* 
72.7 54.9 57.1 <0.0001 
TIMP-1 0.0361   0.025183 
0.0122* 
60  65.95 0.0325 
Cystatin C 0.0025   0.050729 
0.0101* 
61.8  59.6 0.0098 
RBP4    0.046883 
0.0049* 
69.1 52.1 68.6  
Human serum albumin   0.0069* 0.006548 
0.0102* 
50.9  61.7  
Fibrinogen   0.0214* 0.034147 70.9 53.5  0.0019 
Chitinase 3 like protein 0.0055  Not tested    Not tested 0.0139 
MMP-9 Total 0.0409    52.7    
NGAL 0.0262  0.02*  54.5   0.0072 
Calprotectin 0.0164  0.0284      
RNASE-3 0.0465        
Creatinine 0.0005 0.0446 0.0475  61.8 54.9 52.7 0.0009 
TIMP-2 0.0136    60   0.0287 
CC16 0.0284  0.0121 
0.007* 
Not tested 61.8  Not tested 0.0025 
CRP 0.0012 0.0001 
<0.0001* 
0.0027 
0.0013* 
Not tested 54.5 62.0 Not tested 0.0002 
IL6   0.0153*     0.0325 
Desmosine   0.0322*  54.5 (V2) 52.1  0.0386 
(V2) 
fMLPLF     60    
B2M    0.0227* 76.4 56.3 61.2 <0.0001 
MMP-8        0.0170 
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Assessing the final 10 biomarkers on the Leicester BEAT-COPD study gave an AUC of 0.84 (95% 
confidence interval 0.76 to 0.92). At an optimal cut-off of 0.4065, the sensitivity and specificity were 
80% and 76.36 respectively with a PPV of 77.19% and NPV of 79.25%.  
  
 
  
  
  
 
 
Figure 4.7. BEAT-COPD study; Combined Male and females n=55 with final 10 selected biomarkers. 
(a) Scatter plot of the predictive probabilities from models generated for combined male and female 
model (b) ROC curve with AUC shown 
 
The outcomes from each of these studies have demonstrated the relevance of urinary biomarkers to 
COPD exacerbations, and their potential in the stable state to pick out individuals whose prognosis 
may be worse, such as those with frequent exacerbations or emphysema. The main aims were to 
explore biomarkers of pathophysiology of COPD measurable in the urine. it was initially thought that 
there might be some individuals in whom elastin degradation and the action of HNE would be 
marked whilst in others MMP driven processes might be more important, for these reasons, a 
multimarker panel consisting of 10 biomarkers has been selected for further investigations. There 
are 3 pathophysiological pathways in which these biomarkers are involved in this context; MMP 
driven pathway: TIMP-1, TIMP-2, NGAL and  HNE driven pathway: A1AT.  
  
119 
 
 
 
 
Chapter 5. Development of a point of 
care lateral flow test to measure 
biomarkers of interest in urine 
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5.1 Introduction 
Key requirements for the exacerbation alert test (named ‘Headstart’) in order to measure specific 
biomarkers in urine are that it must to be simple to use, rapid and cost-effective. The test system will 
be designed to comprise of a disposable test cassette, similar to a pregnancy test that can measure 
up to 5 analytes in the urine sample, together with a very compact opto-electronic reader. When the 
test cassette is placed in the reader, a timer will start, and a reading automatically taken after a set 
time of 10 minutes. The reader will interpret the concentration of the biomarkers in the sample and 
then save the result to memory. The reader will be Bluetooth enabled so that it will be able to 
transmit the data to a remote server for processing via an appropriate algorithm (the results of 
which will be transmitted back to the patient or Health Care Practitioner, as appropriate. Reports 
back to the patient will be in the form of very simple instructions regarding medication, further 
testing or seeking medical advice, as appropriate. 
5.1.1 Lateral flow technology 
The “Clearblue ®” pregnancy test is the most widely known product that is based on lateral flow 
technology. This is a simple to use rapid, point of care test that can be bought “over the counter” 
with a visible line indicating a positive result for hCG and an absence of a line indicating a negative 
result. A lateral flow test can be qualitive such as the pregnancy test with a yes/no result, or semi 
quantitative, where a low, medium, high result is indicated or quantitative, where a reader is 
required in order to measure the intensity of the line and convert it to a concentration value using a 
standard calibration curve. A typical lateral flow comprises of 4 key components as shown in figure 
5.1. The ‘’sample pad’’ receives the test sample, distributes the sample on to the test strip uniformly. 
It may contain chemicals to modify the sample composition and may also act as a filter. The 
“conjugate pad” holds the detector reagent i.e. antibodies conjugated to gold particles, in a dry 
state, does not interfere with detector reagent stability and releases the detector reagent quickly, 
consistently and quantitatively to provide uniform transfer of detector reagent to the nitrocellulose 
membrane.  The membrane is the surface used to immobilise the capture reagents, upon which the 
immunocomplexes forms (i.e. signals) and controls the overall flow rate of the system. The 
“absorbent pad” serves as the “sink” for the sample, it determines the total sample volume that can 
be processed and typically is not chemically altered. All components are laminated onto a backing 
card and enclosed inside a plastic housing which contains sample ports for addition of the sample.  
There are three main formats as described in more detail in figure 5.2- 5.4. A sandwich assay is 
commonly used where a multi-epitope analyte is available and a competitive and inhibition assay 
where a single epitope analyte is only available. 
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Figure 5.1. A typical lateral flow assay. A strip is enclosed in a plastic housing with a sample port for 
sample addition and a read window where the result can be interpreted by the user in the form of 
test lines and control lines (courtesy of Millipore) 
 
 
Figure 5.2. A sandwich assay format. The analyte in the sample forms a complex with the primary 
antibody-detector conjugate i.e. gold which then forms a complex with a secondary antibody 
immobilised on the nitrocellulose membrane forming a visible line. A control line in this example is 
an anti-species to the primary antibody.   
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Figure 5.3. A competitive assay format. The analyte in the sample competes with the analyte-
detector conjugate i.e. gold with the antibody immobilised on the nitrocellulose membrane.  With 
unlabelled analyte bound to the antibody test line, there is an absence of a visible line.  
 
 
 
Figure 5.4. An inhibition assay format. The analyte in the sample inhibits binding of the detector 
reagent at the test line by forming a complex with the antibody-detector conjugate i.e. gold 
preventing it from binding to the analyte immobilised on the nitrocellulose membrane.  With no 
antibody- detector conjugate bound to the test line, there is an absence of a visible line. 
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5.1.2 Next generation development of the test device 
The first version of the multiplex urine device developed required a sample processing step and 
manual addition of the sample to the device (figure 5.5). Such a test system was evaluated with 
cystic fibrosis patients in their own homes. The biomarkers selected for incorporation into this 
device were A1AT, TIMP-1, TIMP-2 and CRP based on previous studies outlined in this thesis.  This 
patient group was a younger population, who were generally very motivated and capable of 
undertaking self-testing manipulations. It was predicted that a test for people with COPD needed to 
be simpler and more user-friendly, avoiding additional steps required to perform the test. The new 
version developed incorporated a sample wick which could be directly placed in the urine flow and 
then the whole cassette placed directly into the reader (figure 5.6). The reader system selected was 
the cube reader (OpTricon GmbH, Berlin, Germany), this is a simple lateral flow reader that serves as 
an ‘electronic’ eye obtaining exact readings.  The OD readings obtained from the reader ranged from 
0-300 unit where a reading above ‘10’ units was observed as a visual read line on the test. 
The transition to the new version was envisioned to be challenging, since as well as a modification to 
the test strip dimensions itself, the chemistry and reagents also required substantial re-optimisation. 
A new plastic injection-moulding had to be developed specifically to house the new strip and sample 
wick. Finally, the new test had to be validated and verified in-house to ensure that specifications 
were met. During development, the assays were first developed as single assays and then 
multiplexed (Headstart V2). An interim analysis with COPD patients was undertaken to determine 
the usability and acceptability of the complete test system. As there were 10 biomarkers to be 
measured, they were separated into 2 tests each consisting of 5 assays (Headstart V3). The assays 
were subjected to multiple evaluations before they were deemed to be acceptable including 
comparisons to the reference assays and testing with frozen urine samples to ensure the assays 
were within the correct dynamic range.  
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Remove a test device from the foil pouch. 
Hold the sample wick pointing downwards 
in either the urine stream OR collected 
urine sample for 10 seconds then remove 
Replace cap. The pink liquid will start to migrate 
up the test strip. The green line will be replaced 
with a red line – the control line. Insert into the 
adaptor and place the cube reader on top 
Press button on reader to start 
automatic timer of 10 minutes. 
 
 
 
 
 
 
 
Figure 5.5. Headstart V1 procedure. The urine sample prior to application to the test device requires 
a 1 in 10 dilution in a sample buffer supplied in dropper bottle. 
 
 
  
  
 
 
 
 
 
 
 
 
 
Figure 5.6. Headstart V2/V3 procedure. The device containing sampling wick is added directly to the 
urine without any sample processing. 
Add urine sample 
(1ml) to dropper 
bottle with fixed 
amount of buffer  
Insert lid and shake 
gently 
Addition of 2 drops 
to device 
Insert into reader 
and result displayed 
in 10 minutes 
1. 2. 3. 4.
d urine 
sam ple to 
dropper 
bott le
Insert  lid and
shake
Addit i n of 2 
drops to 
device
Insert  into 
reader and 
result  
display d in 
10 m inutes
2. 
3. 
1. 
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5.2 Methods 
5.2.1 Development of new cassette moulding 
Stages of development involved design of cassette, evaluation of prototype assessing flow 
characteristics, performance characteristics and manufacturing aspects. A few iterations were 
assessed before finalising the design, this was evaluated using 3D printed cassettes. The tool was 
developed and first prototypes were again assessed and further modifications were required before 
finalising the design resulting in a small-scale manufacture (figure 5.7). The test strip was optimised 
with urine samples both in terms of dipping the cassette in a urine sample and midstream testing to 
ensure compatibility and ensure that that was no flooding of the test strip and that the flow was 
reproducible and consistent. 
5.2.2 Development of Headstart V2 prototype tests  
As previously mentioned, the first version test required a sample dilution and although an evaluation 
by CF patients in a parallel home monitoring study was successful, it was desirable to modify the test 
to make it more user-friendly for COPD patients.  The previous test required the patient to perform 4 
steps including dilution of the sample into a dropper bottle. 
The second version of the Headstart test was designed to be similar to a pregnancy test in which the 
cassette contained a sample wick to be placed directly in the urine stream.  In addition to the new 
cassette mounding, the chemistry of the test also required further development and optimization, as 
the previous version used a 1 in 5 sample dilution compared to neat urine required for the current 
version. Challenges that had to be addressed were matrix issues (which occur when using neat 
sample) and desensitisation of each of the assays. There were 10 biomarkers selected from chapter 
4 to take forward. As each test device could only house 5 assays, they had to be built into 2 separate 
test devices (a and b), the decision on which device each assay was placed was based on cross 
reactivity testing.  
The strip architecture needed to be optimised in order to fit into the new cassettes. The changes are 
shown in table 5.1 and illustrated in figure 5.8.  Non-critical modifications were required with 
regards to the dimensional changes. The backing card, nitrocellulose and conjugate pad needed to 
be longer in order to allow for more assays to fit into the same strip. The largest change involved 1) 
using a faster nitrocellulose membrane due to the longer length of the strip (from 25mm to 40mm) 
to allow sufficient flow along the strip and 2) switching out the blood separator pad (which was not 
specifically needed for this test) to a wick that acted as the interface between the urine sample and 
the test strip.  
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Details of the assay development are not included in this thesis as the work undertaken by the team 
at Mologic was very extensive.  For the test line and detector reagents for each of the 10 assays, 
evaluation of 3 different antibodies/antigens was undertaken for both capture and detector reagent.  
For each detector reagent, the gold conjugate was optimised in terms of antibody-loading, 
conjugation buffer formulation and pH.  Once conjugated, the gold conjugates were assessed in “wet 
assays” with the different capture reagents on the NC before assessing in a “dry assay” in various 
gold drying buffers and at different OD’s.  The best pairings were selected in combination with the 
other assays to determine if there was any cross reactivity.  This determined which of the 2 test 
devices they were best positioned (a or b).  Optimisation included assessing effect of drying 
temperatures and drying times for both the nitrocellulose and the gold pad as well as assessing 
different line positions on the NC. This was important as assays which were too sensitive required 
the “capture line” closer to the sampling end and assays that required more sensitivity required it to 
be positioned further away as the flow of the analyte is slower further along the strip thus allowing 
more time for the test to develop. 
There were a number of techniques that were used to desensitise some of the assays which was the 
most challenging aspect of development. Small improvements were made such as line positioning 
and changing the NC speed as described above, but the three methods that had the largest effect 
and were all incorporated were: 
- Addition of a pre- absorbance line that was hidden from view just below the window of the 
test device, this removed some of the free analyte as long as the gold was in excess 
and allowed the optimum amount to flow past and bind to the test line 
- Introducing free antibody to the system was used to sequester “excess” analyte in the 
sample, this complex then competed with the analyte/gold labelled antibody to bind to the 
test line. 
- A competition or inhibition format was generally less sensitive than a sandwich assay.
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Figure 5.7. Development of plastic housing from point of concept to manufacturing. 3D printed devices were evaluated before committing to the tool 
development. Which required further refinements before freezing the design and transfer to manufacture.
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Table 5.1. Component change from version 1 (enclosed in a single well housing where by the sample 
is manually added to the test device) and version 2 (with an added wick where the sample is directly 
applied by dipping into a urine sample or midstream urine) 
 Version 1 Version 2 
Backing card 60mm G&L backing card 80mm Lohmann Backing card 
Nitrocellulose membrane 25mm Sartorius CN140 40mm Sartorius CN095 
Conjugate pad 17mm Millipore G041 27mm Millipore 8951 
Absorbent pad 22mm Ahlstrom Grade 222 22mm Ahlstrom Grade 222 
Sample pad 10mm FR-1 blood separator 
pad 
35 x 8 x 2.5mm Essentra wick 
Plastic devices 1 well Forsite diagnostic (base 
and top)  
Custom made, Mologic (base, 
top and lid) 
Desiccant pouch 1g Brownell  1g Brownell 
Foil pouch Riverside Riverside 
 
 
 
 
 
 
  
 
Figure 5.8. Visual representation of the different strip architecture. Version 1 being a shorter strip 
and with a sample pad and version 2, a longer strip with a wick added during assembly.   
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5.2.3 Development of final Headstart V3 prototype tests (a and b) 
The challenge of optimising all 10 assays with a neat urine sample is highlighted by assessing the 
sample dilution required for the ELISAs. These were (in order of dilution factor), RBP4 1 in 2000, B2M 
and NGAL 1 in 100, A1AT 1 in 20, TIMP-1, TIMP-2, CC16 and CRP 1 in 10, fMLP and Fibrinogen 1 in 2.   
Headstart assay (A) consisted of 5 biomarkers, A1AT, TIMP-2, NGAL, Fibrinogen and CRP. All 5 were 
sandwich assays however, there was an additional pre-absorbent line for A1AT and free antibody 
addition for the NGAL assay which was refined to give just the required assay range as otherwise the 
assay had a strong “high-dose hook” effect with high levels of NGAL. A diagrammatic representation 
can be seen in figure 5.11, with a comparison to version 1 in figure 5.10. 
For the NC, all capture lines (not control line) were prepared at 1mg/ml in PBS 1% sucrose. Anti -
A1AT sheep polyclonal pre-absorbent line was plotted at 3mm, anti-A1AT BSA fab was plotted at 
7mm, anti-TIMP-2 sheep polyclonal was plotted at 10mm, anti-NGAL BSA fab was plotted at 13mm, 
anti-Fibrinogen sheep antibody at 16mm, anti-CRP was plotted at 19mm and BSA biotin was plotted 
at 2mg/ml with 10% green food dye in the control at 22mm. All on 40mm CN95 nitrocellulose at a 
deposition rate of 0.05µl/mm. Materials were dried in the Hedinair drier at 60ºC at 10mm speed and 
heat sealed in a foil pouch with 5 x 1g desiccant and cured at 37°C incubator for 18hrs. 
Antibodies were conjugated to gold particles individually and then were added together to make up 
the final OD of 5 for A1AT, TIMP-2, NGAL, Fibrinogen, OD10 for CRP and OD2 for anti-biotin gold 
conjugate in a gold drying buffer (consisting of a tween 20, sucrose and BSA) + 15µg/ml final of free 
anti-NGAL BSA fab. The final conjugate mix was sprayed onto 8951 glass fibre conjugate pad (22mm, 
equivalent to GFDX) at a deposition rate of 0.8µl/ml. Materials were dried in the Hedinair drier at 
60ºC at 5mm speed and stored in a pouch with 5 x 1g desiccant. 
Headstart assay (B) consisted of 5 biomarkers, RBP4, CC16, B2M, TIMP-1 and fMLP, that, with the 
exception of TIMP-1, all were inhibition assays. A diagrammatic representation can be seen in figure 
5.12. 
For the NC, all capture lines were prepared in PBS 1% sucrose. RBP4 was plotted at 1.5mg/ml at 
7mm, CC16 was plotted at 0.5mg/ml at 10mm, B2M was plotted at 0.5mg/ml at 13mm, anti-TIMP-1 
BSA fab at 1mg/ml at 16mm, Ovalbumin-fMLP was plotted at 1mg/ml 19mm and BSA biotin was 
plotted at 2mg/ml with 10% orange food dye in the control at 22mm. All on 40mm CN95 
nitrocellulose at a deposition rate of 0.05µl/mm. Materials were dried in the Hedinair drier at 60ºC 
at 10mm speed and heat sealed in a foil pouch with 5 x 1g desiccant and cured at 37°C incubator for 
18hrs. 
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Antibodies were conjugated to gold particles individually and then were added together to make up 
the final OD of 5 for TIMP-1 and B2M, OD10 for RBP4, CC16 and fMLP and OD2 for anti-biotin gold 
conjugate in gold drying buffer. The final conjugate mix was sprayed onto 8951 glass fibre conjugate 
pad (22mm, equivalent to GFDX) at a deposition rate of 0.8µl/ml. Materials were dried in the Hedinair 
drier at 60ºC at 5mm speed and stored in a pouch with 5 x 1g desiccant. 
For lamination, onto 80mm backing card, the base of the NC was placed at 25mm height, the base of 
the conjugate pad was lined up flush with the base of the backing card. The absorbent pad lines up 
flush to the top of the backing card forming a 7mm overlap with the top of the NC. The strips were cut 
into 5mm wide strips. Each strip was placed into the cassette housing with a wick and sealed shut 
using a specific device closing machine and a cap was placed (green for device ‘a’ and orange for device 
‘b’) before sealing in individual foil pouches with 1g desiccant (figure 5.9). 
 
Figure 5.9. Diagrammatic representation of assembly process for test device version 2 with a green 
lid for A and an orange lid for B. Manual addition of strip and wick but machine closed to ensure 
equal distribution of pressure.
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1.A1AT, TIMP2, 
TIMP1, CRP in 
the sample
Anti-A1AT fab conjugated via PEG to BSA
Gold particle bearing anti-A1AT BSA-Fab
Immuno-capture lines on  NC membrane
4.Detector antibody 
gold conjugates 
lacking analyte 
escape the capture 
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Direction 
of flow
2. Detector antibody 
gold conjugates 
catch analyte BSABSABSA
BSA
BSABSA
BSA
BSABSA
Anti-TIMP2 fab conjugated via PEG to BSA
Anti-TIMP1 fab conjugated via PEG to BSA
Anti-CRP sheep polyclonal
Gold particle bearing anti-TIMP2 Sheep polyclonal
Gold particle bearing anti-TIMP1 BSA-Fab
Gold particle bearing anti-CRP mouse monoclonal
3.Capture 
antibody lines 
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Figure 5.10. Diagrammatic representation of the first version test that measured 4 biomarkers, A1AT, TIMP-2, TIMP-1 and CRP in a 1 in 5 dilution urine 
sample. The sample added to the test device, first reconstitutes the gold from the conjugate pad and releases the 4 gold conjugates. In the presence of 
analyte in the sample, the analyte is recognised and forms a complex with the antibody on the gold conjugate and then migrates up the strip and is 
captured on the antibody immobilised on the nitrocellulose forming a red line.  In the absence of analyte, the sandwich is not formed resulting in an 
absence of a line. The control line not shown consists of an BSA biotin on the capture line and an anti-biotin gold conjugate that when complexed indicate if 
the test is run correctly.  
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Figure 5.11. Diagrammatic representation of the second version test (a) that measured 5 biomarkers, A1AT, TIMP-2, NGAL, Fibrinogen and CRP in a neat 
urine sample. The sample added to the test device, first reconstitutes the gold from the conjugate pad and releases the 5 gold conjugates (and free NGAL 
not shown).  In the presence of analyte in the sample, the analyte is recognised and forms a complex with the antibody on the gold conjugate and then 
migrates up the strip and is captured on the antibody immobilised on the nitrocellulose forming a red line.  In the absence of analyte, the sandwich is not 
formed resulting in an absence of a line. For the A1AT assay, a pre-absorbent line is used to de-sensitise the assay. The control line not shown consists of an 
BSA biotin on the capture line and an anti-biotin gold conjugate that when complexed indicate if the test is run correctly 
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Figure 5.12. Diagrammatic representation of the second version test (b) that measured 5 biomarkers, RBP4, CC16, B2M, TIMP-1 and fMLP in a neat urine 
sample. The sample added to the test device, first reconstitutes the gold from the conjugate pad and releases the 5 gold conjugates. For the 1 sandwich 
assay, In the presence of analyte in the sample, the analyte is recognised and forms a complex with the antibody on the gold conjugate and then migrates 
up the strip and is captured on the antibody immobilised on the nitrocellulose forming a red line.  In the absence of analyte, the sandwich is not formed 
resulting in an absence of a line.  for the 4 inhibition assays, the complex is formed as previously described with the analyte and detector antibody gold 
conjugate but as a result, the complex is no longer able to bind to the capture lines hence a line is not formed.  In the absence of the analyte, the gold 
conjugate will bind directly to the test line producing a red line. The control line not shown consists of an BSA biotin on the capture line and an anti-biotin 
gold conjugate that when complexed indicate if the test is run correctly.
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5.2.4 Materials/reagents 
- Buffer PBST- 1%BSA (10mM phosphate buffered saline pH7.5, supplemented with 1% 
(w/v) BSA) 
- Antigens for Multiplex A: A1AT (Merck Calbiochem, 178251), TIMP-2, (Kent university, 
Canterbury), NGAL (Alere San Diego, RFPR017674), Fibrinogen (BBI, 132-3), CRP (Lee 
Biosolutions, 140-11R) 
- Antigens Multiplex B: RBP4 (BBI, P124-1), CC16 (Novoprotein CU06), B2M (BBI, P122-1), 
TIMP-1 (Novoprotein, C456), fMLP (Sigma, 47729) 
- Fresh urine samples collected from healthy controls 
- Headstart devices a and b (batch SR130717) 
- ELISAs for all 10 biomarkers (as described in chapter 2) 
5.2.5 Equipment 
- Cube reader; Cube/device adaptor; Cable (OpTricon) 
- RFID card wide control + Area under the curve (AUC) 
- Pipettes 
- Universals/Bijou/2 ml Eppendorf tubes 
- Timer 
- Plate shaker/plate washer 
5.2.6 Testing buffer standards 
Standard testing was performed as follows: i) devices were removed from the pouches immediately 
before testing; ii) caps were removed and device was placed on a flat surface; iii) 10 minute timer 
was initiated; iv) With the device laid on a surface, 650µL of each standard was pipetted on to the 
region of the wick closest to the conjugate pad. v) the device was read after 10 minutes using a cube 
reader. vi) once reading was complete, the devices were discarded. 
Standards for Multiplex A & B were made according to table 5.2. 
Devices were taken from the beginning, middle and end of the batch, 9 devices in total and the 
criteria for the standard curve range was determined by the accuracy and CV’s of the replicates.  The 
standard curves were compared to standard curves obtained from the ELISA’s to determine whether 
the range of the assays were acceptable. 
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5.2.7 Headstart Usability study at Leicester 
The current Headstart version was evaluated by 10 patients at Leicester Hospital to evaluate key 
parameters such as usability/ease of use, frequency of testing, data transfer, safety, practicalities 
and recommendations/improvements. The study had ethics approval (REC Ref: 08/H0406/189) – An 
open study to measure imaging biomarkers and inflammatory cells, mediators and biomarkers from 
blood, urine and airway samples from healthy volunteers, asthma patients and COPD patients in 
stable disease and during acute exacerbation. Each patient undertook daily tests for approximately 
30 days. At the end of the study a short questionnaire was completed by each patient. Three non-
COPD volunteers also participated in the short usability study. 
5.2.8 Statistical analysis 
Conversion of cube values from the standards to concentration values used ‘my assay’ an online 
data analysis programme. All data were analysed using Graphpad PRISM Version 7.   
Table 5.2. Standards used for standard testing. The top standard was prepared at shown 
concentrations for all analytes from the stock concentrations and then diluted 1 in 2.5 in the 
standard dilution buffer PBST 1% BSA. 
ng/ml A1AT T2 NGAL FIB CRP RBP4 CC16 B2M T1 fMLP 
1 1000 200 500 1000 25 500 2500 500 100 50 
2 400 80 200 400 10 200 1000 200 40 20 
3 160 32 80 160 4 80 400 80 16 8 
4 64 12.8 32 64 1.6 32 160 32 6.4 3.2 
5 25.6 5.12 12.8 25.6 0.64 12.8 64 12.8 2.56 1.28 
6 10.24 2.048 5.12 10.24 0.256 5.12 25.6 5.12 1.024 0.512 
7 4.096 0.8192 2.048 4.096 0.1024 2.048 10.24 2.048 0.4096 0.2048 
8 0 0 0 0 0 0 0 0 0 0 
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5.3 Results 
5.3.1 Headstart Usability study at Leicester 
There were no adverse issues recorded with using the test device itself. Statistics showed that from 
a planned number of 273 tests, 1.1 % of tests were missed, 7% of tests were run incorrectly (control 
line failed to develop) with an overall success rate of 91.9%.  In parallel, three non-COPD volunteers 
also participated. In this case the statistics showed that from a planned number of 91 tests, 7.7 % of 
tests were missed, 1.1% of tests were run incorrectly (control line failed to develop) with an overall 
success rate of 91.2%.   
Results from the patient questionnaire, regarding frequency of the testing, confirmed that: 60% 
would be happy to perform daily testing; 30% said preferred once a week; and 10% said they would 
take the test only when they were worried. The majority (90%) of patients indicated that having to 
take the Headstart test for the rest of their life would not be a burden. None of the participants 
required any help to collect the urine samples and all confirmed that it was easy to collect the 
sample. With regards to the connectivity, 70% of the patients said they would be able to use a smart 
phone. Of the 30% who were not keen, 67% had no tablet/phone and 33% had no internet. Other 
feedback highlighted issues surrounding the size of the cube reader button, as well as its automatic 
timing function which proved difficult to initiate.  
5.3.2 Standard curves and assay range 
The standard curves run on the multiplex devices are graphically represented in figure 5.13. The 
average was taken from the 9 replicates and entered into ‘my assay’ programme. Shown in tables 
5.3 – 5.7 are the details for each assay with calculated averages, SD and %CV from 9 replicates. The 
backfit is the returned concentration calculated by the standard curve and the accuracy is how close 
that estimated concentration was compared to the expected concentration.  The criteria was: 
accuracy +/- 20% (80-120) for at least 6 of the 7 standards; %CV < 20% and r2 >0.95. The final assay 
ranges for both the multiplex LF devices and ELISA are shown in table 5.8. 
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Table 5.3. A1AT and TIMP-2. The average, SD, %CV, accuracy cube from 9 replicates shown. The r2 
was 0.9993 and 0.9995 for A1AT and TIMP-2 respectively 
 
Table 5.4. NGAL and Fib. The average, SD, %CV, accuracy cube from 9 replicates shown. The r2 was 
0.9995 and 0.9998 for NGAL and Fibrinogen respectively 
 
Table 5.5. CRP and RBP4. The average, SD, %CV, accuracy cube from 9 replicates shown. The r2 was 
0.9998 and 0.9988 for CRP and RBP4 respectively 
  
Table 5.6. CC16 and B2M. The average, SD, %CV, accuracy cube from 9 replicates shown. The r2 was 
1 and 0.9997 for CC16 and B2M respectively 
 
Conc Average  SD %CV Backfit Accuracy 
100 182.3 5.6 3.1 103.3 103.3 
40 152.3 5.9 3.9 38.03 95.06 
16 118.2 7.5 6.3 16.54 103.4 
6.4 78.9 2.5 3.2 6.491 101.4 
2.56 47.5 2.6 5.5 2.373 92.69 
1.024 32.8 1.4 4.2 1.097 107.1 
0.4096 22.9 2.4 10.5 0.411 100.4 
Conc Average  SD %CV Backfit Accuracy 
1000 164 5.8 3.5 1024 102.4 
400 129.1 9.7 6.6 388.9 97.23 
160 117.5 6.5 5.4 158.3 98.96 
64 72 10.5 11.4 67.91 106.1 
25.6 58.2 3.2 5.5 23.58 92.09 
10.24 32.7 3.8 10.2 10.88 106.3 
4.096 16.5 2.9 15.6 4.011 97.93 
Conc Average  SD %CV Backfit Accuracy 
1000 116.9 5.1 4.4 1006 100.6 
400 88.7 3.4 3.9 394.8 98.7 
160 59.2 6.2 10.5 162 101.3 
64 35.9 1.7 4.8 65.3 102 
25.6 21.2 1.4 6.6 22.77 88.96 
10.24 16.4 1.6 9.9 11.21 109.5 
4.096 13.4 1.6 12.3 4.498 109.8 
Conc Average  SD %CV Backfit Accuracy 
250 165.3 0.5 0.3 250.7 100.3 
100 118.1 4.3 3.6 99.23 99.23 
40 76.3 3.2 4.2 39.85 99.63 
16 48.5 2.1 4.4 17.19 107.4 
6.4 26.8 1.7 6.2 5.433 84.89 
2.56 19.4 1.3 6.9 2.48 96.87 
1.024 15.8 2.0 12.7 1.3 127 
Conc Average  SD %CV Backfit Accuracy 
25 244.1 4.7 1.9 25.3 101.2 
10 219.1 5.0 2.3 9.969 99.69 
4 178.0 6.4 3.6 3.927 98.17 
1.6 129.2 2.7 2.1 1.656 103.5 
0.64 75.8 2.9 3.8 0.6137 95.88 
0.256 43.3 0.2 0.4 0.2642 103.2 
0.1024 21.6 0.5 2.3 0.1014 99.06 
Conc Average  SD %CV Backfit Accuracy 
1000 8.6 0.6 6.8 785.9 78.59 
400 12.5 1.8 14.1 478.9 119.7 
160 31.0 6.5 21.1 159.7 99.81 
64 62.7 5.9 9.4 60.96 95.25 
25.6 94.0 9.7 10.3 27.49 107.4 
10.24 125.6 18.2 14.5 9.261 90.44 
4.096 136.5 3.0 2.2 4.415 107.8 
Conc Average  SD %CV Backfit Accuracy 
1000 58.1 3.9 6.8 992.5 99.25 
400 76.5 8.2 10.7 403.1 100.8 
160 115.0 16.4 14.3 159.2 99.47 
64 161.7 4.8 3.0 64.28 100.4 
25.6 194.6 4.5 2.3 25.62 100.1 
10.24 209.6 11.9 5.7 9.931 96.98 
4.096 214.4 1.5 0.7 4.344 106.1 
Conc Average  SD %CV Backfit Accuracy 
2000 15.5 1.1 7.4 1784 89.22 
800 24.0 0.6 2.4 873.3 109.2 
320 45.7 6.6 14.4 319.7 99.91 
128 77.6 2.8 3.6 126.6 98.94 
51.2 115.0 2.3 2.0 50.3 98.24 
20.48 144.9 10.0 6.9 21.51 105 
8.192 168.1 1.8 1.1 7.847 95.79 
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Table 5.7. TIMP-2 and fMLP. The average, SD, %CV, accuracy cube from 9 replicates shown. The r2 
was 0.9992 and 0.9994 for TIMP-2 and fMLP respectively 
 
Table 5.8. Assay range for biomarkers in urine samples.  The samples were run neat in the multiplex 
lateral flow device but diluted for the ELISA, the assay range for the ELISA was recalculated taking 
into account the dilution factor and the range listed as minimum – maximum (actual range). 
 Multiplex LF ELISA 
 Assay range 
(min) 
 
Assay range 
(max) 
 
Assay range 
(min) 
Assay range 
(max) 
ELISA 
dilution 
Assay range 
(min) 
Actual 
Assay range 
(max) 
Actual 
A1AT 4ng/ml 1000ng/ml 0.3ng/ml 80ng/ml 20 7ng/ml 1600ng/ml 
TIMP-2 0.4ng/ml 100ng/ml 0.03ng/ml 2ng/ml 10 0.3ng/ml 20ng/ml 
NGAL 1ng/ml 250ng/ml 0.08ng/ml 5ng/ml 100 8ng/ml 500ng/ml 
Fibrinogen 4ng/ml 1000ng/ml 0.6ng/ml 40ng/ml 2 1ng/ml 80ng/ml 
CRP 0.1ng/ml 25ng/ml 0.02ng/ml 1ng/ml 10 0.2ng/ml 10ng/ml 
RBP4 4ng/ml 1000ng/ml 0.02ng/ml 1.5ng/ml 2000 47ng/ml 3000ng/ml 
CC16 4ng/ml 1000ng/ml 0.03ng/ml 2ng/ml 10 0.3ng/ml 20ng/ml 
B2M 8ng/ml 2000ng/ml 0.01ng/ml 50ng/ml 100 1ng/ml 5000ng/ml 
TIMP-1 0.8ng/ml 200ng/ml 0.03ng/ml 2ng/ml 10 0.3ng/ml 20ng/ml 
fMLP 0.4ng/ml 100ng/ml 0.8ng/ml 50ng/ml 2 2ng/ml 100ng/ml 
 
  
Conc Average  SD %CV Backfit Accuracy 
200 238.8 2.9 1.2 203 101.5 
80 218.3 7.1 3.3 82.3 102.9 
32 181.2 12.0 6.6 29.53 92.27 
12.8 144.9 7.8 5.4 13.84 108.2 
5.12 91.8 6.4 6.9 4.97 97.07 
2.048 51.2 4.4 8.5 2.006 97.94 
0.8192 23.2 1.3 5.4 0.8405 102.6 
Conc Average  SD %CV Backfit Accuracy 
100 29.5 0.6 1.9 78.26 78.26 
40 32.3 3.5 10.8 42.26 105.6 
16 39.9 1.4 3.6 17.92 112 
6.4 59.9 1.1 1.8 5.982 93.47 
2.56 83.2 1.3 1.6 2.61 102 
1.024 110.4 4.9 4.4 1.029 100.5 
0.4096 129.7 4.3 3.3 0.4059 99.1 
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Figure 5.13. Graphical representation of the standard curves for each of the assays within the 
multiplex assay. Nine replicates for each standard were run, the mean and SD are presented in each 
of the graphs for each standard.  The ‘cube unit’ is the reader value obtained by reading the colour 
intensity of the line on the lateral flow strips. 
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Figure 5.14. Graphical representation of the standard curves for each ELISA. Two replicates for each 
standard were run, the mean and SD are presented in each of the graphs for each standard.  
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5.4 Discussion 
As described in this chapter, 2 multiplex assays (a and b) have been successfully developed.  
Multiplex ‘a’ consisted of 5 biomarkers, A1AT, TIMP-2, NGAL, Fibrinogen and CRP and Multiplex ‘b’ 
also consisted of 5 biomarkers, RBP4, CC16, B2M, TIMP-1 and fMLP.  The assays in multiplex ‘’a’’ 
were all sandwich assays, however, 2 of the assays that were too sensitive required further 
manipulation.  The A1AT required an additional pre-absorbent line to remove excess A1AT and the 
NGAL assay required the addition of free antibody into the system which had the same effect.  Three 
of the 5 assays in multiplex ‘’b’’ were inhibition assays, format of which was required to de-sensitise 
the assays. fMLP had to be an inhibition or competition assay due to the small size of the analyte. 
The test system was subjected to a small usability feedback survey with 10 people with COPD and 3 
non-COPD users, who trialled the system for 1 month. Feedback from the volunteers highlighted 
issues surrounding the size of the cube reader button, as well as its automatic timing function which 
proved difficult to initiate as a result of multiple steps. The changes would be addressed by making 
modifications to the button and the reader firmware adapted to simplify the process of running the 
test by removing the choice of reading the test without the timer. It was concluded that after 
implementing these minor changes the technology platform would be deemed acceptable for the 
patients to use with no added burden to their already challenging lifestyle.  
The assays within the multiplex devices correlated with the reference ELISA assays with urine 
samples that covered the expected range r2>0.75. To achieve the same dynamic range for all assays 
to those obtained from the reference assays was more challenging as a) there was no allowance for 
sample dilution for the lateral flow assays compared to the laboratory assays (where a sample 
dilution step was possible), b) It was also important to take into account the large range of levels of 
each biomarker found in the samples that was challenging even for the ELISAs. Observed levels 
throughout all the testing showed that frequently, there were samples that fell outside of the ELISA 
standard curves, below and above. In principle the aim was to get as large a dynamic range as 
possible for each of the assays.  A summary of the performance of each assay is discussed below: 
- The A1AT assay had a good standard curve, CVs were all below 20% and the accuracy 
between 80-120% for all the standards.  The dynamic range of the assay was not as large for 
the multiplex assay (4-1000ng/ml) compared to the ELISA range (7-1600ng/ml). Previous 
testing has suggested that higher levels of A1AT would be found in fresh samples which 
would result in a high dose hook effect. 
- The performance of the TIMP-2 assay was above expectation, the CVs and accuracy were 
within the specifications set and the assay range was similar to the ELISA. 
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- The NGAL assay had a good standard curve, the accuracy of the bottom standard was out of 
specification in this instance (127%), however, removal of the lowest standard from the 
calibration curve would not be detrimental to the assay as similar to the A1AT assay it is 
slightly too sensitive (1-250ng/ml) compared to the ELISA (8-500ng/ml).   
- The Fibrinogen assay had a good standard curve that met all specifications, however, it did 
appear to lack sensitivity (4-1000ng/ml) when compared to the ELISA (1-80ng/ml). This is 
reflected by the correlation with the ELISA with urine samples, it confirms that better 
sensitivity would be beneficial based on frozen sample testing. 
- The performance of the CRP assay met all specifications, the CVs and accuracy were within 
the specifications set and the assay range was an improvement in relation to the standard 
curve obtained by ELISA. 
- The RBP4 assay, similar to the A1AT and NGAL assay was too sensitive and non-optimal at 
the higher range (4-1000ng/ml compared to 47-3000ng/ml for the ELISA). The levels of RBP4 
are not expected to present in urine at the higher range based on previous sample testing 
with frozen samples. It would again be beneficial to further de-sensitise the assay with a 
wider range should the assay be taken forward after evaluation with fresh samples. 
- The CC16 assay had a good standard curve and met all specifications (accuracy and %CV), 
however, it did lack sensitivity (4-1000ng/ml) in relation to the ELISA standard curve (0.3-
20ng/ml), the resulting range is deemed acceptable based on levels found in previous 
samples tested to date. 
- The B2M assay had a good standard curve for the optimised range set and met all 
specifications, however, it did lack sensitivity (8-2000ng/ml) when compared to the ELISA (1-
5000ng/ml), similar to CC16 above, the resulting range is deemed acceptable based on levels 
found in previous samples tested to date. 
- The performance of the TIMP-1 and fMLP assay meets all specifications set and the assay 
range an improvement to those obtained by ELISA. 
 
Out of the 10 assays, 5 of the assays required no known improvements and performed as 
expected. Three of the assays lacked sensitivity – fibrinogen, CRP, CC16 and two assays- A1AT 
and RBP4 were too sensitive. It was unknown if the challenges identified during the testing 
performed to date on frozen sample analysis would be repeatable in fresh urine samples. The 
final tests were deemed to be acceptable for further evaluation with fresh urine samples and in 
the setting for which they have been designed for use. The performance of the test will be 
challenged in further studies.  
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Chapter 6. Verification and validation 
of the point of care multiplex lateral 
flow tests 
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6.1 Introduction  
For laboratory testing and development of the multiplex assays, the samples used were all frozen 
urine samples and, as the samples were limited, a set volume of sample was added per device 
(650µl) which was the minimum volume of sample that could be used for the device to be used 
effectively. It was important to understand the potential implications of using these methods when 
testing in the laboratory environment as compared to how the devices would be used in “real-life” 
situations.  For the planned trial (chapter 7), the two test devices developed in chapter 6 were to be 
used by patients for home monitoring of COPD exacerbations (observational study). The devices 
were to be used one at a time by dipping them into urine, in a jug, and setting the measuring 
instrument (the cube) to read the device after 10 minutes. Ideally the devices would be removed 
from their pouches immediately before testing, dipped in urine and placed on the cube reader 
adaptor to be read 10 minutes later, with the cube programmed with an automatic timer. outside of 
a trial setting, the devices should be suitable for mid-stream testing.  
The following aspects of the use of the device were considered: 
1) Evaluation of different methods of applying the sample to the test devices including pipetting vs 
dipping - Dipping the device into the sample could lead to variation as the test could either be 
dipped into the sample at an angle for 5-10 seconds or it could be performed upright. Visually the 
indication that the device has started to run is the presence of the red gold conjugate flowing in the 
device window and this criterion was used to assess the different methods. 
2) Blood spiking - It is possible that some samples could also contain potential interfering substances 
such as blood. In order to see if blood had any effect on the assays, samples with and without spiked 
blood were tested. 
3) Cross reactivity – Each device consisted of five different assays, cross reactivity studies were 
performed on the devices to understand if any of the assays cross reacted with each other in the 
presence of each analyte.  
4) Sample stability study - stability studies were performed to assess whether samples were stable 
during transport and upon freeze-thawing. Verification of this was required as the patients from the 
planned clinical trial were going to send weekly urine samples by mail to the lab for further analysis. 
Once received, the samples would be tested, aliquoted and frozen at -80°C. In order to determine if 
these processes had any effect on the samples, fresh urine samples were initially tested and then 
subjected to a transport and freeze-thawing study to evaluate any changes in results. 
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5) Samples tested within a 24hr period - in the planned clinical study, the volunteer would be 
running 2 tests from one collected urine sample sequentially. This experiment was designed to 
determine how stable the urine sample was after collection over 24hrs.   
6) Line development/Measurement time - the test was designed for the result to be read after 10 
minutes, the reader has an automatic timer of 10 minutes. However, the time at which the device is 
run and then placed in the reader cannot be controlled. Accordingly, it is important to determine 
whether any deviation from the protocol in terms of delay in reading is likely to affect the test result. 
7) Batch reproducibility - volunteers were likely to receive multiple, and potentially different, batches 
during the trial and therefore, as part of validation it was necessary to ensure that batch-to-batch 
variability was minimal and that the QC criteria was appropriate to identify any batches that were 
likely to be unreliable. 
6.2. Methods 
6.2.1 Materials/reagents 
- Buffer PBST- 1%BSA (10mM phosphate buffered saline pH7.5, supplemented with 1% 
(w/v) BSA) 
- Antigens for Multiplex A: A1AT (Merck Calbiochem, 178251), TIMP-2, (Kent university, 
Canterbury), NGAL (Alere San Diego, RFPR017674), Fibrinogen (BBI, 132-3), CRP (Lee 
Biosolutions, 140-11R) 
- Antigens Multiplex B: RBP4 (BBI, P124-1), CC16 (Novoprotein CU06), B2M (BBI, P122-
1), TIMP-1 (Novoprotein, C456), fMLP (Sigma, 47729) 
- Fresh urine and blood samples collected from healthy controls 
- Headstart devices a and b (batch AD210317, AD240517, AD030417) 
- ELISAs for all 10 biomarkers (as described in chapter 2) 
- Multistix 10 SG Reagent Strips (Siemens) 
6.2.2 Equipment 
• Cube reader; Cube/device adaptor; Cable (OpTricon) 
• RFID card wide control + Area under the curve (AUC) 
• Pipettes 
• Universals/Bijou/2ml Eppendorf tubes 
• Timer 
• Plate shaker/plate washer 
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6.2.3 Testing buffer standards - pipette method 
Standard testing was performed as follows: i) devices were removed from the pouches immediately 
before testing; ii) caps were removed and device was placed on a flat surface; iii) 10 minute timer 
was initiated; iv) With the device laid on a surface, 650µL of each standard was pipetted on to the 
region of the wick closest to the conjugate pad. v) the device was read after 10 minutes using a cube 
reader. vi) once reading was complete, the devices were discarded. 
Standards for Multiplex A & B were made according to table 6.1. 
6.2.4 Testing urine samples 
Pipette method: as described above for the buffer standard testing. 
Dipping method – at a ‘’slant’’: device was dipped into the urine sample at a slant for approximately 
45° for 15 seconds so that the wick was immersed and then laid flat on a surface. The device was 
then read after 10 minutes using the cube reader as already described in section 6.2.3. 
Dipping method – ‘’upright’’: device was dipped into the urine sample held upright so that the wick 
was immersed and removed once the gold conjugate solution was visible in the device read window.  
The device was then laid flat on a surface and read after 10 minutes using the cube reader as already 
described in section 6.2.3. 
Table 6.1. Standards used for standard testing. The top standard was prepared at shown 
concentrations for all analytes from the stock concentrations and then diluted 1 in 2.5 in the standard 
dilution buffer PBST 1% BSA. 
ng/ml A1AT T2 NGAL FIB CRP RBP4 CC16 B2M T1 fMLP 
1 1000 200 500 1000 25 500 2500 500 100 50 
2 400 80 200 400 10 200 1000 200 40 20 
3 160 32 80 160 4 80 400 80 16 8 
4 64 12.8 32 64 1.6 32 160 32 6.4 3.2 
5 25.6 5.12 12.8 25.6 0.64 12.8 64 12.8 2.56 1.28 
6 10.24 2.048 5.12 10.24 0.256 5.12 25.6 5.12 1.024 0.512 
7 4.096 0.8192 2.048 4.096 0.1024 2.048 10.24 2.048 0.4096 0.2048 
8 0 0 0 0 0 0 0 0 0 0 
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6.2.5 Testing dipping variation 
In order to test for variability due to dipping variation, the devices (Batch AD210317) were tested 
with fresh samples using the following methods: Dipping the device in the sample at a slant for 
15seconds; dipping upright with the wick fully immersed into the sample until the device starts 
running and pipetting 650µL of sample on the wick. Urine samples were collected from 21 healthy 
volunteers, and 5 replicates were tested. 
Results were taken from the 5 replicates for each sample for each assay and each method and the 
mean, SD and %CV calculated. Graphs were produced using GraphPad Prism Version 7. 
6.2.6 Blood spiking testing 
According to the literature, the Multistix Test can detect between 150 and 620 µg/l of free 
haemoglobin. Normal blood contains 15 g/dl (150,000,000 µg/l). EDTA-treated blood was diluted 
1/1,000,000 in 3 healthy urines (1/1000 in H2O followed by 1/1000 in urine) and applied to the blood 
reagent pad of a Multistix (Yellow: no blood present, patchy green: intact blood present (moderate), 
green: haemolysed blood present large). 
 
Figure 6.1. Multistix results regarding blood detection in urine. 
In order to establish the maximum amount of blood that the Multistix can detect, 3 healthy urines 
were spiked with the blood diluted 1/100,000 and applied to the blood reagent pad of a Multistix to 
confirm the spiking. Once the samples were spiked with optimal volumes of blood, devices were 
tested with the samples in the same way as in testing urine samples (batch AD240617). 
6.2.7 Cross-reactivity testing 
This was undertaken to establish if there was cross-reactivity between the biomarkers in both 
multiplex devices with the top standards of each assay (the most extreme condition).  
Testing was performed using triplicate devices. The standards used for testing were formulated 
according to table 6.1 and the combinations of standards prepared for this testing are shown in table 
6.2. The batch of devices used was AD240517. A combination where the specific standard was 
missing yet a positive result was obtained for that assay would indicate that there was cross-
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reactivity. The experiment was designed so that should there be cross reactivity then the cause 
would be identified from a secondary analysis of the data. 
Table 6.2. Standards used for cross-reactivity testing. TS stands for Top Standard, ✓ indicates the 
presence of the antigen and X indicates the absence of that antigen on the standard mix. 
Headstart A  Headstart B 
Assay A1AT T2 NGAL FIB CRP Assay RBP4 CC16 B2M T1 fMLP 
TS ✓ ✓  ✓  ✓  ✓  TS ✓ ✓  ✓  ✓  ✓  
A1AT X ✓  ✓  ✓  ✓  RBP4 X ✓  ✓  ✓  ✓  
T2 ✓ X ✓  ✓  ✓  CC16 ✓ X ✓  ✓  ✓  
NGAL ✓ ✓ X ✓  ✓  B2M ✓ ✓ X ✓  ✓  
FIB ✓ ✓  ✓  X ✓ T1 ✓ ✓  ✓  X ✓ 
CRP ✓ ✓  ✓  ✓  X FMLP ✓ ✓  ✓  ✓  X 
6.2.8 Transport /Stability Study 
The objective of the transport study was to collect urines from healthy individuals, pool them 
together, determine high and medium levels of each marker by spiking and testing on both devices 
at specific timepoints after the pooled samples had been exposed to the different conditions. The 
conditions tested were: ambient storage, transport storage (car with TinyTag datalogger to track the 
temperature), and freeze-thaw at -80°C storage. In order to perform this testing, the pooled samples 
were first tested with the device to determine initial levels of the markers. Based on these results 
the pooled samples were split into 10 aliquots and 5 were spiked with multiplex A antigens (A1- A5) 
and the remaining 5 with multiplex B antigens (B1-B5) according to table 6.4.  Following spiking, 
each set of samples for A & B was tested on both of the respective multiplex devices to obtain initial 
timepoint reference values. Sample testing was performed according to 6.2.4 using the pipetting 
method. 
In order to facilitate the study each pooled sample (A1-A5 and B1-B5) were aliquoted as follows: 
• For ambient storage study: 15ml in a universal container 
• For transport study (with TinyTag datalogger): 15ml in a universal container 
• For freeze / thaw study, -80°C Storage: 15ml in a universal container 
• 50 aliquots of 1.5ml in 2ml tubes – to be used as urine QC test for HSV3 batches, -80°C 
Storage 
Each aliquot was tested at different timepoints (1, 4, 6, 8, 12, 15 days) for each study. For each 
timepoint, 2 replicates were tested. 
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Table 6.3. Summary of the spiking of the pooled samples. Five spiked solutions for both A and B 
multiplexes. Spiking was by adding each antigen to the polled urine samples directly from the 
antigen stock according to the respective dilutions. 
 A1 A2 A3 A4 A5 
Dilution µL  Dilution µL  Dilution µL  Dilution µL  Dilution µL  
A1AT 1/1000 150 1/2000 75 1/8000 18.75 0 0 0 0 
T2 0 0 1/6000 25 1/12000 12.5 1/24000 6.25 0 0 
Fib 1/2000 75 0 0 1/500 300 1/1000 150 0 0 
NGAL 1/8000 18.75 1/16000 9.4 0 0 1/4000 37.5 0 0 
CRP 1/40000 37.5 1/80000 18.75 0 0 0 0 1/20000 75 
 B1 B2 B3 B4 B5 
Dilution µL  Dilution µL  Dilution µL  Dilution µL  Dilution µL  
RBP4 1/2000 75 1/4000 37.5 1/8000 18.75 0 0 0 0 
CC16 0 0 1/500 300 1/1000 150 1/2000 75 0 0 
B2M 1/4000 37.5 0 0 1/1000 150 1/2000 75 0 0 
T1 1/4000 37.5 1/8000 18.75 0 0 1/2000 75 0 0 
fMLP 1/2000 75 1/4000 37.5 0 0 0 0 1/1000 150 
 
6.2.9  Comparison of fresh and frozen samples 
A total of 40 fresh urine samples that were a combination of COPD and CF samples (sent by post to 
Mologic >1 day old) were tested with both the multiplex lateral flow tests and the ELISAs. The 
samples were aliquoted into small vials and frozen at -80°C, the fresh samples were stored at 2-8°C. 
The frozen samples were thawed and the fresh samples were equilibrated to room temperature 
before testing within 24 hrs of receipt of samples. The batch of test devices used was batch 
AD240517.  Cube reader results were converted to concentration values for analysis. 
The statistical analysis used to compare results from fresh samples and frozen samples with both 
ELISA and LF was r2, Spearman’s rank test and Bland Altman plots all using GraphPad Prism V7. 
6.2.10 Stability of urine throughout the day 
In order to test the urine variation throughout the day, the devices (Batch AD030417) were tested 
with fresh samples (UD 28, 32, 37, 40, 45, 46) in duplicate (for each device A & B) at different 
timepoints: 12:45-0h, 13:45-1h, 14:45-2h, 15:45-3h, 16:45-4h, 9:00-16h, 12:45-24h. The profiles 
were plotted using Graphpad Prism Version 7.  
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6.2.11 Testing Line development/measurement time 
To test line development, standards with high, medium, low and zero (negative) concentrations of 
antigens were tested in duplicate on devices (Batch AD030417). Standard testing was made using 
the pipetting method. The cube readings were made as soon as the device starts, reading every 10 
seconds for 30 minutes. The Autoclicker software was used together with the Cube reading software 
using 180 repetitions and sleeping time of 3333 million milliseconds. The devices were discarded 
once reading was complete. The standard concentrations used for testing are displayed in table 6.5. 
The results were plotted on graphs with the 10 minute timepoint highlighted. The graphs shown 
were produced in excel.  
Table 6.4. Standards used for Line development test. 
ng/ml A1AT T2 NGAL FIB CRP RBP4 CC16 B2M T1 fMLP 
High 1000 200 500 1000 25 500 2500 500 100 50 
Medium 64 12.8 32 64 1.6 32 160 32 6.4 3.2 
Low 4.096 0.8192 2.048 4.096 0.1024 2.048 10.24 2.048 0.4096 0.2048 
Negative 0 0 0 0 0 0 0 0 0 0 
 
6.2.12  Batch to batch reproducibility 
Three batches were tested by one operator, 5 replicates per batch, with a complete standard curve 
in a randomised order. Pipette method was used for running the assay. Standards were prepared, 
and the same preparation was tested on all three batches (batch 1, SR180917, batch 2 SR260917, 
batch 3 SR031017) Analysis involved assessing correlations between each batch with a desired 
outcome of an r2 greater than 0.95.  
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6.3 Results 
6.3.1 Testing dipping variation 
Three methods of applying the sample to the test device were evaluated, the first 2 methods for 
dipping the device and the third method for the standard laboratory testing of applying a set volume 
of sample to the device using a pipette.  
In principle according to the graphs below in figure 6.2, all results for all three methods fitted within 
the normal variation within the test. There was not one method that stood out as being different.  
Variation was assessed using % CV and identifying the proportion of samples that had higher than 
20% CV for each assay.  
- For the RBP4 assay, method 1, 8/21 samples gave a CV higher than 20% (38%), method 2, 
6/21 samples gave a CV higher than 20% (29%), and method 3, 5/21 samples gave a CV 
higher than 20% (24%). 
- For the CC16 assay, method 1, 1/21 samples gave a CV higher than 20% (5%), method 2, 
0/21 samples gave a CV higher than 20% (0%), and method 3, 0/21 samples gave a CV higher 
than 20% (0%). 
- For the B2M assay, method 1, 2/21 samples gave a CV higher than 20% (10%), method 2, 
0/21 samples gave a CV higher than 20% (0%), and method 3, 1/21 samples gave a CV higher 
than 20% (5%). 
- For the TIMP-1 assay, method 1, 4/21 samples gave a CV higher than 20% (19%), method 2, 
2/21 samples gave a CV higher than 20% (10%), and method 3, 3/21 samples gave a CV 
higher than 20% (14%). 
- For the fMLP assay, method 1, 9/21 samples gave a CV higher than 20% (43%), method 2, 
3/21 samples gave a CV higher than 20% (14%), and method 3, 2/21 samples gave a CV 
higher than 20% (10%). 
 
The general trend was that method 1 gave slightly worse performance than the others and method 3 
gave the least variability. 
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Figure 6.2. Graphical representation of the variation of each assay (cube units) for the samples 
tested with 3 different methods: dipping devices at a slant for 15s, dipping upright until it starts and 
pipetting 650 µL; Each column cluster represents the different samples tested, each column the 3 
different methods tested, Y-axis cube units. Median and interquartile range shown. 
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Table 6.5. The average, %CV for 3 different method of sample application for RBP4, CC16 and B2M (dipping with a slant, dipping upright till the sample has 
run, and pipette application). Highlighted in bold are the results out of specification.  
Sample 
ID 
RBP4 CC16 B2M 
Dipping (slant) Dipping (upright) Pipette Dipping (slant) Dipping 
(upright) 
Pipette Dipping (slant) Dipping 
(upright) 
Pipette 
Average %CV Average %CV Average %CV Average %CV Average %CV Average %CV Average %CV Average %CV Average %CV 
1 16.7 16.6 15.5 9.6 13.1 23.3 66.1 3.4 68.8 7.3 69.2 4.1 82.0 4.9 80.2 7.8 90.9 3.0 
2 30.0 7.9 29.8 7.5 30.1 10.4 130.9 3.6 133.2 5.0 137.0 6.7 90.0 4.2 90.2 4.3 97.4 2.6 
3 27.1 4.2 27.8 15.6 23.8 7.1 107.0 5.1 106.9 8.2 109.2 5.5 90.2 2.2 93.7 5.8 101.3 3.5 
4 18.9 9.8 20.1 4.9 18.7 19.4 85.6 2.0 91.1 6.2 94.7 5.7 112.7 7.1 116.9 4.1 128.6 6.7 
5 22.3 16.6 20.1 16.1 22.3 13.7 67.3 16.3 66.8 6.4 73.2 5.2 71.8 13.6 75.1 5.9 76.1 4.2 
6 16.2 11.6 17.1 22.8 16.8 16.6 64.4 6.5 70.2 9.2 73.8 8.8 42.0 8.2 47.2 13.1 51.2 13.4 
7 13.3 15.6 12.6 10.6 11.4 10.8 72.2 4.0 68.0 4.7 76.6 4.9 104.4 6.7 104.3 1.5 122.8 3.6 
8 16.4 22.2 14.5 25.1 15.5 14.7 56.5 11.9 56.9 12.7 62.3 4.6 52.8 8.0 54.0 13.0 51.0 6.4 
9 17.2 14.6 17.2 11.0 21.3 16.9 115.2 8.2 121.0 4.7 125.3 5.9 69.5 8.5 65.8 7.1 48.7 9.0 
10 10.4 18.7 9.4 13.4 11.5 23.1 68.6 16.6 71.3 5.1 64.6 13.1 37.4 20.2 38.4 7.3 30.7 9.9 
11 16.5 23.6 18.4 7.4 18.0 7.1 105.2 26.5 113.9 7.8 109.0 8.6 36.4 23.3 37.0 8.4 31.0 9.1 
12 17.2 23.4 18.1 3.4 19.0 8.0 119.6 11.2 119.2 4.3 118.6 4.6 68.1 5.1 70.6 5.4 68.4 5.8 
13 14.3 27.3 15.8 17.3 16.2 5.2 100.9 17.7 105.9 5.4 105.9 7.2 46.6 22.4 49.9 8.1 35.8 10.4 
14 15.6 23.0 16.6 23.4 20.7 14.0 55.9 16.4 60.6 8.1 61.3 4.6 64.0 12.6 71.3 5.3 72.3 3.4 
15 28.3 13.2 29.6 17.9 27.2 23.0 117.2 8.9 123.2 7.9 118.4 14.0 102.2 3.7 108.9 6.5 85.4 21.1 
16 9.9 17.5 10.4 36.0 13.7 17.6 105.9 7.8 115.2 7.3 111.4 4.8 47.3 13.1 54.1 5.0 47.7 6.3 
17 24.7 13.0 22.4 18.4 20.9 19.8 134.0 6.2 129.0 6.2 125.4 5.4 99.9 4.0 101.3 4.3 104.1 4.9 
18 34.0 13.0 38.9 6.6 38.4 18.4 122.9 6.6 126.7 4.8 125.4 8.5 113.0 3.2 114.9 3.1 118.8 4.7 
19 22.0 32.5 17.3 20.9 16.4 24.8 83.7 9.4 82.6 7.8 76.9 12.2 79.6 5.5 76.2 5.6 84.2 9.9 
20 11.1 21.7 11.1 25.2 14.2 10.0 45.5 7.6 45.0 9.3 47.2 2.7 51.4 4.3 50.2 10.3 51.1 4.3 
21 8.7 34.1 8.6 22.4 10.1 30.0 58.7 8.3 60.1 8.4 61.3 8.2 68.9 6.3 70.4 6.3 72.2 2.6 
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Table 6.6. The average, %CV for 3 different methods of sample application for TIMP-1 and fMLP (dipping with a slant, dipping upright till the sample has run, 
and pipette application). The results out of specification are highlighted in bold type. 
Sample 
ID 
TIMP-1 fMLP 
Dipping (slant) Dipping 
(upright) 
Pipette Dipping (slant) Dipping 
(upright) 
Pipette 
Average %CV Average %CV Average %CV Average %CV Average %CV Average %CV 
1 206.7 1.1 209.8 2.3 205.3 2.2 40.6 10.5 38.7 8.8 40.9 5.4 
2 35.3 3.6 38.5 9.1 50.4 20.3 41.9 7.9 38.2 9.9 35.4 11.1 
3 41.2 9.1 39.0 5.4 48.3 4.7 43.3 4.9 43.8 6.2 49.6 2.3 
4 48.1 18.8 49.0 15.2 63.1 20.5 52.6 18.7 51.7 2.6 55.9 11.0 
5 189.2 3.9 193.5 2.9 200.8 3.6 19.7 24.3 25.8 4.8 24.5 13.1 
6 69.5 7.1 73.6 4.7 82.5 4.9 13.8 39.4 15.9 20.1 16.5 22.5 
7 58.2 13.1 63.8 10.1 71.9 14.8 62.6 3.4 62.2 6.7 75.9 4.5 
8 96.0 7.8 101.8 6.3 110.3 8.5 14.3 24.9 17.0 22.3 16.6 16.3 
9 38.9 14.3 46.9 14.6 37.2 22.6 23.5 12.1 20.0 23.6 20.0 20.1 
10 94.4 13.0 97.0 7.2 95.8 11.9 16.0 41.9 17.9 20.0 13.8 18.7 
11 10.1 48.4 8.2 21.7 11.8 41.4 9.1 26.0 9.4 11.5 7.0 31.1 
12 34.7 33.0 29.9 21.0 35.9 12.3 27.4 9.2 27.9 20.0 28.5 14.5 
13 22.9 27.4 20.5 16.9 19.5 19.5 13.7 40.3 11.4 15.4 11.5 28.2 
14 129.6 6.9 135.8 4.1 141.4 5.2 21.7 32.8 24.1 9.9 29.6 13.8 
15 27.1 22.9 20.0 16.3 23.7 17.5 21.8 23.0 22.8 19.6 16.1 13.2 
16 24.0 15.4 28.2 26.3 26.6 8.6 9.0 31.1 12.3 8.0 10.6 18.1 
17 57.5 10.0 50.2 8.3 56.5 7.1 47.1 5.8 50.2 6.7 52.7 5.1 
18 38.0 36.3 39.5 19.0 29.6 34.8 57.9 14.4 59.3 2.7 60.5 3.5 
19 240.4 3.4 239.1 2.4 229.2 2.7 31.3 7.1 32.9 11.0 40.0 7.1 
20 33.7 17.5 30.7 18.5 30.2 15.9 17.4 21.2 17.7 40.7 18.2 15.6 
21 70.5 3.3 75.1 6.7 77.7 2.3 29.7 8.7 29.3 5.5 32.9 6.7 
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5.3.2 Blood spiking testing 
The Multistix results suggested that 1/100,000 dilution of blood in urine was the most suitable 
dilution for assessing the potential interference on the tests by the presence of blood.  
According to the data the majority of the assays were unaffected by the addition of blood. There 
were two samples that appeared to give a higher signal for the spiked blood sample in comparison 
to the unspiked samples, these mainly had an impact on the assays in device b: B2M, CC16 and 
TIMP-1. 
The spiked samples gave significantly higher signals in relation to the unspiked samples for these 
three assays which were non-specific as these were a mix of sandwich and inhibition assay therefore 
no pattern was observed. 
The assays that were not affected overall were A1AT, TIMP-2, NGAL, fibrinogen, CRP, RBP4 and 
fMLP. 
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Sample Unspiked urine 
Spiked Urine 
1/100,000,000 EDTA blood 1/100,000 EDTA blood 
1 
   
2 
   
3 
   
 
Figure 6.3. Optimisation of blood spiking for Multistix testing. Multistix results obtained before and 
after spiking three of the healthy urine samples with EDTA treated blood at different concentrations. 
The remaining samples used for testing were also spiked and tested on Multistix and all presented a 
green colour after spiking (Data not shown). 
 
Figure 6.4.  Pre- and post-spike of blood (1/100,000 blood) into 10 urine samples for each individual 
assay. Wilcoxon matched-pairs signed rank test used to determine significance between each group, 
p value <0.05 was deemed significant. 
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6.3.3 Cross-reactivity testing 
The aim of this cross-reactivity testing was to determine if there was any cross reactivity between 
the markers in the multiplex assays. The devices were tested with a mixed antigen solution that 
included the top standard of the respective multiplex assays on that device, with top standards of all 
the assays minus its respective standard and a buffer only sample where all antigens were absent. 
Regarding cross reactivity testing on the sandwich assays, the expected cube unit values of an assay 
on the multiplex should be low in the absence of the corresponding antigen from the standard 
tested. If the cube units for said assay were not low it would mean that something other than the 
antibody for a specific antigen was binding to said antibody, i.e. if A1AT was missing from the mixed 
antigen solution, the A1AT line should have a low line intensity on the A1AT assay, otherwise it 
would indicate that there was cross reactivity with another assay on the multiplex. In analysing the 
data for Multiplex A (figure 6.5), it was clear that in the absence of each antigen in the respective 
assay the cube units were low, which was the expected result for sandwich assays. 
Regarding cross reactivity testing on the inhibition assays (all assays on multiplex B except TIMP-1), 
the expected cube unit values of an assay on the multiplex should be high in the absence of the 
corresponding antigen from the standard tested. If the cube units for said assay were not as high as 
normal it would mean that something other than the antibody specific antigen was binding to said 
antibody, i.e. if RBP4 was missing from the mixed antigen solution, the RBP4 line should have a high 
line intensity, otherwise it would indicate that there was cross reactivity with another assay on the 
multiplex, as something is binding to the anti-RBP4 antibody conjugated to the gold nanoparticles. In 
analysing the data for Multiplex B (figure 6.6), it was clear that in the absence of each antigen the 
respective assay cube units were high, which is the expected result for the inhibition assays. 
Regarding CC16, the reason why the difference between the presence and absence of the antigen 
was not as significant when compared to the other inhibition assays, was because the top standard 
used for the CC16 assay was not high enough to completely inhibit the anti CC16 antibody from 
binding to the test line. 
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Figure 6.5. Graphical representation of the cube unit averages (3 replicates) for cross-reactivity 
experiments on Multiplex A. Each cluster of columns represents an assay of the multiplex device, 
and each coloured column represents cube units for the respective assay when 1 of the antigens is 
missing. “A All” stands for testing of top standard with all the antigens of the multiplex assays. For 
example, for A1AT, when the A1AT standard was missing, there was no signal as expected. 
 
Figure 6.6.  Graphical representation of the cube unit averages (3 replicates) for cross-reactivity 
experiments on Multiplex B. Each cluster of columns represents an assay of the multiplex device, 
and each coloured column represents cube units for the respective assay when 1 of the antigens is 
missing. “B All” stands for testing of top standard with all the antigens of the multiplex assays. For 
example, for RBP4, when the RBP4 standard was missing, there was a signal as expected. 
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6.3.4 Transport stability study 
The objective of the transport study was to collect urines from healthy individuals (spiked) and test 
urine variability after the exposure to different conditions. The conditions tested were: ambient 
storage, transport storage and freeze-thaw at -80°C storage. Ten samples (5 for each multiplex) were 
stored in each test condition. Each set of samples for devices A & B was tested on the respective 
multiplex devices to yield initial timepoint reference values. Each aliquot stored at each condition 
was then tested at different timepoints (1, 4, 6, 8, 12, 15 days).  
The first observation is that that the correlation between room temperature and transport results 
was very good across all assays.  By way of example, the results will focus on RT, -80°C and freeze 
thawing. 
- Regarding the sample variability of A1AT it was clearly shown that A1AT in fresh samples 
was not stable across the 15 days and was likely to continue to deteriorate further over time 
based on the downward trend.  There was a >50% drop even at day 1 for the 2 high samples 
and less so for the low samples. When the sample was frozen there was an immediate 
decrease in levels of A1AT which was then maintained when frozen at -80°C storage. 
However, during multiple freeze thaw cycles the levels dropped further at each cycle. 
- Levels of TIMP-2, similarly to A1AT, also decrease with time but not as dramatic at the start, 
there was possibly a 1-3-day lag time before it rapidly decreased. There was an effect of 
freezing the samples, though not as great a loss as A1AT but again, remained stable once 
frozen.  There was minimal effect with multiple freeze thaw cycles. 
- NGAL remained stable across the entire 15 days and also stable once frozen. There was 
some indication that there was deterioration with multiple freeze thaw cycles, the maximum 
allowance was 3 cycles. 
- Fibrinogen appeared to be fairly stable both over time and with freezing. For the fresh 
samples, there was a slight decrease after 8 days. With freeze thawing, the results were 
quite erratic, there was one sample (A5) that demonstrated a significant decrease at the 3rd 
F/T cycle. 
- CRP unexpectedly with the fresh sample deteriorated at day 4 of testing but then started to 
increase its level after day 12 but not back up to the levels obtained at day 0.  No effect with 
freezing was observed and it remained stable once frozen and with up to 6 freeze thaw 
cycles. 
- RBP4 had an unexpected trend where it increased for some samples with time. However, 
this was likely due to the position on the standard curve where it was not on the linear part 
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of the curve. Overall, stability was good over time and with freezing and multiple freeze 
thaw cycles. 
- CC16 with the high samples was very stable under all conditions. 
- B2M, Similar to CC16 was very stable under all conditions, however there was an upward 
trend with the fresh samples the reason for which was not understood. 
- TIMP-1 deteriorated over the 15 days slightly though was stable at day 1 and up to day 8 
with the high samples, but with the low samples there was a drop at day 4 onwards. 
Freezing the samples was acceptable and they remained stable. Freeze thawing samples 
appeared to cause some deterioration as shown by the variability with some samples. 
- fMLP showed clear evidence that the analyte was not stable even at day 1 (not unexpected). 
There was some indication that freezing the samples improved the stability over time, 
especially when compared directly to the fresh samples, but there was a large variation that 
was not seen with any of the other assays. It was not clear if even when frozen for a longer 
period the analyte was stable. Freeze thawing the samples showed a gradual decrease in 
biomarker level at each cycle. 
 
The overall summary was that for the majority of the assays, the sample needed to be tested on the 
day of collection and that results obtained from the fresh samples sent to Mologic that are days old 
should be regarded with caution.  There was also evidence that frozen samples were not truly 
representative of fresh samples although likely to be proportionally related with the exception of 
fMLP and once the samples have been frozen they do remain stable. Freeze thaw samples not 
recommended, A1AT, NGAL, fibrinogen, TIMP-1, fMLP all showed deterioration with multiple 
freeze/thaw cycles. 
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Figure 6.7. Graphical representation of the concentrations of each assay during the sample stability 
study. The concentrations of each biomarker under each condition across 15 days is shown. ” RT” 
indicates ambient storage, “Transport” indicates car transport storage, “- 80 °C” indicates storage at 
said temperature, ‘’F/T’’ indicates freeze-thawing one sample from 1 to 6 cycles from - 80 °C storage. 
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6.3.5 Fresh and frozen samples 
Samples were tested fresh and freeze-thawed using both ELISA (figure 6.8) and multiplex LF (figure 
6.9).  
ELISA results were as follows: 
A1AT, when measured fresh and freeze-thawed gave good correlation with an r2 of 0.83 however, 
the slope of 0.5 indicated that the levels measured in the frozen samples when compared to the 
fresh samples was approximately 50% lower. This was confirmed with the Bland-Altman plots (Bias -
77.39) where at higher concentrations, the points were outside the 95% confidence intervals (dotted 
lines located on the x axis).  
TIMP-2 fresh vs. frozen samples, correlation was excellent (r2 0.99) with a slope of 1 which indicated 
that both assays produced the same result, this was also confirmed by the Bland-Altman plot (Bias 
202.5)  
NGAL fresh vs. frozen samples, correlation was good (r2 of 0.77) and a slope of 0.92 which indicated 
that both assays produced the same result, this was also confirmed by the Bland-Altman plot (Bias -
0.39). There was one outlier that was not removed from the analysis.  
Fibrinogen fresh vs. frozen samples, correlation was excellent (r2 of 0.95) and slope of 1 which 
indicated that both assays produced the same result, this was also confirmed by the Bland-Altman 
plot (Bias -0.39) no trend was observed and the samples were aligned with y = ‘0’ axis. 
CRP fresh vs. frozen samples, correlation was excellent (r2 of 0.92) and slope of 0.9 which indicated 
that both assays produced the same result, this was also confirmed by the bland-Altman plot (Bias -
136.4), no trend was observed and samples were aligned with y = ‘0’ axis. 
RBP4 fresh vs. frozen samples, correlation was excellent (r2 of 0.97) and a slope of 0.95 was obtained 
which indicated that both assays produced the same result, this was also confirmed by the bland-
Altman plot (Bias 10859), no trend was observed and samples were aligned with y = ‘0’ axis. 
CC16 fresh vs. frozen samples, correlation was excellent (r2 of 0.95) and slope was 1.1 which 
indicated that both assays produced the same result, this was also confirmed by the bland-Altman 
plot (Bias 6.15), no trend was observed and samples were aligned with y = ‘0’ axis. 
B2M fresh vs. frozen samples, correlation was less good (r2 of 0.63) but a slope of 0.95 was obtained. 
However, the trend confirmed by the Bland-Altman plot (Bias 33.27), was within the ranges and 
samples were aligned with y = ‘0’ axis. 
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TIMP-1 fresh vs. frozen samples, correlation was excellent (r2 of 0.99) and a slope of 1 was obtained 
which indicates that both assays produced the same results, this was also confirmed by the Bland-
Altman plot (Bias 138.4), no trend was observed and samples were aligned with y = ‘0’ axis. 
fMLP fresh vs. frozen samples, correlation was very poor (r2 of 0.009) and slope was -0.1 which 
indicated that both assays were not the same. The Bland-Altman plot (Bias 0.26), however did not 
demonstrate this, no trend was observed, and samples were aligned with y = ‘0’ axis. 
With the multiplex assay testing on fresh and freeze/thawed urine samples, the results were not as 
convincing as the ELISA results. Aside from A1AT, the slope results were comparable for the 
remaining nine assays indicating that the measurable levels within the samples for each biomarker 
were similar. The r2 values were low for five of the assays: A1AT, RBP4, CC16, B2M, fMLP, but above 
0.75 for the other 5 assays: TIMP-2, NGAL, fibrinogen, CRP, TIMP-1.  The Bland-Altman plots did not 
add any value to the analysis so are not shown for the multiplex device data.  
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Figure 6.8. Graphical representation of the correlation of fresh and frozen samples for each asssay 
when tested by ELISA.  For the correlation graph the r2 and slope values are shown. A value of 1 in 
each case reflects excellent correlation and agreement of estimated concentrations respectively.  
The Bland-Altman analysis demonstrates the equivalence of the assays when the bias is small and 
the results lie on the y = ‘0’ line. The dotted lines show the +/- 95% confidence intervals. 
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Figure 6.9. Graphical representation of the correlation of fresh and frozen samples for each asssay 
when tested by Multiplex Lateral Flow assays.  For the correlation graph the r2, and slope values are 
shown. For both parameters a value of 1 in each case reflects excellent correlation and agreement of 
estimated concentrations respectively.   
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6.3.6 Stability of urine samples throughout the day 
Six healthy urine samples were tested at intervals for 24 hours. The results are shown in the graphs 
illustrated in figure 6.10. A dotted line at 10 cube units represents the cut-off from what can be seen 
positively by the naked eye (>10 units). In the case of the A1AT assay, there was no obvious trend. 
A1AT in 2 of the 6 samples appeared to decrease throughout the day, one of the samples changed 
from a positive to negative result, this instability would give rise to an incorrect or false result for the 
patient. The other 4 samples appeared to remain stable.  With regards to TIMP-2, in 3 of the 6 
samples, the level of biomarker decreased within the 24-hour period. Fibrinogen did not appear to 
be stable, the samples all contained low levels of fibrinogen, but the difference for 4 of the 6 
samples was a change from a positive to a negative result as shown by the error bars which would 
result in in a false positive. For CRP, all samples contained low/borderline levels of CRP, it cannot be 
determined by this testing whether the biomarker was stable. For RBP4 there was no obvious trend. 
As this was an inhibition assay, to show a deterioration, it would be expected for the cube units to 
increase, this was not the case for any of the samples. There was a trend with TIMP-1 that it 
decreased over 24 hours for the majority of the samples, only 1 sample changed from a clear 
positive to a borderline negative. NGAL, CC16, B2M and fMLP appeared stable throughout the time 
tested. 
The conclusion was that the patient could test the urine at room temperature anytime up to 4 hours 
after producing the sample. 
6.3.7 Line development 
All the antigens showed the expected cube unit values for all 4 concentrations tested. In the case of 
sandwich assays such as A1AT, TIMP-2, NGAL, fibrinogen, CRP and TIMP-1, the values were initially 
low and increased with time, reaching a plateau at approximately 15 minutes. For the inhibition 
assays such as RBP4, CC16, B2M and fMLP, the cube units were initially low and increased with time 
reaching a plateau sooner at approximately 10 minutes (figure 6.11). As the sandwich assays 
continued to develop after 10 minutes it is important that the read time as specified is followed. 
6.3.8 Batch to batch variation 
All batches met the specifications set. Clearly some of the assays correlated perfectly as shown by 
the overlapping lines in figure 6.12. Those assays were A1AT, TIMP-2, NGAL, fibrinogen, RBP4, CC16 
and TIMP-1.  The other assays were still within the specifications set but were not exactly the same. 
In particular, in the case of fMLP, there was a larger variability when compared to the performance 
of the other assays. 
170 
 
 
Figure 6.10. Graphical representation of the stability of fresh samples over a 24hr period for all 10 
biomarkers.  Six samples from healthy individuals were collected and stored at room temperature 
and tested periodically over 24 hours. Mean with range are shown. The dotted line represents the 
visual cut-off i.e. above 10 is a positive read. 
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Figure 6.11. Graphical representation of the test line development for all assays.  The lines show the 
time course of the cube reader output units over 28 minutes following addition of samples (high, 
medium low and negative). the black vertical line is the current read time of 10 minutes. 
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Figure 6.12. Graphical representation of Interbatch validation, comparison of three batches. Green 
represents the r2 of batches 1 vs. 3, blue for batches 1 vs. 2 and orange for batches 2 vs. 3. 
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6.4 Discussion 
Three methods of applying the sample to the test device were evaluated, the first 2 methods for 
dipping the device and the third method for the standard laboratory testing of applying a defined 
volume of sample to the device using a pipette. The hypothesis was that the tests were robust 
enough to allow use of any of these methods. It was predicted that that both dipping methods 
would be similar but either method would be more variable as the volumes of samples applied to 
the device would vary depending on the sample viscosity whereas applying a defined volume of 
sample to the device would be expected to result in lower CVs.  In terms of signal, with all three 
methods similar results were obtained, though method 1 was had higher CVs out of the 2 dipping 
methods. Generally, if the CVs were high for certain samples, this was reflected for all methods.  
Blood spiking into the sample at high levels, as indicated by the Multistix tests, demonstrated that 
apparent CC16, B2M and TIMP-1 results were affected. Accordingly, it is likely that the presence of 
significant haematuria would be an exclusion criterion for the use of the test in these cases. 
There did not appear to be any cross reactivity with the analytes within each of the assays. 
Samples were stored at room temperature, transported and evaluated at intervals over 15 days. The 
samples under both conditions were comparable indicating that time was the key variable. It was 
evident that certain biomarkers were not stable over time and that up to three days was the limit of 
acceptability, after 3 days, deterioration of certain biomarkers occurred that produced unacceptable 
change in some of the biomarkers tested with the multiplex assays. The biomarkers that appeared to 
be stable were NGAL, fibrinogen, RBP4, CC16, B2M, the biomarkers that appeared less stable were 
A1AT, TIMP-2, CRP, TIMP-1, fMLP. Of the unstable markers, A1AT, fMLP and TIMP-2 appear to be the 
most unstable and, for these markers in particular, the results from the returned samples from the 
planned observational study should be regarded with caution.   
With regard to frozen samples stability, the samples that had unchanged biomarker levels (although 
variable) in fresh and frozen were NGAL, CRP, fibrinogen, RBP4, CC16, B2M, TIMP-1, fMLP. The 
samples that had decreased levels of biomarkers from fresh and frozen samples were A1AT, TIMP-2 
but did remain stable after the initial drop. Based on the multiple freeze/thaw experiment, it is 
concluded that it is not recommended, A1AT, NGAL, fibrinogen, TIMP-1, fMLP all showed 
deterioration with multiple freeze/thaw cycles. 
Further investigations into fresh and frozen urine samples with reference ELISAs in addition to the 
multiplex assays indicated that with the exception of A1AT and fMLP the slope values were close to 
‘1’ for the remaining assays. This indicated that the actual concentration of biomarker in fresh and 
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freeze/thaw samples was unchanged. The biomarkers that correlated when run fresh and frozen 
with an r2 >0.8 in ELISA were A1AT, TIMP-2, fibrinogen, CRP, RBP4, CC16 and TIMP-1. The biomarkers 
with reasonable correlation were NGAL and B2M and poor correlation was fMLP. In terms of stability 
of the biomarkers in the samples, the biomarkers with a slope close to 1 +/- 0.1 were TIMP-2, NGAL, 
fibrinogen, CRP, RBP4, CC16, B2M, TIMP-1. Biomarkers with changed levels were A1AT and fMLP.  
The results obtained from the Multiplex testing was not as convincing, only 5 of the 10 assays had an 
r2 >0.75. The reduced lack of correlation for some of these assays in relation to the ELISA results 
suggests that there are potential matrix issues, influenced by the different storage conditions of the 
samples. 
Stability of the urine samples over the day showed that that up to 4hrs gave acceptable results for all 
assays.  From the line development study, it was clear that the sandwich assays continued to 
develop beyond 10 minutes whereas the inhibition assays were stabilised. However, using a 15 
minute read time, the line development had completed for all assays. The requirement for a point of 
care assay is that the result should be obtained at 10 minutes, therefore it is concluded that it is 
important that the user follows the instructions rigidly for both testing immediately and reads the 
device immediately. 
Batch to batch variation was minimal for all assays with the exception of fMLP. The QC specification 
for approving a batch is defined and the results indicate that the batches are reproducible with 
respect to these defined criteria.  
The verification and validation experiments undertaken indicate that the multiplex assays perform 
appropriately, meet the requirements and are suitable for use in the designed clinical trial.  Data not 
shown indicate that the assays are stable for up to 6 months at room temperature and at 
accelerated temperatures of 37°C and 44°C.  
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Chapter 7.  Validation of biomarkers in 
longitudinal study 
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7.1 Introduction 
The aim of this study was to assess the biomarkers in a large longitudinal observational study with 
the planned recruitment of 120 patients over 2 sites who would be testing daily for a period of 6 
months. This would allow the examination of the biomarkers in fresh urine samples daily leading up 
an exacerbation through to recovery.  This is the first study in the world where this has been possible 
as up to this point a) the frequency of urine samples collected has been at most monthly b) samples 
have been collected on the day when the patient has attended the clinic/centre and c) only frozen 
samples have been tested. It is hypothesised that certain biomarkers from the 10 selected 
biomarkers would prove to more useful in diagnosing an exacerbation early i.e. before symptoms 
present. Usually, samples were collected on the day of diagnosis and the actual time at which each 
biomarker appeared in relation to the exacerbation was unknown, the same applied to the recovery 
state and the return of the biomarkers back to ‘baseline’. The outcome from this study would be to 
reduce the number of biomarkers from 10 to 5 so that all the assays could be incorporated into just 
one test device.  
The point of care tests that have been developed as described in chapter 5 enabled the patient to 
test their own urine in the home in real time in just 10 minutes. Had the samples been sent daily to a 
laboratory for analysis using conventional laboratory assays, not only would this have involved 
significant time, cost and resource but some of the biomarkers that have proven to be unstable over 
time and during transport as demonstrated in chapter 6 would potentially have introduced 
variability and false results.  Weekly urine samples from the patients during this study were 
additionally sent to the laboratory for further analysis and validation. 
The patients were also asked to complete a 14 question “symptoms e-diary” and to send a sample 
back to the lab for verification testing once a week. 
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Figure 7.1. Schematic overview of the observational study. Each volunteer ran 2 tests per day for 
approximately 6 months, completed a symptom e-diary per day and sent 1 urine sample to the lab 
by post once a week. 
7.2 Methods 
7.2.1 Study design 
Patients with COPD admitted to two hospitals (Glenfield Hospital, Leicester, and Prince Phillip 
Hospital, Llanelli) were approached from July 2017 to February 2018. Eligible patients were patients 
with a documented clinical diagnosis of COPD and two previous exacerbations in the previous year. 
Exclusion criteria included any clinically relevant lung disease other than COPD, diagnosed as being 
α1-anti-trypsin deficient (PiZ), a history of or current active pulmonary tuberculosis. The study was 
ethically approved (REC Ref: 08/H0406/189) – An open study to measure imaging biomarkers and 
inflammatory cells, mediators and biomarkers from blood, urine and airway samples from healthy 
volunteers, asthma patients and COPD patients in stable disease and during acute exacerbation. The 
Chief investigator was Professor Chris Brightling, Department of Respiratory Medicine, Glenfield 
Hospital, Leicester, UK and sponsored by the University Hospitals of Leicester NHS Trust, Leicester 
Royal Infirmary, Leicester LE1 5WW. Subjects underwent symptom and clinical assessment and had 
blood, sputum (when possible) and a urine sample collected at recruitment, 3 months and at 6 
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months.  If the subject had a suspected exacerbation they returned to the clinic where the same 
assessments were completed and samples were collected. In the case of a confirmed exacerbation, 
the subject was asked to return for a follow up visit at 6 weeks.  As the cube reader had the 
limitation of storing only 1.5 months of data, the individual was asked to attend an additional visit at 
1.5 and 4.5 months so that the data from the reader could be downloaded. The following were 
undertaken: 
Scheduled visits (recruitment/month 3/month 6): Lung function tests were performed, and other 
parameters were recorded: Demographics (height, weight, BMI, gender, race), smoking history, 
COPD history, exacerbation history, medical history, drug history, physical examination, 
questionnaires (SGRQ, MRC, CAT), spirometry.  
Exacerbation visit: An exacerbation was diagnosed by the clinician, this was based on 2 or more of 
the following symptoms: increased shortness of breath (SOB), increased chest tightness, increased 
cough, increased sputum volume and/or prevalence and/or change in colour of sputum.   
Other parameters that were recorded: treatment, any previous exacerbations since last visit, 
medical history, drug history, vital signs, physical examination, spirometry, admission information if 
required.  
Post exacerbation visit: parameters that were recorded: symptomatic information (SOB, chest 
tightness, cough, volume of sputum, sputum purulence), treatment details, any previous visit to GP, 
ED, secondary care visits, physical examination, vital signs, spirometry. 
The patient received training at recruitment and received the starter pack and 3 month’s supply of 
test devices, lot numbers were recorded for each component in the case report form (CRF). 
Starter pack included: 
- Cube reader (OpTricon, Berlin, Germany) 
- Mobile phone (with App- e-diary designed and manufactured by Bond Digital Health 
solutions, Cardiff) 
- Plastic jug for urine collection 
- Shipping accessories for weekly urine sample (sample collection container, sealing tape, grip-
seal bag, stamped addressed envelope, absorbent pad) 
- 3 months supply of test devices (2 devices per pouch)  
Instructions for volunteer provided as shown in figure 7.2. 
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Power calculation for study: the power calculation was calculated by an external contractor (JB 
Medical Ltd, Sudbury, UK). The primary study objective was to quantify the benefit of a range of 
biomarkers, either alone or in combination, as a predictor of acute exacerbation in COPD. This 
outcome mapped conveniently into a straightforward 2x2 contingency table: exacerbation/no 
exacerbation vs predictive biomarker changes/no predictive biomarker changes. This was then 
amenable to conventional chi-squared estimation to identify the presence or absence of an 
association, followed by calculation of the φ statistic, to assess the degree of the association.  
In this circumstance, the fixed variable was the number of exacerbations. The predictor variable 
(biomarker result) could be altered to identify the characteristic or combination of characteristics 
that best predicted the occurrence of an exacerbation. 
The power of the goodness of fit or chi-square independence test was given by: 
 
where F was the cumulative distribution function (cdf) for the noncentral chi-square distribution 
χ2(df), xcrit was the χ2(df) critical value for the given value of α, and λ = w2n: the noncentrality 
parameter where w was the φ effect size. It was assumed w to be either 0.3, representing a 
moderate degree of association between the biomarker changes and exacerbation occurrence, or 
0.5, representing a high degree of association. It was assumed an  of 0.05 and the power of the 
study was explored to detect a difference at either level, based on 120 recruited patients. 
The number of expected exacerbations would depend on the clinical characteristics of the recruited 
population. A recently published UK retrospective study (160) used a GP database to identify the 
annual exacerbation rates in each of these groups, the results of which are shown in table 7.1. In 
order to maximise the number of evaluable exacerbations, it was recommended to focus 
recruitment on patients in GOLD categories. As shown, the expected number of exacerbations in 
these patients over 6 months would be 129. After making an assumption that 15% of patients would 
withdraw, drop out or fail to comply with the testing regimen, it was estimated that we should have 
110 evaluable exacerbations at the end of the 6 month follow-up period. 
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Table 7.1. Expected number of exacerbations, based on GOLD categories 
Category Description Expected 
exacerbations per 
year 
Number of 
patients to be 
recruited 
Number of 
exacerbations 
over 6 months 
GOLD A FEV1>80%; 0-1 
exacerbations; mMRC 
0-1; CAT<10 
0.83 0 0 
GOLD B FEV1 50-79%; 0-1 
exacerbations; 
mMRC>2; CAT>10 
1.17 0 0 
GOLD C FEV1 30-49%; >2 
exacerbations; mMRC 
0-1; CAT<10 
1.79 60 53.7 
GOLD D FEV1<30%; 0-1 
exacerbations; 
mMRC>2; CAT>10 
2.51 60 75.3 
TOTAL   120 129 
 
Solving the above equation for xcrit , the power of the study was calculated to detect an association 
between the test and the outcome, based on a total number of exacerbations of 110. Based on this 
approach, the study would have an 81% power to capture a moderate association (w=0.3) between 
biomarker testing and exacerbation risk, at a critical p-value of 0.05. On the same basis, it had >99% 
power to detect a strong association (w=0.5). 
181 
 
Figure 7.2. Schematic instructions for use provided to each patient. Urine sample collection- Collect a mid-stream sample of urine in the jug provided. 
Collect daily, same time of day between 8am—8pm. Two devices- green capped device first followed by the orange capped device, these represented the 
two tests that were developed, test a (A1AT, TIMP-2, NGAL, fibrinogen, CRP) and test b (RBP4, CC16, B2M, TIMP-1 and fMLP). 
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7.2.2 Individual patient biomarker profiles 
An interim analysis consisting of 24 exacerbations was performed. For each individual biomarker, 
stable and exacerbation levels were compared with regards to concentration levels found in each 
state and if statistically different in each group. 
All data were analysed using Graphpad PRISM Version 7.  Data normality was explored and 
appropriate parametric or non-parametric tests chosen accordingly. Receiver-operator characteristic 
(ROC) analysis and paired Students t-test with significance levels p<0.05 were used to compare 
biomarker levels in different disease states with both transformed and non-transformed data.  
7.2.3 Multiple biomarker analysis  
The analysis performed was identical to what was done previously on the Leicester COPD data 
(Chapter 4, section 4.3.6.3). A baseline value was calculated for each individual patient which 
differed from the previous analysis whereby the baseline was calculated from 5 consecutive days 
which was not previously possible due to the infrequent collection of samples. A separate stable and 
exacerbation sample was selected, and the percentage difference was calculated.  Using logistic 
regression analysis, the % difference values for both the stable and exacerbation samples were 
analysed for all 10 biomarkers and in addition, separate models were developed to determine the 
minimal number of biomarkers required to produce promising and acceptable results in terms of 
sensitivity, specificity, positive predictive values and negative predictive values. 
All data were analysed using SPSS (version 21), Graphpad PRISM Version 7.  Data normality was 
assessed, and appropriate parametric or non-parametric tests chosen accordingly. Receiver-operator 
characteristic (ROC) analysis and Wilcoxon’s signed rank test with significance levels p<0.05 were 
used to compare biomarker levels in different disease states.  Logistic regression was used to 
develop predictive models, combining biomarkers that determined the outcome of exacerbation. 
Internal validation was addressed by dividing the cases into 80% training set and 20% test set. This 
process was repeated 5 times using assignment to training and validation sets by random number 
generation in SPSS. 
7.2.4 Patient profiles with algorithm 
The logistic regression equation (s) generated from 7.2.3 was applied to all the data in the interim 
analysis. The probability risk scores were plotted for each patient using Graphpad prism V7. A rolling 
average of 3 days was calculated for the risk scores. 
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Added parameters were the EXACT-PRO total value which was collected during the study by the 
patient daily using the App. The EXACT® is a 14-item daily diary designed to provide a direct measure 
of patient-reported symptoms of COPD exacerbation by capturing unreported, symptom-defined 
events, and standardizing the evaluation of symptoms around medically treated events, including 
magnitude of change around events seen in the emergency room or clinic and before and after 
hospitalization. Advantages of a standardized, validated daily diary-based symptom assessment in 
exacerbation studies include uniform metrics, reduced recall bias, and the ability to fully characterize 
exacerbations of COPD, including the estimated 50% to 70% of events that are unreported. 
The EXACT® Total score is an interval-level scale ranging from 0 to 100, where higher scores indicate 
a more severe condition. The EXACT® Total score is used to assess exacerbations of COPD.  The 
associated algorithm incorporates recalculating the threshold values periodically and post 
exacerbation. 
7.3 Results 
7.3.1 Outcomes from entire study 
105 patients were recruited in the entire study, however, not all data were included due to 
withdrawals and missing data. Specifically, 9 patients (9%) withdraw from the study, 2 patients (2%) 
ran the test incorrectly and data from 7 patients (7%) was missing due to a Bluetooth issue with the 
readers. In total, there were 47 patients (45%) in the exacerbation set who took part in the study for 
a total of 8711 days and 40 patients (38%) in the non- exacerbation set who took part in the study 
for a total of 6514 days. For the exacerbation set, of those days, no exacerbation was recorded on 
8622 days, a doctor confirmed exacerbation was recorded on 59 days and a patient confirmed 
exacerbation, with no doctor confirmation, was recorded on 30 days. This represents a total of 89 
confirmed exacerbations. The exacerbations were spread across the patients who experienced them 
as in Figure 7.3a. As can be seen from the plot, most of the patients (n = 22) who experienced an 
exacerbation in the study experienced just a single exacerbation. However, some patients also 
experienced two exacerbations (n = 14), three exacerbations (n = 6), four exacerbations (n = 2), six 
exacerbations (n = 1) and seven exacerbations (n = 1). The doctor confirmed exacerbations (most 
reliable data as verified by a clinician) were spread across the patients who experienced them as in 
Figure 7.3b. These results were similar to the previous plot. The numbers of patients who 
experienced the different numbers of exacerbations in the study were: one exacerbation (n = 21), 
two exacerbations (n = 10), three exacerbations (n = 3), four exacerbations (n = 1) and five 
exacerbations (n = 1). 
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Figure 7.3. Distribution of exacerbations across all patients. a) The distribution of the doctor and 
patient confirmed exacerbations across all patients who experienced them.  b) The distribution of 
the doctor confirmed exacerbations across all patient who experienced them. 
7.3.2 Patient characteristics for all patients in the study 
105 patients consented to the study. The majority of the patients were male (69%) and the biggest 
comorbidity was hypertension (13%). A summary of the demographics and characteristics is shown 
in table 7.2. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 
strategy, the patient group fitted into the GOLD B criteria (FEV1 50-79%; 0-1 exacerbations; 
mMRC>2; CAT>10) with average FEV1 of 51.13, average mMRC and CAT score of 2.83 and 19.86 
respectively.  The majority of the patients did experience 0-1 exacerbation however, they were not 
followed over a 1 year period, some of the patients may have had further exacerbations in the following 6 
month period. Although there was no obesity recorded, there was some indication by the BMI results (mean, 
SD 27 ± 5.5) that there would have been some patients with a BMI over 30 who would have been considered 
to be obese.  
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Table 7.2. Characteristics of the patients included in the entire observational study (n=105). Data are 
shown as mean (SD), mean (range) or number (%) 
Male  No (%) 72 (68.6%) 
Smoking, pack-years Mean (SD) 46.33 (28.82) 
Current smokers Mean (%) 13 (12.38%) 
Ex-smokers No (%) 91 (86.67%) 
BMI, kg/m2 Mean (SD) 27.11 (5.46) 
CAT Score Mean (SD) 19.86 (8.37) 
mMRC Score Mean (SD) 2.83 (1.19) 
SGRQ-C Total Score Mean (SD) 46.38 (21.63) 
Comorbidities    
Heart failure No (%) 4 (3.81%) 
MI No (%) 2 (1.90%) 
Angina No (%) 0 (0%) 
HTN No (%) 14 (13.33%) 
Stroke No (%) 1 (0.95%) 
Lung cancer No (%) 0 
IBD No (%) 0 
Cirrhosis No (%) 0 
Bowel cancer No (%) 0 
Chronic Kidney disease No (%) 0 
Diabetes No (%) 5 (4.76%) 
Obesity No (%) 0 
Prostate cancer No (%) 1 (0.95%) 
Bladder cancer No (%) 0 
Anxiety and depression No (%) 2 (1.90%) 
no changes since last visit No (%) 0 
None No (%) 2 (1.90%) 
Other No (%) 20 (19.05%) 
Physiology and Imaging    
heart_rate_bpm Mean (SD) 77.34 (13.67) 
saturation Mean (SD) 95.81 (1.87) 
respiratory rate Mean (SD) 17.07 (2.51) 
fev1_predicted1 Mean (SD) 2.62 (0.53) 
fvc_predicted Mean (SD) 3.36 (0.74) 
fev1_measured Mean (SD) 1.36 (0.59) 
pre_bd_fev1_predicted Mean (SD) 51.96 (19.81) 
pre_bd_fvc Mean (SD) 2.72 (0.71) 
pre_bd_fvc_predicted Mean (SD) 80.37 (21.24) 
pre_bd_fev1_fvc Mean (SD) 50.63 (14.93) 
post_bd_fev1 Mean (SD) 1.45 (0.65) 
post_bd_fev1_measured Mean (SD) 55.43 (23.13) 
post_bd_fvc_measured Mean (SD) 2.83 (0.83) 
post_bd_fvc Mean (SD) 82.69 (25.03) 
post_bd_fev1_fvc Mean (SD) 51.13 (16.62) 
GP visits in 12 months prior to recruitment (n = 80)  Mean (range) 0.9875 (0-8) 
Hospital visits in 12 months prior to recruitment (n = 80)  Mean (range) 0.375 (0-8) 
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7.3.3 Verification of results from patients 
The 4-parameter logistic regression (4PL) was used to convert the cube raw values to concentration 
values. As the name implies, it has 4 parameters that need to be estimated in order to “fit the 
curve”. The equation for the model was: 
 
Where x = the independent variable and y = the dependent variable.  
The four estimated parameters consist of the following: 
a = the minimum value that can be obtained (i.e. what happens at 0 dose) 
d = the maximum value that can be obtained (i.e. what happens at infinite dose) 
c = the point of inflection (i.e. the point on the S shaped curve halfway between a and d) 
b = Hill’s slope of the curve (i.e. this is related to the steepness of the curve at point c). 
The 4PL curve fit included a background correction step, the mean of the blank sample (buffer only) 
was subtracted from the raw data measurements. The blank-corrected values were then used in the 
fitting. The standard data points (concentration vs. measurement) were plotted on semi-log axes 
and a 4PL fit was applied to the data points. The concentrations of the samples were determined 
from the fit. The conversion of cube values to concentration values was performed using Excel. 
To determine if the patient data were within the standard curve the concentrations and raw values 
were plotted on the X and Y axes on the same graph as the standard curve (figure 7.4). As each batch 
of devices represented different production lots, each lot had a separate standard curve. For this 
analysis three lots were taken AD280317, RB070817 and RB180817 and all data available per lot 
were plotted i.e. multiple patient data. As can be seen in figure 7.4 there is significant variability 
between different lots with batch AD280317 assays with a smaller dynamic range and lower top 
standard compared to the other 2 batches. This was the first lot assessed and based on the data 
coming from the patients, improvements were made to the standard curves for subsequent batches.  
The large dynamic range required for each assay was challenged in this study with fresh sample 
testing from a variety of patients. A1AT was the one assay which did not encompass the majority of 
patients. The levels of A1AT in fresh samples were higher than those levels found in frozen samples 
therefore the assay was “too sensitive” so some samples had raw signals that were higher than the 
dynamic range of the assay with the risk of hooking (decreasing in signal with extremely high A1AT 
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levels).   In the case of the TIMP-2, fibrinogen, CRP and TIMP-1 assays, the higher levels were all 
within the standard curve but there were a few samples below the standard curve. This was not 
deemed to be of concern as it is expected from previous studies to date that for some patients 
where their baseline levels are on the lower part of the curve, the increase in signal in the event of 
an exacerbation would be measurable and be within the standard curve range.  The assay range for 
NGAL was improved after the first batch which led to a better range and samples tested with the 
remaining batches were within range. All the competition assays experienced a lack of sensitivity, 
with a high proportion of samples with raw signals higher than the standard curve (classified as 
negative).  The only competition assay that caused a level of concern was fMLP where by the assay 
range became narrower after batch AD280417 resulting in fewer samples with raw signals that fell 
within the dynamic range.  
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Figure 7.4. Concentration plotted against raw cube value and representation on the standard curve 
for three batches of devices. Each row represents each individual assay and three different batches 
of the multiplex devices. The measured biomarker concentrations received from the patients home 
testing was plotted against the calculated concentrations from each standard curve. If the measured 
samples were within the dynamic range of the assay, then all would be green.   Red = High (over the 
standard curve, yellow = low (below the standard curve, Green= within the standard curved. O = 
patient data, + = Standard curve values. Graphs were created by Dr Clare Lendrem (Newcastle 
university) 
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7.3.4 Outcomes from the interim analysis 
In the interim analysis, the data for all the patients who experienced an exacerbation were 
considered during the study.  This consisted of a subset of 22 patients described below for a total of 
2985 days.  
From the interim analysis, in 22 patients, 33 exacerbation events occurred. Most of the patients (n = 
17) who experienced an exacerbation in the sub study experienced just a single exacerbation. 
However, some patients also experienced two exacerbations (n = 3) and three exacerbations (n = 2). 
As exacerbation results were not available for all (received on the actual day), 24 exacerbations were 
taken forward for analysis (taken across 22 patients). 
7.3.4.1 individual patient biomarker profiles 
Stable and exacerbation samples were selected as shown in table 7.3. The stable sample was 
selected based on being at least 30 days prior to or after an exacerbation event. There was just one 
sample that did not conform to this rule which was taken just 5 days prior to the exacerbation 
(Head092), this was due to the limited number of available stable samples for this patient. 
The biomarker levels in both of these groups are shown in table 7.4.  Even with the small sample size 
it was possible to see significance (p value <0.05) for some of the biomarkers, namely A1AT, 
fibrinogen, RBP4, CC16 and fMLP when looking at raw or transformed data. The criteria for the AUC 
was > 0.6 or <0.4. Of the 10 biomarkers, A1AT, RBP4 and CC16 met these specifications. 
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Table 7.3. selected data for analysis and indication of days pre- or post-exacerbation. The number of 
days between the stable and exacerbation sample are shown. 
Patient ID Day of stable sample Day of exacerbation  Difference (days) 
Head001 35 91 56 
Head001 78 164 43 
Head002 96 119 23 
Head004 51 78 27 
Head006 140 179 39 
Head009 15 36 21 
Head011 85 122 37 
Head013 46 179 133 
Head019 11 25 14 
Head019 158 187 29 
Head028 15 37 22 
Head030 3 16 13 
Head031 12 42 30 
Head035 36 57 21 
Head037 2 15 13 
Head050 40 53 13 
Head055 24 49 25 
Head106 2 12 10 
Head118 3 15 12 
Head092 4 9 5 
Head099 41 61 20 
Head102 41 57 16 
Head074 20 31 11 
Head076 11 27 16 
 
Table 7.4. Biomarker levels at stable and exacerbation with statistical tests 
Biomarker Unit Stable Exacerbation Statistical tests 
Median (IQR) Median (IQR) Paired  
t test 
Paired t test  
(transformed 
 data) 
AUC 
A1AT ng/ml 313.70 (92.06-962.50) 108.80 (44.51-562.00) 0.2440 0.0478 0.36 
TIMP-2 ng/ml 1.41 (1.23-2.76) 2.28 (0.92-3.33) 0.0843 0.5987 0.54 
NGAL ng/ml 8.69 (2.98-24.83) 4.91 (1.84-18.36) 0.4974 0.5513 0.43 
Fibrinogen ng/ml 15.97 (5.18-46.42) 7.90 (2.91-21.04) 0.0404 0.0553 0.36 
CRP ng/ml 0.44 (0.20-0.96) 0.51 (0.12-2.04) 0.2051 0.4919 0.55 
RBP4 ng/ml 44.35 (17.19-97.98) 68.96 (31.73-162.40) 0.0184 0.0093 0.62 
CC16 ng/ml 99.82 (27.46-207.20) 164.10 (61.52-543.20) 0.2248 0.0480 0.60 
B2M ng/ml 49.17 (24.96-132.10) 58.10 (38.57-165.20) 0.0530 0.1063 0.59 
TIMP-1 ng/ml 3.26 (1.20-8.04) 2.78 (1.05-5.71) 0.3880 0.1219 0.42 
fMLP ng/ml 5.00 (2.91-16.95) 6.43 (3.33-18.89) 0.0320 0.1031 0.56 
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7.3.4.2 Multiplex biomarker analysis 
When assessing the final 10 biomarkers on the Leicester BEAT-COPD study, an AUC of 0.84 (95% 
confidence interval 0.76 to 0.92) was achieved (chapter 4). At an optimal cut-off of 0.4065, the 
sensitivity and specificity were 80% and 76.36 respectively with a PPV of 77.19% and NPV of 79.25%. 
The minimal number of biomarkers that could be used without compromising the results was 5.  The 
selected 5 biomarkers using logistic regression modelling was CC16, CRP, B2M, A1AT and RBP4 
which gave an AUC of 0.8304 (95% confidence interval 0.7479 to 0.9129). At an optimal cut-off of 
0.4049, the sensitivity and specificity were 81.82% and 80% respectively with a PPV of 80.36% and 
NPV of 81.48%.  
The same analysis was applied to the results from the observational study.  The baseline was 
calculated from n=5 days either prior to or after the exacerbation depending on the availability of 
data.  The selected baseline values for each patient with reference to the stable and exacerbation 
samples are shown in table 7.5. For all exacerbation events, the stable sample n=1 was selected for 
the analysis at least 10 days prior to the event. For 79% of the exacerbation events, the baseline 
samples n=5 were selected prior to the exacerbation n=19 and but for 5 patients the BL had to be 
calculated post event (Head030, Head037, Head106, Head118 and Head092). 
The percentage change for the stable and exacerbation samples was calculated from the average 
baseline value as explained in the methods section of this chapter. 
For all 10 biomarkers, an AUC of 0.86 was obtained (95% confidence interval 0.75-0.96.  At an 
optimal cut-off of 0.577, the sensitivity and specificity were 75% and 91.67% respectively with a PPV 
of 90% and NPV of 78.57%. 
A second model with the minimal number of biomarkers was developed, with just 5 biomarkers, 
namely, TIMP-2, fibrinogen, CRP, CC16 and B2M. In this case an AUC of 0.82 was obtained (95% 
confidence interval 0.7-0.94).  At an optimal cut-off of 0.5159, the sensitivity and specificity were 
75% and 83.33% respectively with a PPV of 81.82 and NPV of 76.92. 
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Table 7.5. selected data for analysis and indication of days pre- or post-exacerbation 
Patient ID Baseline 
samples 
Day of 
stable 
sample 
Day of 
exacerbation  
BL Difference 
from exacerbation 
(days) 
Stable Difference 
from exacerbation 
(days) 
Head001 19-23 35 91 68 56 
Head001 19-23 78 164 141 43 
Head002 81-85 96 119 34 23 
Head004 26-30 51 78 48 27 
Head006 124-128 140 179 51 39 
Head009 2-6 15 36 30 21 
Head011 62-66 85 122 56 37 
Head013 30-34 46 179 145 133 
Head019 1-5 11 25 20 14 
Head019 1-5 158 187 182 29 
Head028 1-5 15 37 32 22 
Head030 74-78 3 16 -62 13 
Head031 1-5 12 42 37 30 
Head035 21-25 36 57 32 21 
Head037 75-79 2 15 -64 13 
Head050 23-27 40 53 26 13 
Head055 12-16 24 49 33 25 
Head106 46-50 2 12 -38 10 
Head118 33-37 3 15 -22 12 
Head092 60-64 4 9 -55 5 
Head099 23-26 41 61 35 20 
Head102 21-25 41 57 32 16 
Head074 3-7 20 31 24 11 
Head076 1-5 11 27 22 16 
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Figure 7.5. Combined Male and females n=55 with final 10 selected biomarkers (BEAT-COPD study). 
(a) Scatter plot of the predictive probabilities from models generated for combined male and female 
model (b) ROC curve (and AUC values)  
  
Figure 7.6. Combined Male and females n=55 with 5 selected biomarkers (BEAT-COPD study). (a) 
Scatter plot of the predictive probabilities from models generated for combined male and female 
model (b) ROC curve (and AUC values)  
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Figure 7.7. Combined Male and females n=24 with all 10 selected biomarkers (new study). (a) Scatter 
plot of the predictive probabilities from models generated for combined male and female model (b) 
ROC curve (and AUC values)  
   
Figure 7.8. Combined Male and females n=24 with 5 selected biomarkers (new study). (a) Scatter 
plot of the predictive probabilities from models generated for combined male and female model (b) 
ROC curve (and AUC values). 
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7.3.4.3 Patient biomarker profiles with Algorithm (5 biomarkers) 
The logistic regression equation generated for the second algorithm (5 biomarkers) was applied to 
all the daily results from all 22 patients.  The risk scores generated were plotted for 6 patients that 
experienced 1-2 exacerbations. A rolling average was calculated - an average of the last 3 values in 
each data set to allow for missing data and to smooth out short fluctuations and highlight longer-
term trends. The EXACT-PRO total score which was calculated from a set of 14 questions was also 
plotted.  EXACT-PRO is used as a research tool for prediction of exacerbations and to determine the 
severity of the exacerbation.  It has its own algorithm that uses the total score generated, which is 
re-calibrated monthly and in the case of an event a new baseline is calculated. There are set criteria 
for predicting an exacerbation looking a difference from the baseline.  Only the raw total scores are 
shown with the risk score. 
Interpretation of the 6 different profiles (figure 7.9): 
Head011: The patient had 1 exacerbation at day 122, this was predicted by the risk score where it 
appeared to be raised at day 104, 18 days prior to the reported exacerbation. The EXACT-PRO total 
score was also raised but only 2 days prior to the exacerbation. The exacerbation was not resolved at 
day 168 as shown by the risk score, on average, the recovery time post exacerbation was 6 weeks as 
indicated by clinical experts. 
Head004:  This patient had 2 reported exacerbations at day 78 and day 143.  For the first 
exacerbation, the risk score was not predictive, it was raised prior to the exacerbation on day 49 
onwards (29 days prior to reporting the event).  The risk scores were significantly raised, for a long 
period of time (day 89-124) before returning back to baseline for approximately a week.  It is 
predicted that this was a severe exacerbation which was not reported early enough and hence un -
resolved resulting in a re-exacerbation on day 143 (the risk scores started to become elevated on 
consecutive days after day 133 (10 days prior to the second exacerbation. As reflected by the EXACT-
PRO total score, the first exacerbation was also not predicted at the time of exacerbation or after 
but there were peaks on day 43, day 52 which did correlate with the biomarker risk score and was 
raised at the second exacerbation just 2 days prior.   
Head019: this patient had 2 reported exacerbations at day 25 and day 187. Both these exacerbations 
were predicted by the risk scores. However, it is not so obvious as the profile is variable.  The trend is 
such that that the scores did return back to baseline levels after day 33 until day 184 but there were 
times during this period where they were above the cut-off set. For exacerbation 1, the number of 
days prediction for the test was 1 day and for EXACT-PRO, approximately 3 days. For the second 
exacerbation, the number of days prediction for the biomarkers was approximately 2 days and for 
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EXACT-PRO, although there were missing data, it appears to be 5 days.  Due to the correlation of the 
biomarkers and symptoms, it does confirm that these 2 events were ‘real’ exacerbations. 
Head030: The patient had 1 exacerbation at day 16, this was predicted by the risk score on the 
actual day and continued to be raised until day 19 (3 days post exacerbation).  EXACT-PRO also 
confirmed that this was an exacerbation and the number of predictive days prior to the exacerbation 
event on day 16 was 1 day. Overall the total EXACT-PRO score was higher than most which is 
indicative that this patient’s condition was more severe. 
Head035: the patient had 1 exacerbation on day 57.  The risk score was able to identify this 
exacerbation and this was on day 51 (6 days prior to the exacerbation event).  The risk score 
remained high up to the last day (day 126), either indicating that the exacerbation was not resolved 
or the algorithm needs to be recalibrated after each exacerbation. EXACT-PRO total score was also 
raised prior to the exacerbation but not as early (day 54) and then remained at this level on average. 
Head106: the patient had 1 exacerbation on day 12. This patient profile was selected as the data was 
not used for the analysis and therefore used as a test data set.  The risk score was raised prior to the 
exacerbation day at day 5 (7 days prior to the exacerbation) and seemed to be returning back to the 
baseline levels at day 50.  There was no indication that the EXACT-PRO score was able to predict the 
exacerbation but did have a high value on day 12 and then peaked again on day 36 which is a similar 
time as the second risk score peak. 
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Figure 7.9. Patient profiles with probability risk scores plotted against day with EXACT-PRO total 
score. The risk score is derived from the applied algorithm to the biomarker measurements. The 
EXACT-PRO total score is derived from the symptom questionnaire completed by the patient. Red 
dotted line is day of exacerbation. Grey dotted line is a universal cut-off level based on previous 
analysis. 
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7.4 Discussion 
The chosen biomarkers were the same whether selected on the basis of freeze/thawed samples or 
fresh sample analysis. Although the 10 biomarkers were not selected from just one study but from a 
total of 3 (Birmingham, AERIS and Leicester BEAT-COPD), the same methodology used for analysis on 
the BEAT-COPD study when applied to the current study produced comparable performance results. 
Evaluation of the 10 markers in the BEAT-COPD study (frozen samples) provided an AUC of 0.83 
whereas, in fresh samples from the current study a comparable AUC of 0.86 was obtained. This is an 
excellent outcome, as it confirms that the selected biomarkers not only show promise in different 
cohorts but also in fresh samples since, to date, all analysis has been conducted on frozen and older 
samples.  Additionally, the measurement of the biomarkers was different, namely, the original 
measurements were performed by trained operators using more accurate and sophisticated ELISAs 
whereas the new measurements were all from lateral flow technology, a 10 minute read time with 
the added variability of being performed by the patients themselves, all of them elderly with 
moderate to severe COPD. 
Analysis was undertaken that refined the 10 biomarkers to 5 or less based on 2 studies (Leicester 
BEAT-COPD and the recent observational study). On the basis of the Leicester BEAT-COPD analysis, 
the most promising panel was CC16, CRP, B2M, A1AT and RBP4, whereas for the observational 
study, the selected biomarkers were CC16, CRP, B2M, fibrinogen, and TIMP-2.  Thus, the three 
common biomarkers are CC16, CRP and B2M.  For the observational study, A1AT was excluded from 
the refined biomarker selection due to the poor quality of the data where it was found that urine 
levels of A1AT in fresh samples were much higher than those in frozen samples and the assay range 
was not sufficient to encompass these levels.  Therefore, this could be an explanation as to why the 
same 5 biomarkers were not selected for both studies (BEAT-COPD and current study).  It does 
confirm that the three common biomarkers add the most weight to the panel with some added 
value by including 2 more biomarkers.  
In the current study, it was shown that that the algorithm generated from the selected 
baseline/stable and exacerbation sample data when applied to the remainder of the unseen data 
yielded meaningful patient profiles relating to recovery, pre-exacerbation (prediction) and the 
EXACT-PRO pro total scores. Included in the ‘’unseen’’ set were additional exacerbation events for 
example: patient 106 was not included in the training set and neither was the second exacerbation 
event for patient Head004, the resulting risk scores did reflect the state of the patient with known 
information. At a glance, Head004 is interesting as this could have been a case where, had the 
patient reported the exacerbation early and started treatment early, the severity of the event could 
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have been reduced.  However, this is only speculation and the effectiveness of the test would need 
to be assessed in a randomised controlled trial. 
If the results from the final analysis continue to look promising there is a significant benefit to 
introducing a simple point of care test to enable the patients to monitor their condition in the home. 
Based on a survey feedback from the patients in the study indicated that the test was simple to use, 
was not burdensome and the majority would be happy to test on a frequent basis - daily or every 
three days. 
Limitations of the study, the point of care assay, quality of the data received and the statistical 
analysis. 
The planned recruitment of 120 patients into the study was not achieved due to a lack of patients 
available to participate at each of the sites within the time frame of the study as well as delays with 
providing the kits to the sites in a timely manner. The number of patients that were recruited was 
105 of which 9 withdrew from the study. In addition, there was an unexpected issue with the 
Bluetooth cube readers where data failed to upload to the cloud and was not saved resulting in a 
loss of data (n=7). The key reason for not reaching the target number of exacerbations of 110 was 
due to the population group. The COPD patients recruited fell more into the lower risk category as 
shown by the demographic data rather than the high risk/more severe population resulting in a total 
of 89 exacerbations of which 30 exacerbations were self-diagnosed by the patient. The failure of the 
patients to visit the centre for a diagnosis by the clinician demonstrates the need for a home 
diagnostic test as often the patients live in remote locations and find it difficult to travel especially 
when they feel unwell. The lower numbers of exacerbations as well as the severity of the patients 
would have to be considered when analysing the final set of data. 
The data that was received back from the patient was checked and ‘’ cleaned up’’ by this, only valid 
results were included in the data analysis.  The control line was an indication on whether the test 
devices were run correctly, and those results that were below the cut off were excluded. There were 
2 patients who were not able to run the test correctly despite training, the entire results from these 
patients were excluded. There was an assumption that the volunteer was complying with the 
instructions provided, for example, to read the test after exactly 10 minutes and that the midstream 
urine collected was used immediately.  The time of testing was recorded by the reader therefore, it 
was clear that in all cases device B was run immediately after device A and that they were run daily 
as requested. The timing was not consistent in that whilst there were a few individuals that tested at 
a set time each day, some individuals tested at random times even throughout the night.  
203 
 
The A1AT and fMLP results were used with caution as the assay ranges for both of these were not 
optimal for the urine samples. For the A1AT assay there was a possible hook effect– high levels of 
A1AT would potentially be erroneously lower for some patients. For fMLP, the narrow range of the 
assay did not allow small changes in the biomarker levels to be measured. For the final selection of 
the biomarkers these two assays were excluded from the analysis and the result was that they were 
not needed in order to achieve the desired assay performance and the other 8 biomarkers were 
sufficient. 
The statistical analysis performed is not the only method that could be used to generate a final 
monitoring algorithm. In order to choose the best five biomarkers from the ten candidates in the 
trial there are a number of statistical approaches that could be evaluated. For example, a time series 
model, called a Dynamic Linear Model (DLM), could be fitted to the biomarkers from each patient, 
which would then model the progression of each biomarker for each patient over time. This model 
could then be used to make predictions of the biomarker levels for each patient one day, two days, 
etc. into the future. Another method of analysis could be using a Bayesian approach or neural 
networks, which is a type of machine learning. 
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Chapter 8. General discussion 
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8.1 Introduction 
The purpose of the work described in this thesis was to explore if and how key biomarkers of lung 
tissue degradation (caused by neutrophil-driven inflammation) partition into urine, where they can 
be quantified and used as a new diagnostic tool.  
 
Specific objectives: - 
- Develop and characterise assays for degradation products of collagen, elastin and other 
molecules  
- Develop assays for neutrophil enzymes (e.g. MMPs, Elastase), and protease inhibitors, to 
study the different ratios involved in disease progression 
List of questions: 
- Which biomarkers released by inflamed lungs find their way into urine? 
- Does molecular size influence the extent to which individual biomarkers in the urine reflect 
the state of lung inflammation? 
- Can reliable immunoassays be made for key biomarkers (in particular, small molecules) of 
interest to this study? 
- Is it possible to utilise the kidney as a “sentinel” of inflammatory activity elsewhere in the 
body? 
- Are there any patterns in the urinary biomarker profile to indicate which organ/tissue is the 
source? 
 
Thirty-Six biomarkers were selected for analysis based on known biological pathways involved in 
COPD. Assays in the form of ELISA, lateral flow or fluorescent substrate were acquired, those that 
were not commercially available were developed which involved immunogen design, bio-
conjugation techniques, antibody generation/characterisation and assay development.  Two of the 
most complex assays are described in Chapter 2, desmosine being a small molecule, where antibody 
generation was challenging, the resulting assay was validated against the gold standard method LC-
MS/MS and MMP activity where current lateral flow assays were not sensitive enough to measure 
low levels of active MMP-9 (and other MMPs) in urine. The assays were used to quantify analytes in 
urine from normal donors, patients with inflammatory lung disease in a stable state and during 
exacerbation. With a subset of samples, parallel assays on blood as well as urine were conducted to 
determine if this could provide an insight as to whether certain biomarkers were transmitted 
through the kidneys or synthesised by the kidney. Of the thirty-six biomarkers there were just two 
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that were not measurable in urine, these were TNFα and MBP.  There was no relation to molecular 
weight observed. Biomarkers found in urine that were higher than what has been reported. 
8.2 Main findings 
In discussing these complex relationships, simple, integrated diagrams are used to clarify the key 
patterns that can be derived from the results. 
 
 
Figure 8.1. KEY: Colour code for biomarker groupings 
8.2.1 Urinary biomarkers in health, disease and severity 
The first observation is that levels of biomarkers in urine from both stable COPD and CF are 
significantly different compared to samples taken from healthy individuals. This has already been 
proven in other sample matrices such as sputum, blood, EBC and BAL fluid, but to the best of our 
knowledge, has not previously been demonstrated in urine with the exception of desmosine where 
levels have been found to be increased in stable disease and exacerbations. Out of the 17 
biomarkers tested, when comparing to the healthy urine samples, there were 3 markers associated 
with CF  (creatinine, NGAL and MMP-8) which were elevated and for COPD there were 3 biomarkers 
(Fibrinogen, IL-6 and IL-1β) which were also elevated however, they were also elevated in samples 
obtained from people with suspected UTI indicating that they were not specific to COPD. There were 
9 biomarkers that overlapped both CF and COPD, 4 of which were also increased in UTI. There were 
three biomarkers NGAL, HNE, RBP4 from the panel of 17 whereby the levels found in urine were not 
significantly different to that found in healthy urines but were elevated in UTI, this is summarised in 
Figure 8.1. Of note is that from the 17 biomarkers evaluated, it was the proteases/ effector 
molecules that were associated with UTI. This was not unexpected as the infection is local and such 
molecules might be anticipated to be present in the urine. Limitations are that the control group 
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were not age matched to either the COPD or CF group and in addition, the sample size of the control 
group was small (n=40) compared to all the other cohorts.  
The second observation was that there were increased levels of proteases in urine samples collected 
from females compared to males, similarly there were higher levels of protease inhibitors in males 
compared to females (figure 8.2). The elevation of NGAL in females relative to males has been 
demonstrated previously in studies evaluating NGAL as an acute kidney infection (AKI) marker 
though the cause of the difference is unknown (161). The general observation of increased 
proteases in females and increased protease inhibitors in males is a novel finding not previously 
reported.  With the understanding that women are more susceptible to the development of COPD 
(162), it does suggest that the elevated unregulated proteases found in the urine could be related to 
this greater susceptibility.  
The third observation is that there were clusters of biomarkers that correlated with each other and 
the correlations were stronger when stratified by gender. Cluster 1 consisted of 7 biomarkers, the 
majority of which were effector molecules (MMP-8, MPO, Calprotectin, NGAL, HNE, MMP-9 and IL-
8), it is shown that the chemokine - IL-8 correlated with all biomarkers in the cluster with the 
exception of calprotectin in females but not in males. This could be due to the fact that there were 
higher levels of all these biomarkers in females such that there were measurable included compared 
to the males where there was lower (perhaps absent) levels. This result was consistent in not only 
COPD but also CF (one of the cohorts in particular). Cluster 2 consisted of again 7 biomarkers, a 
mixture of different groups, protease inhibitors, signalling molecules, other molecules and 
consequence molecules (TIMP-2, Cystatin C, fMLP, B2M, RBP4, Creatinine and desmosine). In males 
there were more biomarkers that correlate, albeit not strongly (Spearman’s r values of >0.7), with 
certain biomarker pairings i.e. fMLP and creatinine, fMLP and TIMP-2, TIMP-2 and Desmosine, RBP4 
and cystatin C, RBP4 and B2M, RBP4 and creatinine. Interestingly, RBP4 did not appear to be gender 
specific, yet it correlated with a greater number of biomarkers in males relative to females. Cluster 1 
biomarkers; HNE and MPO consistently correlated in stable/recovery and exacerbation states, 
cluster 2 biomarkers; TIMP-2 consistently correlated with creatinine. In COPD exacerbations (AERIS 
cohort), 4 biomarkers (MMP-8, MMP-9, HNE and MPO) from cluster 1 remained with a high 
correlation (Spearman’s r >0.8) whereas the correlation with NGAL was lost in AECOPD, in this 
instance, the levels of NGAL were significantly higher in AECOPD (Wilcoxon matched-pairs signed 
rank test) but unchanged for the other 4 biomarkers. In cluster 2, there were 3 biomarkers that 
correlated strongly (Spearman’s r >0.8) with each other in both stable and AECOPD (B2M, Cystatin C 
and creatinine), however, the correlation with TIMP-2 was lost in AECOPD, in this instance the levels 
of TIMP-2 were unchanged as were the other three biomarkers therefore the reasoning is not clear.   
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The same strong correlations that exist with urine biomarkers were not found in blood and in 
addition the correlations overall were weaker in blood with all biomarkers (figure 8.5). Interestingly 
in a study evaluating neutrophil mobilisation during stable and exacerbation states (92), a secondary 
finding was that MPO and HNE were strongly correlated in blood (ρ=0.72, P,0.001, Spearman rank 
correlation) in stable state and modestly in exacerbation state (ρ=0.4, P,0.05, Spearman rank 
correlation). In the analysis performed as shown in figure 8.5, HNE was not tested therefore the 
correlation with MPO could not be calculated for the comparator analysis, however based on 
previous correlations between MPO and HNE, the findings from the Andelid study were not as 
strong as the correlations found in urine (AERIS study r=0.87).  There are limited studies reporting 
correlations between different biomarkers in other sample matrices but from the analysis performed 
here, it is concluded that in urine, the expected correlations with biomarkers with shared cellular 
origin are strong and this is not replicated in blood. An explanation for this is that biomarkers in 
urine can reflect physiological or pathophysiological changes better than in blood where 
mechanisms are in place in order to maintain homeostasis. 
The fourth observation was that there were biomarkers in the urine that could differentiate 
between severity of disease. For instance, in 2 COPD cohorts, a single biomarker (IL-1β) was 
significantly increased in the frequent exacerbator compared to the infrequent exacerbator.  IL-1β, 
an innate immune cytokine involved in the initiation and persistence of inflammation, has been 
shown to be increased in frequent exacerbators compared to infrequent exacerbators by 
measurement of gene and protein expression in sputum with a p value of 0.018 and 0.065 
respectively (163). This association was weaker that that shown in urine described in this thesis, 
indicating that urinary IL1β might be a better indicator of disease severity than in other biological 
fluids such as serum.  
 In addition, a combination of markers was able to predict the conversion of an infrequent 
exacerbator to a frequent exacerbator 1 year in advance, a better predictor than previous history of 
exacerbations which is currently used in practice. This would need to be evaluated in a different 
cohort and with a larger number of subjects in order to confirm this result.  
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Figure 8.2. Biomarkers that were significantly different in health and disease and gender specific biomarkers. A) biomarkers that were shown to be 
significantly different (non-parametric unpaired t test p <0.05) in different disease state, stable CF, stable COPD and UTI compared to control group. 
Overlapping biomarkers across all three groups were IL-6, Active MMP, MMP-9 total and HSA, biomarkers specific to lung disease CF and COPD shown. B) 
biomarkers that were different between males and females derived from results obtained from 1 x stable COPD cohort and 2x stable CF cohort. The colours 
of each biomarker represent different classes based on previous literature. Purple indicates effector molecules, brown for protease inhibitors, black for 
non-immune biomarkers, yellow for consequence molecules and blue for assumed renal biomarkers 
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Figure 8.3. Correlations between urinary biomarkers in stable state. A) cluster 1, healthy, stable COPD, stable COPD males, stable COPD females and B) 
cluster 2, healthy, stable COPD, stable COPD males, stable COPD females.  Cluster 1 consists of mostly effector molecules (purple) + chemokine IL-8 (green) 
and cluster 2 consists of a mixture of protease inhibitors (brown), renal markers (blue), elastin degradation molecule (yellow) and signalling molecule fMLP 
(green). Strength of correlation was measured by non-parametric Spearman’s r with 3 different gradients of line thickness; thin line between 0.7-0.8; 
median thickness line 0.8-0.9; and thick line 0.9-1. For cluster 1, in females, there was an excellent correlation between 0.9-1 for neutrophil degranulation 
proteins MMP-9, MPO, HNE and MMP-8 with correlations with fMLP. In males, strong correlations >0.8 for MPO, MMP-9 and calprotectin.  For cluster 2, in 
females, there were strong correlations between 0.8-0.9 for protease inhibitors cystatin C, TIMP-2 and renal markers, creatinine and B2M. In males, strong 
correlations 0.8-0.9 with cystatin C, TIMP-2 and creatinine and good correlation with desmosine (0.7-0.8) and creatinine.  
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Figure 8.4. Correlations between urinary biomarkers in stable and exacerbation.  A) cluster 1, COPD, stable COPD, AECOPD and B) cluster 2 COPD, stable 
COPD, AECOPD.  Cluster 1 consists of all effector molecules (purple) + chemokine IL-8 (green) and cluster 2 consists of a mixture of protease inhibitors 
(brown), renal markers (blue), elastin degradation molecule (yellow) and signalling molecule fMLP (green). Strength of correlation was measured by non-
parametric spearman’s r with 3 different gradients of line thickness; thin line between 0.7-0.8; median thickness line 0.8-0.9; and thick line 0.9-1. For cluster 
1, Four biomarkers correlated in all 3 groups (>0.8), these were MMP-9, MPO, HNE and MMP-8, there were more biomarkers that correlated in stable state 
compared to exacerbation this also applied to cluster 2 biomarkers. this indicated that in AECOPD there were dysregulation of biomarkers that resulted in a 
lack of correlation i.e. changes in the biological pathways.
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8.2.2 Changes in levels of certain urinary biomarkers are indicative of exacerbation in 
retrospective samples 
Biomarkers found in urine reflected pathological changes occurring in the lungs both in stable 
disease and in exacerbation. It was found that certain biomarker levels were lower in the stable 
state and elevated in the exacerbation state, these findings were in line with results obtained from 
other biological fluids such as sputum, BAL fluid and blood. Samples from three different COPD 
cohorts were analysed (all retrospective samples), and were collected prior to the exacerbation, or 
after or both. Statistical analysis, simply comparing levels of biomarkers measured in stable/recovery 
and exacerbation states, showed significant differences in levels (p<0.05) for certain biomarkers 
(figure 8.4). Elevated biomarkers included effector molecules, protease inhibitors, non-immune 
markers; CRP, fibrinogen, CC16 and renal markers. A1AT was significantly increased in AECOPD for 
all cohorts indicating that this was a robust marker of exacerbation. Biomarker that failed to meet 
significance between stable and AECOPD in all three cohorts were signalling molecules and 
consequence molecules which could be due to the timing of when the exacerbation sample was 
collected i.e. too late for signalling molecules and too early for the consequence molecules. In urine 
samples, the biomarkers are cleared unlike in blood where they may remain for prolonged periods 
of time (persistent systemic inflammation).   
 
The relative differences in levels of the other biomarkers and differentiation between stable and 
exacerbations states with the three cohorts could be for the following reasons.  Firstly, not all 
biomarkers were evaluated in all three cohorts i.e. CRP, RNASE3, CHI3L1, CC16 were not tested in 
the Birmingham cohort, therefore it is unknown if levels of these markers were significantly different 
between the two disease states Secondly, although the 3 cohorts were similar (demographics shown 
in Chapter 4), there could be some underlying factors that cause differences in baseline levels i.e. 
the AERIS cohort patients were more severe than Leicester for example, with 60% GOLD3/4 
compared to 52%. Thirdly, as previously stated, the time of sample collection may have an impact. 
For the Birmingham cohort the samples were collected at exacerbation and a follow up recovery 
sample at 6 weeks compared to the other two studies whereby a stable sample was collected 
followed by an exacerbation sample. It could be that the levels of biomarkers at recovery are 
different from a true stable sample. For the AERIS study; pre-exacerbation samples were collected 
between 3-66 days before the exacerbation therefore, not all are ‘’true stable’’ samples whereas for 
the Leicester study, the stable samples were collected in good time prior to the exacerbation in most 
cases so would be classed as ‘’true stables’’ These were all factors that needed to be considered 
when selecting biomarkers for the final device. 
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The demonstration of significance using population threshold averages was encouraging as from 
previous studies it was established that the it was the change from baseline levels of the urinary 
biomarkers to exacerbation that was fundamental when looking at this type of data. It was shown in 
chapter 3 that there were differences due to gender, age and severity that would influence the 
baseline values. As a result, a different method of analysis was required in order to establish the true 
utility of urinary biomarkers levels. This was achieved by calculating the % change from stable to 
AECOPD or AECOPD to recovery for each individual and a change of greater than 10% was deemed 
to be reflective of a positive change from the ‘baseline’. Limitations were that only a single time 
point was available and in practice a baseline would be calculated from more frequent data points 
taken at a stable state.  The Leicester cohort was more representative of what would be done in 
practice as samples were collected at multiple stable time points and an average of these provided a 
more representative baseline. In addition, a single biomarker was not likely to be effective and a 
combination of biomarkers would be required, the analysis of which was undertaken manually for 
the Birmingham and AERIS data and by logistic regression analysis for the BEAT-COPD data. Through 
the multiple analysis methods, the most promising 10 biomarkers were selected for further analysis.  
A further limitation was that these samples were frozen, and verification and validation studies 
undertaken in Chapter 6 demonstrated that there were differences in the levels of some of the 
biomarkers when comparing fresh and frozen samples although the correlations were comparable. 
The measurement of biomarker levels was undertaken using more sophisticated and accurate assays 
such as ELISAs which would not be suitable for point of care testing by individuals in the home.  The 
question is whether a simple lateral flow assay will be reproducible, robust and quantitative to be 
able to replicate these results. 
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Figure 8.5. Urine biomarkers associated with AECOPD. Biomarkers that were increased in 
exacerbation compared to a stable or recovered state with significance levels p <0.05. Birmingham 
cohort consisted of samples collected from patients at exacerbation and at 6 weeks. The AERIS 
cohort comprised samples collected at stable (or pre-exacerbation, sometimes only days prior) and 
at exacerbation. The Leicester cohort consisted of samples collected at stable state and at 
exacerbation.  
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8.2.3 Changes in levels of selected urinary biomarkers are indicative of exacerbation in 
prospective samples 
Daily samples were collected and tested by people with COPD for 10 biomarkers over a period of 
approximately 6 months. An interim analysis of this study indicated that there were 5 biomarkers 
that, when combined, could be useful in predicting and diagnosing an exacerbation. This was the 
first true longitudinal study where daily inputs other than symptoms or lung function tests 
(spirometry) could be collected. Other longitudinal studies involved collection of samples less 
frequently during stable disease i.e. monthly, thence more frequently during the exacerbation 
period for the first 2 weeks and subsequently at 4-6 weeks when recovered. The details of some of 
these studies are presented in the introduction, table 1.1.  The 10 biomarkers that were measured 
with the point of care tests were A1AT, TIMP-2, NGAL, Fibrinogen, CRP, RBP4, CC16, B2M, TIMP-1 
and fMLP.  In our study, in addition to the daily urine testing undertaken by the patient in the home, 
scheduled visits were arranged at day 0, and every 1.5 months till the end of the study and 
unscheduled visits; exacerbation and follow up after 2 weeks.  At all these visits blood samples and 
urine samples were collected. The correlations of the biomarkers in blood relative to urine were very 
different, the clusters of urine biomarkers already reported in Chapter 3 were not replicated in 
blood. Notably, the effector molecule correlations (cluster 1) were not observed and in stable state 
there were 2 very interesting pairings in blood – A1AT and B2M and CRP and TIMP-1 and in 
exacerbations, Cystatin C and CHI3LP1. In urine, a new pairing was observed, namely IL1β and 
periostin, which could be attributed to the fact that these were fresh samples in this particular 
study, although it would need to be validated, the biomarkers may have been degraded in stored or 
freeze/thawed samples. 
The model developed used 5 biomarkers, TIMP-2, Fibrinogen, CRP, CC16 and B2M. The performance 
obtained using logistic regression analysis gave an AUC of 0.82 (95% confidence interval 0.6957-
0.9363). This was based on results from the prospective, longitudinal study where data were 
obtained from patients running daily tests. 
The results that were obtained from the study described here were screened for validity, namely, 
results that were classed as being incorrect were removed where the control line result did not fall 
within a specified range. Usually, the invalid tests were due to the incorrect positioning of the reader 
or device in the holder. The patients were monitored for the first 2 weeks and additional training 
was provided if required, however, there still remained results that were incorrect post-training 
highlighting the need to make the system more user-friendly. Samples were also sent to the 
laboratory once a week where the tests were repeated. It was not possible to confirm if the results 
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from the same samples were equivalent due to the time difference from when the sample was 
collected and received (1day + later), some biomarkers were shown to be unstable over time and 
under transport conditions. We were therefore reliant on the testing results received from the 
patients.  
It was observed that due to the different baseline values for each individual the biomarker results 
for some of the assays did not always fit within the dynamic range. The A1AT assay for example, was 
too sensitive and there were several measurements that were above the standard curve. This was 
anticipated as results from a previous cystic fibrosis home study had highlighted a difference 
between fresh and frozen samples. However, the extent of this was not known until the present 
study. The assay was modified and introduced during the study, however, it did complicate the 
analysis as data obtained from the new assay would need to be analysed separately thus reducing 
the sample size and not possible for this interim analysis with limited data. 
The statistical analysis used to select the 5 biomarkers took just one baseline (average of results 
taken from 5 consecutive days), one stable result and one exacerbation result. Subsequently, the % 
change of the stable and exacerbation result from the baseline was calculated for each individual 
biomarker and it was these variables that were inputs for the logistic regression analysis to 
determine how the probability of an exacerbation occurring depended on each variable. This 
determined a set of weights that could be applied to the terms to produce an index or risk score. 
Whilst this provided an early insight there are other approaches that could be used to improve 
accuracy a) a continuous re-calculation of the baseline b) use of variables based on slope as well as 
extent of change calculated from previous days on a continuous basis c) use of other more 
sophisticated methods other than logistic regression such as ‘artificial’ neural networks (ANN). ANN 
captures associations or discovers regularities within a set of patterns and can cope with noise, 
complexity and non-linearity found in biological data.  It is often used in cases where the 
relationships are difficult to describe adequately with conventional approaches. This type of 
machine learning on such data is likely to be the most appropriate due to the complexity of the data 
and the changes that occur over time as the disease becomes more severe and exacerbations 
become more frequent. 
The date of exacerbation was defined as the day on which the patient contacted the research centre 
and a diagnosis was made. In certain instances, the patient may have waited several days before 
making the initial contact, therefore we were reliant on the patient to provide correct history of 
previous events and dates for when the symptoms first presented. This is a practical problem and 
underpins the reason such a test would be valuable to the patients. The patients recruited to the 
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trial completed the daily EXACT-PRO symptoms e- diary which has been proven to be successful in 
several trials, concluding that the EXACT tool was reliable, could determine frequency, severity and 
duration of AECOPD (164) (165).  However, a poor performance in AECOPD detection has also been 
reported (166), which highlights the complexities of defining an exacerbation due to the 
heterogenous nature of the exacerbations. This notwithstanding, the electronic symptom recording 
is far superior to paper-based recording with compliance of 94% and 73% respectively (167) and is 
one of the most accurate methods developed to date for recording patient symptoms during clinical 
trials. The reason for the poorer compliance with the patient diaries is retrospective backfilling of 
diary entries and sometimes forward-filled diary cards for upcoming, future assessment points. 
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Figure 8.6. Biomarker correlations associated with AECOPD as shown in blood and urine. A) paired 
urine and B) blood samples collected from patients in stable state C) paired urine and D) blood 
samples collected from patients at exacerbation. Stable and exacerbation samples were matched 
from the same patient. Only the biomarkers where correlation was obtained are shown. At a glance, 
both TIMP-1 and TIMP-2 correlated in blood but not in urine, B2M correlated with A1AT in blood but 
not urine (weak correlation) and B2M correlated with Ac-PGP in blood and not urine and finally, 
CHI3LP1 correlated with Cystatin C at exacerbation but not in stable state. 
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8.2.4 Urinary biomarker profiles in individual patients confirm already documented biological 
pathways 
From knowledge of the biomarker biological pathway it was expected that the order in which the 10 
selected biomarkers presented themselves would start with the signalling molecules i.e. fMLP 
followed by IL-6 induced CRP/FIB/B2M, expected thereafter would be the effector molecules (NGAL) 
and lastly, the protease inhibitors (TIMP-1/TIMP-2/A1AT). It is not apparent where RBP4 and CC16 fit 
into the biological pathway as they are not recognised biomarkers of COPD exacerbations and their 
functionality in this regard is accordingly unclear. 
From inspection of some of the daily biomarker recordings and time series, there were 3 
observations: 
- Biomarker levels varied from one patient to another and would therefore require 
standardisation 
- The delay between a change in biomarker level and the diagnosis of an exacerbation was 
variable 
- There may be interactions between individual biomarkers that will influence the overall 
predictive power of the method 
An appropriate statistical method/analysis would be able to establish from this complex data which 
biomarkers individually are relevant and that would feed into the algorithm. Most time-series 
analysis techniques involve some form of filtering out the noise in order to make the pattern more 
apparent.  Two examples of individual patient profiles taken from the observational study are shown 
in figure 8.6  
In one patient profile (Head51) for AECOPD 1, indicated by the dotted red lines, RBP4 and NGAL are 
raised 5 days prior to the event which occurred on day 55 and CRP 4 days prior with a second burst 5 
days after the event (day 60), however for AECOPD 2, it was RBP at 4 days prior, NGAL 3 days prior 
and CRP 2 days prior and the second burst was in this case RBP4 and NGAL with a very slight increase 
in CRP levels. This could be because the 2nd exacerbation event is within 6 weeks of the 1st event and 
the kidneys are “leakier”. In some cases (data not shown) RBP4 is released post-exacerbation 
therefore this profile is not reproduced in all patients. In the case of another patient (Head72), there 
was 1 exacerbation event at day 57, B2M, RBP4, CC16 levels become raised at day 47 (10 days prior 
to the event), TIMP-1 at day 51 (7 days prior to the event).  The order of ‘peaks’ was CC16 at day 52, 
followed by TIMP-1 at day 56, B2M at day 58 and RBP4 at day 63, there were 2nd peaks at day 65, 68, 
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63 and day 70 and the 4 biomarkers returned back to baseline levels, in particular TIMP-1 at day 74. 
The other biomarkers were present but at lower levels.  
The differences could possibly be explained as a result of treatment, some treatments could affect 
the levels of biomarkers, in this instance, inhibition of biomarker during treatment might be 
expected followed by an increase following cessation of treatment. This could also explain the 
second peak for some of the biomarkers shown Head072 (figure 8.6). Macrolide antibiotics, include 
erythromycin, azithromycin, clarithromycin and roxithromycin, exhibit antibacterial and anti-
inflammatory actions (168) and have been implicated in altering the production of a wide variety of 
molecules and parameters that influence the inflammatory response (cytokines, oxidant production, 
chemotaxis and degranulation of neutrophils). Doxycycline, a potent inhibitor of MMP enzymes is 
also known to reduce CRP levels in plasma (169). 
Although all the patients were given steroids (some were also prescribed antibiotics), the 
exacerbations from the observational study have not yet been stratified into those with bacterial or 
viral infections i.e. determination of neutrophil or eosinophil derived exacerbations. Further 
stratification may provide further insights and understanding on the differences between the 
biomarker profiles for individual patients. 
While there may be different responses relating to individual physiological states or idiosyncratic 
biochemical anomalies, each example constitutes a real biological phenomenon.  If such an example 
makes biological sense there is reason to take the occurrence seriously, in that it can provide an 
understanding of possible biologic profiles that may be encountered in at least some of the subjects 
enrolled in future clinical trials, or in subsequent routine use. 
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Figure 8.7. Biomarker profiles established through clinical study. Two profiles are shown on the left 
with close up graphs for the exacerbations shown on the right. Patient “Head51” experienced 2 
exacerbation events shown by the dotted red line and Patient “Head72” experienced 1 exacerbation 
event shown by the dotted red line. For Head51, 3 biomarker profiles are shown that demonstrated 
an increase in level from stable to exacerbation. For Head72, 3 different biomarker profiles are 
shown that increased leading up to the exacerbation. RBP4 in this instance increased after the event 
but before the events for Head51. 
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8.3 Biological relevance of selected biomarkers contributing to prediction of exacerbations 
Based on documented roles and origins, a diagram has been constructed to show the interactions 
between the biomarkers evaluated in this thesis (figure 8.7).  B2M, RBP4 and CC16 have not been 
rigorously evaluated in any sample matrix with regard to their association with COPD exacerbations. 
B2M has been shown to be elevated in chronic inflammation, which is consistent with the fact that 
the surface of lymphocytes and monocytes (intimately associated with inflammatory processes) are 
particularly rich in B2M. Free B2M circulates in the blood as a result of shedding from cell surfaces or 
intracellular release regulated by cytokines(170).  Once released, B2M is cleared from the blood by 
glomerular filtration, a physiological feature that has been used for estimation of the glomerular 
filtration rate (171).  Although much is known about the source, fate and function of B2M, further 
work is required to identify the relationship of these three biomarkers with the processes underlying 
COPD exacerbation. Very little is known about the other 7 biomarkers in ‘’urine’’ (from the final 
selection of 10 biomarkers), especially with regard to their origin and whether they are lung derived 
or produced locally in the kidneys. Whilst these details are not yet known, it is clear that they are 
useful in prediction of exacerbations. 
It has been demonstrated through the research described in this thesis that the presence of 
particular products in urine reflect physiological or pathophysiological changes that occur in the 
lungs.  The findings support the original hypothesis, which can now be refined with the addition of 
the new evidence (including 2 other promising biomarkers that did not end up in the final 10 due to 
the restriction in numbers that could be taken forward). 
To summarise, the key elements of the hypothesis are supported by evidence from these studies, or 
the evidence must be evaluated in the light of known complicating factors adopted into the 
hypothesis, as follows:  
- As neutrophil leukocytes, in particular, infiltrate the lungs and become activated, large 
amounts of proteases and other molecular biomarkers (indicated below) are produced and 
these spill-over into the blood. Significant elevations in levels of neutrophil-associated 
biomarkers (above the levels found during stable disease, or on recovery) at exacerbation 
are clearly consistent with this hypothesis.  The biomarkers involved are: - 
o signalling molecule fMLP  
o cytokine-induced fibrinogen, CRP and B2M 
o tissue-derived protease inhibitors; TIMP-1, TIMP-2, A1AT, Cystatin C  
o lung-derived marker: CC16  
o Elastin degradation product: Desmosine 
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- Any active protease in the blood will quickly encounter the kidneys and, as the kidneys have 
a copious vascular supply and high blood perfusion rates, they cannot risk any protease-
mediated tissue damage, so, they produce their own inhibitor supplies (TIMP-1, TIMP-2). 
There is a lack of direct evidence to support this, but blood concentrations and paired urine 
concentrations do NOT correlate, which indicates that the biomarkers are derived from 
elsewhere locally, pointing to the kidneys as the source of the inhibitors. There is already 
evidence that the kidney has the capacity to express substantial amounts of TIMP-1 and 
TIMP-2 (172) and SLPI (173). 
- During episodes of acute inflammation, the kidneys are affected by the presence of active 
inflammatory mediators in the blood, causing inflammation-related changes in the 
molecular permeability of the glomeruli and, consequently, measurable changes in urinary 
concentration of certain biomarker molecules. Evidence to support this is to be found in the 
significantly higher levels of certain biomarkers at exacerbation than the concentrations in 
stable or recovered states (such as the changes reported for RBP4 and B2M) and the finding 
of large molecular weight molecules in the urine such as A1AT, CRP and fibrinogen during 
episodes of acute lung inflammation. 
- Consequently, kidneys can be utilised as sentinel organs, releasing molecular messages that 
warn of impending exacerbation, although the messages need to be de-convoluted in order 
to be understood. 
- Small but measurable amounts of inflammation biomarkers traverse the kidney to become 
detectable in the urine it is to be expected that differential filtration and metabolic effects 
can effectively scramble the overall biomarker message. 
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Figure 8.8. Interactions between the biomarkers involved in COPD exacerbations 1) inactivation of 
A1AT caused by A1AT deficiency 2) inactivation/oxidation of A1AT caused by ROS 3) inactivation 
caused by active MMP-9 4) HNE derived degradation of collagen and/or elastin 5) MPO resulting in 
destroying of bacteria 6) calprotectin involvement of inflammatory cell recruitment 7) NGAL 
reduction of available iron required for bacterial growth 8) HNE activation of MMP-9 9) inactivation 
of TIMPs resulting in increased MMP-9 10) IL-8 induced released of MPO from neutrophils 11) IL1β 
induced release of MMP-9 12) Ac-PGP activation of CXCR2 resulting in increased IL-8 13) induced 
release of MMP-9  14) NGAL/MMP-9 complex inhibits MMP-9 inactivation resulting prolonging 
MMP-9 damage 15) systemic inflammation associated with poor clinical outcomes (exacerbations 
and mortality) 16) IL-8 stimulated migration of neutrophils to site of injury 17) decreased inhibition 
function resulting in increased HNE 18) release of Ac-PGP from degradation of collagen 19) release 
of desmosine and fragments from degradation of elastin.  
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8.4 Future impacts of the research 
COPD is characterised by daily symptoms of breathlessness, cough and wheeze with persistent 
impairment in lung function tests. At times there is worsening of the symptoms leading to 
exacerbations. COPD patients already monitor their health at home – not by means of biomarkers of 
disease status but by patient perceivable signs and symptoms. When their symptoms worsen, they 
contact emergency services or their GP. Exacerbation symptoms are often unclear and patients’ 
ability to recognize them is variable. Some patients seek help promptly, whilst others delay, 
increasing the likelihood of hospital treatment.  
Exacerbations are caused by several different triggers, including major events such as viral and 
bacterial infections as well as a series of smaller disturbances culminating in destabilisation of the 
disease. In most COPD exacerbations there is evidence of airway inflammation which could be either 
a cause of the exacerbation or a consequence of a new infection. Most measurements of 
inflammation have concentrated on sampling blood or sputum at the time of the exacerbation, 
compared with values from samples taken several weeks apart during periods of disease stability. 
These approaches have not led to an adopted test, due to lack of clinical sensitivity and specificity 
and challenges in obtaining the samples at times when management could be usefully altered. The 
few telemonitoring strategies to predict onset of COPD exacerbations have not been successful, 
possibly due to the absence of direct and objective measures of inflammation, moreover, the largest 
trial to date demonstrated that telemonitoring had no significant clinical benefits but posed a 
substantial impact on workload for healthcare providers (174). The challenge is to develop reliable 
near-patient tests of inflammation which can be measured frequently in different settings, including 
the patient’s home that can be introduced into the existing patient care pathways.  To be successful, 
such tests need to be simple for the user, yet sophisticated enough to deconvolute the 
heterogeneous inflammatory responses that precede the clinical presentation of an exacerbation.  
Through the use of urine as the sample, the proposed point-of-care test is minimally invasive, easy 
to use, rapid in time-to-result and with simple-to-understand results.  With these characteristics it 
can easily be integrated into the patients' routine at home.  The simplicity-in-use will encourage the 
patient to maintain a high frequency of use to improve accuracy and extent of warning. Sputum is 
far from an ideal sample, due to the invasive method of collection and the complexities of 
processing the sample which makes it less suitable for point-of-care testing. Blood may be more 
convenient but too invasive for frequent testing. Profiling of inflammatory mediators in urine 
samples provides a simple and robust measure of respiratory inflammation in COPD patients and can 
be done repeatedly within a patient’s own home or in the clinic. 
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The potential benefits of improved advanced warning of an exacerbation are: 
- An early warning or reassurance, and additional information to patients to manage their 
condition more efficiently.  Experts suggest 20-40% patients struggle to recognise 
exacerbations. 
- Help for healthcare professionals in planning and prioritising primary care/community 
service interventions in a more clinically- and cost-effective way.     
- Prompts for patients to seek help earlier for exacerbations, especially for those who would 
otherwise seek help too late 
- Reduction in unnecessary referrals to secondary care and hospital admissions 
- Reduction in misuse of rescue packs, ambulance usage, and emergency presentations to 
A&E 
Should this test be able to provide an early indication that an exacerbation is imminent, clinicians 
would have an opportunity to treat more patients in the community, reducing visits to hospital and 
emergency admissions. For the patient, access to this technology would result in a better quality of 
life by empowering the patient to take control in managing their own condition.  
Before the test can be adopted (i.e. used in practice by patients) more diagnostic evidence is 
required, especially with regard to the performance of the test (sensitivity and specificity, negative 
and positive predictive value), usability data and realistic insights in health economics, care 
pathways and patient attitudes and concerns. The development of health economic models would 
provide robust evidence on clinical utility and cost-effectiveness of the test, data for which should be 
gained from a randomised clinical study where the benefits of early diagnosis would be 
demonstrated. Early models have been developed by the MedTech and In Vitro Diagnostics Co-
operative (MIC) in Newcastle. Without these trials it would not be possible for such a test to be 
adopted, as sufficient evidence is essential to convincingly demonstrate benefits and to prove that 
the introduction of the test does not cause harm to the patient (e.g. anxiety or the intrusion of 
increased contact with the healthcare professionals or, the worst-case scenario, a missed 
exacerbation diagnosis leading to death. 
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8.5 Limitations and strengths 
Prior to the observational study, the only clinical samples made available for this research were 
kindly donated via various clinical partners from sample banks populated by samples collected in 
clinical studies not designed with longitudinal collection or with appropriate frequency over 
sufficiently long timescales. It was, therefore, not possible to access samples gained from studies 
designed to test the core hypothesis that urinary biomarker profiles can predict or confirm 
exacerbation. This introduced bias to the some of the early analyses. For example, the UTI cohort 
consisted of female volunteers only, the healthy cohort patients were not age matched and, for the 
COPD and CF cohorts, any potential effects of treatments for COPD were not assessed as a potential 
confounding factors.  These need to be taken into consideration upon reviewing the results, as some 
of the groups may not always be comparable. 
A power calculation was conducted for the number of patients recruited into the observational 
study but sample size estimation was not taken into account for the other studies (this, of course, 
was limited by the availability of samples). The number of samples in the cohorts was deemed 
acceptable, based on previous calculations with >100 individual samples in the COPD ECLIPSE cohort, 
CF imperial study, CF QUB study, UTI Cardiff study.  The COPD matched 
stable/exacerbation/recovery samples were from >50 patients in each of the COPD Birmingham, 
Leicester and Aeris cohorts. In these cases, the sub analyses did create smaller groups that were not 
always large enough to enable normally acceptable levels of significance to be reached. 
Other methods of analysis for multiple comparisons would be more appropriate than what was used 
in chapter 3. A correction for multiple testing would have been more suitable and representative of 
the data. 
For biomarker selections samples were tested from multiple cohorts (n=3). Final biomarker selection 
was based on results from all studies, to compensate for COPD heterogeneity. Although it was not 
possible to perform the same analyses for all individual studies, common biomarkers were found to 
be promising and robust.  
8.6 Conclusion 
Prior to the research described in this thesis, biomarkers involved in known biological pathways had 
been identified and quantified through studies undertaken by analysis of lung biopsies, sputum, BAL 
fluid and blood.  However, this thesis describes the first investigation of a large panel of biomarkers 
detected in urine samples from subjects in various stages of COPD.  This has provided new insights 
into the relevance and origin of the biomarkers. Prototype point-of-care tests were developed that 
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could be used routinely by patients in their own homes to monitor their inflammation status and 
predict pulmonary exacerbations. This was evaluated in a prospective observational study, results of 
which were used to develop a simple algorithm that showed the potential for differentiating 
between stable state and exacerbation events. Technology that enables patients with COPD to 
measure biomarker levels on a daily basis in the home would make it possible to harness the 
otherwise hidden time-course of the selected biomarker levels as the basis for diagnosis and 
prediction of exacerbation.  The research described here is part and parcel of a major research 
programme carried out within the Mologic R&D group and constitutes investigations designed and 
directed by the author, and conclusions derived from the author’s analysis of the data collected by 
the biomarker immunoassays.  The findings constitute a key scientific foundation for a new approach 
to personalised medicine for COPD sufferers.   
8.5 Future work 
The findings and conclusions need to be comprehensively validated in line with medical device 
regulations and clinical best-practice before consideration for adoption. Other questions to be 
answered are: 
- Is there evidence for renal response to circulating inflammatory agents, resulting in renal 
production of biomarkers? 
- What are the factors that may influence trans-renal passage, or the renal production of 
biomarkers in response to circulating inflammatory mediators? 
- What is the influence of co-morbidities and medications on biomarker baseline levels as well 
as any masking effect? 
 
Further work needs to be done on COPD biomarkers where the origin and functionality is unknown.  
In order to determine the origin of the biomarkers that end-up in the urine and their association 
with the kidneys in particular, it will be necessary to use various complementary techniques such as 
immunoblotting, qRT-PCR, immunocytochemistry and in situ hybridisation.  These techniques could 
be used to localise and quantify the selected biomarkers in biopsy samples. Immunoblotting and 
qRT-PCR using samples derived from kidney cell lines in vitro (podocyte, glomerular endothelial, 
tubular) would permit accurate quantification of relative expression at RNA and protein levels. 
Immunocytochemistry would enable localisation of proteins in clinical samples although not 
adequate for quantitation. In situ hybridisation would permit localisation of the mRNA in tissue and 
show whether the proteins in question are being synthesised at that site. 
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Development of a sophisticated algorithm that could learn the patients profile in real time and 
improve the prediction on a personalised level.  This type of machine learning could also incorporate 
other factors such as comorbidities, treatment, gender, severity of disease and symptoms and make 
sense of noisy data. 
Further investigation of desmosine and active MMPs, in particular MMP-9 and MMP12 would be 
worthwhile. Although these markers were not selected for further analysis due to the lack of 
evidence derived from the retrospective sample testing to support the usefulness of these markers 
in exacerbation, it could have been that these markers presented earlier than the day of diagnosis 
which could have been approximately 3 days post symptoms.  The assays have been developed and 
are available to be incorporated in a study with more frequent testing leading up the exacerbation.  
Other applications could be for other respiratory diseases such as CF. CF exacerbations are mainly 
caused by bacterial infections whereby COPD exacerbations are of bacterial and viral origin. Studies 
to date have been promising however, not as extensive investigated compared to COPD. 
Further clinical trials are required to prove that that the test has the required diagnostic accuracy, 
demonstrate patient benefit and cost savings and help identify the best ways to integrate these 
products into existing NHS care pathways.  
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I. Development and validation of novel assays 
I.i Desmosine  
Recent advances in detection techniques have been focused on sophisticated laboratory methods, 
especially liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) (125, 175) 
and high-performance capillary electrophoresis with laser-induced fluorescence (176). These 
techniques have allowed quantification of desmosine at a concentration as low as 0.1ng/ml in urine 
(177, 178) and enabled great progress in understanding desmosine as a means for identifying 
exacerbation and monitoring therapeutic intervention in COPD (97, 98). Previously reported 
immunoassays for desmosine and isodesmosine appear to have been based on antibodies with low 
affinity and low specificity. Although there are a few reports of enzyme immunoassay (EIA) and 
radioimmunoassay (RIA) methods (179, 180), they have not been widely adopted or validated 
against the reference standard LC-MS/MS methods. 
The aim was to develop an EIA and a lateral flow assay (LF) assay for accurate quantification and high 
throughput testing of desmosine in urine samples in the laboratory, at the point of care (PoC) or in 
the home. Both the EIA and LF assays were configured in the competitive assay format, with an 
ovalbumin-desmosine conjugate presented on the solid-phase (as the capture reagent) and a tracer 
antibody attached to either an enzyme label (alkaline phosphatase) or particulate label (40nm gold 
particles).  The particular technical challenges in developing these assays include a) poor 
immunogenicity of desmosine, even when conjugated as a hapten to an immunogenic carrier 
molecule (181), b) the close structural similarity of related collagen cross-linkers (isodesmosine, 
pyridinoline (PYD) and deoxypyridinoline (DPD)) which are also present in urine (182) c) the presence 
of desmosine as mixtures of free DES and DES containing peptides in test samples (extreme 
molecular heterogeneity) (182, 183) and d) the need  for agreement between the immunoassay 
results and a reference isotope dilution LC-MS/MS assay (97, 182). 
These challenges could not be overcome by manipulating the assay format or assay type but by 
seeking antibodies with optimum performance at the level of molecular recognition.  The solution to 
the problem was, therefore, to generate and refine high-performing antibodies in terms of affinity 
and specificity. 
I.i.i Materials and Methods 
Antibody development and characterisation. Desmosine was conjugated to Keyhole limpet 
hemocyanin (KLH) as a carrier protein with glutaraldehyde as the cross-linking agent following 
standard, well-known procedures. The KLH-desmosine conjugate (2mg) was emulsified with 2ml 
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Freunds complete adjuvant and 2ml saline and injected subcutaneously into two sheep.  The sheep 
were then boosted once a month for 4 months with 0.5mg of the KLH-desmosine conjugate in 
incomplete Freund’s adjuvant and bled 2 weeks after each injection, according to normal, approved 
procedures. At week 32 sheep CF1316 was put on hold for 5 months, with no further booster 
injections until week 52 to allow the B-cell response to mature.  At week 52, it was re-boosted with a 
new batch of KLH-desmosine (sonicated) in incomplete Freund’s adjuvant.  The cycle of 
immunisations was repeated using 0.1mg per injection.  
Measurement of antibody titre by ELISA. The materials and reagents are described in an earlier 
section 2.2.4.4 The titre of the anti-desmosine antibody in the serum was measured by serial dilution 
of the serum in sample diluent (50mM tris buffered saline pH8, supplemented with 0.1% (v/v) 
Tween20 and 1% (w/v) BSA) and evaluated using the following protocol.  Diluted serum samples 
(100μl) were added to duplicate wells and incubated for 1 hour at room temperature with gentle 
agitation.  Donkey anti-sheep IgG alkaline phosphate conjugate (Sigma, Cat No, A5187) was diluted 1 
in 30,000 in the sample diluent and added to each microtitre well (100μl), incubated for 1hour with 
gentle agitation. After the final plate wash, the colorimetric detection step was initiated by the 
addition of 100μl of pNPP solution to each well. Once colour had been allowed to develop, the 
absorbance was measured at 405nm using an Omega plate reader. The sheep anti-desmosine 
CF1316 antibodies were sampled at various stages of the immunisation process to detect desmosine 
was tested at a dilution of 1 in 3200 over the 29 months. 
Competitive EIA for urinary desmosine. As described in section 2.2.4.4. 
Desmosine LF competitive immunoassay. Desmosine-ovalbumin conjugate was immobilised onto 
Sartorius CN140 nitrocellulose membrane at 1mg/ml using an Isoflow flatbed dispenser (Imagene 
Technology), dried in a tunnel dryer (Hedinair, UK) at 60°C and stored with desiccant prior to use.  
Affinity purified sheep anti-desmosine (CF1316) antibody was conjugated to 40nm gold colloid in a 
suspension buffer of 20mM borate pH9.3 to a final concentration of 15µg/ml. Following a 10min 
incubation, any unbound colloid was blocked with a final concentration of 2mg/ml BSA in PBS.  The 
sheep anti-desmosine gold conjugate was sprayed onto Millipore GO41 glass fibre pads in a 
deposition buffer containing 3% (w/v) BSA, 5% (w/v) sucrose and 1% (v/v) Tween 20 using an Isoflow 
flatbed dispenser. The sprayed conjugate pads were dried in a tunnel dryer at 60°C and stored with 
desiccant prior to use.  Both prepared membranes and conjugate pads were laminated and 
assembled into LF devices (VWR Cat No SLINM00810) according to an in-house protocol. Samples 
were diluted 1 in 5 in sample diluent (PBS, 0.1% (v/v) Tween20, 1% (w/v) BSA) and 80µl was applied 
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to the device.  Following a 10min incubation the signals generated were quantified using a LF device 
reader (LFDR101; Forsite Diagnostics, York, UK).   
Assay specificity. The specificity of both EIA and LF assays were evaluated by measuring the degree 
of cross-reactivity of 3 known cross reactive compounds, isodesmosine, PYD and DPD. Test samples 
were made with each compound covering a wide range of concentrations (0.05 – 500,000 ng/ml), 
including desmosine as the definitive analyte. The cross reactivity was determined by calculating the 
concentration required to generate a signal equivalent to 50% of the maximum desmosine signal 
when the back-ground signal was subtracted. For each compound, the 50% inhibitory concentration 
was then expressed as a percentage of the concentration of desmosine required to give a 50% signal 
reduction.  
The Octet QK (ForteBio, CA, USA) system was used to measure the intermolecular binding between 
the antibody and the target compounds. The Octet instrument used streptavidin biosensors to 
immobilise the biotin-desmosine (Pierce EZ-link Sulfo-NHS-biotinylation kit Cat No 21425) to the tip 
of the biosensors enabling further interactions with the anti-desmosine antibody for binding 
measurements. Ligand/protein loading concentrations were optimized prior to this experiment to 
obtain affinity and kinetic measurements. Samples were dispensed into 96-well micro-titre plates 
(Greiner bio-one GmbH, Cat No 655209) at a volume of 200µl per well.  The operating temperature 
was maintained at 30°C. Streptavidin-coated biosensor tips (Fortebio) were pre-wetted with kinetic 
buffer (Fortebio) for 20 minutes in order to establish a baseline.  After a 60 second kinetic buffer 
wash step, biotinylated desmosine, PYD and DPD (10µg/ml) were contacted with the streptavidin 
sensors for 30 seconds.  Subsequently the sensors were added to the wells containing anti-
desmosine CF1316 at decreasing concentrations for kinetic measurements (association step -1300 
seconds and dissociation step-1500 seconds). 
Validation of assays with an isotope dilution LC-MS/MS reference method. Urine samples were 
analysed for desmosine by 3 methods – liquid chromatography tandem mass spectrometry (LC-
MS/MS) chosen as the reference standard, and the 2 new methods (EIA and LF). Total urinary 
desmosine and isodesmosine were measured using a validated isotope dilution LC-MS/MS assay 
(125) with modifications described previously (178). The lower limit of quantification is 0.1ng/ml. 
Hydrolysed samples were analysed on the LC-MS/MS and EIA. Non-hydrolysed samples were 
analysed on both the EIA and LF assay.  Creatinine measurements were obtained using a creatinine 
parameter assay kit from R&D systems (Cat KGE005).  
Clinical validation of assays. Patients with acute exacerbations of COPD (AECOPD) admitted to 2 
hospitals (Birmingham Heartlands Hospital and University Hospital Birmingham) were recruited 
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between September 2012 and January 2014. Patients were eligible for the study if they had (i) major 
symptom deterioration (reduced sputum volume, altered sputum colour, development of dyspnoea) 
for 2 or more consecutive days at home and (ii) documented clinical diagnosis of COPD. Patients 
were excluded if they had a documented history of cancer of the bronchus, interstitial lung disease, 
active pulmonary tuberculosis, pneumonia or any other severe disease likely to confound results. 
The study was approved by the local ethics committee and informed written consent was obtained 
within 24 hours of admission. Subjects underwent symptom and clinical assessment, completed the 
COPD assessment test, they were imaged by computed axial tomography (CAT), and urine samples 
were collected. Diary cards for symptoms were also given out at recruitment and post broncho-
dilator spirometry was performed at day 56.  
Refinement of antibodies to improve assay specificity. Epoxy-activated Sepharose 6B was obtained 
from GE Healthcare (cat No 17-7087-01). Samples of PYD and DPD were purchased from TLC 
Pharmachem (Cat No 1543-050A2 and 1543-048A2 respectively). The coupling buffer was (0.2M 
NaH2CO3 pH 9.0), the blocking buffer was (1.0M Ethanolamine pH 8.0), wash buffer A was (0.1M 
sodium acetate, 0.5M NaCl pH 4.0) and wash buffer B was (0.1M Tris 0.5M NaCl pH 8.0) The 
desmosine column was prepared previously using the same method as described below. 
Preparation of PYD and DPD epoxy sepharose columns: The method of coupling followed standard 
protocols as recommended by the manufacturer.  PYD or DPD (3mg in each case) were dissolved in 
coupling buffer and solutions were added to the epoxy sepharose gels prepared as instructed and 
mixed for 18 hours at 37°C. The coupling fluid was decanted off and the absorbance at 280nm was 
measured to gain an indication of the extent of coupling.  The absorbance for both filtrates had 
reduced by about 50% suggesting that about 1.5mg of each had bound to the epoxy sepharose. 
After a wash and blocking step, the gels were allowed to stand overnight at room temperature and 
subsequently washed with buffer A, buffer B and finally, PBS wash before packing into columns.  
Each column was stored in PBS buffer with sodium azide. 
Affinity purifications: For the initial experiments a simple antibody extraction/purification step was 
used, based on a desmosine affinity column to extract anti-desmosine antibodies from the whole 
anti-serum. This fraction is referred to as ‘pre-purification’ reagent hereafter.  To further enhance 
specificity in subsequent experiments a multi-step refinement scheme (figure A) was used to 
produce the ‘post-purification’ reagent, starting with 1.2 µm pre-filtered whole anti-serum (20ml).  
This was passed through the PYD column as the first step. The fall- through was passed through the 
DPD column and, finally, the fall-through from that column was passed through the desmosine 
column to produce the fully refined antibody (post-purification reagent).  This procedure was carried 
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out with an AKTA purification system. The antibodies were eluted from each column with 0.1M 
glycine pH 2.7, which was immediately neutralized with 60µl of 1M tris pH 9 per ml of sample before 
being dialyzed against PBS overnight. After dialysis, sodium azide was added to a final concentration 
of 0.05% (w/v) before concentration with a Vivaspin 6 (Sartorius AG). The refined antibody 
concentrations were determined in terms of absorbance at 280nm, assuming an extinction 
coefficient of 1.4 = 1mg/ml. 
 
Figure A. Purification scheme for sheep anti desmosine CF1316, by sequential immunoadsorption on 
a set of antigen affinity columns 
Evaluation of refined antibody in assays: EIA and LF assays were developed with the refined antibody 
and the specificity of the assays was established by testing these with desmosine, PYD and DPD as 
described above.  
Statistical methods. All data were analysed using GraphPad Prism 5 (Graphpad, software, La Jolla, 
CA, USA). Data normality was identified and appropriate parametric or non-parametric tests chosen 
accordingly. Two tailed tests were used throughout. Mann-Whitney or students t-test were used to 
compare levels of urinary biomarker excretion, normalized to urinary creatinine. Significance was 
assumed if p<0.05. 
I.i.ii Results 
Antibody development and characterisation. The antibody titres from each test-bleed determined 
by EIA after a 1:3200 dilution are shown in figure B.  Although some sheep produced higher affinity 
antibodies, the anti-serum from sheep CF1316 was selected on the basis of its performance in the 
immunoassays.  High titres (signifying stronger B-lymphocyte responses and/or affinity maturation) 
started after week 52, following a beneficial holding period and repeated immunization.  Increases in 
titre continued up to week 116.  
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Figure B. The progression of antibody binding efficiency from Sheep anti desmosine CF1316 
collected over 78 weeks of immunisations, with a 20-week rest after the 32-week booster.    
Analytical validation. Both EIA and LF assays underwent rigorous testing to determine the lowest 
limit of detection (LLOD), spike recovery and linearity with urine samples and intra and inter-assay 
repeatability as described in the FDA Bioanalytical Method Validation Guidance for Industry. The 
typical calibration curves of both assays are depicted in figure C.  
a)      b) 
 
Figure C. Example desmosine calibration curves for (a) EIA; each data point represents the mean of 
replicate measurements (n=12) of each calibrator giving a curve fit (r2) of 0.9995, (b) LF assay; each 
data point represents the mean of replicate measurements (n=12) with each standard with an r2 of 
0.9997. 
LLOD: The lower limit of detection for the EIA was 0.82ng/ml with an upper limit of 200ng/ml. For 
the LF assay, the range was from 1.37ng/ml-1000ng/ml which fully covers the clinical range.      
Spike recovery: Six urine samples spiked with 250ng/ml desmosine were diluted 1 in 5 in sample 
diluent. These were then run in the EIA to give percentage recoveries ranging from 79% to 120%, 
with an average recovery of 100.7%.  For the LF assay, 3 urine samples spiked with 80ng/ml 
desmosine gave a percentage recovery range of 103-124% with an average of 116.7% all within the 
acceptable range of ±25%. 
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Linearity: Five urine samples with desmosine concentrations ranging from 583-710ng/ml were 
diluted 1 in 5, 1 in 10, 1 in 20 and 1 in 40 for the EIA linearity testing.  The accuracy obtained for the 
1 in 10 based on the concentrations determined from the 1 in 5 dilution ranged from 98-110%. For 
the 1 in 20 dilution, the range was 96-117%, for the 1 in 40 dilution it was 109-124%. For the LF 
assay, 4 urine samples with desmosine concentrations ranging from 668-802ng/ml were diluted 1 in 
5 and 1 in 10. For the 1 in 10 dilution, the accuracy ranged from 80-94%, any greater dilution did not 
provide an acceptable accuracy. 
Intra assay precision: For the EIA, 12 replicates of each standard ranging from 0.82ng/ml to 
200ng/ml were run by one operator, the %CV obtained ranged from 1.4-3%. For the LF, 12 replicates 
of each standard ranging from 1.37ng/ml to 1000ng/ml produced %CV ranging from 4.1-8.9%.  LF 
devices are prone to higher variability so it is expected to generate higher CV’s then plate assays, but 
all CV’s were within the acceptable specification of <20%. 
Inter assay precision: One operator repeated the EIA assay on 3 different plates (12 replicates for 
each standard ranging from 0.82ng/ml to 200ng/ml).  For plate 1, the %CV ranged from 3.3-7.7%, 
plate 2, 3.2-9.4% and for plate 3, 4.0-7.1%, all below acceptable level of 10%.  The standard curve fit 
(r2) for each plate was 0.9980, 0.9983 and 0.9986 respectively. For the LF assay, three separate 
batches were prepared, and 10 replicates of each standard were run ranging from 1.37ng/ml to 
1000ng/ml, the resulting %CV for batch 1 was 4.7-8.1%, for batch 2, 3.8-11.7% and for batch 3, 3.2-
8.9%. The r2 for each batch was 0.9995, 0.9993 and 0.9940 respectively. Satisfactory precision results 
were obtained for both assays.  
Assay specificity: Specificity of the antibody was evaluated in both the EIA and the LF assay. Figure D 
displays the amounts of interfering substances needed to achieve 50% of the uninhibited signal in 
the desmosine assays, expressed as concentrations (ng/ml). The cross reactivity of the EIA and LF to 
isodesmosine was 0.89 and 1.33% respectively; this is of no practical consequence for diagnosis, as 
the molecule fulfils essentially the same biochemical role as its isomer, desmosine.  Both occur as 
cross-linking molecules in elastin and are effectively identical biomarkers.  Actual cross-reactivities to 
PYD and DPD in the EIA assay were 0.02 and 0.06% respectively and the LF assay cross reactivity was 
0.86 and 1.40%, respectively. 
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a) 
 
b) 
 
Figure D. Cross reactivity with PYD and DPD. Concentrations at 50% desmosine inhibition for each 
compound were determined from the graphs above and used to calculate the percentage cross 
reactivity (a) EIA 50% B/B0 concentration for desmosine, isodesmosine, PYD and DPD were 10, 1125, 
50000 and 17500ng/ml respectively (b) LF 50% B/B0 concentration for desmosine, isodesmosine, 
PYD and DPD were 30, 2250, 3500 and 2000ng/ml respectively. 
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Further investigations of the antibody affinity and specificity were carried out by determining the 
binding kinetics with the Fortebio Octet biosensor. Figure Ea is the generated kinetic sensorgram for 
biotinylated desmosine loading (10µg/ml) to a specified biosensor with an on-rate (association) and 
off-rate (dissociation) binding to the antibody at various dilutions (7.5µg/ml, 1.5µg/ml and 
0.3µg/ml).  The raw data were processed to fit a 1:1 binding model to extract kinetics and affinity 
measurements (see figure Eb).  The measured kinetic rates and affinities of streptavidin sensors 
immobilized with biotinylated desmosine, PYD and DPD resulted with on-rates of 75460 M-1 s-1, 
24920 M-1 s-1 and 23740 M-1 s-1, off-rates of 1.458 x 10-5 s-1, 1.38 x 10-5 s-1 and 8.495 x 10-6 s-1 
and affinity (equilibrium dissociation constants) of 19.33nM, 5.54nM and 3.58nM.  These results are 
summarized in figure 5c. The affinity KD for desmosine was 1.9 x 10-10 which is a 28.6 fold increase 
over the affinity for PYD and an 18.5 fold increase over that for DPD.  The results suggest that assay 
format (including the antigen conjugation) and procedure had a significant impact on the specificity 
as demonstrated by the negligible cross reactivity observed with the immunoassays.  
a)            b) 
 
 
 
 
c) 
Figure E. Binding affinities of anti-desmosine. a) typical raw data sensorgram collected from 
protein/ligand binding experiment.  A sensorgram is the kinetic profile of biotinylated desmosine 
10µg/ml immobilised on streptavidin sensors measuring on-rates (association) and off-rates 
(dissociation) of antibodies with gradient dilutions of 7.5µg/ml, 1.5µg/ml and 0.3µg/ml (top to 
bottom), b) example of processed data analysed to 1:1 fitting (red line). c) summary kinetic values 
(Kdissociation, Kassosication) and affinity (equilibrium dissociation, KD) 
Validation of EIA and LF assays with the LC-MS/MS reference method. Urine samples were 
analysed for desmosine by 3 methods, isotope dilution LC-MS/MS (175) (chosen as the reference 
standard) and the two new immunoassays. Hydrolysed and non-hydrolysed samples were run for 
comparison in the EIA, but only non-hydrolysed samples were run on the LF tests due to limited 
sample volumes (Table A).  Both the EIA and LF values were strongly correlated with the LC-MS/MS 
results. The best correlation to the reference assay was observed using the EIA with non-hydrolysed 
samples (Spearman’s rank = 0.84, p = <0.0001) whereas hydrolysed samples had a lower correlation 
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(Spearman’s rank = 0.79, p = <0.0001).  The LF (non-hydrolysed samples) gave a Spearman’s rank 
correlation with the LC-MS/MS and EIA (non-hydrolysed samples) of 0.78 and 0.72 respectively.  
Table A. Desmosine measured in urine samples from COPD patients and healthy individuals. 
                 COPD                    Healthy Mann-Whitney  
 Median IQR Median IQR p value 
LF (non-hydrolysed) 47.8 (25.1-80.0) 28.0 (23.1-34.6) 0.0040 
EIA (non-hydrolysed) 20.0 (6.5-43.0) 4.6 (2.7-6.7) <0.0001 
EIA (hydrolysed) 4.4 (1.4-9.5) 0.1 (0.1-0.4) <0.0001 
LC-MS/MS (hydrolysed) 16.4 (9.5-27.3) 5.5 (3.9-11.4) <0.0001 
 
PYD and DPD concentrations in the samples were measured with the LC-MS/MS giving levels ranging 
from 15-763ng/ml PYD and 2-288ng/ml DPD.  The impact of these on the correlation was analysed 
by excluding those samples with high background values of PYD and DPD as measured by LC-MS/MS. 
Of the 120 clinical samples, 9 were found to have both PYD and DPD at elevated concentrations (PYD 
over 400ng/ml and DPD over 50ng/ml).  A further 18 were found to have just DPD elevated above 
50ng/ml.  When these samples were removed from the data set, the correlations between LC-
MS/MS and EIA were re-calculated to give Spearman’s rank values that were negligibly different 
from that of the complete set for the EIA (from 0.84 to 0.86). However, a significant improvement 
was found in the correlation of the LF assay results, with an increase in spearman’s rank from 0.78 to 
0.85, making it comparable to the EIA. This is, consistent with the observation that the LF assay is 
more prone to cross-reactivity than the EIA with this antibody and assay format. 
Clinical validation of assays. The 30 COPD patients who all donated samples at day 0 (exacerbation), 
were 53% male (16/30), had an average age of 67.27, median of 60 pack years (IQR 33.8-93.8), and 
FEV1 of 1.05 (IQR 0.76-1.36).  The 20 healthy controls were mostly male (16/20; 80%) and had a 
mean age of 38.6 (range 22-67). Two were known to have well controlled asthma, and 1 was a 
current smoker.   Statistically significant differences were observed between desmosine levels in 
urine samples from COPD patients and samples from healthy volunteers. 
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a)     b)  
 
 
 
  
c)     d) 
 
 
Figure F. Analysis of healthy (n=20) and COPD (n=100) groups for desmosine/creatinine ratios by 2 
statistical tests; unpaired t-test Mann-Whitney test a) LF and b) EIA (both using non-hydrolysed 
samples) and ROC procedures c) LF and d) EIA (non-hydrolysed samples) 
a)     b)  
 
 
 
 
c)     d) 
 
 
 
Figure G. Bland-Altman plots for LF determination of desmosine compared to standard method LC-
MS/MS a) pre-refined and b) post-refined and ROC analysis between samples from healthy 
individuals and COPD patients c) pre-refined and d) post-refined 
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Refinement of assays to improve specificity. The specificity of the new antibody (pre and post 
purification by affinity separation) was evaluated in both the EIA and the LF assay with all 4 
compounds, desmosine, isodesmosine, PYD and DPD. For the EIA version minimal improvement was 
observed.  The PYD cross-reactivity changed from 0.033% to <0.01% (pre- to post-purification) and 
for DPD 0.10% to <0.01%. The pre-purified antibody LF version cross reacted with PYD and DPD at 
0.56 and 1.27% respectively, but this interference was removed by the use of the refined antibodies 
(0.01% for both) which is consistent with the tendency for the LF assays to be more susceptible to 
antibody cross reactivity. LF assays and EIAs using the pre-purified and post-purified reagents were 
re-tested with 98 and 90 samples respectively from the original study. Prior to the refinement, a 
mean bias of 117.5% was observed in LF when compared to the isotope dilution LC-MS/MS method, 
with 95% confidence interval of limits of agreement being 16.6-218.4% (figure G).  After refinement, 
the mean biases improved to -39% with 95% confidence interval of limits of agreement of -166.1-
87.99%. The refinement did not significantly change the diagnostic performance. 
In EIA (figure H), a similar bias was found in the pre-refined assay and improvement was observed 
with the refined assay bias from 45.8 to -18.3%. 95% confidence intervals of -69.3-160.8 was 
observed for the pre-refined compared to -127.9-91.2 for the post-refined. Similarly, the diagnostic 
performance was not significantly changed when comparing samples collected from healthy and 
COPD individuals. 
 
a)     b)  
 
 
 
 
c)     d) 
 
Figure H. Bland-Altman plots for EIA compared to LC-MS/MS a) pre-refined and b) post-refined and 
ROC procedures between healthy and COPD samples c) pre-refined and d) post-refined 
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I.i.iii Discussion  
The heterogeneity of DES and DES-containing peptides in urine is an important factor affecting any 
immunoassay aimed at testing fresh, unmodified urine samples in the home or at the point of care.  
Currently, assays used in the laboratory for desmosine are thought to only detect the free, 
unattached desmosine. To estimate total elastin degradation, urine samples are generally pre-
treated with an extended, aggressive acid hydrolysis at 108°C (lasting between 12 and 48 hours) to 
release desmosine from all the peptide forms before analysis by LC-MS/MS (97). The overall process 
is very slow and laborious but highly accurate due to the use of stable isotope dilution, such that it is 
considered as a reference assay in this study (184).  
When both EIA and LF assays were evaluated in this study, it was found that intra assay, inter assay 
repeatability, linearity, and spike recovery all met the required acceptance criteria of FDA guidelines. 
The assays correlated well with the reference LC-MS/MS assay, with a Spearman’s rank coefficient of 
0.84 for the EIA and 0.78 for the LF test. The concentration ranges varied between the assays and, in 
particular, between hydrolysed and non-hydrolysed samples as measured by the EIA with a median 
of 6.2ng/ml and 26ng/ml respectively.  This potential underestimation in hydrolysed samples could 
be due to differences in sample preparation prior to running the assays. Both EIA and LF (non-
hydrolysed) provided higher median values than the LC-MS/MS (hydrolysed), the differences 
between assays could be influenced by increased susceptibility to cross reactivity. The correlation 
between the LF and the LC-MS/MS was improved with the omission of samples containing high 
levels of PYD and DPD supporting the theory that cross reactivity is responsible for this and the 
overestimated values generated, particularly with the LF assay. Alternatively, there are likely to be 
differential effects of desmosine attached to residual “stubs” of fragmented elastin. Other EIA assays 
previously developed have suffered from cross reactivity to isodesmosine up to 45% (185) and to 
PYD up to 20% (186). The EIA used in this study was based upon a polyclonal antibody with sufficient 
affinity and specificity, raised in sheep in response to a synthetic immunogen derived from 
desmosine, following a well-defined immunization protocol for difficult antigens. Although better 
correlation has previously been reported between EIA and HPLC (187), the samples used were aortic 
tissue samples and limited comparative data is available with urine. Moreover, other EIAs previously 
developed for urine used hydrolysed samples (133). 
The EIA of this study was developed for use with non-hydrolysed urine samples, which is a 24-hour 
process. The LF version further reduced the assay time to just 10 minutes, without compromising the 
differentiation between COPD patients and healthy individuals (AUC=0.80-0.88).  The ability to 
identify and quantify the presence of free desmosine, as well as desmosine attached to peptide 
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stubs in untreated urine samples, provides a step-change improvement in the value of desmosine as 
biomarker of inflammatory damage to tissues in which elastin is present. 
The results show that extensive refinement of anti-DES antibody improved its specificity in the EIA 
and LF assay formats.  
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I.ii Measurement of MMP activity (ELTABA) 
Mologic’s “ELTABA” technology (enzyme linked transformation affinity binding assay) was designed 
to detect the protease activity “footprint” of neutrophil leukocytes. The test detects the combined 
enzyme activity of enzymes secreted by neutrophils (and others) - matrix metalloproteinases 
(MMPs) and neutrophil elastase (HNE) - rather than just concentration of the enzyme molecules. 
Three ELTABA platforms are described, each of which can be modified to measure other enzymatic 
activity (within limits): 
▪ ELTABA: the 1st test developed by Mologic which was a ‘negative’-read test for measuring 
the composite activity of MMPs and HNE. This test was developed to measure the enzyme 
activity in wound fluid. 
▪ Reverse ELTABA, the 2nd test developed: a ‘positive’ read derivative of the original version 
(above).  It is a more sensitive assay than ELTABA but requires a more labour-intensive 
sampling procedure. 
▪ Ultimate ELTABA: an ultra-sensitive ‘positive’ read test for active MMPs only, this test was 
developed specifically to measure low concentrations of MMPs in urine. 
I.ii.i ELTABA 
Instead of detecting the enzyme molecules themselves, the assay detects a specially designed 
indicator peptide that is acted upon (cleaved) by the enzymes.  The test is not specific to HNE and 
MMP-9 but has a strong bias towards them.  This means that high concentrations of active MMP 2, 
for example, will also be detected.  The procedure requires a short pre-incubation step of 10 
minutes with the sample to allow enzyme digestion to take place.  The presence of protease activity 
above a particular threshold results in the formation of a single visible red line (indicating the 
presence of significant neutrophil infiltration), while the absence of excessive neutrophil activity 
results in the formation of two visible red lines.  The two lines appear only when the protease 
activity in the sample is below the detection threshold. 
The principles underlying the Mologic ELTABA protease assay are set out in the diagrams and 
descriptions below.  The indicator molecule (peptide) contains two binding domains and a region 
containing an amino sequence cleavable by the relevant proteases, as shown in figure I. 
One of the two binding domains is recognised by a capture molecule immobilised on the test line of a 
lateral flow test strip, while the other is recognised by a binding partner molecule carried on gold 
particles. When the protease activity is low, most of the indicator peptide molecules remain intact, so 
enabling the formation of two lines to give reassurance that all is well with the proteolytic enzyme 
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balance and, hence, there being no serious infection or inflammation (Figure IA). Proteolytic enzymes 
in test samples with excessive proteolytic activity can cleave the peptide, so destroying the ability of 
the indicator molecule to form a bridge between the antibodies on the gold particles and those on the 
test line (Figure IB). Thus, the formation of a single line indicates the presence of a damaging 
neutrophil infiltration.  This relationship between result and clinical condition is intuitive, for it means 
that a two-line result is good and just one line is bad. 
I.ii.ii Reverse ELTABA 
Reverse ELTABA on the other hand, gives a “positive read” (strong test line) for a positive sample 
(i.e. high proteolytic activity) and a “negative” (absent test line) for a negative sample (low 
proteolytic activity). 
• In samples with normal levels of protease activity the peptide remains intact and the test 
line is absent.  
• In samples with high protease activity the peptide is degraded, which results in the 
appearance of an easily visible TEST line.  
• The peptide used for Reverse ELTABA the same as that used for the original ELTABA format, 
but it is pre-complexed with polystreptavidin (PSA).  
One of the three binding domains (1st) is recognised by Pre-Absorption lines contained in a hidden 
capture zone, a second is recognised by a capture molecule immobilised on the test line (BSA-Biotin) 
of a lateral flow test strip and a third is recognised by a binding partner molecule carried on gold 
particles (biotin gold). When the protease activity is low, most of the indicator peptide molecules 
remain intact.  These intact indicator molecules are captured in the hidden capture zone, resulting in 
an absent test line. Proteolytic enzymes in test samples with excessive proteolytic activity can cleave 
the peptide, releasing the PSA with the 2 epitopes to form a bridge between the antibodies on the 
gold particles and those on the test line (Figure JD) 
Thus, the formation of a single line indicates the absence of a damaging neutrophil infiltration, and 
two lines indicate the presence of a damaging (pathogenic) degree of neutrophil infiltration. 
I.ii.iii Ultimate ELTABA 
This ‘positive’ read assay depends on a unique antibody that recognizes a cryptic epitope exposed 
only once the peptide has been cleaved by the target enzyme(s). The Ultimate ELTABA antibody was 
raised in response to an immunogen derived from the cleaved indicator peptide (stub).  For the 
assay the antibody is labelled with gold particles as the visible indicator.   
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Figure I.  Principle of the ELTABA MMP/HNE activity test. A) diagrammatic representation of the 
ELTABA indicator peptide, 1st binding domain binds to the immobilised streptavidin test line and 2nd 
binding domain binds to the antibody conjugated to gold B) The effect of a relevant protease on the 
ELTABA indicator peptide.  Note that the two binding domains become separated by cleavage of the 
cleavable sequence. C) Diagrammatic representation of an ELTABA test on a healthy sample with a 
low level of relevant protease, the intact peptide remains resulting in the formation of two lines – a 
test line and a control line D) Diagrammatic representation of an ELTABA test on a unhealthy sample 
with a high level of relevant protease, the peptide sandwich is not able to form, resulting in the 
formation of only 1 line – the control line. 
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Figure J.  Principle of the Reverse ELTABA MMP/HNE activity test. A) diagrammatic representation of 
the Reverse ELTABA indicator peptide B) The effect of a relevant protease on the indicator peptide.  
Note that the two binding domains become separated by cleavage of the cleavable sequence. C) 
Diagrammatic representation of the Reverse ELTABA test on a sample with a low level of relevant 
protease, resulting in the disappearance of the test line.  A “test complete” or control line is included 
on the strip in the usual way D) Diagrammatic representation of the Reverse ELTABA test on a 
sample with a high level of relevant protease, resulting in the appearance of the test line.  A “test 
complete” or control line is included on the strip in the usual way.   
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Figure K.  Principle of the Ultimate ELTABA MMP activity test. A) diagrammatic representation of the 
Ultimate ELTABA indicator peptide B) The effect of a relevant protease on the indicator peptide.  Note 
that the two binding domains become separated by cleavage of the cleavable sequence. C) 
Diagrammatic representation of the Ultimate ELTABA test on a sample with a low level of relevant 
protease, resulting in the disappearance of the test line.  A “test complete” or control line is included 
on the strip in the usual way D) Diagrammatic representation of the Ultimate ELTABA test on a sample 
with a high level of relevant protease, resulting in the appearance of the test line.  A “test complete” 
or control line is included on the strip in the usual way.   
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I.ii.iv Materials and Methods 
Disposable 96-well polystyrene plates were obtained from Nunc (Maxisorp™ flat bottomed) or 96 
well plate coated with PSA (Nunc, 442404). MMP-9 was supplied by Alere San Diego and activated 
with APMA.  Anti-cleaved stub antibodies were obtained from sheep immunised with various 
peptides covalently attached (via glutaraldehyde cross-linking) to the carrier keyhole limpet 
hemocyanin (KLH) using same method as used for desmosine described above. Peptide stubs for 
immunisations and peptides for assay were synthesised at Mologic.  The sheep Anti-cleaved stub 
serum was affinity purified against solid-phase immobilised peptides. The affinity-purified antibody 
fraction was subsequently conjugated to alkaline phosphatase (AP) using kits supplied by Innova 
biosciences (cat No. 702-0010). Donkey anti-sheep alkaline phosphatase was supplied by Sigma (Cat 
No, A5187). pNPP substrate solution was obtained from Sigma (Cat No N2765). MMP buffer (Aq. 
Solution of 50mM Tris, 100mM sodium chloride, 10mM Calcium Chloride, 50μM 20mM zinc chloride, 
0.025% Brij 35, 0.05% sodium azide at pH 8.0). Wash buffer for plate assay (50mM tris buffered 
saline pH8, supplemented with 0.1% (v/v) Tween20). 
 
Antibody development and characterisation. Antibodies were generated to recognise a cleaved 
peptide sequence, the designed peptide sequence GPQGIFGQ, a target for MMP digestion is known 
to be cleaved between G and I, however, it was unknown if the cleaved stub GPQG or IFGQ was 
more immunogenic. It was also unknown whether it was better to immunise with a short peptide 
consisting of 4 amino acids or if it would be better to immunise with a longer peptide with the 
required sequence exposed. Four peptides were designed, prepared and conjugated to KLH as 
shown in table B for immunisations in sheep.   
 
Table B. Details of the immunogens (sequence and ID), the sheep ID the peptides that were used to 
assess the titres of the antibodies. 
Immunogen sequence Immunogen 
Name 
Sheep ID Peptide 
name 
Peptide sequence 
KLH-CGPQG MOL223 CF1532/CF1533 A3 B-GPQG 
IFGQC-KLH MOL224 CF1520/CF1521 A1 IFGQ-B 
IFGQGPQGC-KLH MOL225 CF1522/CF1523 A2 IFGQGPQG -B 
KLH-CIFGQGPQG MOL226 CF1524/CF1525 A4 B-IFGQGPQG 
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The titre of the anti-cleaved stub antibody in the serum was measured by serial dilution of the serum 
in sample diluent (50mM tris buffered saline pH8, supplemented with 0.1% (v/v) Tween20 and 1% 
(w/v) BSA) and evaluated in a plate assay using the following protocol.   
Each peptide A1-A4 (1μg/ml in PBS) was added to a 96 well plate coated with polystreptavidin 
(Nunc, 442404) 100μL per well, and incubated for 1 hour at room temperature with gentle agitation.  
The sensitised-well surfaces were blocked after the plates had been washed 3 times with wash 
buffer (50mM tris buffered saline pH8, supplemented with 0.1% (v/v) Tween20).  Wash steps were 
carried out between the blocking step and each of the incubation steps. The blocking buffer 
consisted of 50mM tris buffered saline pH8, supplemented with 0.1% (v/v) Tween20 and 1% (w/v) 
BSA, which was left in place for 1hour at room temperature.  Diluted serum samples (100μl) were 
added to duplicate wells and incubated for 1hour at room temperature with gentle agitation.  
Donkey anti-sheep IgG alkaline phosphate conjugate was diluted 1 in 30,000 in the sample diluent 
and added to each microtitre well (100μl), incubated for 1hour with gentle agitation. After the final 
plate wash, the colorimetric detection step was initiated by the addition of 100μl of pNPP solution to 
each well. Once colour had been allowed to develop, the absorbance was measured at 405nm using 
an Omega plate reader (BMG labtech, UK).  Selected antibodies were affinity purified using the 
specific peptides they were raised and conjugated to AP against and then analysed by ELISA to 
determine the most appropriate assay format to give the best sensitivity. 
 
Assay format development: Peptides containing the cleavable sequence (GPQGIFGQ) were 
synthesised with a biotin or Pegylated biotin attached to either the C-terminus (MOL038 and 
PCL008-A2 respectively) or the N-terminus (MOL310 and MOL378 respectively). 
Table C. Details of the peptides, sequence and ID. Two peptides have been designed with each one 
having an alternative form with a PEG linker. Added to the 8AA sequence is the ALP sequence. 
Antibodies are available at Mologic that recognise the ALP sequence. 
Peptide ID Sequence 
MOL038 Biotin-GPQGIFGQESIRLPGCPRGVNPVVS 
PCL008-A2 Biotin-PEG-Asp -AEEAc-AEEAc- GPQGIFGQESIRLPGCPRGVNPVVS 
MOL310 SIRLPGCPRGVNPVVSGPQGIFGQ- Biotin 
MOL378 SIRLPGCPRGVNPVVSGPQGIFGQ-AEEAc-AEEAc- PEG-Asp Biotin 
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The peptide can be anchored to a solid phase either by binding to a streptavidin capture via the 
biotin or to sheep antibody CF1060 capture via the ALP sequence, the proposed formats described in 
figure L were evaluated using the following protocol. 
 
Ultimate ELTABA Plate assay. For ALP binding to the plate, microtitre plates were sensitised 
overnight with 100μl per well of anti-ALP affinity purified antibody (CF1060) at 1μg/ml in PBS.  The 
sensitised-well surfaces were blocked after the plates had been washed 3 times with wash buffer. An 
additional wash step was required to remove the blocking buffer before use. For biotin binding to 
the plate, 96 well plate coated with polystreptavidin (Nunc, 442404) were used. Active MMP-9 was 
diluted in MMP buffer to give concentrations between 39 and 2000ng/ml (or as required) to 
generate the standard curve. Peptide was incubated with the standard or undiluted urine sample for 
30 minutes, at the end of the incubation period, 100μl was added per well and incubated for a 
further 1hour at ambient where the peptides were immobilized by the streptavidin or CF1060 bound 
to the plate. After a subsequent wash step, each sheep antibody conjugated to Alkaline phosphatase 
were added at a dilution of 1/500 (100μl/well) and incubated for 1 hour at ambient. After the final 
plate wash, the colour reaction was initiated with the addition of 100μL of pNPP solution to each 
well.  Once colour had been allowed to develop, the absorbance was measured at 405nm using an 
Omega plate reader and the standard curve was approximated in a sigmoid 4 parameter logistic 
model. 
Ultimate ELTABA Lateral flow assay. Antibody CF1060 or polystreptavidin was immobilised onto 
Sartorius CN140 nitrocellulose membrane at 1mg/ml using an Isoflow flatbed dispenser (Imagene 
Technology), dried in a tunnel dryer (Hedinair, UK) at 60°C and stored with desiccant prior to use.  
Affinity purified sheep anti-cleaved stub antibody was conjugated to 40nm gold colloid in the 
optimal suspension buffer. Following a 10min incubation, any unbound colloid was blocked with a 
final concentration of 2mg/ml BSA in PBS.  The sheep anti-cleaved stub gold conjugate was sprayed 
onto Millipore GO41 glass fibre pads in a deposition buffer containing 3% (w/v) BSA, 5% (w/v) 
sucrose and 1% (v/v) Tween 20 using an Isoflow flatbed dispenser. The sprayed conjugate pads were 
dried in a tunnel dryer at 60°C and stored with desiccant prior to use.  Both prepared membranes 
and conjugate pads were laminated and assembled into LF devices (VWR Cat No SLINM00810) 
according to an in-house protocol. Active MMP-9 was diluted in MMP buffer to give concentrations 
between 8 and 500ng/ml (or as required) to generate the standard curve. 12.5µl volumes of peptide 
at 2µg/ml was incubated with 80µl of standard or undiluted urine sample for 10 min, at the end of 
the incubation period, 87μl was added per well. Following a 10 min incubation the signals generated 
were quantified using a LF device reader (LFDR101; Forsite Diagnostics, York, UK).   
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Figure L. Different formats evaluated with different combinations of peptides and antibodies. Format 
1 (F1)- Format 4 (F4) are shown. Antibodies are listed that are expected to work in this format, the 
figure on the left demonstrate the binding of the intact peptide (i.e. no enzymatic activity) with no 
visible signal. The figure on the right demonstrate the binding of the antibody to the peptide when 
cleaved. 
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Comparison with a commercial assay kit. The commercial kit (Sensolyte®520 MMP-9 Fluorimetric 
Assay kit, AS-71155) was designed for specifically detecting MMP-9 in biologic samples such as 
culture medium, serum, plasma, synovial fluid, and tissue homogenate.  A monoclonal anti-human 
MMP was used to pull down both pro and active forms of MMP from the mixture first, and then the 
activity of MMP-9 was quantified using fluorescence resonance energy transfer (FRET) peptide.  An 
MMP-9 standard AMPA activated in-house was run on both the kit and a lateral flow format of the 
invention at a range of 250ng/ml – 4ng/ml.  For the commercial assay the MMP-9 was diluted in an 
MMP buffer supplied in the kit and a Tris buffer saline 1% Tween20 for lateral flow devices.   
 
Detection of enzyme activity in wound fluid and inhibition of enzyme activity.  Wound samples 
from 18 patients were tested on the ultimate ELTABA device to measure active MMPs in this biologic 
matrix as there was expected to be high levels of MMP in this sample matrix.  The samples were 
extracted from a swab (Copan, 552C.US) in MMP buffer and then frozen at -20°C until use.  The 
addition of a chelating agent (5mM EDTA) to the sample to inhibit the protease activity was 
undertaken to determine the specificity of the device to calcium dependent enzymes e.g.  MMPs. 
Each wound sample was diluted 1 in 20 in MMP buffer and 75µl was placed in a collection device 
with a defined amount of peptide (25ng/test).  The collection device was rotated vigorously in order 
for the sample to mix sufficiently with the substrate solution. This reaction mixture was incubated at 
ambient temperature for 10 minutes before running on the assay as previously described. 
Detection of enzyme activity in urine. Samples collected from people with COPD, CF and healthy 
state were tested on the Ultimate ELTABA devices. The respiratory samples were a mixture between 
exacerbation and stable samples. 
Specificity of the assay to MMPs. Various MMPs (1, 2, 3, 7, 8, 9, 10, 11, 12, and 13) were tested on 
the Ultimate ELTABA device at 2µg/ml, 1µg/ml and 0.5µg/ml diluted in MMP buffer.  
I.ii.v Results 
Assay format selection. In the plate assay, 2 different formats were evaluated, with either CF1060 or 
polystreptavidin immobilised on the solid phase.  There were four formats selected figure M with a 
streptavidin capture line, the selected peptide/sheep antibody parings were MOL378/CF1522 and 
PCL008-A2/CF1525 as predicted.  Both peptides contained a PEG-Asp -AEEAc-AEEAc required to 
reduce any steric hindrance. With a CF1060 capture line, the selected peptide/sheep antibody 
pairings were MOL038/PCL008-A2/ CF1522 and MOL378/CF1525 as expected.  The best 
combinations summarised in figure N confirmed that format 4 using sheep antibody CF1522 with 
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Figure N. Comparison of best performing 
peptide for each format. Both peptides with 
a PEG linker were deemed to be the most 
effective. Format 1 and format 2 produced 
standard curves with wider dynamic ranges 
(both used a streptavidin capture line).  
Format 2 in both ELISA and lateral flow was 
the most optimal format. 
1 1 0 1 0 0 1 0 0 0 1 0 0 0 0
0
1
2
3
4
F o r m a t  1 -  4 :  B e s t  c o m b i n a t i o n s
M M P - 9  ( n g / m l )
O
D
4
0
5
F o r m a t  1  P C L 0 0 8 - A 2
F o r m a t  4  P C L 0 0 8 - A 2F o r m a t  3  M O L 3 7 8
F o r m a t  2  M O L 3 7 8
peptide MOL378 gave the best performance. This was also repeated in lateral flow format and the 
same combination was selected and taken forward. 
 
  
  
 
 
 
 
 
 
 
 
  
 
 
 
Figure M. Selection of best performing format in ELISA. Standard curves were obtained with format 
1 and 2 when using peptides with a PEG linker. For formats 3 and 4 standard curves were obtained 
with peptides with and without PEG linkers as expected with no signals with the other peptides. NSB 
was obtained with MOL310 with format 3. 
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Figure O.  Comparison of Ultimate ELTABA 
with commercial kits. A graph comparing the 
ability of a commercially available active 
MMP assay kit and Ultimate ELTABA with the 
same standard applied to both assays. 
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Comparison with reference assay. The same MMP in-house standard run on both assays showed 
equivalence when comparing the RFU and lateral flow reader values. Both assays measure the 
lowest standard and have similar assay ranges. The reference assay had a run time of approximately 
3 hours compared to 20 minute Ultimate ELTABA test. 
 
 
 
 
 
 
Detection of enzyme activity in wound fluid. MMP-9 present in the sample cleaved the indicator 
molecule at the cleavage site, exposing the recognisable epitope thus allowing the gold conjugate to 
form a complex with the cleaved stub. The lines that were formed were assessed by their relative 
intensities. The presence of a test line indicated that there was protease present in the test sample. 
A negative test line indicated a zero or low level of protease that was below the detectable limit. 
Stages in between these extremes indicated different levels of protease in the test sample. The 
intensity of the developed coloured lines was measured visually and with a Forsite Lateral flow 
device reader. Figure P(A) shows that addition of EDTA to the wound samples inhibits the readout, 
confirming the presence of MMP in the samples and also confirms that the assay is specifically 
measuring active MMPs.  
Detection of enzyme activity in urine. Laboratory testing with reference assays have shown that 
protease activity is higher in urine from COPD and CF patients than in urine collected from healthy 
volunteers, this was confirmed with limited sample testing with Ultimate ELTABA as shown in figure 
P(B).  Good discrimination between healthy and disease states with the lateral flow tests was shown. 
Specificity of ultimate ELTABA with MMP. A bias towards MMP-13, MMP-9, MMP-2, MMP-12 and 
MMP-8 was observed in figure Q. The commercial MMP-9 did not behave in the same way as the 
other MMPs as it appeared to hook at the highest concentration. This was not reproduced with the 
inhouse MMP-9. 
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Figure P. specificity of Ultimate ELTABA with wound fluid and urine. a) Inhibition of enzyme activity 
in wound fluid by addition of EDTA to the sample. Red dotted line indicates the visual cut-off 
between positive and negative result. b) Detection of enzyme activity in urine, unpaired t test values 
show a significance difference between disease state and healthy with p values <0.05. 
 
 
  
  
 
 
 
Figure Q. Ultimate ELTABA MMP selectivity. A) MMP 1-13 evaluated at 3 different concentrations b) 
summary of MMP’s in order with a selected concentration of 2µg/ml with a bias towards MMP13, 
MMP-9, MMP2, MMP12 and MMP-8. Cut off value for the forsite reader is shown by the dotted line 
i.e. discrimination between a negative and positive visual read. 
I.ii.vi Discussion 
The test is deemed acceptable for measurement of MMP in urine samples. Verification experiments 
conclude that the assay range in in line with a commercial ELISA kit, that there is an indication that 
there is a difference between healthy and diseased states, conformation that the assay is measuring 
MMP as shown by inhibition studies and that the assay is measuring the correct MMPs believed to 
be present in relevant inflammatory conditions such as COPD and Cystic Fibrosis. 
